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ABSTRACT 
 
The phosphoinositide-dependent protein kinase 1 (PDK1), a master kinase in the PI3K 
signaling pathway, has gained importance as a potential therapeutic target for cancer since 
several of PDK1’s substrates regulate processes for tumor cell growth and survival. As an 
alternative to the ATP-competitive strategy, we proposed the regulatory PIF pocket on 
AGC kinases as a drug target site to develop allosteric inhibitors with greater kinase 
selectivity. A screening identification of a hit compound and its biological evaluation 
proved that small molecules can allosterically trigger PDK1 activity by modulating the 
phosphorylation-dependent conformational transition. The optimization approach yielded 
3,5-diarylpent-2-enoic acids whose allosteric mechanism was proven using mutants and 
cocrystallography. In addition to the SAR study, we applied isothermal titration 
calorimetry to analyze binding energetics of allosteric activators. Structure-based drug 
design led to a second compound class containing a dicarboxyl-moiety with improved 
potency and selectivity. Using a prodrug strategy the cell activity and the proof of 
mechanism was established. Further structure optimization of 3,5-diarylpent-2-enoic acids 
provided new insights on inhibition efficacy of small molecules toward the atypical 
protein kinase C, PKCζ that can occur via binding the PIF pocket. These results 
demonstrated for the first time, that PIF pocket-directed ligands can be both activators and 
inhibitors of AGC kinases. 
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ZUSAMMENFASSUNG 
 
Die Phosphoinositol-abhängige Kinase 1 (PDK1), eine Masterkinase des PI3K 
Signalweges, stellt ein wichtiges therapeutisches Target für Krebs dar, da viele ihrer 
Substrate Prozesse der Krebsentstehung regulieren. Mit der Entdeckung der PIF-Tasche 
wurde ein allosterisches Zentrum der AGC Kinasen für die Entwicklung allosterischer 
Modulatoren, alternativ zur ATP kompetitiven Strategie, gefunden. Die Identifizierung 
einer Hitverbindung und deren biologische Evaluierung bestätigten, dass kleine Moleküle 
die PDK1-Aktivität durch Modulation phosphorylierungs-abhängiger Konformations-
übergänge allosterisch triggern können. In einem Optimierungsprozess wurden 3,5-
Diarylpent-2-ensäuren synthetisiert und deren allosterischer Mechanismus mit Mutanten 
und Kokrystallen bewiesen. Zusätzlich zu den Struktur-Wirkungs-Beziehungen wurden 
mittels isothermaler Titrationskalorimetrie die Bindungsenergien der Aktivatoren 
bestimmt. Strukturbasiertes Wirkstoffdesign führte zu einer zweiten Verbindungsklasse, 
wobei mit einer zusätzlichen Carboxylgruppe die Steigerung der Potenz und der 
Selektivität erreicht wurde. Die Zellaktivität und der Proof of Mechanism der Substanzen 
konnten mittels einer Prodrug-Strategie bestimmt werden. Eine weitere 
Strukturoptimierung der 3,5-Diarylpent-2-ensäuren lieferte allosterische Inhibitoren der 
atypischen Proteinkinase C, PKCζ. Diese Ergebnisse zeigen auf, dass die PIF-Tasche-
Liganden sowohl als Aktivatoren als auch als Inhibitoren der AGC Kinasen fungieren 
können. 
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1 Introduction 
1.1. Protein kinases 
Protein kinases constitute about 2% of human genes and build the second largest and 
most extensively studied gene families in the human genome.1  
Protein kinases are pivotal regulatory enzymes that change the properties of a substrate 
by attaching the γ-phosphate group from the cofactor ATP to the hydroxyl group of serine 
(Ser), threonine (Thr) or tyrosine (Tys) residues and are thus characterized with regard to the 
substrate specificity in three classes, Ser/Thr, Tys and dual specificity protein kinases.2 In 
addition, based on the similarity between the amino acid sequences of the enzyme catalytic 
domains, Manning et al. classified the kinases into nine major groups, AGC, TK, TKL, STE, 
CK1, CMGC, CAMK, Other, and Atypical (Figure 1).3   
 
Figure 1: Classification of the protein kinases into nine major groups3 
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The subgroup AGC family of Ser/Thr protein kinases was already defined in 1995 by Steven 
Hanks and Tony Hunter. The high analogy to the sequence alignments of the catalytic domain 
of the members provided a basis.4 The term AGC family derives from the appropriate 
members cAMP-dependent protein kinase 1 (PKA), cGMP-dependent protein kinase (PKG) 
and protein kinase C (PKC).2  
Protein kinases have emerged as an important class of pharmaceutical targets in 
consequence to the altering the substrate function and triggering a signaling cascade by 
phosphorylation. Thus, they play a crucial role in signal transduction controlling and 
regulating cellular processes. In fact, overexpression of protein kinases or loss of kinase 
regulatory mechanisms are observed in many human diseases, such as cancer, inflammation, 
neurological (e.g. Alzheimer’s disease) and metabolic disorders (e.g. diabetes type-2). 
Moreover, they are in contrast to protein-protein interaction considered to be more druggable 
by small molecule weight inhibitors. Not surprisingly, protein kinases are currently among the 
most important drug target class for the treatment of diverse human diseases.5 With several 
compounds on the market (Table 1) and dozens of inhibitors as drug candidates in clinical 
trials, small molecule compounds continue to attract attention.6 The majority of the protein 
kinase directed drugs has been used for oncology therapy. But, this development is joined by 
a particular difficulty, relatively poor target selectivity causing additional site effects. As ATP 
is the essential cofactor to reach kinase activity, the development of kinase inhibitors focuses 
on small molecules competing for the ATP binding site. The crucial drawback is the high 
degree of conservation of the ATP binding site and consequently it is difficult to achieve 
specific inhibitors. Accordingly, it is a major challenge in this area to develop a drug that 
selectively suppresses the activity of one kinase to minimize the risk of side effects as the 
majority of protein kinases inhibitors compete for the ATP binding site.7   
 
Table 1: Some examples of launched tyrosine kinases inhibitors8 
 
Tyrosinekinase 
inhibitor Name Company Target Indication 
FDA 
approval 
Imatinib Gleevec® Novartis Bcr-Abl, PDGFRA, PDGFRB,KIT 
Chronic myelogenous 
leukemia (CML) 2003 
Sorafenib Nexavar® Bayer VEGFR2,3 Primary kidney cancer 2005 
Erlotinib Tarceva® Hoffmann-La Roche EGFR1 
Lung cancer, 
Pancreatic cancer 2005 
Sunitinib Sutent® Pfizer VEGFR2, PDGFRA, PDGFRB, KIT, FLT3 
Renal cell carcinoma 
(RCC) 2007 
Lapatinib Tykerb® GlaxoSmithKline ERBB2 Breast cancer, Solid tumors 2007 
Pazopanib Votrient® GlaxoSmithKline VEGFR, PDGFR, KIT Renal cell carcinoma 2009 
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1.2. 3-Phosphoinositide-dependent protein kinase-1 (PDK1): a master 
regulator of AGC kinases 
The phosphoinositide-dependent protein kinase 1 (PDK1), a Ser/Thr protein kinase, is in 
the centre of growth factor and insulin signaling and is a master kinase which phosphorylates 
the activation loop of at least 23 protein kinases from the AGC group (Figure 2).2   
      Upon insulin and growth factors binding to the extracellular domain the receptor tyrosine 
kinase (RTK) becomes dimerized, phosphorylated and activated. Thereby creates RTK a 
binding site for the p85, a regulatory unit of phosphoinositide 3-kinase (PI3K), (Figure 2). 
This leads to the full activation of PI3K. Once activated, PI3K converts the phosphatidyl-3,4-
biphosphate [PIP2] into phosphatidylinositol-3,4,5-triphosphate [PIP3], a potent second 
messenger, essential for cell growth and survival.9 This reaction is reversed by hydrolizing 
PIP3 to PIP2 by PTEN. PTEN, the phosphatase and tensin homologue deleted on chromosome 
ten, acts as a tumor suppressor preventing uncontrolled cell growth by keeping cells from 
growing and dividing in an uncontrolled way and triggering cells to undergo apoptosis.10 PIP3 
in turn serves as a membrane-bound docking site for proteins with an N-terminal pleckstrin 
homology (PH) domains, such as PDK1 and PKB, one of its substrate. The PH domains 
interact with the membrane PIP3 resulting in the recruitment of PDK1 and PKB (also termed 
Akt) to the plasma membrane where the two enzymes co-localize. Thus, upon PI3 kinase 
activation, PDK1 catalyzses the phosphorylation of the Thr308 residue in the activation loop 
of PKB and leads to a partial activation of PKB. 11-13 The maximal activation of PKB is 
reached by phosphorylation of the hydrophobic motif (HM) residue Ser473 by mammalian 
target of rapamycin complex 2 (mTORC2).14 The mTOR protein kinase is the catalytic 
component  that forms two distinct multiprotein complexes called mTORC1 and mTORC2 
and has among PI3K and PDK1 a key role in this signaling pathway.15, 16   
PDK1 has received attention, firstly as the kinase that phosphorylates PKB at the 
activation loop on the residue Thr308 in a PIP3 dependent manner. Secondly, PDK1 has been 
shown to phosphorylate and activate other AGC kinases. The remaining PDK1 substrates lack 
a PH domain and consequently do not interact with PIP3. By contrast, the substrates SGK, 
RSK, PKCs and S6K have a homologous region of their activation loops including a 
consensus substrate recognition site for PDK1.16 This phosphorylation site is C-terminal to 
the kinase catalytic domain next to the hydrophobic motif. PDK1 is able to interact with the 
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substrates by a prior-phosphorylation of this hydrophobic motif.12, 17 The detailed molecular 
mechanism is described in chapter  1.5.  
Importantly, PDK1 is constitutively active because of the intrinsic ability to trans-
phosphorylate its own Ser241 residue and has a wide distribution in cells by binding to 
soluble inositiol phosphates that anchor PDK1 to the cytosol.2  
 
Figure 2: Distinct regulatory mechanism of PDK1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The PI3 kinase signaling pathway is promoted by stimulation of cells with insulin and growth factors. Thereby 
phosphoinositide 3-kinase (PI3K) activates and generates phosphatidyl-3,4-biphosphate [PtdIns(3,4)P2]  and the 
second messenger phosphatidylinositol-3,4,5-triphosphate [PtdIns(3,4,5)P3] which induce the activation of 
certain members of the AGC subfamily. 
 
1.3. PDK1 as a drug target 
Inhibition of PDK1 has been gained high interest due to its crucial role in transducing 
PI3K signaling pathway. Short treatments with PDK1 inhibitors may affect a decrease of the 
activation of some substrates of PDK1. A total inhibition of PDK1 activity by compounds is 
expected to have more effects on broader signaling pathways, besides the effects of PKB. 
Additionally, PDK1 has been emerged as a potential therapeutic target for cancer since 
several of the substrate protein kinases, comprising PKB, RSK and S6K, regulate processes 
which are essential for the tumor cells, such as cell growth and survival.18, 19 Their 
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unphysiological activity leads in the majority of cases to cancer. Loss of regulation arises in 
mostly cases from an up-regulation or mutation of upstream signal molecules, such as growth 
factors, or by the loss of the feed-back mechanism decreasing phosphatase activity. Moreover, 
deregulation of the tight control of such cellular functions also triggers diabetes type-2, 
autoimmune diseases, inflammation, neurological and metabolic disorders.20 One paramount 
example is S6K. S6K, as a downstream target of PDK1, plays a crucial role in the metabolic 
disorder diabetes type-2. PDK1 phosphorylates the activation loop of S6K that require 
phosphorylation of both HM and activation loop for fully activity. Subsequently, S6K 
activates a negative feedback loop by inhibiting the insulin receptor substrate-1 (IRS1) 
regulating the insulin action (Figure 2). In this line, S6K has a key role in insulin resistance. 
Obesity and diabetes type-2 is associated with increased activity of S6K.1, 21 Studies with S6K 
deficient mice confirmed the mice hypersensitive to insulin and they were protected against 
diet-induced obesity.22 Identification of PDK1’s inhibitors could lead to the development of 
therapeutic strategies for the treatment of these disorders preventing the activation of S6K and 
enhancing the insulin sensitivity. In case of cancer PDK1 is a validated target. The indication 
diabetes type-2 needs to be more investigated. 
 Hence, proper regulation of the PDK1 is critical for prevention of the overexpression of 
its substrates. The suppression of the activity of the PDK1 substrates provides an attractive 
approach and qualifies PDK1 as a potential target for development of novel therapeutics for 
the treatment of cancer, diabetes type-2 and other diseases.  
 
1.4. Structure of AGC kinases 
PDK1 and other AGC kinases display a characteristic bilobal structure that is shared by 
all protein kinases (Figure 3A).17, 23 This bilobal fold was firstly presented by X-Ray crystals 
for cAMP-dependent protein kinase (PKA, Figure 3B) in 1991 and defined the structural 
features of the catalytic domain of kinases. The aminoterminal small lobe consists of five 
stranded β-sheets and the carboxy-terminal lobe is larger and heavily α-helical. The ATP 
binding site is located in a deep cleft between the N-lobe and the C-lobe. Hence, the bound 
ATP sits below the highly conserved phosphate pocket that links the β-1 and β-2 strands and 
directs the γ-phosphate outwards while the adenine ring lies deep in the groove between the 
two lobes. PDK1 and its substrates contain also a central located phosphorylation site at the 
activation loop. Usually, when the AGC members are active, they are phosphorylated on a 
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critical residue including serin (PDK1), threonine and tyrosine of their activation loop (Figure 
3C). PDK1 requires phosphorylation on Ser241 for catalytic activity and there is an in vitro 
and in vivo evidence that PDK1 catalyzes the autophosphorylation of this site.23-25  
 
Figure 3: A: Ribbon diagram representing the catalytic domain of PDK1 and B: of PKA.  
C: Alignment of the amino acid sequence surrounding the activation loop and the 
HM of a couple of AGC subfamily kinases. The bold residues correspond to those 
that become phosphorylate.17, 26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Most PDK1 substrates have additionally another carboxy-terminal regulatory domain, the 
hydrophobic motif which sits at the very end of the C-terminus and folds back on the small 
lobe. This extended loop terminates in the sequence FXXF (Figure 3C) and binds to a 
particular hydrophobic site on the catalytic core complementing the catalytic domain. 
Interestingly, PDK1 does not posses an equivalent extension C-terminal to its catalytic 
domain and lacks the HM. Rather; a pleckstrin homology (PH) domain resides on the C-
terminus. This PH domain shared PDK1 with PKB and it provides the mutual binding to PIP3 
as described in more details in chapter  1.2. In addition, the PH domain of PDK1 exhibits a 
broad specificity binding to numerous phosphoinositides and inositol phosphates. This 
characteristic is given due to the spacious phosphoinositide binding pocket in the PH domain 
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of PDK1.27-29 A further structural domain of PDK1 is a hydrophobic groove, termed PDK1 
interacting fragment pocket (PIF pocket) that is located on the small lobe. Interestingly, other 
members of the AGC family possess an equivalent hydrophobic pocket. The following 
chapter describes the discovery of the PIF pocket and highlights its functions which mediate 
phosphorylation dependent conformational transitions and its importance as regulatory 
feature. Phosphorylation of the activation loop and of the PIF pocket is essential for maximal 
activation of AGC kinases.  
 
1.5. The PIF pocket, a regulatory site in PDK1 
The discovery of the PIF pocket and its regulatory functions were first described by our 
collaborator R.M. Biondi in 2000.26 The PIF-binding pocket of PDK1 is a hydrophobic 
surface pocket located on the small lobe of the catalytic domain and separated from the ATP 
binding site (Figure 4). It is formed by the surrounded amino acids Lys115, Ile118 and Ile119 
on the αB-helix, Val124, Val127 on the αC-helix, Leu155 on the β5−sheet and αG-helix. All 
these residues are arranged to a 5 Å-deep cleft (Figure 5). An equivalent hydrophobic motif 
(HM) binding pocket regulatory site exists also on other AGC kinases.  
 
Figure 4: Surface representation of the PDK1 kinase domain. Location of the PIF pocket  
     separated from the ATP binding site is highlighted. ATP is shown in stick format. 
 
 
 
 
 
 
 
 
 
 
As exemplified with the PKA structure (Figure 5), the C-terminal hydrophobic motif of 
almost all AGC kinases except PDK1 comprising the sequence FXXF acts as physiological 
ligand of the own PIF pocket. This intramolecular peptide motif utilizes a considerably larger 
area for interaction than just the hydrophobic pocket. In contrast to other AGC kinases PDK1 
ATP 
PIF 
pocket 
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does not possess an intramolecular ligand, the C-terminal extension to the catalytic core, and 
lacks the hydrophobic motif. Thus, in PDK1 the PIF pocket remains unoccupied and is 
accessible for transient docking of the HM of its substrates.  
Consequently, PDK1 makes use of the PIF pocket both, for the allosteric regulation of 
the catalytic activity and as docking site for transient interactions with the substrate proteins 
via their C-terminal peptide motif (HM). Thereby, PDK1 phosphorylates different substrates 
in different ways. Some substrates are phosphorylated constitutively by PDK1 whereas 
others, such PKB can be phosphorylated by PDK1 in response to the same cellular agonist but 
with different temporal regulation. The differential phosphorylation of its substrates relies on 
the specific ability of PDK1 to recognize and to interact with its substrates.  
 
Figure 5: PIF pocket comparison of PDK1 and PKA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A: Schematic representation of the surface. B: Stereo image of the residues linking the PIF pocket and the 
phosphate pocket. 17 
 
 
PDK1 detects selective inactive conformations of AGC substrates because they have 
disrupted PIF pockets and their hydrophobic motifs are available for interactions with the 
PIF-pocket of PDK1. Binding of the peptides increases the intrinsic catalytic activity of PDK1 
and enables PDK1 to phosphorylate almost all substrates, including S6K, SGK, RSK and the 
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atypical PKCs. This docking interaction with the PDK1 PIF-binding pocket results in full 
activation of the substrate kinases (Figure 6A).11, 30, 31 Through the occurred phosphorylation 
the binding of the phosphorylated HM to the own PIF pocket (active kinase) is prompted and 
helps stabilize the active conformation (Figure 6A). Subsequently, the affinity of the 
substrates to their phosphorylated hydrophobic motif increases. In contrast to the inactive 
conformations, the active conformations of AGC substrates are not detectable by PDK1 
because their PIF pockets are occupied by their own HM and the docking site is not accessible 
for interaction anymore. As the only known exception, the phosphorylation of PKB does not 
require the interaction with the PIF pocket of PDK1. As already described in chapter  1.2 and 
as shown in Figure 6B, both PDK1 and PKB bind their PH domain to the PIP3 bound on the 
membrane enabling the phosphate transfer. 
 
Figure 6: Mode of action of PIF pocket discriminates between two pathways A and B.  
PDK1’s phosphorylation of all substrates except PKB depends on transient docking 
interactions with the PIF pocket. 
 
    A: PDK1 dependent phosphorylation and activation of S6K, SGK, RSK, aPKC.  
 
 
 
 
 
 
  B: PKB phosphorylation and activation by PDK1. 
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1.6. The PIF pocket as a novel allosteric target site 
Many studies have been reported with the focus on PIF pocket showing PDK1’s PIF 
pocket is essential for the phosphorylation and the following activation of a set of AGC 
kinases.
 
To investigate whether the ability to phosphorylate and activate the AGC substrates 
remains Biondi et al. generated Leu155Glu mutants of PDK1’s PIF pocket. The in vitro 
results suggested the docking site is blocked for the substrates PRK2, S6K1, SGK, PKC and 
PRK but not for PKB.11 The substrates were phosphorylated and activated very weakly 
compared to the wild-type PDK1. To further confirm the requirement of an intact PIF pocket 
for binding and phosphorylation of S6K by PDK1, Collins et al. examined the in vivo 
influence of the PIF pocket as substrate interacting site using embryonic stem cells harbouring 
the Leu155Glu knock-in mutation.32, 33 Thus PDK1 exhibited its catalytic activity but received 
also a functionally inactive PIF pocket. Interestingly, the embryonic stem cells were viable 
and the PDK1 mutants induced the expected activation of PKB, whereas S6K1, RSK and 
SGK remained inactive. These in vivo mutagenesis results provided further evidence that the 
PIF pocket is crucial for binding and phosphorylation of S6K1, RSK and SGK by PDK1, 
except PKB. In addition, investigations with phospho- and dephospho-HM peptides of 
different AGC kinases indicated a direct influence on the catalytic activity binding on PDK1’s 
PIF pocket.  
Based on these results, the PIF pocket has emerged as a possible site for drug 
development. Small compounds as potential drugs directed to the PIF pocket are predicted to 
have two effects.  
Firstly, occupying the PIF pocket as docking site for the substrates the compounds inhibit 
the substrates’ activation which require the interaction with the PIF pocket (Figure 7). An 
inhibitor avoids the activation of the PIF substrates, such as SGK1, SGK, PKC, PRK, but not 
PKB. Binding of a drug molecule to the regulatory PIF pocket site may also increase the 
catalytic activity despite the blockade of the targeting site for the substrates. This effect is 
similar to the effects of the Leu155Glu mutant, which renders an active protein but blocks the 
docking interaction site.  
Secondly, the catalytic activity can be modulated by an allosteric mechanism. Compounds 
binding to the PIF pocket in AGC kinases will probably induce a conformational transition on 
the ATP binding site, similar to the effect of the phosphorylated HM peptide that also 
influences the conformation of the ATP binding site binding the PIF pocket. In case the ligand 
stabilizes a specific conformation of the PIF pocket the catalytic activity of PDK1 will 
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increase. Thereby the ligand acts as a kinase activator. Any aberrant ligand stabilizing 
conformation of the PIF pocket causes a decrease of the PDK1’s activity to the point of an 
inhibition. An allosteric inhibitor of this type would inhibit not only the substrates that depend 
on the PIF pocket interaction but also PKB. 
 
Figure 7: Novel mode of action of PIF pocket targeting compounds discriminates  
     between two pathways. 
 
    A: S6K, SGK, RSK, aPKC: PIF pocket binding compounds prevent docking 
  no activation. 
 
 
 
  B: PKB: Activation not affected by PIF pocket-target compounds.  
PIF pocket binding compound does not affect catalytic activity. 
 
 
 
 
1.7. Specificity of compounds targeting PDK1 
PDK1 was discovered in late 90s and is still relatively new drug target.34 Biochemical and 
genetic studies have shown that PDK1 is a critical activator of other downstream kinases that 
are important promoters of cancer progression and affected a rise in drug development based 
on PI3K/PDK1/PKB signaling pathway. Upregulation of PDK1 pathway due to 
overexpressed growth factor receptor proteins and PTEN mutation notably triggers the 
downstream signaling. Moreover, a wide range of all human cancers possess significant 
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overstimulation of the PDK1 signaling pathway 17, 35, 36 whereby PDK1 represents a most 
promising target. Directly inhibition of this protein kinase by small molecules is predicted to 
result in effective control of cancer cell proliferation, particularly because in vivo results 
suggest an incomplete inhibition of PDK1 in cancers where PTEN is mutated. Mice with 10-
20 % of PDK1 protein are healthy although they are smaller. However, when they are crossed 
with knockout mice in a PTEN deficient background, that have spontaneous tumors, the mice 
with less PDK1 activity have less tumors and extended lifespan.17 As binding of ATP is 
essential for kinase activity, the discovery of small molecule ligands that compete for the ATP 
binding site has been the main source for new kinase inhibitors. Hence, many studies have 
been reported with the focus on the development of ATP-competitive inhibitors targeting the 
ATP binding site of PDK1.16, 35, 37-42  
In the course of an evaluation of ATP-competitive PDK1 inhibitors various classes of 
small-molecules have been published in patents and papers. The inhibitors differ in their 
chemical scaffold but they share common characteristics corresponding to the hydrophobic 
nature of the ATP binding site. In addition they include fragments that occupy residues 
responsible for coordination of the ATP cofactor.  
Several of the published PDK1 directed inhibitors are based on two drug classes, firstly 
staurosporine analogues and secondly sulindac and celecoxib as actual non steroidal anti 
inflammatory drugs (NSAIDs), that inhibit cyclooxygenase (COX) activities. Few 
staurosporine derivatives have been identified as PDK1 inhibitors, CGP39360, CGP41251 
and UCN-01. Staurosporine, CGP39360 (Figure 8), a very potent broad-range kinase inhibitor 
significantly reduced the PDK1 activity in vitro with an IC50 of about 220 nM but it exhibited 
the most potency toward PKCα (IC50 < 3 nM). CGP41251 inhibited PDK1 moderately (IC50 < 
1.72 µM). However, it showed more selectivity toward PKCα with an IC50 of 0.04 µM.43 The 
most potent staurosporine derivative, UCN-01 (7-hydroxy-staurosporine, Figure 8), exhibited 
an IC50 value of 5 nM and is in clinical trials for treatment of cancer.44-47 Unfortunately this 
inhibitor turned out to be non specifically targeting many other kinases such as PKC and 
Chk1.48-50 Several additional reports of PDK1 inhibitors have also appeared in the literature.  
Different bisindolyl maleimides (BIM) and LY333531 are known to suppress the PDK1 
activity as well. These inhibitors are cognates of staurosporine differing slightly in the 
chemical structure. BIMs possess a maleimide moiety instead of lactam as head group and 
there is no second covalent bond between the indole rings compared to the indolecarbazole 
from staurosporine (Figure 8).27, 51 This compound class was originally reported as selective 
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inhibitors of PKC which when tested against a small set of other kinases showed less 
specificity than thought.51  
One inhibitor derived from the NSAIDs was Sulindac. Sulindac was found to have an 
ability to induce apoptosis in colon cancer cells through inhibition of PDK1. 52, 53 Another 
example of an effective PDK1 inhibitor from the NSAID class is Celecoxib (Celebrex®, 
Figure 8), a cyclooxygenase-2 (COX-2) inhibitor with an analgesic activity. Arico et al. 
reported in 2002 the inhibition of PDK1’s enzymatic activity by celecoxib in colon cancer 
HT29 cells (IC50 = 3.5 µM).54 Kulp et al. (2004) examine also the effect of celecoxib toward 
PDK1 and confirmed its inhibitory influence (IC50 = 48 µM).55 In conclusion, both NSAIDs 
were neither very potent nor specific inhibitors. Actually, Celecoxib was developed as a 
selective inhibitor of cyclooxygenase-2 (COX-2) and additionally it was founds besides its 
analgesic effect to inhibit various isoforms of carbonic anhydrase (CA). This is further 
difficult because higher concentrations are required toward PDK1.55  OSU-03012 (Figure 8) 
was developed as an anticancer agent by blocking PDK1 activity without COX-2 activity in 
an effort to optimize Celecoxib. OSU-03012 mediated cell death in different cancer cells 
through inhibition of the PDK1/PKB pathway. Anyway, Zhang et al. denied the mechanism 
of action of this agent suggesting OSU-03012 acts through multiple mechanisms.35, 56, 57  
 
Figure 8: Chemical structures of selected PDK1 kinase inhibitors 
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Feldman et al. described in 2005 the identification of three ATP-competitive PDK1 
inhibitors BX-795, BX-912 and BX-320 (Figure 9) consisting of an aminopyrimidine 
backbone. The inhibitors were identified in a screening of compound libraries measuring 
PDK1- and PIP2-mediated PKB activation.16 Among the class of aminopyrimidines there are 
more recent publications with a set of indolinone based PDK1 inhibitors. In a patent 
application of Bayer Schering Pharma AG in 2006 the (3Z)-3-(1H-pyrrol-2-ylmethylene)-1,3-
dihydro-2H-indol-2-one was used as starting point for medicinal chemistry lead optimization, 
since the unsubstituted compound BS (Figure 9) displayed an inhibition of PKB in 
lowmicromolar range in a biochemical screening using a PDK1 mediated PKB2 activation 
assay.35, 40 In 2007, Islam et al. disclosed the synthesis and SAR of inhibitors derived from the 
above mentioned high-throughput screening lead BS. A potent (inhibition in nanomolar 
range) and selective inhibitor, BX-517, was discovered and optimized by exploring 
substitution at the C-4’ position of the pyrrole (Figure 9). Due to the close homology between 
PKA and PDK1 the selectivity assay was restricted to PKA what should provoke critical 
thinking.  The optimization study was focused on improvement of ADME and solubility 
properties and resulted in a moderately success. Only few compounds could be found with 
better pharmacokinetic properties accompanied by loosing cellular potency.38, 39, 51 Another 
recent study presented a novel series of dibenzo[c,f][2,7]naphthyridines (Figure 9) as potent 
and selective PDK1 inhibitors. A crystal structure of PDK1 with the inhibitor was explored to 
provide insights into structure-based design.58 
 
Figure 9: Chemical structures of further selected PDK1 kinase inhibitors. 
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Further fused heterocycles have been described as PDK1 inhibitors and it becomes 
apparent that most of the compounds are subsequent optimizations of celebrex and 
staurosporine scaffolds to mimic the plain adenine moiety to be adaptable for the ATP 
binding site. In two recently patents, filed by Vernalis & D Limited59 and Vertex Pharma60, 
benzimidazole based scaffolds were developed to target the ATP binding site of PDK1. 
Researches at Vernalis have discovered pyrazole substituted benzimidazole derivatives with 
up to a nanomolar inhibition potency (Figure 10) using a fragment based design within 
literary search. Subsequent optimization led to higher affinity compounds.59, 61 Binch et al. 
from the Vertex Pharma filed a patent with benzimidazoles combined with a pyridine, 
pyrimidine or triazin moieties.60 
 
Figure 10: General structures of PDK1 inhibitors: Patents of Vernalis & D Limited (a) and   
                  Vertex Pharma (b) 
 
 
 
 
 
 
 
 
 
 
Numerous additional PDK1 inhibitors directed to the ATP binding site are published and 
reviewed.35 Herein a short overview with representative structure classes is given in order to 
present the course of action in drug discovery focused on PDK1. Nevertheless, due to the 
relative structural conservation of ATP binding sites for several protein kinases and resulting 
cross reactions with many different kinases, the risk of dose limiting off-target effects 
increases and it is a challenge to find a new candidate for clinical trails. In fact, not only in 
case of PDK1 the most ATP-competitive inhibitors show limited selectivity,62, 63 implying that 
certain protein kinases have not been considered as suitable for drug development, in 
particular protein kinases for which closely related isoforms exist. This raises the question in 
drug discovery programs, which promising concept could lead in enhancing selectivity.  
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Currently, the trend toward multi-kinase target strategy is increased in an attempt to become 
enhanced antitumor efficacy and safety profiles compared to single target drugs. Now that the 
structures of many kinases have been determined, this may reveal the distinct features and 
design rules enabling to find an appropriate drug.64 Moreover, several programs directed to 
non-ATP-competitive kinase inhibitors have been launched. 
 
1.8. Allosteric Inhibitors 
As an alternative and as a complement to ATP binding site-directed compounds, that are 
referred also as Type I inhibitors (Figure 11A), there is increasing interest in the development 
of non-ATP-competitive strategies for protein kinase drug developments. Non-ATP-
competitive drug strategy could avoid the poor target selectivity and could extend the 
therapeutically indications.7, 65 The interest in allosteric drugs arose together with the success 
in the development of G-protein-coupled receptors (GPCR) drugs that bind at sites 
topographically distinct from the orthosteric site. Allosteric modulators of GPCR provided 
high selectivity and led to a greater diversity in the repertoire of pharmacological effects.66-68 
During the last few years, a series of protein kinase inhibitors have been referred as non 
ATP-competitive inhibitors although most of them target at least partially the ATP binding 
site. They are also termed as Type II inhibitors and occupy in addition to a part of the ATP 
binding site a neighbouring area (Figure 11B). They act in this manner in some extent in a 
different, non-competitive mechanism of inhibition. These inhibitors induce a conformational 
shift in the target enzyme and the kinase is no longer able to function. Well known 
representatives of Type II inhibitors are imatinib and sorafenib (Table 1). However, although 
Type II inhibitors are more selective than Type I inhibitors, they are not completely specific 
due to similar hydrophobic regions adjacent to the ATP binding site among the protein 
kinases. Furthermore, there is also a strategy to inhibit the kinase activity utilizing an 
allosteric inhibitor, Type III inhibitors. Allosteric inhibitors act by binding to a part of the 
enzyme, which is distinctly separated from the active site (Figure 11C) and by inducing a 
conformational shift (similar to inhibitors Type II) in the target enzyme such that the kinase is 
no longer able to function properly. Type III inhibitors have been developed for instance for 
mitogen-activated protein kinase (MAPK).69, 70 These Type III inhibitors bind to allosteric 
sites within the kinase domain, but there are also allosteric inhibitors directed to regulatory 
regions. Akt inhibitors that target the PH domain and the hinge region have been identified 
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and investigated showing selective behavior between the three AKT isoforms.71, 72 Thus, Type 
III inhibitors are the most selective compounds so far.  
 
Figure 11: The three classes of small molecule kinase inhibitors73 
 
 
 
 
 
 
 
 
 
 
 
 
Interestingly, the characterization of novel allosteric sites as druggable sites might enable 
the development of drugs with more subtle modulation of the protein kinase activity as 
compared to the complete inhibition of the enzymatic activity. In addition the targeting of 
allosteric-regulatory sites could potentially generate inhibitors, but also protein kinase 
activating drugs.  
Discovering the PIF pocket of PDK1 as an allosteric site that is situated distant to the ATP 
binding site and that serves as a regulatory site for interaction with the substrates we were 
able to identify and suggest this allosteric fragment as a possible target for drugs. 
Furthermore, we have provided recently first evidence that a small molecule can trigger 
activation of PDK1.23  
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1.9. State of the art: low molecular weight compounds targeting the 
allosteric PIF pocket in PDK1 
1.9.1. First compounds designed to bind to the PIF pocket of PDK1:   
activators of catalytic activity 
The preliminary work was carried out by Dr. M. Engel and Dr. R.M. Biondi (Research 
group Phosphosites (PS)). It concerns the discovery of the PIF pocket in PDK1 and its key 
role in the molecular mechanism for the conformational transitions that take place upon 
activation of AGC kinases.11, 26, 31 Thereby, biochemical and molecular studies shed light on 
the fact that this binding site is required for intermolecular interactions of PDK1 with its 
substrates. To identify first small molecules which bind to the PIF pocket a virtual screening 
approach was employed.74 The entry point was provided by the comparison of the crystallized 
PDK1 PIF pocket with that of the closed, active conformation of PKA within the C-terminal 
HM. The HM contains two subpockets where the phenyl residues of the terminated sequence 
FXXF dock (Phe347, Phe350, Figure 12A). Then the definition of a pharmacophore model 
followed. In the effort to identify compounds with an affinity to the PIF pocket a 3D in silico 
screening of a commercial compound database was performed using the Unity 3DTM-software 
(Tripos Software) and compounds possess feature similar to the phenyls (Figure 12A) were 
selected. Finally, the effect of a subset of selected compounds on the activity of different 
AGC protein kinases was tested in vitro. This search resulted in two hit classes, I and II as 
illustrated in Figure 12B. The small weight compounds allosterically activate PDK1 
mimicking the phosphorylation dependent conformational transition.74 Both compounds 
scaffolds turned out to be particular interest due to their influence on the activity of PDK1 
toward a polypeptide substrate that comprises the activation loop residues of PKB, known as 
T308tide. The molecules with the scaffold of I and II increased the PDK1 activity. Further 
characterizations indicated that these compounds competed with the PIF pocket for the 
binding to PDK1. The first consequent publication restricts to the compound series I because 
of their low AC50 and their relatively specificity toward PDK1, characterizing additionally the 
mechanism of action of these compounds by mutagenesis experiments of PDK1, interaction-
displacement studies and isothermal calorimetry.12, 74 
Based on the first hit compounds I and II, I was able to synthesize the first improved 
allosteric modulators of PDK1 (III, Figure 12B).75 As part of the present thesis, I optimized 
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this new compound series further and carried out a part of the biological evaluation, which 
will be described in detail in the results chapters  3.1,  3.2 &,  3.3. 
 
Figure 12: A: Close up of the PIF pocket74  B: Hit compounds 
 
A                                                                        B 
 
 
 
 
 
 
 
 
 
 
The active compounds, identified in the screening, display several common structural 
features, two aromatic rings connected by a three or four atom chain with a side chain 
carrying a carboxyl function. The requirement of the carboxyl group in compound 1 was 
investigated comparing to the requirement of the phosphate on the phosphorylated HM (P-
HM) polypeptides and comparing on the methyl ester derivative of 1. PDK1 was activated by 
polypeptides P-HM but not by non P-HM. Moreover, the ester derivative was inactive. The 
physiologically achieved negative charge of the carboxyl group in I seems to mimic the 
phosphate moiety contacts. Mutation studies provided evidence that I binds to the PIF pocket 
abolishing the activation of PDK1. Mutants of the PIF pocket did not show PDK1’s activity 
decrease. Further biochemical studies of PDK1 mutants identified Gln150 and Arg131 as the 
most important residues in a sulphate binding site next to the PIF pocket that was find out 
analyzing the crystal structure of PDK1 within the comprising residues Arg131, Thr148, 
Lys76 and Gln150. In the following a series of related compounds containing chlorine 
substituents at different positions on the left phenyl moiety was synthesized and tested against 
a panel of AGC kinases. Substituents on meta and para positions are favored and increase the 
activity toward PDK1. Substituents on the ortho position and on the right phenyl moiety 
greatly decrease the compounds’ ability to activate PDK1. The intrinsic activity of the related 
AGC kinases was not affected by compound 1.  
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A docking model was built on the basis of the mode of interaction of the C-terminal 
Phe347 und Phe350 to PKA, whereas the carboxylate was positioned to achieve the 
interaction with the positive charge of Arg131 (Figure 13A). Figure 13B displays the 
mechanism of PDK1 activation caused by compound I highlighting the most important 
residues.  
 
Figure 13: A: Model for compound I docking to the PIF pocket on PDK1. B: Scheme for  
       the activation of PDK1. 74 
 
 
 
 
 
 
 
 
 
 
 
In conclusion, the results provide the evidence that low molecular weight compounds can 
modulate the conformational inactive-active transition of PDK1 by targeting the PIF pocket 
(Figure 13A & B).74 
 
1.9.2. Further PIF pocket-directed compounds referred in the literature 
       The published results of the PS group concerning the discovery of the PDK1 interacting 
fragment pocket, its regulatory properties and in particular the evidence that the PIF pocket is 
amenable to low molecular weight molecules binding, has caused interest and initiated new 
approaches to identify new allosteric modulators of PDK1. Nevertheless, our approach is a 
relatively new one from a drug discovery point of view. Only two reports including new 
strategies to identify PIF pocket-directed compounds have been published so far. Firstly, 
NMR-based fragment screening and 1H- 15N TROSY experiments have been performed by 
researcher at Pfizer Global Research and Development in order to identify selective small 
molecule modulators of PDK1.76 Stockman et al. analyzed a library of chemically diverse 
compounds in a NMR screening for fragments as an alternative to high throughput screening 
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(HTS). Thereby, the goal was to identify allosteric and ATP-competitive scaffolds exploiting 
the PIF pocket site and the ATP binding site. Three activators of PDK1 were identified 
(Figure 14) whereas these fragments activated PDK1 weakly at high concentrations. In a 
saturation transfer difference NMR experiment compound A turned out to compete ATP and 
B and C to bind at the ATP site and PIF pocket, respectively. B and C are structurally similar 
compared to compound class I. They contain also a negative charged carboxyl group but they 
differ in its position. Due to this fact they could have a distinct binding mode and need more 
characterization to be proven as PIF pocket-directed compounds. The data was generated 
through a Caliper assay and 19F NMR assay to provide evidence for the binding sites of the 
molecules A, B and C. In summary, since it is known that hits from this NMR spectroscopic 
method are weaker potent than hits from HTS, this NMR spectroscopic approach offers an 
option to identify new fragments as starting points for drug development but it does not 
provide an advance in finding high potent and specific target compounds.  
 
Figure 14: NMR-based fragment screening hits as ATP-competitive and allosteric PIF 
                  pocket modulators, respectively 
 
 
 
 
 
 
 
 
More recently, Merck Research Laboratories presented the discovery of alkaloids as PIF 
pocket specific ligands using ultrahigh throughput screenings (uHTS) TR-FRET and 
Alphascreen for lead identification.77 Therefore, a biotinylated peptide substrate (PDK1tide) 
was developed. It engages both the ATP and the PIF pocket of PDK1 pursuing a bisubstrate 
analogues strategy that is considered to identify highly selective and potent inhibitors. This 
strategy was selected with the goal to indentify both ATP-competitive inhibitors and allosteric 
ligands, since PDK1 possesses at least three ligand-binding pockets. In this screening 
campaign, alkaloid 1 was identified as a hit (Figure 15). However, the authors did not provide 
experimental evidence that the compound really targeted the PIF-binding pocket. 
Interestingly, alkaloid 1 lacks the carboxyl function. For this reason alkaloid compounds are 
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supposed to inhibit PDK1 activity in contrast to compounds including a carboxyl group 
achieving different mechanism of action.  
Thus, these results confirmed our findings that different types of small molecules and less 
diversity in structure can induce different mechanism of action of kinases, activation or 
inhibition. Testing a series of compounds against a panel of AGC kinases we were able to 
find activators and inhibitors of AGC kinases. Compounds with the scaffold of I (Figure 12B) 
proved to be potent activators of PDK1. Compound 1 (Figure 12B) served as lead structure 
for this study to design and synthesize new modulators of PDK1’s activity binding the PIF 
pocket. 
 
Figure 15: Chemical structure of alkaloid 1 
 
 
 
 
 
 
 
 
1.10. Atypical PKCs 
Protein kinase C family as a member of AGC superfamily consists of at least eleven 
related isoforms that form three subfamilies based upon the structure of their regulatory 
domains: the conventional/classical (cPKCs), the novel (nPKCs) and the atypical (aPKCs) 
PKCs (Figure 16).78 All isoforms of PKC have conserved and variable (C1, C2) domains that 
are connected by a hinge region and all of them possess a pseudosubstrate (PS) binding site. 
The C1 domain contains cysteine-rich motifs that serve as sites for diacylglycerol (DAG) and 
phorbol esters binding.79 The C2 domain serves for phospholipids binding that occur in a 
calcium-dependent manner.80 The conserved domain is composed of the ATP binding site and 
the substrate binding site and defines PKC members within the AGC kinase superfamily.10 
The activation mechanism differs between the three PKC subfamilies. 
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Figure 16: Structure of Protein Kinase C Isoforms81 
 
 
 
 
 
 
 
 
 
 
To the conventional PKCs belong PKCalpha, -beta1, -beta2 and –gamma. These enzymes 
require phosphatidylserine, diacylglycerol (DAG), phorbol esters and calcium (Ca2+) to 
become optimal activated.82  
The novel PKCs consist of the isoenzymes PKCdelta, -epsilon, -eta and -theta. They are 
not regulated by Ca2+ but can be activated by phorbol esters and DAG in the presence of 
phosphatidylserine.82 
Finally, the atypical PKCs are regulated neither by Ca2+, nor by phorbol esters and by 
DAG. The aPKCs possess in their regulatory region an atypical C1 domain, thought to 
participate in lipid binding. Therefore, the aPKCs are activated by lipid components such as 
phosphatidyl inositol, phosphatidic acids, ceramide and arachidonic acid.82 Besides the 
atypical C1 domain aPKCs possess a PB1 (Phox and Bem 1) domain, which is involved in 
protein-protein interactions, the regulation of catalytic activity and a pseudosubstrate 
domain.78 The isoforms PKCzeta (PKCζ), PKCiota (PKCι) and PKClambda (PKCλ), whereas 
PKCλ is the mouse orthologue of the human ι, belong to the atypical subfamily and display a 
strong homology among each other. In spite of a 72 % sequence homology at the amino acid 
level of PKCζ and PKCι, the recent data suggested that both kinases are not functionally 
redundant.83 Expression profiling studies have revealed that both kinases have distinct 
patterns of expression in various biological systems. PKCι/λ showed a ubiquitous expression, 
whereas PKCζ exhibited a more restricted pattern of expression. Additionally, investigations 
of the effect of genetic disruption demonstrated different effects on embryonic development 
in the mouse. Knockouts of PKCι/λ are embryonically lethal,84 whereas knockouts of PKCζ 
resulted in viable mice that exhibit immunological deficiencies in the NF-κB (nuclear factor 
kappa B) pathway.83, 85 Moreover, PKCζ and PKCι/λ are integrated in distinct downstream 
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signaling pathways. With further experiments it has been shown that PKCζ rather than 
PKCι/λ is involved in the NF-κB pathway by phosphorylation of Ser311 of the RelA 
subunit.86, 87 Using PKCζ– or PKCι –deficient mouse embryo fibroblasts from knockouts of 
PKCζ and PKCι/λ, the PKCζ deficient fibroblasts exhibited defects in the NF-κB signaling 
and PKCι deficient fibroblasts did not.85-87 Besides, recently Levy et al. succeeded in 
providing evidence on a previously uncharacterized mechanism of the NF-κB regulation. The 
study revealed a contrariwise role of the phosphorylated Ser311 residue in the NF-κB 
pathway. The phosphorylation of Ser311 by PKCζ abolished the binding of histone 
methyltransferase GLP to the RelA subunit and disrupted the following GLP-mediated 
methylation of histone H3 enabling NF-κB to become transcriptionally active. Consequently, 
PKCζ acquires a critical role as mediator of the chromatin changes necessary for effective 
NF-κB target gene expression.88, 89  
 
1.11. PKCζ as drug target 
The knockout study, described above, gives evidence that PKCζ plays a critical role in the 
activation of the eukaryotic transcription factor NF-κB. Several more studies demonstrated 
additionally PKCζ’s involvement in the activation of NF-κB in cell types and organs such as 
B-cells, T helper cells, T lymphocytes, lung and liver but not in muscles.90-94  
NF-κB is composed of several related transcription factors: p50, p52, RelA (p65), c-Rel 
and RelB and plays an important role in the immune system. NF-κB regulates genes 
controlling of the immune system, apoptosis, cell growth and tissue differentiation.17, 95, 96 The 
essential function of NF-κB is to prevent the TNFalpha-induced cell death. There are two 
signaling pathways leading to the activation of NF-κB dimers, the canonical pathway and the 
non-canonical pathway.97-100 In both cascades TNFalpha or other pro-inflammatory cytokines 
stimulate the activation of the IKK complex. In this thesis the focus is directed to the 
canonical pathway as it includes PKCζ in its transductional regulation. In the canonical 
pathway the activation of NF-κB dimmers, a complex of p50 and ReIA (Figure 17), occurs 
due to IKK-mediated and due to PKCζ-mediated phosphorylation of IκB.101, 102 
Phosphorylated IκB proteins lead to their subsequent proteasomal degradation enabling the 
active NF-κB dimer to translocate into the nucleus and induce the anti-apoptotic target gene 
expression. 
 
                                                                                                                                   Introduction 
 
 25 
Figure 17: NF-κB activation: the canonical pathway 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The binding of TNFalpha to the receptor TNFR leads to the recruitment and activation of the IKK complex 
comprising IKKalpha, IKKbeta, NEMO and ELKS. The IKK complex then phosphorylates IκB, and PKCζ 
phosphorylates the subunit ReIA leading to degradation by the proteasome. Finally NF-κB translocates to the 
nucleus to activate target genes. 
 
 
Considered together the transcription factor NF-κB and consequently PKCζ play 
fundamental role in immune and inflammatory responses. Not surprisingly, constitutive 
activation of NF-κB is implicated in several disease conditions including inflammatory 
disorders and autoimmune diseases as well as in some forms of cancer, such as leukemia, 
lymphoma, colon cancer and ovarian cancer.103 Since PKCζ is a molecular switch in this 
signal transduction, it represents an interesting and important target for the development of 
novel therapeutics to treat the corresponding diseases. In particular, PKCζ may provide a 
specific therapeutic target for the prevention of these diseases because direct inhibition of NF-
κB will cause toxicity due to the protective role of NF-κB in all cells and tissues.104, 105 
Moreover, further studies suggested that atypical PKCζ is required for chemotaxis in various 
cancer cell lines, such as breast, lung and leukemia cell lines. These results indicate that 
targeting PKCζ may emerge as an effective method for blocking both, cancer cell chemotaxis 
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and tumor associated immune responses. Although in oncology the target validation studies 
have mainly been focused on the other atypical PKC isoforms PKCι so far, the literature 
generated an oncogenic role of PKCζ. Immunoblotting experiments with the human 
lymphoma cell line U937 demonstrated that PKCζ takes a central position in the TNFalpha-
induced pathway. The TNFalpha mediated activation of NF-κB in U937 cells resulted in 
enhanced PKCζ phosphorylation and activation and in the following transcription of anti-
apoptotic genes by NF-κB.106 The tumor cell response to chemotherapeutics and cytokines 
was examined by Filomenco et al. in 2002 expressing stably kinase-dead and dominant 
negative PKCζ mutant in U937 cells. The results revealed that PKCζ inhibition by etoposide, 
an anti-cancer chemotherapy drug, led to acceleration of apoptosis in leukemic cells. 
Moreover, the etoposide-influenced inhibition of PKCζ led to a sensitization of cells growth 
in nude mice.107 
Some more studies demonstrated that PKCζ phosphorylates further substrates that are 
involved in the regulation of apoptosis. De Thonel et al. investigated the role of PKCζ in 
immature myeloid KG1a leukemic cells. The study revealed PKCζ as a regulator of Fas cell 
death signaling showing a resistant effect on Fas-induced apoptosis.108 The role of PKCζ 
regulating apoptosis is also supported by the study of Bezombes et al. demonstrating that 
overexpression of PKCζ in U937 confers resistance daunorubicin and 1-ß-D-
arabinofuranosylcytosine. These drugs are used for the therapy of acute myeloblastic 
leukemia.109 
Summing up, the literature data shed light on PKCζ as a clear target for the development 
of potent drugs with antileukemic effect and for treatment of inflammatory diseases. 
However, PKCζ regulates additionally the insulin-stimulated glucose transport in muscle and 
adipose tissues.110, 111 Skeletal muscle and adipocytes express the major transporter GLUT4 
and require insulin for glucose uptake. Binding of insulin to receptors leads to translocation of 
glucose transporters from the cytoplasm into plasma membrane, allowing glucose to enter the 
cell. Defects of the insulin action lead to insulin resistance that is manifested by decreased 
glucose uptake and subsequently to diabetes type-2.110, 111 PKCζ acts as a transducer protein 
of glucose transport in response to activated PI3K via interaction with insulin receptor 
substrates (IRS). Activation of PKCζ could trigger the signal transduction leading to GLUT4 
translocation and glucose transport into the cell. Thus, the inactivation of this enzyme might 
lead to hyperglycaemia and to insulin resistance.111 Indeed, Lee et al. presented in a recent 
study in vivo experiments using PKCζ/IL-6 double-knockout mice that indicate PKCζ 
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ablation in non-hematopoetic cells but not in the hematopoietic system was sufficient to drive 
inflammation and IL-6 synthesis in the adipose tissue, as well as insulin resistance.112 
However, it should be taken into account that knockout studies cannot be compared well 
with the situation where an enzyme is inhibited by a small molecule drug. It can be expected 
that inhibition by a drug, which happens part-time and too less than 100 %, will not have the 
same detrimental side effect than a complete knockout of PKCζ. Therefore, the final 
validation of PKCζ as a target can best be done with a suitable small molecule inhibitor. 
 
1.12. Inhibitors of PKCζ 
PKC kinases as a pleiotropic family regulate various cellular processes in multiple cell 
signaling pathways including proliferation, glucose metabolism, differentiation, cell survival 
and apoptosis. Elevated level of the particular isoforms were found in various cancer forms, 
such as breast, lung, liver, colon and prostate cancer as well as hematopoietic lymphomas and 
leukemias.113, 114 However, the biological functions of each PKC isoforms differ in their 
action of the tumor progression. For this reason investigations on selective PKC inhibitors 
have attracted great attention during the last years in order to develop potential anti PKC 
agents. Several inhibitory compounds with large structural variety and with different 
mechanisms of inhibition have been proposed.115, 116 Promising examples entered already 
clinical trials for several human cancers. Among others, Enzastaurin (LY317615), 
Midostaurin, Bryostatin, Safingol and ISIS 3521 (Figure 18) have been conducted in clinical 
studies. 
Enzastaurin and Midostaurin derived from optimization approaches of Staurosporine to 
achieve more selective analogues for clinical trials. Staurosporine was discovered in a 
screening for PKC inhibitors117 and showed good inhibition of PKC in in vitro models.118 
Staurosporine’s poor selectivity has not been hampered further clinical developments to find 
analogues with more specificity for PKC isoforms and other kinases as it shows nanomolar 
activity against many protein kinases. Enzastaurin was described first as a selective inhibitor 
of PKCβ but afterwards it showed also an inhibitory effect toward PKCε. Enzastaurin entered 
the Phase III clinical trials and turned out to be applicable for different type of cancer. 
Midostaurin was originally proposed as an inhibitor of multiple isoforms of PKC but it turned 
out as a multi kinase inhibitor. Midostaurin showed also inhibition effects toward Kit, FLT3, 
VEGFR and PDGFR.116 In clinical studies Midostaurin entered Phase II and has been tested in 
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combination with other chemotherapeutics. Enzastaurin and Midostaurin are competitive 
inhibitors binding the ATP binding site (Table 2).116 
 
Figure 18: Structures of the PKC inhibitors Enzastaurin, Midostaurin, Bryostatin and  
   Safingol 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Some examples of PKC inhibitors in clinical trials.116 
 
 
 
The naturally occurring macrocyclic lactone Bryostatin targets the regulatory phorbol 
ester receptor which means the DAG binding pocket of cPKCs and nPKCs and induces the 
inhibition of the corresponding PKCs.119 Furthermore, it inhibits phorbol ester induced 
tumorgenesis and differentiation of leukaemia cells.120, 121 Clinical studies were conducted 
with Bryostatin with disappointing results due to dose-limiting toxicity and were discontinued 
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Enzastaurin PKCβ ATP binding site 
competitive 
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(Table 2).116 Safingol, a synthetic drug displayed low efficacy and was discontinued already 
in Phase I of the clinical trials (Table 2).  
To summarize, these examples discussed here reached clinical trials but they display 
relatively poor target selectivity related to one isoforms of the PKC family. This is attributed 
to structural conservation of ATP binding sites of the PKC isoenzymes. Therefore, most of 
the PKC targeting compounds cross-react with other kinases. However, it has been 
challenging to find specific kinase inhibitors due to the high degree of homology in the ATP 
binding site pocket between the 11 PKC isoforms. An additional challenge in finding a 
selective inhibitor of PKCζ constitutes the closest homologue PKCι form. Although several 
attempts were made to develop compounds able to inhibit selectively PKCζ and several 
inhibitors were referred to as selective, the approaches failed in finding a truly selective and 
effective target molecule. The so-called PKCζ selective inhibitors have been identified by 
screening libraries and natural compound resources. We will focus the attention on three 
recently published compound classes. These include PKCzI257.3 (N-(4-
((dimethylamino)methyl)benzyl)-1H-pyrrole-2-carboxamide)122, Hydroxyphenyl-benzopyran-
4-ones123 and 2-(6-Phenyl-1H-indazol-3-yl)-1H-benzo[d]imidazoles (Figure 19). 124 
PKCzI257.3 was screened out from a compound library including two hundred compounds in 
a substrate-specific strategy with an IC50 of 28 µM. N-(4-((dimethylamino)methyl)benzyl)-
1H-pyrrole-2-carboxamide exhibits a small molecule nature contrary to the widely employed 
peptide pseudo-substrates. This inhibitor prevents the EGF induced breast cancer cell 
chemotaxis and migration. The specificity of the compound was evaluated only against PKCα 
whereby there are no data available about the selectivity toward the most closely related 
PKCι.122 Yuan et al. identified in a screening including a library with structurally diverse 
heterocyclic compounds hydroxyphenyl-1-benzopyran-4-ones as inhibitors of PKCζ 
enzymatic activity. The isoforms selectivity was investigated with a panel of kinases using a 
Millipore kinase profiler.123 This class of compounds was proved as selective only compared 
with classical or novel PKCs without details about the specificity toward PKCι. In an 
optimization effort Trujillo et al. identified a potent and PKC isoform selective compound 
class of 2-(6-Phenyl-1H-indazol-3-yl)-1H-benzo[d]imidazoles (Figure 19) starting with 6-
phenyl-3-benzimidazole. The most active analogue showed a good activity against PKCζ and 
CDK-2, but it turned out to be a moderately potent across the range of other kinases which is 
another hardly manageable feature of compounds targeting the ATP-binding site.124 Thus, 
there are no truly PKCζ−selective inhibitors described in the literature so far. 
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Figure 19: Structures of PKCζ inhibitors.122-124 
 
 
 
 
 
 
 
 
 
 
 
1.13. Allosteric approach to inhibit PKCζ 
Despite a lot of efforts have been directed at finding selective ATP-competitive PKCζ 
inhibitors, a marginal success was achieved. In recent years the trend is toward non-ATP site-
directed approaches as they provide an alternative strategy to find highly specific kinase 
inhibitors.7, 125 An alternative mechanism for the non ATP-competitive inhibition exhibits 
allosteric one. This is indicated not least by the fact that the allosteric site is less conserved as 
the ATP binding site. Additionally, the inhibition of allosteric sites stabilizes the inactive 
conformation of the kinase. Moreover, the development of resistance to kinase inhibitor 
therapy due to mutation in the ATP binding site that is known with ATP-competitive 
inhibitors can be prevented by an allosteric inhibitor.  
As already precisely described in chapter  1.7 we suggested the PIF pocket that is situated 
on the catalytic domain of the AGC protein kinase family as an allosteric targeting site for the 
development of allosteric inhibitors. Based on the example of PDK1 it is shown, the binding 
of the C-terminal peptide motif of substrate proteins provokes an allosteric activation of the 
catalytic activity of PDK1. In case of PKCs and other substrate kinases the hydrophobic motif 
on the C-terminus binds intramolecular in the PIF pocket of the appropriate kinase (Figure 6) 
stabilizing the active structure. In our previous work we were able to show that by binding to 
this site, small weight molecules could prompt allosteric conformational changes affecting the 
activity of PDK1. Thus the small weight molecules mimic the activatory effects of the natural 
peptide ligands, the phosphorylated hydrophobic motif (HM) peptides, in the catalytic 
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domain. The PIF pocket is limited to about 60 AGC kinases and is less conserved with amino 
acids than the ATP binding site. In comparison to other PKC isoenzymes PKCζ exhibits six 
different PIF pocket residues (Figure 20). This fact suggests that the development of PIF 
pocket-directed compounds could result in a specific compound toward PKCζ without 
influencing the activity of any other PKC isoenzyme and other AGC members. Thus, the 
variability of the PIF pocket within the AGC family may enable selectivity. 
 
Figure 20: Alignment of the amino acid sequences of representatives from all PKC 
subfamilies (cPKCs: alpha, beta, nPKCs: delta, theta, epsilon and aPKCs: iota and zeta) and 
PDK1. 
 
                       430       440       450       460       470       480 
                         |         |         |         |         |         | 
PDK1            MDGTAAEPRPG--------------------------------AGSLQHAQPPPQPRKKR 
PKCalpha        NQEEGEYYNVPIPEGDEEGNMELRQKFEKAKLGPAGN---KVISPSEDRKQPSNNLDRVK 
PKCbeta         SQEEGEYFNVPVPPEGSEANEELRQKFERAKISQGTKVPEEKTTNTVSKFDNNGNRDRMK 
PKCdelta        -DNSGTYGK---------------------------------IWEGSS---------KCN 
PKCtheta        -DEVDKMCH---------------------------------LPEPELNKERPSLQIKLK 
PKCepsilon      -DNRGEEHRAASSPDG------------------------QLMSPGENGEVRQGQAKRLG 
PKCiota         -DQVGEE-K-----------------------------------EAMNTRESGKASSSLG 
PKCzeta         -KDDSEDLK-----------------------------------PVIDGMDGIKISQGLG 
 
                       490       500       510       520       530       540 
                         |         |         |         |         |         | 
PDK1            PEDFKFGKILGEGSFSTVVLARELATSREYAIKILEKRHIIKENKVPYVTRERDVMSRL- 
PKCalpha        LTDFNFLMVLGKGSFGKVMLADRKGTEELYAIKILKKDVVIQDDDVECTMVEKRVLALLD 
PKCbeta         LTDFNFLMVLGKGSFGKVMLSERKGTDELYAVKILKKDVVIQDDDVECTMVEKRVLALPG 
PKCdelta        INNFIFHKVLGKGSFGKVLLGELKGRGEYFAIKALKKDVVLIDDDVECTMVEKRVLTLAA 
PKCtheta        IEDFILHKMLGKGSFGKVFLAEFKKTNQFFAIKALKKDVVLMDDDVECTMVEKRVLSLAW 
PKCepsilon      LDEFNFIKVLGKGSFGKVMLAELKGKDEVYAVKVLKKDVILQDDDVDCTMTEKRILALAR 
PKCiota         LQDFDLLRVIGRGSYAKVLLVRLKKTDRIYAMKVVKKELVNDDEDIDWVQTEKHVFEQAS 
PKCzeta         LQDFDLIRVIGRGSYAKVLLVRLKKNDQIYAMKVVKKELVHDDEDIDWVQTEKHVFEQAS 
 
                       550       560       570       580       590       600 
                         |         |         |         |         |         | 
PDK1            DHPFFVKLYFTFQDDEKLYFGLSYAKNGELLKYIRKIGSFDETCTRFYTAEIVSALEYLH 
PKCalpha        KPPFLTQLHSCFQTVDRLYFVMEYVNGGDLMYHIQQVGKFKEPQAVFYAAEISIGLFFLH 
PKCbeta         KPPFLTQLHSCFQTMDRLYFVMEYVNGGDLMYHIQQVGRFKEPHAVFYAAEIAIGLFFLQ 
PKCdelta        ENPFLTHLICTFQTKDHLFFVMEFLNGGDLMYHIQDKGRFELYRATFYAAEIMCGLQFLH 
PKCtheta        EHPFLTHMFCTFQTKENLFFVMEYLNGGDLMYHIQSCHKFDLSRATFYAAEIILGLQFLH 
PKCepsilon      KHPYLTQLYCCFQTKDRLFFVMEYVNGGDLMFQIQRSRKFDEPRSRFYAAEVTSALMFLH 
PKCiota         NHPFLVGLHSCFQTESRLFFVIEYVNGGDLMFHMQRQRKLPEEHARFYSAEISLALNYLH 
PKCzeta         SNPFLVGLHSCFQTTSRLFLVIEYVNGGDLMFHMQRQRKLPEEHARFYAAEICIALNFLH 
 
                       610       620       630       640       650       660 
                         |         |         |         |         |         | 
PDK1            GKGIIHRDLKPENILLNEDMHIQITDFGTAKVLSPESKQARANSFVGTAQYVSPELLTEK 
PKCalpha        KRGIIYRDLKLDNVMLDSEGHIKIADFGMCK--EHMMDGVTTRTFCGTPDYIAPEIIAYQ 
PKCbeta         SKGIIYRDLKLDNVMLDSEGHIKIADFGMCK--ENIWDGVTTKTFCGTPDYIAPEIIAYQ 
PKCdelta        SKGIIYRDLKLDNVLLDRDGHIKIADFGMCK--ENIFGESRASTFCGTPDYIAPEILQGL 
PKCtheta        SKGIVYRDLKLDNILLDKDGHIKIADFGMCK--ENMLGDAKTNTFCGTPDYIAPEILLGQ 
PKCepsilon      QHGVIYRDLKLDNILLDAEGHCKLADFGMCK--EGILNGVTTTTFCGTPDYIAPEILQEL 
PKCiota         ERGIIYRDLKLDNVLLDSEGHIKLTDYGMCK--EGLRPGDTTSTFCGTPNYIAPEILRGE 
PKCzeta         ERGIIYRDLKLDNVLLDADGHIKLTDYGMCK--EGLGPGDTTSTFCGTPNYIAPEILRGE 
 
 
                       670       680       690       700       710       720 
                         |         |         |         |         |         | 
PDK1            SACKSSDLWALGCIIYQLVAGLPPFR---------AGNEYLIFQKIIKLEYDFPEKFFPK 
PKCalpha        PYGKSVDWWAYGVLLYEMLAGQPPFD---------GEDEDELFQSIMEHNVSYPKSLSKE 
PKCbeta         PYGKSVDWWAFGVLLYEMLAGQAPFE---------GEDEDELFQSIMEHNVAYPKSMSKE 
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PKCdelta        KYTFSVDWWSFGVLLYEMLIGQSPFH---------GDDEDELFESIRVDTPHYPRWITKE 
PKCtheta        KYNHSVDWWSFGVLLYEMLIGQSPFH---------GQDEEELFHSIRMDNPFYPRWLEKE 
PKCepsilon      EYGPSVDWWALGVLMYEMMAGQPPFE---------ADNEDDLFESILHDDVLYPVWLSKE 
PKCiota         DYGFSVDWWALGVLMFEMMAGRSPFDIVGSSDNPDQNTEDYLFQVILEKQIRIPRSLSVK 
PKCzeta         EYGFSVDWWALGVLMFEMMAGRSPFDII--TDNPDMNTEDYLFQVILEKPIRIPRFLSVK 
 
                       730       740       750       760       770       780 
                         |         |         |         |         |         | 
PDK1            ARDLVEKLLVLDATKRLGCEEM-EGYGPLKAHPFFESVTWENLHQQTPPKLTAYLPAMSE 
PKCalpha        AVSICKGLMTKHPAKRLGCGPE--GERDVREHAFFRRIDWEKLENR---EIQPPFKPKVC 
PKCbeta         AVAICKGLMTKHPGKRLGCGPE--GERDIKEHAFFRYIDWEKLERK---EIQPPYKPKAR 
PKCdelta        SKDILEKLFEREPTKRLGVTGN------IKIHPFFKTINWTLLEKR---RLEPPFRPKVK 
PKCtheta        AKDLLVKLFVREPEKRLGVRGD------IRQHPLFREINWEELERK---EIDPPFRPKVK 
PKCepsilon      AVSILKAFMTKNPHKRLGCVASQNGEDAIKQHPFFKEIDWVLLEQK---KIKPPFKPRIK 
PKCiota         AASVLKSFLNKDPKERLGCHPQ-TGFADIQGHPFFRNVDWDMMEQK---QVVPPFKPNIS 
PKCzeta         ASHVLKGFLNKDPKERLGCRPQ-TGFSDIKSHAFFRSIDWDLLEKK---QALPPFQPQIT 
 
                       790       800       810       820       830       840 
                         |         |         |         |         |         | 
PDK1            DDEDCYGNYDNLLSQFGCMQVSSSSSSHSLSASDTGLPQRSGSNIEQYIHDLDSNSFELD 
PKCalpha        GK-GAENFDKFFTRGQPVLTPPDQLVIANIDQSDFEGFSYVNPQFVHPILQSAV------ 
PKCbeta         DKRDTSNFDKEFTRQPVELTPTDKLFIMNLDQNEFAGFSYTNPEFVINV----------- 
PKCdelta        SPRDYSNFDQEFLNEKARLSYSDKNLIDSMDQSAFAGFSFVNPKFEHLLED--------- 
PKCtheta        SPFDCSNFDKEFLNEKPRLSFADRALINSMDQNMFRNFSFMNPGMERLIS---------- 
PKCepsilon      TKRDVNNFDQDFTREEPVLTLVDEAIVKQINQEEFKGFSYFGEDLMP------------- 
PKCiota         GEFGLDNFDSQFTNEPVQLTPDDDDIVRKIDQSEFEGFEYINPLLMSAEECV-------- 
PKCzeta         DDYGLDNFDTQFTSEPVQLTPDDEDAIKRIDQSEFEGFEYINPLLLSTEESV-------- 
 
 
The PIF pocket residues of the individual protein kinases are displayed in yellow. The residues labelled in red 
are specific for PKCiota and PKCzeta. The blue labelled residues represent the highly conserved ATP binding site 
and the grey residues belong to the hydrophobic motif including the phosphorylatable rest ( = intramolecular 
ligand of the PIF pocket). The numbering is based upon the PKCepsilon. 
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2 Aim and work strategy of the present study 
2.1. Scientific objective 
The first kinase drug imatinib mesylate (“Gleevec®”) was introduced in US in 2001 and 
set the stage for protein kinases as drug targets. It was followed by several other small 
molecule kinase inhibitors that were launched, primarily for oncology application. However, 
protein kinase drug developments are still hampered by severe problems in the development 
of specific compounds. The reason for the lack of specificity is that most compounds target 
the ATP binding site, which is a relatively conserved site in the over 500 protein kinases 
encoded by the human genome. As an alternative to the ATP binding site-directed approach 
the interest has been increased in non ATP-competitive strategy to yield highly potent and 
specific drugs for protein kinases and to prevent side effects. Most interestingly, the 
characterization of novel allosteric sites as drugable sites might enable the development of 
drugs with more subtle modulation of the protein kinase activity as compared to the complete 
inhibition of the enzymatic activity. Since aberrant activation of the PI3K/PDK1 signaling 
pathway is associated with diseases such as cancer and diabetes, compounds that modulate the 
PDK1 activity gained interest to be useful as therapeutic agents.  
With the discovery of the PIF pocket as an allosteric regulatory site between PDK1 and its 
substrates, we have provided a specific and selective control in the PI3K signaling 
transduction. Consequently, we suggested a novel pharmacological approach using the PIF 
pocket in PDK1 as a target site for small compounds in order to inhibit the phosphorylation of 
these substrates that require interaction with the PIF pocket. Hence, compounds directed to 
the PIF pocket are predicted to have more specificity. Actually, we were able to provide 
evidence that small drug like molecules can trigger activation of PDK1 binding the PIF 
pocket. In our initial work we identified hit compound classes (I and II, Figure 21) that 
modulate the PDK1 activity. These compounds display several common structural features: 
non polar bicyclic scaffold with non polar substituents and a polar side chain carrying a 
carboxyl function. Based on these results our group synthesized a series of compounds, 
comprising variations of substituents, extensions of the structure and ring variations to 
investigate the structure activity relationships (SAR). 
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Figure 21: Hit compounds identified in a virtual screening 
 
 
 
 
 
 
 
 
 
 
 
  
 
The final goals of this thesis were: 
1) to develop small molecule compounds which act via an allosteric mode by binding 
to the PIF pocket, 
2) to optimize selectivity for PDK1 but potentially also for the atyplical Protein kinase 
C isoform PKCζ, which belongs to the same subfamily of AGC protein kinases, 
and  
3) to increase potency of allosteric modulators directed to the PIF pocket of PDK1 to 
the nanomolar range. This goal was important to demonstrate druggability of the 
PIF pocket. 
 
2.2. General concept to design allosteric modulators of PDK1 and 
PKCζ 
One of the present thesis aims was to optimize the hit compound 174 (Figure 21) by 
targeted structural modifications in order to enhance the potency and selectivity and to 
evaluate the binding mechanism of the compounds with the enzyme. The focus was directed 
to overcome the structural drawbacks of 1, especially the existence of the chiral centre 
yielding a racemic mixture that needs more effort to isolate the active enantiomer and the 
sulfanyl moiety that can undergo oxidations and retro Michael reactions. Moreover, due to the 
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low affinity this compound class rendered further studies difficult. The docking model 
presented in Figure 13 served as starting point for the development of further small 
compounds targeting the PIF pocket of the AGC kinases. Already during my diploma thesis I 
was able to synthesize a new potent allosteric modulator III75 (Figure 21).  
The working strategy used in this thesis is depicted in the following scheme (Scheme 1). 
Starting point is the molecular design of potential modulators of PDK1 and PKCζ, based on 
the hit compound 1, followed by the synthesis considering the minimal structural 
requirements for compounds to bind to the PIF-binding pocket and the evaluation of the 
biological activity and selectivity of the compounds.  
 
Scheme 1: Design concept of allosteric modulators of PDK1 and PKCζ,ι 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As long as there was no cocrystal structure available, the rational design was performed 
based on molecular modelling supported by biochemical analysis of the effect of the 
compounds on protein kinases which are mutated in residues within the PIF pocket. In order 
to measure the effect of the synthesized compounds on the PDK1 catalytic activity we 
performed a radioactive kinase activity assay employing T308tide, a peptide derived from the 
activation loop of PKB, as a substrate. In order to characterize biochemically the binding site 
we compared the ability of the compounds to activate wildtype PDK1 versus PDK1 proteins 
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mutated within the PIF-binding pocket. Moreover, we studied the specificity of the 
compounds toward a panel of AGC kinase. To elucidate relationships between structural 
properties, binding affinity and allosteric activation we performed isothermal titration 
calorimetry experiments with selected compounds. Obtaining first novel PIF-binding pocket-
directed compounds with higher potency, we were also able in collaboration with the Institute 
Pasteur (Paris) to cocrystallize PDK1 with the compound and we could use the X-Ray 
analysis results for further improvement of the affinity of the compounds to the PIF pocket. 
Having these results we were able to gain insight into binding mode of the compounds and the 
molecular mechanism underlying the allosteric activation. 
The following traditional medicinal chemistry strategies were employed to optimize the 
new hit compound III: 
    ▪ Variation of the ring substituents 
    ▪ Extension of the structure 
    ▪ Rigidification 
Verifying the ring substituents and their position at the phenyl moiety we wanted to evaluate 
the most favourable derivatization model for further search of more active compounds. 
Moreover, the focus was on additional H-bonding interactions of the mostly hydrophobic PIF 
pocket. Furthermore, the extension of the allosteric modulator structures aimed with a special 
interest to find out when the maximum of the PIF pocket is filled out keeping good potency of 
the compounds. The rigidification strategy also served to investigate the structural features of 
the target site with regard to optimization of the target molecules.   
First we designed 3,5-diphenylpent-2-enoic acids (Scheme 2) as new structural analogues 
containing a double bond as replacement of the chiral centre of the lead compound I where 
the combination of two sp3 and one sp2 hybridized C-atoms in the chain connecting the 
benzene rings is retained. Additionally, by introducing a shorter olefinic carboxyl side chain 
we wanted to reduce the total number of rotatable bonds. Moreover, we replaced the A-phenyl 
moiety with other aromatic systems and we introduced polar ether groups in the backbone 
chain. Furthermore, we planned to prepare cyclized chalcones and we inserted fused 
heterocycles to the carbon chain to create more scaffold rigidity. Isothermal titration 
calorimetry experiments were performed to evaluate the affinity of the compounds to the PIF 
pocket of PDK1. 
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Scheme 2: General structures 
 
 
 
 
 
 
 
 
 
 
 
 
On the basis of the biological and the SAR results of the 3,5-diphenylpent-2-enoic acids 
and exploiting the cocrystal structure we designed a chimeric compound for further 
improvement of the potency toward PDK1. We combined the carbonyl function from the lead 
compound 1 with the short side chain from compound III (Scheme 3). In addition, we planned 
to introduce a second carboxyl function, to vary the substituents on the phenyl moieties and to 
replace the phenyl residues by different aromatic systems. Moreover, we changed the 
dicarboxylic functionality into the corresponding bisacetoxymethyl ester derivatives to 
convert the 2-(3-oxo-1,3-diphenylpropyl)malonic acids into prodrugs to enhance their 
bioavailability.  
 
Scheme 3: General structures 
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The malonic moiety of the 2-(3-oxo-1,3-diphenylpropyl)malonic acids provided 
additionally a synthetic access to another substance class, the corresponding monoacid 
derivatives. A comparison with the corresponding 2-(3-oxo-1,3-diphenylpropyl)malonic acids 
can shed light on the significance of the polar moiety. 
Additionally, in order to extend the first approach that is outlined above we evaluated the 
role of the phenyl moiety B of compound III (Scheme 4) because we found that those bigger 
residues on this position lead to an inhibitory effect on the PKCζ activity. Thereby we 
introduced different aromatic residues and investigated their influence on PKCζ  activity. 
 
Scheme 4: General structures 
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3 Results 
3.1. Synthesis, structure-activity relationships and thermodynamic 
characterization of 3,5-diphenlypent-2-enoic acids as allosteric 
activators of the protein kinase PDK1 
3.1.1. Scientific rationale 
As explained in the introduction (chapter  1.8), allosteric inhibitors might represent a 
superior alternative to the traditional ATP-competitive drugs, also because they might allow a 
more subtle modulation of the protein kinase activity provides the allosteric inhibition.7 In this 
regard, by characterizing the molecular mechanism of regulation of PDK1 and discovering of 
the PIF pocket we provided a novel allosteric drugable site. Actually, we were able to develop 
first small molecule compounds that can trigger the PDK1 activity in vitro by interaction with 
the PIF pocket. Thereby the PIF pocket-directed compounds could potentially generate 
inhibitors but also protein kinase activating drugs. 
 
Figure 22: Structures of the hit compound 1 and the new lead compound 2Z 
 
 
 
 
 
                                     1 (AC50 = 25 µM)                                        2Z 
 
 
Compound 1 (Figure 22) was identified as an activator of PDK1 with an AC50 of 25 µM.74 
We used the structure as starting point in an effort to synthesize more potent and selective 
compounds using structure based drug design. In the following we describe the structure 
refinements of 1 that led to a novel series of 3,5-diarylpent-2-enoic acids as PIF-binding 
pocket-directed compounds, their SAR data on their allosteric activation potency and as well 
as the binding energetics of allosteric activators. Using isothermal titration calorimetry (ITC) 
we shed light on relationships between structural properties, binding affinity and allosteric 
activation. Moreover, presenting the cocrystal structure of compound 2Z with PDK1 we 
discuss the general requirements for HM/PIF-binding pocket compounds. With the obtained 
O
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S
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cocrystal structure we were also able to elucidate the allosteric mechanism changes of PDK1 
induced by the 3,5-diarylpent-2-enoic acids that are normally triggered by binding of 
phosphorylated HM motifs. 126 
 
3.1.2. Synthesis 
     The optimization approach was focused on two general changes of compound 1 to gain the 
target molecules more drug-like. Firstly, the chiral centre should be replaced to circumvent a 
racemic mixture with unknown contribution of each enantiomer to the total activity. 
Secondly, analogues should lack the sulfanyl moiety, which is prone to oxidations and 
potentially retro-Michael reactions. The design of the new structural analogues, 3,5-
diarylpent-2-enoic acids, resulted at replacement of the chiral centre by a double bond while 
retaining the combination of two sp3 and one sp2 hybridized C-atoms in the chain connecting 
the benzene rings, thus leading to compound 2Z (Figure 22). 
Syntheses of 2 and analogues 3-17 started with a Claisen-Schmitt condensation (Method 
A) between acetophenone and a series of benzaldehydes 2d-17d to obtain the chalcones 2c-
17c (Scheme 5). To selectively reduce the conjugated double bond of the chalcones we 
utilized a convenient hydride transfer reaction (Method B) from 3,5-bis(ethoxycarbonyl)-1,4-
dihydro-2,6-dimethylpyridine (HEH) catalyzed by silica gel,127 which quantitatively afforded 
the saturated ketones 2b-17b. In order to perform the reaction we had first to synthesize the 
reducing agent.128 The synthesis of Hantzsch-1,4-dihydropyridines we performed under 
microwave irridation, whereas ethylacetate, formaldehyde and ammonium acetate reacted at a 
rate of 2:1:1. Olefination of the carbonyl group in 2b-17b was achieved by Horner-
Wadsworth-Emmons reaction (HWE) (Method C) with triethyl phosphonoacetate, yielding 
E/Z-mixtures of ethyl 3,5-diphenylpent-2-enoates (2a-17a, Scheme 5) which could be 
efficiently separated by flash column chromatography in all cases. We intentionally chose the 
reaction conditions to favour formation of both stereoisomers in order to isolate both 
compounds and test them separately. In the last step the ethyl ester was hydrolyzed (Method 
D) under basic conditions to yield the free 3,5-diphenylpent-2-enoic acids (2E -17E, 2Z -
17Z). All these synthesis steps containing the corresponding reaction mechanisms are already 
described in the diploma thesis for compound 2Z.20, 75 
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Scheme 5a: Synthesis of compounds 2E-17E, 2Z-17Z 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a: (i) Method A: NaOH, EtOH, 1 h, rt; (ii) piperidine, EtOH, reflux, 16 h; (iii) Method B: 3,5-
bis(ethoxycarbonyl)-1,4-dihydro-2,6-dimethylpyridine, toluene, silica gel, 70 °C, 16 h;  (iv) Method C: triethyl 
phosphonoacetate, NaH, DME, 80 °C, 4 h; (v) Method D: NaOH, EtOH, rt, 3 h. For substituents R see Table 3, 
Table 4 and Table 5. 
 
 
An even more rigid, cyclized analogue 25E was prepared by condensation of 4-
chlorobenzaldehyde 2d with 1-indanone, reduction of the resulting cyclized chalcone, HWE 
reaction, and subsequent ester hydrolysis (Scheme 6). 25E was isolated as diastereomeric 
mixture exclusively in the (E)-form. 
 
Scheme 6a: Synthesis of 25E 
 
 
 
 
 
a: (i) Method A: NaOH, EtOH, 1 h, rt; (iii) Method B: 3,5-bis(ethoxycarbonyl)-1,4-dihydro-2,6-
dimethylpyridine, toluene, silica gel, 70 °C, 16 h; (iv) Method C: triethyl phosphonoacetate, NaH, DME, 80 °C, 
4 h; (v) Method D: NaOH, EtOH, rt, 3 h.  
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In another subset of compounds we replaced the ring A benzylic methylene by oxygen or 
sulphur. The strategy for the synthesis of these hetero analogues of 2Z is illustrated in Scheme 
7. Bromoacetophenone was subjected to an SN reaction with 4-chlorophenol 18c and 4-
chlorophenyl mercaptane 19c, respectively, to yield 2-(4-chlorophenoxy)acetophenone 18b 
and 2-(4-chlorophenylthio)acetophenone 19b. The final compounds, (E)- and (Z)-4-(4-
chlorophenoxy)-(18E, 18Z) and (E)-4-(4-chlorophenylthio)-3-phenylbut-2-enoic acid (19E), 
were obtained via HWE reaction (Method C) and hydrolysis (Method D) analogously to the 
3,5-diphenylpentenoic acids. 
 
Scheme 7a: Synthesis of compounds 18E, 18Z and 19E 
 
 
 
 
 
 
 
 
 
 
 
a: reagents and conditions: (i) K2CO3, EtOH, 80 °C, 1 h; (ii) 5 % BnNEt3Cl, 30 % NaOH, CH2Cl2, rt, 16 h; (iii) 
Method C: triethyl phosphonoacetate, NaH, DME, 80 °C, 4 h; (iv) Method D: NaOH, EtOH, rt, 3 h. For 
substituents X see Table 6. 
 
 
In addition, we prepared heterocyclic analogues via two different synthetic pathways 
(Scheme 8). Rap-Stoermer reaction of salicylaldehydes 20c and 21c with phenacyl bromide 
(Method E) provided the substituted 2-benzoylbenzofurans 20b and 21b129 while synthesis of 
2-(4-chlorobenzoyl)benzothiophene 22b was accomplished by a one-step nucleophilic 
aromatic displacement of an activated nitro function by mercaptoacetophenone followed by 
an intramolecular aldol condensation.130 The heterocyclic precursors were further processed to 
the corresponding acrylic acids (20-21, 22E, 22Z) analogously to compounds 2b-17b. Finally, 
we also reduced the acrylic acids (20E/Za -21E/Za) to the corresponding propionic acids 
(23a-24a) by means of a catalytic transfer hydrogenation (Method F) using sodium 
hypophosphite in combination with Pd/C. 
(i) 18b
(ii) 19b
18b-19b
X
O
18c-19c
(iii) (iv)
Cl
18Ea, 18Za, 19Ea
X
EtOOC
X
HOOC
Cl Cl
18E, 18Z, 19E
O
Br
Cl
HX
+
X = O, S
                                                                                                                                           Results 
 43 
Scheme 8a: Synthesis of compounds 20-21, 22E, 22Z, 23 and 24 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a: reagents and conditions: (i) Method E: K2CO3, EtOH, reflux, 2 h; (ii) K2CO3, DMF, 0 °C to rt, 3 h; (iii) 
Method C: triethyl phosphonoacetate, NaH, DME, 80 °C, 4 h; (iv) Method F: NaH2PO2·H2O, 10 % Pd/C, 
EtOH/H2O, 60 °C, 2.5 h; (v) Method D: NaOH, EtOH, rt, 3 h. For substituents R see Table 7 and Table 8. 
 
 
For 2E and 2Z, we determined the E/Z configuration exemplarily using 2D-NOESY-1H-
NMR (see experimental chapter).75 The E/Z assignment of the other compound pairs was 
done by comparison of the corresponding NMR spectra with those of 2E and 2Z. Thus, by 
introducing a shorter olefinic carboxyl side chain we reduced the total number of rotatable 
bonds from seven (1) to five (2Z). 
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3.1.3. Biological results 
3.1.3.1. Biological Activity of the 3,5-diarylpent-2-enoic acid analogues 
The biological in vitro activity of the compounds toward PDK1 was studied in a 
radioactive kinase activity assay in the Department of Medicine I (Universitätsklinikum 
Frankfurt/Main) by our collaborator group under the supervision of Dr. Ricardo M. Biondi.26 
Additionally, the specificity of the compounds against a panel of other AGC protein kinases 
was tested. All reactions were performed in a 96 well format in the presence of [γ-32P]ATP 
using T308tide, a peptide derived from the activation loop of PKB, as a substrate. The 
incorporation of 32P was quantified using Phosphorimager and the corresponding Software 
Image-QuantTM. All kinase assays were done in duplicates. The intensity of the obtained spots 
directly correlates with the activity of the enzyme compared to the control values with DMSO 
alone were normalized to 100 %. 
The effects of substituents on the ability of the compounds to activate PDK1 and selected 
AGC kinases and the corresponding structure activity relationship (SAR) conclusions are 
listed in Table 3, Table 5, Table 6, Table 7, Table 8, Table 9. We tested different 
concentrations of the compounds. Using Kaleidagraph software we calculated subsequently 
the half maximal activity (AC50) and maximal activities of the compounds, compared to the 
basal activity (set to 100 %). As presented in the individual tables (Table 3-Table 9) the 
results of this study revealed that the obtained geometric isomers of the 3,5-diarylpent-2-enoic 
acid analogues possessed different intrinsic potency toward PDK1. Thereby, the isomers 
carrying the carboxyl group cis relatively to the phenyl ring B (2-16Z, 18-24Z, Figure 22) 
exhibited an increase on the activation potency of PDK1. In contrast, the isomers with the 
opposite conformation were mostly inactive. The only exception displayed compound 17. 
Both geometric isomers of 17 disclosed a relatively similar AC50 (Z = 7.6 µM; E = 8.8 µM). 
However, both isomers activated PDK1 with only low efficacy. 
Initially, our chemical strategy regarding the innovative PDK1 activators was focused on 
the substitution of 3,5-diarylpent-2-enoic acid analogues with hydrophobic substituents, 
mostly halogens, on different positions at the 5-phenyl moiety. We can conclude that the 
halogen substitution on the para position improved relatively selective the PDK1 activation 
potency in case of the cis 3,5-diarylpent-2-enoic acid analogues (2Z, 4Z, 5Z) (Table 3). The 
activity of the compounds increased in the following order F < Br < Cl. The compounds 
carrying additionally to the halogen group on the para position a second halogen either on the 
meta position (7Z) or on the ortho position (8,9) are characterized by AC50 values in low 
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micromolar range. The introduction of a para-trifluormethyl group at the 5-phenyl moiety in 
6Z resulted in a 4.4-fold activation potency but a moderate AC50 (7.1 µM). An ethyl 
substitution into the phenyl ring A at the para position abolished the activating effect on 
PDK1 considerably. The results in table below also indicate that several of the 3,5-diarylpent-
2-enoic acid analogues triggered additionally an inhibition effect on some related AGC 
kinases. Compounds 2E,Z, 3E,Z and 8Z exhibited stronger inhibition potency toward PKCζ 
whereas compounds 5E, 6E, 7E and 10Z showed only a slight inhibition. Some compound 
showed also a weak inhibition of S6K and SGK.  
 
Table 3: Activity of 3,5-diarylpent-2-enoic acids analogues substituted at the 5-phenyl moiety     
               with hydrophobic substituents toward PDK1 and a panel of AGC kinases 
 
 
 
 
Compound Ar PDK1 
   Amax         AC50      
   fold           µM         
PKCζ 
50 µM 
PKBβ 
50 µM 
PKA 
50 µM 
SGK 
50 µM 
S6K 
50 µM 
2Z 
2E 
 4.0 
ne           
8.0 
ne 
40 
50 
ne 
ne 
ne 
ne 
ne 
ne 
ne 
ne 
3Z 
3E 
 2.2 
ne           
9.5 
ne 
45 
50 
80 
80 
ne 
ne 
ne 
75 
90 
85 
4Z 
4E 
 3.3 
ne           
41.0 
ne 
ne 
ne 
ne 
ne 
ne 
ne 
ne 
ne 
ne 
ne 
5Z 
5E 
 3.9 
ne           
9.8 
ne 
nd 
70 
ne 
ne 
ne 
ne 
ne 
ne 
ne 
ne 
6Z 
6E 
 4.4 
ne           
7.1 
ne 
ne 
60 
ne 
ne 
ne 
ne 
ne 
ne 
ne 
ne 
7Z 
7E 
 2.4 
ne           
2.8 
ne 
nd 
70 
70 
ne 
nd 
ne 
ne 
ne 
ne 
85 
8Z 
8E 
 2.1 
ne           
4.7 
ne 
50 
nd 
ne 
ne 
nd 
nd 
80 
ne 
75 
75 
9Z 
9E 
 3.9 
ne           
4.0 
ne 
nd 
ne 
ne 
ne 
nd 
nd 
ne 
ne 
ne 
ne 
10Z 
10E 
 1.4 
ne           
> 30 
ne 
70 
ne 
ne 
ne 
ne  
ne 
80 
ne 
ne 
ne 
            Values in % catalytic activity (DMSO-treated control = 100%)                          nd: not determined; ne: no effect 
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F
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       Furthermore, we synthesized also derivatives including fluorine atoms on the phenyl moiety 
B at varied positions (11-13) and we substituted the phenyl ring by pyridine moiety (14). 
Thereby, we have succeeded to isolate only the corresponding E isomers. The PIF-binding 
pocket of PDK1 appeared to be not accommodating for the substituents on the phenyl moiety B 
since the E analogues afforded a decrease of the kinase activity. But besides activation of PDK1 
these compounds promoted selective inhibition of other AGC kinases, in particular PKCζ and 
S6K. This emerging effect on PKCζ was exploited in another part of my thesis for the 
development of PKCζ selective inhibitors. With respect to PDK1 activators, we decided to omit 
the derivatization of the phenyl moiety B.  
 
Table 4: Activity of 3,5-diarylpent-2-enoic acids analogues substituted at the 1-phenyl moiety     
               toward PDK1 and a panel of AGC kinases 
 
 
 
Compound Ar PDK1 
   Amax          AC50     
    fold           µM       
PKCζ 
50 µM 
PKBβ 
50 µM 
PKA 
50 µM 
SGK 
50 µM 
S6K 
50 µM 
11Z 
11E 
 - 
ne           
- 
ne 
- 
50 
- 
ne 
- 
nd 
- 
80 
- 
85 
12Z 
12E 
 - 
80           
- 
ne 
- 
55 
- 
ne 
- 
nd 
- 
ne 
- 
ne 
13Z 
13E 
 - 
ne           
- 
ne 
- 
50 
- 
ne 
- 
nd 
- 
80 
- 
85 
14Z 
14E 
 
- 
75         
- 
ne 
- 
ne 
- 
ne 
- 
nd 
- 
ne 
- 
ne 
          Values in % catalytic activity (DMSO-treated control = 100%)                             nd: not determined; ne: no effect 
 
 
       To explore the requirements to increase the potency binding to PDK1, we prepared 
compounds substituting the phenyl moiety A with different aromatic systems (Table 5). We 
determined that the aromatic analogues improved moderately the potency. The naphthyl 
analogue showed the highest increase of potency (3.6 fold). Despite the aromatic derivatives 
exhibited an elevated activation of the enzyme this substitution was less beneficial relating to the 
poor AC50 values. As already described above, compound 17 constituted an exception. In 
opposite to 15 and 16 whose E isomers did not show any activity effect, there is hardly any 
difference in activity between the geometric isomers of 17. Interestingly, the aromatic derivatives 
F
F
F
N
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showed a slight inhibition effect toward PKA and S6K and compounds 15Z and 16Z showed 
even a stronger inhibition of PKCζ. 
 
Table 5: Activity of 3,5-diarylpent-2-enoic acid analogues substituted with different aromatic     
               systems at the 5-phenyl moiety toward PDK1 and a panel of AGC kinases 
 
 
Compound Ar PDK1 
   Amax          AC50     
    fold           µM         
PKCζ 
50 µM 
PKBβ 
50 µM 
PKA 
50 µM 
SGK 
50 µM 
S6K 
50 µM 
15Z 
15E 
 3.2 
ne           
6.0 
ne 
10 
ne 
ne 
ne 
60 
nd 
ne 
ne 
ne 
80 
16Z 
16E 
 3.6 
ne           
6.0 
ne 
15 
30 
ne 
ne 
30 
nd 
ne 
70 
ne 
70 
17Z 
17E 
 
3.1 
2.2           
7.6 
8.8 
ne 
ne 
ne 
ne 
60 
ne 
ne 
ne 
ne 
80 
          Values in % catalytic activity (DMSO-treated control = 100%)                             nd: not determined; ne: no effect 
 
 
Derivatization of the backbone chain by insertion of ether and thioether groups served to 
increase the polarity of the scaffold. This modification resulted in a significantly decrease of 
potency (AC50 = 22.8 µM, Table 6). For the phenyloxy- and phenylthio-substitued series, both 
a slight reduction of the maximum activation of PDK1 and an increase of the AC50 values was 
noted compared with 2Z (18E and 19E). The trans-4-chloro-phenoxy compound 18Z was 
completely inactive. However, the inhibitory profile of the ether and thioether analogues 
regarding the related AGC kinases is comparable to the corresponding 3-carbon chain 
analogues (3,5-diarylpent-2-enoic acids) with a slightly increased inhibitory potency toward 
PKCζ and S6K. Particular the derivative including the thioether function (19E) exhibited 
enhanced potency toward PKCζ 
 
Table 6: Activity of 3,5-diarylpent-2-enoic acids analogues substituted at the backbone       
               chain with ether and thioether groups toward PDK1 and a panel of AGC kinases 
 
 
 
N
H
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Compound X PDK1 
   Amax          AC50     
    fold           µM         
PKCζ 
50 µM 
PKBβ 
50 µM 
PKA 
50 µM 
SGK 
50 µM 
S6K 
50 µM 
18E 
18Z 
O 
3.0 
ne           
22.8 
ne 
72 
72 
ne 
ne 
nd 
nd 
ne 
ne 
82 
85 
19E S 2.6           22.8 22 ne nd ne 80 
              Values in % catalytic activity (DMSO-treated control = 100%)                      nd: not determined; ne: no effect 
  
 
        The same trend was observed for the biological in vitro data of compounds that were 
synthesized incorporating two carbons of the backbone chain into heterocycles (Table 7) to 
increase binding affinity but also to probe the potential overall conformation required for a 
compound to bind to the PIF-binding pocket. The scaffold rigidification of the afforded 3-
benzofuran-2-yl-3-phenylacrylic acid derivatives (20E, 21E) and (E)-3-(5-chlorobenzo-
[b]thiophen-2-yl)-3-phenylacrylic acid did not improve notably the activity toward PDK1 and 
led to AC50 values that are extraordinary high. However, enhanced inhibition potency on 
PKCζ is also observed in case of compounds 22E and 22Z.  
 
Table 7: Activity of rigid analogues substituted with ether and thioether groups toward  
               PDK1 and a panel of AGC kinases 
 
 
 
Compound X R PDK1 
   Amax          AC50     
    fold           µM         
PKCζ 
50 µM 
PKBβ 
50 µM 
PKA 
50 µM 
SGK 
50 µM 
S6K 
50 µM 
20E O Cl 3.2        31.6 60 85 nd ne ne 
21E O Me 3.6       41.3 85 ne nd ne ne 
22E 
22Z 
S Cl 
3.1 
ne           
13.2 
ne 
20 
20 
ne 
ne 
40 
ne 
ne 
50 
75 
85 
         Values in % catalytic activity (DMSO-treated control = 100%)                              nd: not determined; ne: no effect 
 
 
      In a further effort we reduced the double bond to a single bond (Table 8) what did not 
induce any changes in the activatory potency. Both the maximal activity and the half maximal 
                                                                                                                                           Results 
 49 
activity of compounds 23 and 24 (AC50) are approximately within the same range and 
comparable to compounds 20-22. 
 
Table 8: Activity of rigid analogues substituted with ether group toward PDK1 and a panel 
    of AGC kinases 
 
 
 
Compound R PDK1 
   Amax          AC50     
    fold           µM         
PKCζ 
50 µM 
PKBβ 
50 µM 
PKA 
50 µM 
SGK 
50 µM 
S6K 
50 µM 
23 Cl 2.9        19.0 ne ne ne ne ne 
24 Me 2.7       29.1 75 ne 70 ne ne 
                 Values in % catalytic activity (DMSO-treated control = 100%)                nd: not determined; ne: no effect 
 
 
Rigidification of the compound incorporating two carbons of the backbone chain into 2,3-
dihydroindene, whereas the acrylic acid residue is situated on the 1-position of the 2,3-
dihydroindene moiety, resulted in a decrease of activity toward PDK1 (Table 9). (E)-2-(2-(4-
Chlorobenzyl)-2,3-dihydro-1H-inden-1-ylidene)acetic acid did not exhibit any additional 
effect on the related AGC kinases except a weak inhibition of PKCζ , suggesting that the 
benzene ring of the 2,3-dihydroindene was not fixed with the right dihedral angle relative to 
the double bond..  
 
Table 9: Activity of rigid analogues without additional polar groups toward  
                PDK1 and a panel of AGC kinases 
 
Compound 
 
PDK1 
   Amax          AC50     
    fold           µM         
PKCζ 
50 µM 
PKBβ 
50 µM 
PKA 
50 µM 
SGK 
50 µM 
S6K 
50 µM 
25 
 
1.8        30.0 45 85 ne ne ne 
       Values in % catalytic activity (DMSO-treated control = 100%)                                                                ne: no effect 
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3.1.3.2. PIF pocket Mutant Assay to confirm that compound 2Z activates 
PDK1 by targeting the PIF-binding pocket. 
 The in vitro data of the series of 3,5-diarylpent-2-enoic acids revealed that most of 
corresponding cis isomers are good activators of PDK1. However, among the compounds we 
tested, several showed also inhibition potency mainly toward PKCζ.  To corroborate that 
these effects were mediated by binding of the compounds to the PIF-binding pocket, the 
kinase activity assay was supplemented by further biochemical assays. In one effort we 
performed mutation assays whereas the experiments were done in our collaborator laboratory 
of Dr. Ricardo M. Biondi. We constructed first mutants of the PIF-binding pocket of PDK1 
by conversion of leucine to serine at amino acid 155 (L155S), valine to threonine at amino 
acid 127 (V127T) and by conversion of isoleucine to alanine at amino acid 119 (I119A). The 
mutated amino acids were situated within or surrounding the HM/PIF pocket. Subsequently, 
we choose compound 2Z, since it was the first new lead structure we synthesized in the 
optimization study of compound 1. Similarly to the 24 amino acid polypeptide PIFtide, 
characterized to bind to the PIF-binding pocket and activate PDK1, 26 compound 2Z increased 
the activity of wild type (wt) PDK1 with the same activation efficacy (data for PIFtide not 
shown) and it displayed a 4-fold lower AC50 than the hit compound 1. Having 2Z we 
evaluated biochemically the ability of 2Z to activate the recombinant wt PDK1 versus PDK1 
proteins mutated. For comparison, we performed the mutant assays also with compound 1. As 
shown in Figure 23 incubation of wt PDK1 both with PIFtide and with the compounds has led 
to activity increase. But with the replacement of serine into lysine all three effectors (PIFtide, 
2Z and 1) did not affect the kinase activity. This can be attributed to the fact that the character 
of the PIF-binding pocket is completely changed in the mutant PDK1L155S. This result 
suggested that the PIF-binding pocket site was required by all three effectors. In contrast, the 
mutant PDK1V127T discriminated between the natural ligand and the small molecule 
compounds 2Z and 1. On the one hand the ability of 2Z to activate PDK1 was lost toward the 
PDK1V127T mutant. On the other hand, the assay of the same mutant and PIFtide resulted in an 
increase of the enzyme activity. This was not surprising since previous experiments revealed 
that PDK1 mutants of V127 with larger hydrophobic residue (Leu) led to retained ability to 
bind and be activated by PIFtide. The subsequent downregulation of the enzyme to interact 
and phosphorylate the substrate SGK, that relies on the binding of its hydrophobic motif to 
the PIF-binding pocket on PDK174, was triggered by this PDK1V127T mutant. Thus, we can 
conclude that the residue at position 127 is not essential for HM polypeptides while a valine 
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residue at position 127 within the hydrophobic PIF-binding pocket is necessary for the 
binding of the small molecule compound 2Z. Interestingly, we found out that the PDK1I119A 
mutant was well activated by 2Z, whereas both compound 1 and PIFtide caused a decrease of 
the PDK1I119A activity. Taken together, the mutagenesis results strongly indicate that the 
compounds mediated their effects via the PIF pocket. However, there were significant 
differences on the requirements between 2Z, 1 and PIFtide, which had also been suggested to 
bind to the same site.  
 
Figure 23: PIF pocket mutant assay 
 
 
 
 
 
 
 
 
 
 
 
 
 
Biochemical evidence from site-directed mutagenesis that the PIF-binding pocket of PDK1 is the target site of 
2Z. The effect of 2Z on PDK1 specific activity was measured with recombinant wild type enzyme and PIF 
pocket-binding mutants as indicated. Mutation of valine-127 to threonine abrogates the activation of PDK1 by 
2Z but not by the 22 amino acid residue peptide PIFtide. For comparison, results obtained with the original 
compound 1 are also given. Concentrations of the compounds used were 2 µM for PIFtide and 20 µM for 1 and 
2Z. 
 
 
3.1.4. Cocrystallization of 2Z with PDK1 as further biochemical evidence for 
binding of the small molecule compound in the PIF pocket. 
In a further approach we cocrystallized 2Z with PDK1 to confirm the localization of the 
compound 2Z in the PIF-binding pocket. All crystallization experiments and analysis were 
carried out by Valerie Hindie at the Institute Pasteur in Paris supervized by Dr. Ricardo M. 
Biondi. The obtained results of the crystallographic data related to the allosteric mechanism of 
PDK1 activation by 3,5-diarylpent-2-enoic acids were published in more details parallel to 
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our SAR study by our project collaborators.126 In this thesis the special focus is on the 
structural informations of the binding mode between 2Z and the PIF pocket to elucidate the 
crucial interactions and to explain the differences in activity between the geometric isomers. 
In Figure 24A the resolved X-Ray structure indicates that 2Z is bound in the PIF-binding 
pocket of PDK1. The crucial factors which may lead to enhancement of the kinase activity are 
the interactions of the carboxyl group with the amino acids of the PIF pocket. The carboxyl 
group forms hydrogen bonds with R131, T148 and K76 which are highlighted by dashed 
yellow lines. Additionally, the carboxyl forms a water mediated H-bond with Q150 (red ball). 
This was only achievable by the compounds that carry the carboxyl group on the cis position 
that is fixed by the double bond. The carboxyl group of the trans isomers appeared to be 
pointed to the opposite direction in case the phenyl moieties bind in the same modus in the 
PIF pocket as the cis isomers. Therefore, these compounds cannot make these activating 
interactions leading to loss or lack of activity. Moreover, the carboxyl group of the trans 
isomers cannot contribute to ionic interactions as is the case with compound 2Z that appeared 
to mimic the phosphate group of phosphoserine/threonine residues from the natural ligands, 
which are expected to bind to the equivalent site. Furthermore, the cocrystal figure reveals 
that the two phenyl moieties of 2Z occupy two hydrophobic subpockets that are separated by 
L155 and bordered by V127. This fact may explain the lack of activity of compound 2Z on 
PDK1 proteins mutated at these sites (Figure 23). In contrast, the ethyl branch of I119 borders 
one side of the pocket and interacts only marginally with the chlorine of 2Z, therefore, 
explaining why the substitution for a smaller hydrophobic residue did not affect the ability of 
2Z to activate PDK1. Moreover, the cocrystal structure discloses additional Van der Waals 
contacts, an edge to face CH-pi interaction between the phenyl ring B and phenylalanine F157 
that might increase the compound affinity to the allosteric pocket (Figure 24B). Therefore, 
having the activity assay results of compounds with varying substituents on the phenyl moiety 
B (Table 4) we decided to focus on modifying the phenyl ring A (Figure 22), especially the 
X-Ray structure suggested larger unfilled space in the ring A subpocket of the PIF pocket 
binding site.  
Summing up, these results, together with the biochemical studies performed here in 
solution with PIF-binding pocket mutants of full length PDK1, provide evidence that the PIF-
binding pocket serves as the binding site for 2Z. The results indicated additionally that the 
broad range of interactions of the carboxyl moiety of the cis compounds with phosphate 
binding site residues is essential to prompt the activation of PDK1.  
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Figure 24: X-Ray structure of PDK1 in complex with 2Z (PDB: 3HRF) 
 
  A                                                                                                            B 
 
 
 
 
 
 
 
 
 
 
 
A: Compound 2Z bound in the PIF-binding pocket of PDK1. The pocket is bordered by the αC helix and the 
short αB helix as indicated. Dashed yellow lines display the interactions of the carboxylate group with R131, 
T148 and K76 and with Q150 via a water molecule (red ball). L155 divides the hydrophobic groove into two 
subpockets which are occupied by the benzene rings. Phenyl ring B (3-phenyl, see Figure 21) additionally 
contributes to the binding energy by forming edge-to-face CH-π interactions with F157. As shown in Figure 23, 
mutation of V127 to threonine abolished the activation by 2Z. The structure was generated using PYMOL. B: 
Scheme of the T-shaped CH-pi interaction of the phenyl ring B with F157.  
 
 
3.1.5. Validation of allosteric activators binding characteristics to PDK1 via 
Isothermal Titration Calorimetry (ITC). 
To validate the affinity of the new identified activators to PDK1 we performed binding 
studies with selected compounds using ITC. We wanted to figure out whether the trans 
isomers lack binding to the PIF pocket or if there is binding that is uncoupled from allosteric 
activation. 
ITC is a biophysical measurement technique that has been widely applied to study 
biomolecular interactions in dilute solutions e.g. protein-ligand interactions. The 
measurements are carried out in an adiabatic ITC system (Figure 25A) and provide in a single 
experiment informations on thermodynamic quantities such as enthalpy (∆H), entropy (∆S), 
reaction stoichiometry (N) and binding affinity (Ka).131 These parameters are related to each 
other by the Gibbs-Helmholtz equation: 
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∆G = - RT · lnKa           →      ∆G = ∆H - T∆S 
 
∆H is released (or absorbed) upon the interaction between the ligand and the protein 
monitored over the time. Nonlinear regression fitting to the binding isotherm (ORIGIN 
software) gives the Ka. From the value of Ka, the free energy of binding ∆G and entropy of 
binding ∆S can be determined (Figure 25B).  
Thus the results give information about the binding affinity of the ligand to the target and 
give insights into the mechanism of binding. Entropically driven binding is associated with 
hydrophobic interactions due to an increase in solvent entropy and release of water upon 
binding. In contrast, enthalpically binding is associated with Van der Waals and H-bonding 
interactions. Both entropy and enthalpy contribute to the free energy which is directly related 
to binding affinity and which has a negative value in case of spontaneous reactions. In 
medicinal chemistry the ITC method finds more and more application, since the 
thermodynamic data help to guide inhibitor optimization. Thermodynamic data aid to select 
lead compounds based on the balance between entropy and enthalpy. In general, a 
predominant enthalpy of binding indicates a high proportion of specific, directed bonds. In 
contrast, entropy driven ligands are too hydrophobic and thus it is difficult to increase their 
affinity to the binding pocket.132 However, high affinity can only be achieved if both enthalpy 
and entropy contribute favourably. Nezami et al. described that enthalpy-dominated binders 
are doubtlessly the preferred starting point for lead optimization. Characterizing 
allophenylnorstatine-based inhibitors of plasmepsin II, an antimarial target, Nezami et al. 
found out that an optimal balance with the free energy partitionned approximately as one-
third enthalpy and two-thirds entropy (T∆S) is required in order to overcome the enthalpy-
entropy compensation effect. Thus only compounds with this combination reached nanomolar 
affinity to the target plasmepsin II.133 
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Figure 25: A: Schematic diagram of an ITC instrument. B: Typical ITC data. Top panel: raw   
                       ITC data. Lower panel: Binding isotherm 
 
A                                                                             B 
 
 
 
 
 
 
 
 
 
 
 
A: The ITC instrument contains of a sample cell and a reference cell that are enclosed by an adiabatic shield. 
The system maintains a constant temperature difference between both cells that is compensating by an electronic 
feedback mechanism that controls the heaters that are located adjacent to both cells. Endothermic reactions lead 
to an increase of the heat output and exothermic to a decrease. The amount of power that is required to maintain 
the constant temperature between the cells is measured. 
B: In a typical ITC experiment a solution of a ligand is titrated into a cell containing a solution of the protein at 
constant temperature. During each injection heat is released or absorbed in direct proportion of the amount of 
bound ligand to the protein. At the beginning the ligand is completely bound to the protein leading to a maximal 
heat signal that diminishes as the protein becomes saturated until only background heat of dilution and 
mechanistic effects are observed. Integration of the heat changes of injections yield in resulting enthalpy H. A 
plot of the obtained heats from each injection against the molar ratio of the ligand leads to a sigmoidal binding 
curve. 
 
 
In this study we performed the ITC experiments investigating the binding interactions of 
selected 3,5-diarylpent-2-enoic acids to PDK150-359. The measurements were conducted by 
injecting compound solution into the ITC cell containing the PDK150-359 solution in pH 7.5 
media at 20 °C. Each experiment showed an exothermic course. The heat of the compound 
dilution that was involved at each injection was determined separately by injecting the 
corresponding compound solution into the buffer. To obtain the intrinsic binding isotherms 
we subtracted the dilution isotherm from the protein-compound-isotherm. The 
thermodynamic parameters obtained for the interactions are presented in Table 10. 
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Table 10: Thermodynamic parameters for the binding interactions of selected compounds to      
                  PDK1 and their effects on catalytic activity of PDK1 
 
 
 
 
 
Kinase activity 
assay 
ITC 
No. Ar 
Amax a 
fold 
AC50 a,b 
µM 
Ka c 
M-1 
Kd c  
µM 
∆H d 
kcal/mol 
T∆S e 
kcal/mol 
∆G f 
kcal/mol 
∆H/∆G 
% 
2Z 4.0 g 8.0 g 9.67E4 10.3 -1.82 4.87 -6.73 27.1 
2E Cl  ne ne - nb     
3Z 2.2 9.5 - nd     
3E 
Cl
 
ne ne - nd     
5Z  3.9 9.8 4.78E4 20.9 -3.07 3.20 -6.32 48.6 
5E Br
 
ne ne - nd     
6Z 4.4 7.1 9.66E4 10.4 -1.94 4.79 -6.73 28.8 
6E F3C
 
ne ne - nd     
7Z 2.4  2.8 7.18E4 13.9 -3.71 2.80 -6.56 56.6 
7E Cl
Cl
 
ne ne - nd     
8Z 2.1 4.7 1.71E5 5.9 -2.08 4.93 -7.07 29.5 
8E 
Cl
Cl
 
ne ne - nd     
9Z 3.9 4.0 1.62E5 6.2 -1.79 5.19 -7.15 25.0 
9E Br
F
 
ne ne - nb     
16Z 3.5 6.0 7.26E4 13.8 -4.56 1.96 -6.67 68.3 
16E 
 
ne ne - nb     
17Z 3.1 7.6 9.63E4 10 -4.09 2.60 -6.73 60.8 
17E HN
 
2.2 8.8 - nb     
 
a: Mean value of at least two independent experiments, standard deviation <20%. b: As a particularity for 
compounds with activatory properties, it was necessary to indicate the maximum activation that was achievable 
with a compound, as compared to the basal activity of PDK1 (set to 100%). Based on two independent titrations 
of PDK1 with 16Z, c:standard deviations for Ka and Kd are of 11%, error bars for ∆H, T∆S, and ∆G are of  
d 
 + 
0.30 kcal/mol,  e + 0.37 kcal/mol, and  f  + 0.07 kcal/mol, respectively. g values were taken from126. h  mixture of 
isomers, ca. 75% Z/25% E for 16, and 70% Z/30% E for 17. ne: no effect; nb: no binding; nd: not determined.  
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Figure 26 depicts the binding isotherm obtained for the geometric isomers 16Z and 16E 
that we are using in the following to point out the general characteristics of the appropriate 
isomer interactions with PDK1. The typical curve shape of an ITC experiment is 
demonstrated in the top panel for compound 16Z whereas each injection of the ligand to the 
protein resulted due to the occurred binding in exothermic pulses. These pulses decreased 
until a plateau is reached when the protein is saturated by the ligand. In case of the trans 
isomer, 16E, there is no a characteristic curve shape. The only experiment signals resulted 
from the measurement of the background and dilution heats. The integrated peak intensities of 
compound 16Z plotted against the molar ratio and their following fitting furnished ∆H = - 
4.56 kcal/M, Ka = 7.26 * 104 M-1 or in terms of equilibrium dissociation constant Kd = 13.8 
µM (Kd = 1/Ka). The stoichiometry was near by 1 which applied for all cis isomers. For the 
trans isomer 16E no thermodynamic data are obtained since no binding was detected. 
 
Figure 26: Binding isotherm obtained by ITC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characterization of 2Z and 2E isomers interactions with PDK150-359 by ITC. The top panel shows the raw heat 
signal for successive injections of dissolved compounds 16Z and 16E into a PDK150-359 solution at 20°C. The 
bottom panel shows the integrated heats of injections corrected for heats of dilution for 16Z (filled squares) and 
16E (open squares), with solid lines corresponding to the best fit of the data to a bi-molecular binding model. No 
binding of compound 16E to PDK150-359 is detected in conditions where 16Z shows clear binding. 
Thermodynamic parameter values are given in Table 1.  
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In this context it is important to draw attention to the compound 17E. The ITC experiment 
revealed that this compound did not bind to the PDK1. In contrast, in the biological in vitro 
assay 17E exhibited a weak activation. Based on these results we can not explain this 
characteristic. We can only assume that the ATP could play a role. The ITC measurements 
were carried out in the absence of ATP, the radioactive kinase assays contained ATP. We 
speculate that the interaction of 17E with the PIF-binding pocket in the activity assay can by 
given by the influence of ATP triggering allosteric cooperative effects. Consequently a 
slightly more active conformation of PDK1 becomes stabilized. Thereby the indole ring might 
promote the binding by H-bond interaction with Q150, thus distinguishing 17E from the other 
trans configured compounds which were analyzed by ITC. 
      Summarizing, the ITC results confirmed the main potency of cis isomers we obtained 
already form the in vitro assays and the X-ray structure. The strong binding is only possible 
with the carboxyl group that has the cis configuration. Furthermore, we obtained similar 
results for all tested compounds (E and Z isomers of 2, 3, 5, 6, 7, 8, 9, 16, 17) indicating that 
the phosphate binding site accommodated all cis compounds in a similar way leading to the 
same position of the phenyl ring B into the subpocket on the PDK1 PIF-binding pocket as 
experimentally described for 2Z.  
 
 
3.1.6. Interrelationships between Thermodynamic Binding Signature, 
Structure, and Activity of selected 3,5-diarylpent-2-enoic acids toward 
PDK1. 
Analyzing the ITC experiments we found out that there is no general agreement between 
the estimated Kd values and the AC50 values from the activity assay. In the following we shed 
light on the consequential influences of structural features on the affinity and activity of 
selected compounds toward PDK1.  
First of all, I would like to focus the attention on the edge-to-face CH-π interaction of the 
phenyl ring B with F157 that we already described in the chapter  3.1.4 presenting the 
cocrystal structure (Figure 24).134 This kind of T-shaped interactions is found to be 
predominant among other aryl aryl interactions and plays a crucial role in stabilizing the 
ligand protein binding. The interaction energy of the T-shaped benzene dimers is - 2.4 
kcal/mol.135, 136 Moreover, such hydrophobic interaction is found to be the most favored 
formation in solution.134 Using the software PYMOL we calculated the separation between 
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the 2Z C4 and the ring centre of F157 in the cocrystal that amounts 3.22 Å. The distance is 
significantly shorter than the sum of the C-H…C Van der Waals radii and thus indicative of a 
rather strong interaction. Moreover, insertion of substituents or heteroatoms influences T-
shaped configurations.137 Derivatization of the ring B by fluorine substituents on para, ortho 
and meta positions and by replacement of pyridine led effectively to a decrease of the activity 
of PDK1. Therefore, we decide for further investigations not to modify ring B but we focused 
our optimization approach on substitutions on ring A. This decision is based additionally on 
our crystal structure of the compound 2Z suggesting larger unfilled space in the ring A 
subpocket of the binding site (Figure 24). Analyzing the calorimetric results we observed a 
further interesting issue. In chapter  3.1.3 we presented the biological activities of the halogen 
substituted derivatives and there was no major difference in activation potency (AC50) among 
the compounds substituted with mono halogens on the ring A (2Z, 5Z, 6Z). However, the 
dichlorosubstituted compounds, 7Z and 8Z, emerged with distinct, remarkable properties. As 
shown in Figure 27 compound (Z)-5-(3,4-dichlorophenyl)-3-phenylpent-2-enoic acid (7Z) 
broke the general correlation between AC50 ( = 2.8 µM, Table 10) and Kd (= 13.9 µM, Table 
10). The thermodynamic data indicated additionally that 7Z exhibited the biggest loss of 
binding entropy compared to 2Z. We could not explain this feature but we suggested that the 
3-Cl was impeding the hydrophobic interaction of the substituted phenyl ring with the pocket. 
In contrast, (Z)-5-(2,4-Dichlorophenyl)-3-phenylpent-2-enoic acid, 8E, was characterized by a 
distinct and interesting behavior displaying the lowest Kd what correlated with the obtained 
AC50 value. Nevertheless, its potency to allosterically activate PDK1 was striking due to the 
decrease to about half of the Amax of 2Z. We may suppose the o-chlorine of 8E induced a 
rather “antagonist” like behavior of the compound. 
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Figure 27: General correlations based on calorimetric measurements 
 
 
 
 
 
 
 
 
 
 
 
A: Enthalpy-entropy compensation phenomenon observed upon binding of Z isomers to PDK1. Large changes in 
the binding enthalpies (∆H) and binding entropies (T∆S) were measured. However, the observed linear 
relationship between the ∆H and T∆S values with a slope of 1 shows that a favourable increase in binding 
enthalpy was compensated by an equal unfavourable loss of entropy in the binding free energy (∆G = ∆H-T∆S), 
which left nearly unchanged the binding affinity (Kd = exp[∆G/RT]). B: A gross linear correlation was observed 
between the AC50 values for PDK1 activation and the dissociation constants as measured by ITC. This 
correlation suggested that for most compounds, the binding affinity to the intermediate active conformation of 
the kinase, which might be represented rather by the AC50, does not differ strongly from the affinity to the 
activated conformation of the kinase, which might be described by the Kd. Only for compound 7Z (not used to 
calculate the trend line), a low AC50 was associated with an over-proportionally high Kd. 
 
 
Although entropically driven ligand-protein binding is usually attributed to structural 
features, in that case hydrophobic interactions, we observed that both dichloro substituted 
compounds (7Z, 8Z) showed different thermodynamic profile. The 2,4-dichloro substituted 
analogue 8Z displayed a predominantly entropy-driven binding and the 3,4-dichloro 
substituted analogue 7Z did not (Table 1). We cannot provide a final answer based on our 
current data, but a possible reason for the difference could be due to the resulting location of 
the compounds within the hydrophobic pocket. The more entropy-driven binding of ring A in 
8Z might allow a greater flexibility of positioning within the hydrophobic pocket in order to 
avoid a steric clash of the 2-chlorine with either T128 or Q150 (compare with ring A position 
of 2Z, Figure 3), whereas the binding positions might be more restricted in the case of highly 
directed H-bonds and dispersion forces which usually contribute to the enthalpy term. Such an 
entropy-enabled binding shift might propagate into sub-optimal interaction of the 8Z carboxyl 
side chain with R131, resulting in a reduced allosteric activation without compromising 
binding affinity. Comparing compounds 8Z with 9Z we revealed that the “antagonist”-like 
properties result not only of entropy-driven binding alone. The steric impact like from the o-
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chlorine plays also a significant role. This was corroborated by the fact that the maximum 
activation potency of the 4-bromo derivative 5Z was not affected when a smaller o-fluorine 
was introduced (cf. 9Z) despite the significant increase in the entropy/enthalpy ratio of 
binding. It will be interesting to see whether 8Z binds to and stabilizes the intermediate active, 
basal conformation of the PIF pocket without causing major conformational changes.  
As described in chapter  3.1.3.1 we decided to enlarge the ring A moiety motivated by the 
decrease of the AC50 obtained with 7Z in comparison to 2Z (almost 3-fold). Using ITC we 
investigated the quality of the interactions between the extended aromatic rings and the PIF-
binding pocket with the resulting naphthyl and indolyl derivatives (16Z, 17Z) that did not 
abolish the PDK1 activity. The calorimetric data of these compounds showed the highest 
∆H/∆G ratios in the analazed series (16Z: 68.3%, 17Z: 60.8%). The ratios resulted from a 
marked increase of the enthalpy relative to the entropy of binding (Table 10). All halogen-
substituted phenyl analogues except 7Z indicated completely different thermodynamic 
characteristics. We can suppose that the increase of the binding enthalpy is attributable to CH-
π interactions resulting from higher π-electron density of the unsubstituted bicyclic rings 
combined with the larger surface. Although one unit CH-pi interaction contributes around 1 
kcal/mol to the total enthalpy,138 we hypothesized that multiple CH groups participated 
simultaneously in interactions with pi electrons, thus adding up to a significant increase in 
enthalpy, consistent with our experimental data. According to the cocrystal structure, the 
following residues of the PIF-binding pocket were possible candidates for a putative 
interaction with the extended π-electron system of 16Z or 17Z:  most certainly the geminal 
dimethyl of L155, and – depending on which rotamer of the naphthyl or indolyl linking bond 
is preferred – either the terminal methyl of I118 or γ-methylen of the K115 side chain (cf. 
Figure 3). Both of the latter residues are within reach of the bicyclic rings of 16Z and 17Z, 
and the two possible corresponding rotamers could dock into the subpocket provided that the 
available space is slightly increased by a movement of the I119 chain. Since terminal methyls 
of Leu, Ile or Val are more commonly found in CH-pi interactions,138 we included a 
hypothetical interaction between the naphthyl of 16Z and the methyl of I118 in the interaction 
scheme for 16Z (Figure 28). 
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Figure 28: Binding scheme model summarizing interactions of activator compound 16Z with                    
                   the PDK1 PIF-binding pocket 
 
 
 
 
 
 
 
 
 
 
 
 
Blue dotted lines denote interactions that have been identified for the analogue 2Z in the cocrystal structure with 
PDK1; red dotted lines indicate the assumed interactions as inferred from the ITC experimental data.  
 
 
Altogether, compounds with extended aromatic system interact substantially different 
from halogenated phenyl compounds, although the Kd values were in the same range what is 
due to the enthalpy-entropy compensation. We observed the enthalpy-entropy compensation 
effect also analyzing the thermodynamic parameters of the analogues 10Z and 15Z which 
displayed different activation potencies toward PDK1. It is most probable that both 
compounds can only bind to the PIF pocket in the in the same manner as the p-chlorophenyl 
ring of 2Z when I119 moves away in order to avoid a steric clash (Figure 24). While the 
active compound 15Z carries a p-phenyl substituent that contributes to additional CH-π 
interactions which could compensate for an entropic penalty, the p-ethyl substituted 10Z, 
which is incapable of forming additional CH-π bonds, was nearly inactive. Summarizing, the 
less favourable entropy that is associated with potential movements of side chains could be 
compensate by the assumed reinforcement of CH-π interactions resulting in an enthalpy gain. 
 
3.1.7. Overall Correlations between Enthalpy and Entropy of Binding and 
the Biological Activity Parameters of Allosteric PDK1 Activators. 
Isothermal Titration Calorimetry provides information on the binding forces of ligands to 
the target proteins. It is increasingly apparent that the major contributor to binding of all 
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active compounds is ionic interaction. In our study, we found a surprisingly broad 
thermodynamic binding spectrum, from mainly entropy-driven to predominantly enthalpy-
driven binding. We performed a correlation analysis plotting the thermodynamic binding 
signature against the activity data. The obtained plot revealed two strong relationships; as the 
most obvious correlation we identified a sharp enthalpy-entropy compensation effect, which 
has been described for many ligand-receptor systems such as agonists and antagonists 
interacting with membrane receptors139-141 and inhibitors binding to HIV protease142 (see 
∆H/T∆S correlation, Figure 27A). This effect describes the fact that among a series of 
compound analogues with comparable size, any increase in binding enthalpy is accompanied 
by a loss of entropy to about the same degree, leading to little or no change in the binding 
affinity.143, 144 The compensation effect was most obvious when comparing the group of 
halogenated compounds (2Z, 6Z, 8Z and 9Z) with 16Z and 17Z (Figure 27A). The bicyclic 
aromatic rings caused binding with highly favourable enthalpy, probably due to additional 
CH-pi interactions as described above (Figure 28). Our ITC data indicated that the additional 
binding enthalpy was gained at the cost of entropy, accounting for the enthalpy-entropy 
compensation in the concrete case. A possible explanation for the concomitant loss of entropy 
with 16Z and 17Z could be that due to the higher polarity of the π-electron-rich rings, the 
contacting water molecules are less ordered and less entropy is gained upon water release 
from the compound. In contrast, fewer enthalpically favourable Van der Waals or CH-π 
interactions are possible with one phenyl ring where the density of the π-electrons is further 
decreased by halogen substituents. Apparently, this loss of H-bond capacity in the 
halogenated compounds was exactly balanced out by an opposite increase in hydrophobic 
interaction, giving raise to the entropy term. These mutual compensation processes prevented 
significant changes in the total binding free energies of compounds (compare e.g. 2Z, ∆G = -
6.73 kcal/mol with 16Z, ∆G = -6.67 kcal/mol) which otherwise differed substantially in their 
∆H/∆G ratio (Table 10). This phenomenon is not uncommon in the lead optimization process 
and has to be overcome in order to increase binding affinity (see chapter  3.1.8 below).  
Another relationship became apparent when the thermodynamic binding profiles were 
correlated with the activatory potency of the compounds. We observed a rough correlation 
between the AC50 values for PDK1 activation and the dissociation constants as measured by 
ITC (Figure 27B). This correlation suggested that for most compounds, the binding affinity to 
the intermediate active conformation of the kinase, which might be represented rather by the 
AC50, does not differ strongly from the affinity to the activated conformation of the kinase, 
which might be described by the Kd. The variations in activation efficacy (Amax) did not affect 
                                                                                                                                           Results 
 64 
this correlation. The relationship between AC50 and Kd was not self-evident since binding to 
the intermediate active state and dissociation of the complex after the conformational change 
could be perceived as two separate events characterized by divergent affinity constants. Our 
finding rather suggests that during the allosteric activation by the majority of compounds, 
only subtle and rapid changes occur within the PIF-binding pocket itself, while the overall 
geometry of the PIF-binding pocket remains unaltered. 
 
 
3.1.8. Implication of the Calorimetric Characterization for Lead Selection 
and Optimization. 
Since several years ITC has been enforced as a method to guide the lead evaluation and 
optimization in drug development providing a partition of the binding energy into its 
enthalpic and entropic components. Empirically obtained calorimetric data presented in 
numerous studies suggest that compounds that exhibit an enthalpy dominated binding are 
particularly suitable to increase ligand affinity.142, 145 Favourable binding enthalpy provides 
several advantages since Van der Waals and H-bonding interactions as enthalpy-driven 
interactions are more difficult to engineer. A good geometric complementary between the 
involved functional groups of drug and receptor is required for optimal electrostatic 
interactions between the ligand and the target. To optimize the entropy contribution on the 
other hand has proven much easier, as this is almost inevitably achieved by introducing non-
polar groups which increase the hydrophobic effect. However, it is more difficult to increase 
ligand affinity when binding interactions become highly hydrophobic and rigid.146 From the 
perspective of allosteric modulators, it might be worth discussing whether 8Z, which 
displayed stronger binding in connection with the opposite trend in activation potency, should 
not be pursued in parallel as lead compounds toward the development of non-activators or 
even allosteric inhibitors. However, since very high affinity can only be achieved if both 
enthalpy and entropy contribute favourably and in a balanced manner to the binding free 
energy,133, 145 enthalpy-dominated binders are doubtlessly the preferred starting point for lead 
optimization. Moreover, it was reported by Nezami et al. that in order to overcome the 
enthalpy-entropy compensation effect, an optimal balance with the free energy partitioned 
approximately as one-third enthalpy and two-thirds entropy (T∆S) was required.133 Only 
compounds with this combination reached nanomolar affinity to the target plasmepsin II in 
the reported case; the same conclusion could also be drawn for allosteric glycogen 
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phosporylase inhibitors in a recent study. jmedchem38 In that sense, calorimetric analysis has 
disclosed 8Z rather as a “dead end” since the balance has been reached already (∆H/∆G = 
29.5 %) and any addition of another chemical moiety would provoque enthalpy/entropy 
compensation effects without substantially increasing ∆G. Similarly, the thermodynamic 
binding data for 9Z revealed the compound as a less appropriate starting point to escape 
enthalpy-entropy compensation, even though the AC50 was two times lower than that of 2Z 
(Table 10). 
In summary, 16Z and 17Z were found to possess the most ideal thermodynamic lead 
profile among the compounds analyzed by ITC, since the enthalpic term strongly 
predominates the binding free energy.  
 
 
3.1.9. Conclusion 
In an effort to enhance the efficacy and the selectivity of the first identified hit compound 
1 and the new lead compound 2Z (Figure 22) toward PDK1 we developed a series of 3,5-
diarylpent-2-enoic acid analogues. As 2Z was the first analogue that we isolated from this 
compound family and that exhibited a good potency toward PDK1, it was selected for the 
evaluation of the actual binding site in a mutagenesis study and in a cocrystallization 
approach. Thus, we were successful to prove the PIF pocket, a protein kinase catalytic domain 
which is not adjacent to or overlapping with the ATP binding site as the binding site of 2Z. 
Obtaining the cocrystal structure of 2Z bound to the PIF pocket of PDK1 we confirmed the 
series of 3,5-diarylpent-2-enoic acid analogues as truly allosteric compounds. It should be 
mentioned that many inhibitors reported in the literature to be “allosteric” still bind to the 
ATP binding site at least partially. Like in the case of imatinib mesylate (Gleevec), the term is 
used to signify that an inactive, open conformation of the kinase is stabilized.7 Investigating 
the biological potency and utilizing an ITC approach with selected compounds we observed 
interesting structure-activity and interrelationships between thermodynamic profile, structure 
and activity of the set of compounds. First of all, the main potency showed compounds 
bearing the carboxyl moiety in the cis position. Moreover, the similar ITC results for all cis 
and trans isomers suggested that the phosphate binding site accommodated all cis compounds 
in a similar way. In general, the thermodynamic data of the new series revealed binding with 
variable proportions of entropy and enthalpy. This broad thermodynamic spectrum seemed to 
result form the enthalpy-entropy compensation effect we could prove comparing the analysis 
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plot of the halogenated compounds with the bicyclic compounds. Our ITC results indicated 
also some important CH-π interactions between ligand and receptor that can essentially 
contribute to increased selectivity and potency of PIF pocket-directed compounds which have 
been identified by virtue of their favourable binding enthalpy. The bicyclic analogues 16Z and 
17Z turned out to have the highest ∆H/∆G ratio on the basis of favourable binding enthalpy 
values most likely due to the attributable CH-π interactions. Based on these best 
thermodynamic profiles and biological potencies toward PDK1 we selected 16Z and 17Z as 
new lead structures to further improve potency. Thus we achieved additional informations 
about structural requirements the compounds must have included to become good affinity and 
activity toward the PIF pocket of PDK1.  
Altogether, we could confirm that compounds consist of two aromatic moieties connected 
by an aliphatic chain, bearing a two atom membered side chain with a free carboxylic group 
own the ability to function as a PDK1 activator. Thereby, in case of 3,5-diarylpent-2-enoic 
acid series only the carboxyl moiety of the cis analogues can exploit their carboxyl moiety to 
interact with the crucial phosphate binding site residues. And that's not all: we found out a V-
shaped overall conformation of the aryl rings toward each other is required to achieve 
complementarity to the binding pocket. These prototype compounds – despite the low 
molecular masses – already displayed activities in the low micromolar range, suggesting that 
mass and ligand efficiency should remain in a reasonable range after lead optimizsation. 
Nevertheless, to further confirm PDK1 as the target effects on the downstream proteins 
should be investigated. In the case of PDK1, activation of the catalytic activity is achieved by 
binding to the HM/PIF-binding pocket, which at the same time blocks the activation of all 
substrates (S6K, RSK and some PKC) with the exception of PKB. S6K, RSK and some PKC 
require transient interaction with the pocket. Thus the compounds might act differentially on 
the two subsets of PDK1 substrates which either require docking interaction with the PIF-
binding pocket or not. Hence, in-depth investigation of the compounds´ effects on the cellular 
signaling pathways – using genetic tools and detailed phosphorylation analysis – are required 
and will be subject of our future studies. In particular, detailed analysis in a cellular setting 
will be required to study the biological effects of PIF-binding pocket targeting compounds 
with high (e.g. 6Z) vs. low (e.g. 8Z) concomitant allosteric activation of PDK1 catalytic 
activity. 
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3.2. Prodrug approach of 2-(3-oxo-1,3-diphenylpropyl)malonic acids as 
potent allosteric activators of PDK1 to enable the bioavailability of 
the high polar dicarboxylic acids 
3.2.1. Scientific rationale 
Initial optimization of the allosteric PDK1 activator 1 (Scheme 9) identified from a library 
of commercial compounds led to the first larger series of 3,5-diphenylpent-2-enoic acids as 
PIF pocket-directed compounds. We were able to provide the activation characteristics in 
biophysical and biochemical assays, the SAR results and characterization of the cocrystal 
structure. Indeed, the results demonstrated that the compounds influenced PDK1’s activity 
targeting the PIF pocket, but they displayed low affinity, rendering further studies difficult. 
For further improvement of the potency toward PDK1 we designed a chimeric compound 
combining the carbonyl function from the lead compound 1 with the short side chain from 
compound class III (Scheme 9). Another goal was to mimic better the two negative charges 
of the phosphate group present in natural ligands of the PIF pocket, the HM phosphopeptides 
of the PDK1 substrate proteins. 
Thus, herein we present 2-(3-oxo-1,3-diphenyl-propyl)malonic acids (IV) as a new class 
of PDK1 activators with improved potency and high selectivity toward close homologues. 
Unfortunately, when used in cell assays these were completely inactive, presumably due to 
their highly dianionic structure. To overcome this transport barrier, a prodrug strategy was 
adapted and investigated as alternative approach for intracellular potency replacing the 
dicarboxylic functionality into the corresponding bisacetoxymethyl ester derivatives. 
 
Scheme 9: Allosteric modulators design concept 
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Furthermore, the malonic moiety of the 2-(3-oxo-1,3-diphenylpropyl)malonic acids 
provided a synthetic access to another substance class, the corresponding monoacid 
derivatives. A comparison with the corresponding 2-(3-oxo-1,3-diphenylpropyl)malonic acids 
should shed light on the significance of the polar moiety in relation to the PIF pocket of 
PDK1. 
 
3.2.2. Synthesis 
In our design strategy to create a chimeric compound we retained the carbonyl function 
from the hit compound 1 while keeping the short side chain from the new lead compound 2Z. 
In addition, since the natural ligands of the PDK1-PIF pocket are phosphor peptides17, 26we 
planned to introduce a second carboxyl function to better mimic the phosphate group.  
The malonic acids derivatives (IV) were prepared by the synthetic route shown in Scheme 
10.  
 
Scheme 10: Synthesis of the compound class IV (4 A-V).a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a reagents and conditions: (i) Method G: bromomethyl-methylether, NaH, DME, 0 °C, 1 h; (ii) Method A: 
NaOH, EtOH, 1 h, rt; (iii) Method H: diethyl malonate, MgO, toluene, reflux, 2h; (iv) Method I: diethyl 
malonate, K2CO3, ethanol, reflux, 2 h; (v) Method J: diethyl malonate, NaH, methanol, reflux, 2 h; (vi) Method 
K: 10 % HCl, methanol, reflux, 2 h; (vii) Method L: NaOH, EtOH, reflux, 4 h; For substituents Ar1 and Ar2 see 
Table 11. 
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The target compounds were available in three steps starting from the already previously 
described 1,3-(heteroaryl/aryl)-prop-2-en-1-ones (chalcones) 1A-V (see  3.1.2). These are 
available by classical Claisen-Schmitt condensation (Method A) of benzaldehydes or 
heteroarylaldehydes with acetophenones or heteroaryl methyl ketones and were converted to 
the corresponding dialkyl 2-(3-oxo-1,3-diheteroaryl-/arylpropyl)malonates via base-catalyzed 
Michael addition of CH-acidic malonates. Due to the mild base nature, ease of product 
isolation and good activity most of the Michael adducts 2A,B,D,H,K,N,P-S,U,V could be 
obtained with magnesium oxide in toluene.147 Because of the limited activity of magnesium 
oxide depending on the solvent and the substrate the remaining malonate derivatives were 
obtained using alternative catalysts, potassium carbonate for 2G and sodium hydride for 
2C,E-J,L,M,O,T.148, 149 Treatment with diethylmalonate and magnesium oxide or potassium 
carbonate in ethanol gave the diethyl intermediates and with sodium hydride in methanol 
occurred transesterification leading to the dimethyl intermediates. Hydrolysis of these 
malonate analogues afforded the corresponding (3-oxo-1,3-diheteroaryl/arylpropyl)malonic 
acids 4A-V. 
The diacid functionality in turn provides the synthetic access on the one hand to the 
decarboxylated compounds and on the other hand to the cell permeable prodrug derivatives 
since the membrane transport barrier is presumably a major reason for the lack of cellular 
activity of the (3-oxo-1,3-diheteroaryl/arylpropyl)malonic acids. The corresponding synthetic 
route is outlined in Scheme 11. 
 
Scheme 11: Synthesis of compounds 5 A,H,Q and 6 A-D,F-I,K,N,Q-S,U.a 
 
 
 
 
 
 
 
 
 
 
a reagents and conditions: (viii) Method M: bromomethyl acetate, NEt3, DMF, rt, 4 h; (ix) Method N: 160-170 
°C, 2 h. For substituents Ar1 and Ar2 see Table 11. 
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Pyrolysis of the corresponding malonic acid analogue at about 165 °C gave rise to the 
decarboxylation leading to the 5-oxo-3,5-diheteroaryl/arylpentanoic acids 6A-D,F-I,K,N,Q-
S,U.150 Treatment of the (3-oxo-1,3-diheteroaryl/arylpropyl)-malonic acids 4A-V with bromo 
methylacetate and triethylamine in dimethylformamide afforded the bisacetoxymethyl ester 
derivatives 5A,E,G-I,L,N,O,Q,R in modest yields.151 
Synthesis of 4M (Scheme 10), derived from the 4-hydroxyacetophenone, required 
protection of the nucleophilic alcohol function in order to obtain the corresponding chalcone 
1M and the malonate derivative 2M in good yields. The methoxymethyl (MOM) group was 
chosen as protecting group and introduced by using bromomethyl-methylether with sodium 
hydride in dimethylformamide.152 Finally, the methoxymethyl group was cleaved under acidic 
conditions to give the desired dimethyl 2-(1-(4-chlorophenyl)-3-(4-hydroxyphenyl)-3-
oxopropyl)-malonate 3M followed by hydrolysis to furnish the target molecule 4M.152 
 
 
3.2.3. Biological results 
3.2.3.1. Biological characterization in vitro of dicarboxyl PDK1 activators 
I studied the effect of the malonic acid analogues on the activity of His-PDK1 50-556 
using a radioactivity kinase assay. The kinase was incubated with the radiolabeled phosphate 
from [γ-32P]ATP in the presence of T308tide as substrate peptide and the compounds. The 
amount of the radioactivity incorporated into the substrate was measured (see  3.1.3.1).153 The 
concentration necessary to achieve half maximal activation (AC50) and maximum activation 
(Amax) were determined using eight different concentrations. The results are summarized in 
Table 11. In parallel we measured the effect of 2Z that possess only one carboxyl group but 
the same phenyl moieties as 4A. As described previously 2Z prompted a 3 fold increase in 
PDK1 activity.20 Most of the dicarboxyl compounds raised the PDK1 activation to higher 
levels and had lower AC50 than 2Z. Several potent analogues were produced.  
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Table 11: In vitro specificity of the 1,3-diaryl malonyl propanones and the corresponding    
                 monoacids. 
 
 
  
Kinase activity 
assay   
Kinase activity 
assay 
No. Structure Amax 
a
 
fold 
AC50 a,b 
µM No. Structure 
Amax a 
fold 
AC50 a,b 
µM 
4A 
 
 
4.0 2.5 6A 
 
O
Cl
COOH
 
3.0 > 20 
4B 
 
O CH(COOH)2
Cl
 
2.6 4.0 6B 
 
O
Cl
COOH
 
nd nd 
4C 
 
 
2.0 > 10 6C 
 
 
nd nd 
4D 
 
 
3.7 1.4 6D 
 
 
nd nd 
4E 
 
 
3.0 12.0 - -    - - 
4F 
 
 
4.0 0.4 6F 
 
 
4.0 10 
4G 
 
 
3.8 2.0 6G 
 
 
2.5 20 
4H 
 
 
5.5 2.0 6H 
 
 
4.0 15 
4I 
 
 
3.5 10.0 6I 
 
 
nd nd 
4J 
 
 
nd nd - -    - - 
4K 
 
 
5.0 4.0 6K 
 
 
nd nd 
                                                                                                                                           Results 
 72 
4L 
 
 
3.0 6.8 - -    - - 
4M 
 
 
ne ne - -    - - 
4N 
 
 
7.0 16.0 6N 
 
 
nd nd 
4O 
 
 
3.6 0.2 - -    - - 
4P 
 
 
ne ne - -     - - 
4Q 
 
 
4.0 < 1.0 6Q 
 
 
2.5 5.0 
4R 
 
 
3.6 3.3 6R 
 
 
nd nd 
4S 
 
 
4.8 2.0 6S 
 
 
nd nd 
4T 
 
 
3.0 14.0 - -     - - 
4U 
 
 
3.7 0.6 6U 
 
 
1.5 0.5 
4V 
 
 
3.6 0.7 - -    - - 
 
Values in % catalytic activity (DMSO-treated control = 100%)                            nd: not determined; ne: no effect 
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The significant difference in activity between the compound class III and IV (Scheme 9) 
is shown in Figure 29 with three representative activation curves that were created using 
KaleidaGraph software. When we compared the compounds it was evident that both malonic 
acid analogues exhibited a pronounced increase of activation potency in comparison with the 
acrylic acid derivative 2Z. Furthermore, the AC50 values which can be found explicitly in the 
Table 11 are lower.  
 
Figure 29: Effect of 2Z and the dicarboxylic compounds 4A and 4H on PDK1 activity  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The predominant contribution of the dicarboxyl moiety to the affinity of the compounds to 
the PIF pocket of PDK1 is also clearly apparent from the Table 11. Nevertheless, we observed 
strong dependence on the AC50 to the ring substituents, too. Substitution in the para position 
of the phenyl ring A was appropriate to have higher potency and lower AC50 as we presented 
in the previous SAR analysis with the structure class III. The phenyl ring substituents were 
systematically varied, since the type and pattern of halogen substitutions were found to 
influence the potency of the PIF-binding compounds strongly. A chlorine substituent in para 
position (compound 4A) induced a 4-fold increase in activity whereas an introduction of a 
chlorine atom in the meta position (compound 4B) led merely to a 2.6-fold activation of 
PDK1. Within the halogen substituents the AC50 improved in the following order Cl < Br < I 
at comparable 4-fold activation. The iodine analogue 4F showed a significantly lowered AC50 
in the high nanomolar range (0.4 µM). The potency of the iodine derivatives was slightly 
further enhanced by replacement of phenyl ring B by naphthyl 4O (AC50 = 0.2 µM). An 
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extraordinarily high effect was observed in case of the para-trifluormethyl malonic acid 
derivative 4H displaying 5.5-fold activation potency toward PDK1. Although the 4-
ethylphenyl malonic derivative 4K exhibited also a pronounced activation it was less 
beneficial relating to the poor AC50. Additional introduction of a halogen chlorine into the 
phenyl ring B in the 4-position of the above presented compounds 4A,D,F,H,K abolished the 
activating effect on PDK1 considerably. Interestingly, the activity did not decrease 
introducing a chlorine atom in 2-position of the phenyl ring B (compound 4H). 4M, the 
hydroxyl analogue, and 4P, the 4-phenlythiophene analogue, did not influence PDK1 activity 
at all. Besides introduction of small residues in para and meta position, further modification 
of the phenyl moiety A by naphthyl (4Q), its derivatization by 5-methoxylation (4R) or 
additional exchange of the phenyl ring B by naphthyl (4S) resulted in a 3-4.8-fold increase of 
potency. However, the AC50 values were comparably high. Additionally, an indole derivative 
(4T), a phenanthrene derivative (4U) and also a carbazole compound (4V) were prepared. 
While 4T exerted a moderate 3-fold activation, the replacement of the phenyl moiety by the 
condensed phenyl rings phenanthrene and carbazole led to potent activators with nanomolar 
AC50 values. 
       Moreover, we studied the specificity of the 2-(3-oxo-1,3-diphenylpropyl)malonic acid 
4A-V toward a panel of AGC kinase. The series showed not only a high potency toward 
PDK1, most of them have also a high selectivity for the PDK1 PIF pocket over PIF pockets of 
closely related AGC kinases (Table 12).  
 
Table 12: In vitro specificity of 2Z and the dicarboxyl compounds 4A and 4H. 
 
 
Cpd. 
 
[µM] PDK1 
(%) 
S6K1 
(%) 
PKCζ 
  (%) 
SGK 
(%) 
PKBβ 
(%) 
PKA 
(%) 
PRK2 
(%) 
RSK 
(%) 
MSK 
(%) 
2Z 2 100 ne ne ne ne ne ne - - 
 
50 280 ne 40 ne 110 90 ne - - 
 
200 280 60 6 60 ne 60 ne - - 
4A 2 280 ne ne ne ne ne ne ne ne 
 
50 380 ne 80 ne 110 ne ne 160 95 
 
200 400 130 50 ne ne ne ne 142 100 
4H 2 370 ne ne ne ne ne ne ne ne 
 50 570 90 ne ne 83 180 110 140 100 
 200 520 110 ne ne 100 207 110 200 80 
      Values in % catalytic activity (DMSO-treated control = 100%)                                              ne = no effect 
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However, compounds 2Z and 4A displayed an inhibitory effect toward PKCζ in the range 
of higher concentration. 2Z induced also a slight inhibition of the AGC kinase PKA. 4A 
exhibited additionally a slight activation effect toward RSK, and 4H both RSK and PKA. 
Nevertheless, in conclusion with the compound class IV we were able to obtain several potent 
and selective compounds, especially since we are focused on allosteric modulation of kinase 
targeting the PIF pocket that is less conserved as the ATP binding site.  
The second substance class presented here, the monoacid derivatives 6A-D,F-I,K,N,Q-
S,U, exhibited generally reduced activation potency and turned out to be weaker activators 
than the corresponding dicarboxyl analogues. In Figure 30 the differences between the 
monoacid and malonic acid analogues are shown with two representatives 4F vs. 6F (left 
panel) and 4H vs. 6H (right panel)). The effect of these compounds on PDK1 activity I 
measured in parallel in a radioactivity kinase assay. It is obvious that all four compounds 
prompted the PDK1 activation in higher levels than 2Z, but the malonic acids were 
characterized by a more noticeable activation effect on PDK1. It must to be noted that we 
observed the highest activation potency with compounds 6F and 6H among the monoacid 
derivatives 6 A-D,F-I,K,N,Q-S,U. However, in our effort to obtain very potent and selective 
PDK1 activators we directed the attention to the malonic acid analogues for further 
experiments. For some compounds AC50 values could not be accurately determined because 
they went below the concentration of enzyme present in the assay. Attempts to measure Kd 
values by ITC failed because of the highly exergonic dilution behavior of the malonic acid 
derivatives. Instead, a novel technique called thermophoresis was employed to measure the Kd 
of 4H, which was found to be 70 nM. 
 
Figure 30: Comparison of the effect of the dicarboxylic compounds 4F and 4H on PDK1    
                  activity versus the appropriate monoacid analogues 6F and 6H 
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3.2.3.2. PIF pocket Mutant Assay to confirm that compound 4H activates 
PDK1 by targeting the PIF-binding pocket 
The series of 2-(3-oxo-1,3-diphenylpropyl)malonic acids (IV) reached higher levels of 
PDK1 activation in vitro in comparison with the first presented series of 3,5-diarylpent-2-
enoic acids. In order to verify the binding site of the compounds we performed mutation 
experiments like we performed already for the previous compound class III. Laura Lopez 
Garcia (Biondi group) characterized the binding site of the compound 4H on different PIF 
pocket-binding mutants of PDK1 measuring the activity in the presence or absence of 4H and 
comparing the results with the PIFtide. The results gave the evidence that 4H requires the PIF 
pocket of PDK1 as the target site.154 
In addition to the mutation analysis we utilized Alpha-screen technology to investigate the 
ability of the compounds to displace the PIFtide binding. In this way we could corroborate 
that the effects were mediated by binding of the compounds to the PIF-binding pocket. In 
fact, Laura Lopez Garcia was able to show that compound 4A and 4H displaced the binding 
of the PIFtide with comparable potency indicating that both compounds display the same 
affinity to the PIF pocket despite differences in their activation potency toward PDK1.154  
In summary, the in vitro data presented in  3.2.3.1, the biochemical studies performed with 
PIF pocket binding mutants and the Alpha-screen displacement study confirmed that the PIF-
binding pocket serves as the binding site for compound class IV. Moreover, the results 
indicated once again the importance of the carboxyl moiety which is essential to prompt the 
activation of PDK1 targeting the phosphate binding site residues. And finally, two 
carboxylate groups enhanced the affinity to the PIF pocket. 
 
3.2.3.3. Cell permeation studies using a prodrug strategy 
All dicarboxylic acid compounds were inactive in cellular assays. Due to the high polarity 
of the carboxylate groups the free acid containing compounds did not penetrate the cell 
membrane. In an effort to improve the bioavailability a prodrug strategy was developed and 
investigated. In the past years the prodrug approach has been increasingly used when drugs 
have unattractive physicochemical properties such as poor aqueous solubility, low 
lipophilicity and chemical instability. Prodrugs as inactive derivatives will be converted into 
the pharmacologically active drug within the cells by chemical or enzymatic 
transformations.155 Due to the fact that in most animal and human tissues esterase activity can 
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be found the esterification of the available carboxylate groups constituted an obvious and 
proven prodrug strategy. Since we wanted to explore the suitability of our compounds as 
potential enhancers of insulin signaling and glucose uptake in particular, the L6 skeletal 
muscle cell line was chosen as a model cell line.156 Thus, we used the corresponding methyl 
and ethyl malonate derivatives of the diacids as prodrugs (Scheme 12), particularly because 
these kind of esters were available as the precursor of the 2-(3-oxo-1,3-
diphenylpropyl)malonic acids. Nevertheless, this attempt failed due to the resistance to 
cleavage by esterase enzymes in the rat L6 skeletal muscle cell line. Indeed, the best known 
prodrugs are alkylesters,153 however, many of them are not labile enough in vivo to ensure a 
sufficiently high rate and extent of prodrug conversion. For example, simple alkyl ester of 
penicillins have no therapeutic potential.153, 157 Another probable reason can be attributed to 
the steric crowding.  
 
Scheme 12: Performed prodrug strategies and the hydrolysis of the bisacetoxymethyl ester       
                    analogue 6H 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Since there was no cell permeation of the malonic acid 4H we tested the permeability of the corresponding 
prodrugs 2H and 5H. Prodrug 5H was found to be metabolic labile and its enzymatic hydrolysis resulted in the 
free malonic analogue 4H. 
 
 
In case of this drug class these problems were overcome by preparing an acyloxyalkyl 
ester, which in general shows a higher enzymatic lability in cells than simple alkyl esters. 
Thereby the acyloxyalkyl ester undergo initial enzymatic cleavage of the terminal ester to 
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generate an unstable intermediate, the hydroxymethyl ester, which rapidly dissociates to the 
free acid analogue and formaldehyde.153, 157, 158  
We synthesized the bisacetoxymethyl esters 5A,H and 5Q starting from selected malonic 
acid derivatives. As expected these ester derivatives were inactive in cell-free assays. The 
para-trifluormethyl malonic acid analogue 4H turned out to be the most potent PDK1 
activator. Thus we selected its prodrug 5H for the evaluation of its ability to cell permeation 
and hydrolysis to the potent analogue 4H within the cells. 
The cellular conversion of bis(acetoxymethyl) 2-(3-oxo-1-phenyl-3-(4 (trifluoromethyl)-
phenyl)propyl) malonate was evaluated using the rat L6 skeletal muscle cell line which 
displays esterase activity in the differentiated form.31 Prior to each experiment, before 
treatment with compound 5H, L6 cells were serum-starved (2 % FBS containing medium) for 
4 days to transform them into myogen differentiated cells. The accumulation of the prodrug 
(5H) and the corresponding 2-(3-oxo-1-phenyl-3-(4-(trifluoromethyl)phenyl)propyl-)malonic 
acid (4H) in cells was monitored by mass spectrometry. The samples were subjected to the 
HPLC analysis after purification by extraction with ethyl acetate under acidic conditions, 
followed by subsequent separation of the supernatant, evaporation to dryness and 
resuspension in methanol. The bisacetoxymethyl ester displayed good membrane permeability 
and released to the free dicarboxylic acid form inside the cells upon enzymatic hydrolysis 
which occurred most likely in two steps, as already established for the acyloxyalkyl ester of 
penicillin. Firstly, enzymatic cleavage of the terminal ester formed the highly unstably 
bis(hydroxymethyl) 2-(3-(4-chlorophenyl)-3-oxo-1-phenylpropyl)malonate and secondly, the 
dissociation to 4H and formaldehyde. The formation of the corresponding malonic acid 4H 
occurred in a linear concentration-dependent increase after 3 hours (Figure 31A).  
For the subsequent analysis of prodrug degradation and the release of the compound 4H 
we chose a concentration of 20 µM of the used prodrug. The prodrug degradation of 5H 
appeared only in moderate concentrations in the cells and declined steadily, thereafter, most 
likely because of the rapid conversation of 5H in the cytoplasm. In contrast, the accumulation 
of the malonic acid 4H derivative increased and was maximal after approximately 60 min of 
incubation (Figure 31B). A disappearance of the corresponding prodrug, shown in the same 
figure, was noted. In a further experiment we measured the stability of the prodrug in tissue 
culture medium (DMEM). We observed that after one hour, the prodrug form was also 
degraded to more than 90 % in the cell medium, probably because of esterases leaking from 
the cells. However, the results of the hydrolysis of the prodrug to the free dicarboxylic acid 
with different concentrations and the enhanced formation of the corresponding malonic acid 
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despite the degradation of the prodrug suggest that the process of the intracellular release of 
the prodrug is no the limiting step. The above mentioned decay of the prodrug seems to be 
caused using the medium. Otherwise, an additional influence of the cell esterases would likely 
lead to an absence of the prodrug and drug in the cells leaving the disintegrated and high polar 
target compound in the medium.  
 
Figure 31: A: Dependency of intracellular formation of 4H on the prodrug concentration. 
                  B: Time course of the intracellular accumulation of 4H and concomitant dis-             
                       appearance of the prodrug 5H. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The prodrug 5H is efficiently taken up by rat L6 cells and converted into the active compound 4H. A: L6 cells 
were incubated for 2 h with the indicated concentrations of prodrug 5H, then extracted with ethylacetate and the 
content of 4H quantified using HPLC-MS/MS. B: L6 cells were incubated with 20 µM of the prodrug 5H or 
with 4H for the indicated times, the cells extracted and the compounds quantified. Analysis revealed that 4H 
(▲) is released from 5H (♦)in a time-dependent manner, whereas 4H itself is not cell-permeable (●).  
 
 
In parallel we analyzed whether the free malonic acid can accumulate in the cells using 
the same experiment conditions like for 5H. This compound could not be detected neither in 
the soluble nor in the insoluble cell fractions indicating that it does not enter any cell 
compartment (data not shown).  
Having established that 5H accumulated in L6 cells and released large amounts of 4H, we 
further characterized via cell fractionation the distribution of the prodrug 5H and of the 
produced target molecule 4H. For this purpose, the cells were incubated with 4H and 5H, 
then disrupted mechanically by an ultrasound sonotrode and the cell debris was separated by 
centrifugation. After the addition of HCl and the extraction with ethyl acetate the samples 
were quantified by LC-MS. As expected in case of incubation with 4H there was no 
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compound detectable both in the cell pellet and in the supernatant. In case of 5H the 
converted malonic acid derivative was only detectable in the supernatant, thus ruling out 
enrichment in the cell membrane fraction.  
Taken together, the bisacetoxymethyl ester analogues of IV has been shown to function as 
prodrug that is capable of increasing cell permeability as evaluated in rat L6 skeletal muscle 
cells and opened the way for evaluation of the activity of this kind of compounds in cells.  
 
3.2.3.4. Proof of mechanism in cells: allosteric activators of PDK1 inhibit 
PIF pocket dependent pathway but not PKB pathway 
The results from the prodrug approach showed that it is possible to improve significantly 
the cell permeability of 2-(3-oxo-1,3-diphenylpropyl)malonic acids. The bisacetoxymethyl 
ester prodrug (5H) exhibited good cell permeation and enzymatic hydrolysis to the free 
malonic acid analogue (4H). Having shown that 4H is a very potent PDK1 activator in cell 
free assays, we focused to the next goal: the proof of mechanism in cells. It was essential to 
investigate if the compound that is directed to the PIF pocket in PDK1 would inhibit the 
phosphorylation of kinases whose require the docking of their P-HM to the PIF pocket of 
PDK1 (Figure 32, top panel). As described in more details in chapter  1.5 PDK1’s PIF pocket 
is necessary for the docking with substrates such as S6K, SGK and RSK and results in full 
activation of these kinases. The only exception is PKB whose phosphorylation does not 
depend on docking interactions with the PIF pocket.  
For this purpose, HEK293 cells were treated with the prodrug 5H and the effects of the 
compounds analyzed by immunoblotting using fluorescence-labeled secondary antibodies.154 
Results showed an inhibition of S6K activation without affecting PKB (data not shown). The 
dicarboxylic compound 4H that was measured in parallel did not show any effect in HEK293 
cells, according to its high polarity and lack of ability to permeate cell membranes. These data 
supported that compound 5H was cell permeable and that its active metabolite 4H blocked the 
PIF pocket for interaction with S6K.  
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Figure 32: Proof of mechanism scheme. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thus we were able to proof for the first time the novel mechanism of action of a small 
molecule targeting the PIF pocket of PDK1. Furthermore, these experiments had confirmed 
5H as an invaluable tool to further analyze the effects of PIF pocket inhibition in a range of 
diseases in which PDK1 was involved. In this regard, we observed an inhibition of PDK1’s 
substrate S6K (Figure 32, lower panel) that is involved in cell growth and survival processes 
playing an essential role in tumor cells.18, 19 Due to the lack of inhibition of PKB affecting the 
PDK1 PIF pocket and due to S6K’s influence of the insulin receptor substrate-1 (IRS) 5H has 
also become interesting for treatment of diabetes type-2. As already described in more details 
in chapter  1.3, S6K regulates the insulin action via a negative feedback mechanism and 
increased activity of S6K was observed in obesity and diabetes type-2. Nevertheless, for this 
purpose, more experiments are necessary and have to be performed.  
 
3.2.4. Crystal structure of PDK1 in complex with 2-(3-(4-chlorophenyl)-3-
oxo-1-phenylpropyl)malonic acid (4A)  
To gain insight into the mode of binding of the dicarboxylic compounds with the protein 
cocrystallization of 4A by soaking the compound with the His-PDK1 50-556 form was 
carried out by our collaborator Jörg Schulze from Biondi’s group. The cocrystal structure 
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shows the location and interactions of the two carboxylates (Figure 33). 4A contains the same 
two ring systems as 2Z, previously published.20 One carboxylate group occupies a position 
similar to 2Z, interacting with Lys76, Thr148 and Arg131. The second carboxylate group 
forms an additional salt-bridge interaction with Arg131, which plays an important role in the 
allosteric activation mechanism. The structure highlights the importance of Arg131 in the 
mode of action of the allosteric activators of PDK1. The description of the allosteric changes 
and overall influence on the PDK1 conformation is beyond the scope of this work. 
 
Figure 33: Crystal structures of PDK1 in complex with 2Z and 4A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.5. Chromatographic Separation of the Enantiomers of 4H  
The compound class of 2-(3-oxo-1,3-diphenyl-propyl)malonic acids (IV) (Scheme 9) was 
obtained by an addition of malonic ester to the corresponding chalcone (chapter  3.2.2) 
resulting in a racemic mixture. All the synthesized compounds possess a chiral center which 
is expected to confer to the enantiomer distinct activities toward the kinase PDK1. To analyze 
whether the biological activity was more or less restricted to one of the distinct stereoisomers, 
we attempted to separate the enantiomers via chiral HPLC. For this experiment, we chose 
compound 4H since it was the most potent analogue toward PDK1 and since it was selected 
for the prodrug evaluation. Within a student’s project in the field of specialization in 
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medicinal chemistry Michael Zender had the challenge to separate different racemic mixtures 
in cooperation with Kazmaier’s group. Besides other compounds, he was able to obtain the 
individual enantiomers of the compound 4H using a chiral HPLC method (Figure 34 and 
Figure 35). Unfortunately, there was no time to assign the absolute stereochemistry of the 
stereoisomers. But, testing of the enantiomerically pure forms separated by chromatography 
in vitro toward PDK1 (Table 13) we proved that Enantiomer 2 was significantly more potent. 
Having additionally the cocrystal structure of the active compound 4H with the PDK1 we can 
suggest that Enantiomer 2 is the (S)-2-(1-phenyl-3-(4-(trifluoromethyl)phenyl)-propyl)-
malonic acid since the malonic acid moiety is turned toward the amino acids Arg131, Lys76 
and Thr148 (Figure 33). Having found that the S-enantiomer is the eutomer, accounting for 
most of the biological activity of the racemate, future optimization schemes should include 
the enantioselective synthesis of the S-enantiomers. 
 
Table 13: PDK1 activity of the individual enantiomers of 4H. 
 
 
Cpd. 
 
[µM] PDK1 
(%) 
2 131 
50 268 
Enantiomer 1 (R) 
 
200 291 
2 326 
50 562 
Enantiomer 2 (S) 
 
200 545 
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Figure 34: Enantiomer 1 
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Figure 35: Enantiomer 2 
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3.2.6. Discussion and Conclusion 
With the compound series of 3,5-diphenylpent-2-enoic acids (III) we have already 
provided evidence that compounds blocking the PIF-binding pocket might be able to prevent 
phosphorylation of PDK1 substrate proteins. An important requirement for potent activators 
of PDK1 is a carboxyl moiety that can mimic the phosphate group of phosphoserine/-
threonine residues from natural ligands, which is expected to bind to the equivalent site. With 
the aim of further increasing potency, we modified the lead compounds I and III by 
introduction of a second carboxyl function. Indeed, compared to the monocarboxylic acids I 
and III, the dicarboxyl function generally caused a considerable increase in activatory 
potency and affinity. This observation might parallel several earlier reports on 
phosphotyrosine mimetics which also profited from two negative charges, e.g. malonic acid 
residue or combination of COOH and tetrazole. Cyclohexylmalonic acid as nonpeptidic 
tyrosine kinase, SykCSH2, inhibitor was identified as a potent phosphotyrosyl mimetic159 and 
in the case of the growth factor receptor-bound protein-2 bicarboxyl analogues bind to the 
SH2 domain 2 with similar strength as the phosphonate-based phosphotyrosyl mimetics do.160 
However, it remains to be seen whether the malonic group of the here presented 2-(3-oxo-1,3-
diphenylpropyl)malonic acids 4A-V occupies the same space as the phosphate moiety of the 
natural peptide ligands of PDK1. A complex between PDK1 and a corresponding 
phopshopeptide has not been published so far.  
Different 2-(3-oxo-1,3-diphenylpropyl)malonic acids were synthesized and tested for their 
potency toward PDK1 and other AGC kinases (Table 11 & Table 12). The most potent 
activators were 4F,O,U and 4V two of which contained a p-iodophenyl moiety. Halogen 
bonding has been demonstrated to increase the binding affinity. It is presumable that iodine 
mainly interacts with hydrophobic pocket space via Van der Waals attraction, however the 
data suggest that halogen bonding to carbonyl of Lys 115 might also contribute to the binding 
affinity. The increase in affinity as assumed based on the AC50 values was only 1.8-fold from 
4A (4-Cl) to 4D (4-Br), but 3.5-fold from 4D to 4F (4-I). This jump from 4-Br to 4-I is in 
accordance with the highest halogen binding potential of iodine but may also be a 
consequence of the shorter distance to the Lys115 carbonyl. Even though the cocrystal 
structure of 4F with PDK1 showed the distance between p-iodine and the Lys-backbone 
carbonyl exceeds 4 Å, thus being too large for significant interaction according to the 
literature value 3.50 Å.161 This cannot rule out the possibility of halogen bonding in solution, 
which might just be impaired by the rigidity of the crystallized protein. At least, the cocrystal 
discloses a clear orientation of the iodine toward the carbonyl oxygen. Our experimental data  
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also argue for an iodine contribution to binding that exceeds the Van der Waals interactions 
seen in the cocrystal.  
It can well be assumed that the conformation displayed in the cocrystal does not reflect 
the fully active conformation of PDK1 as induced by compound binding in solution. In this 
respect further experimental verification of the potential halogen bonding is required, e.g. by 
NMR techniques. An alternative explanation independent on halogen bonding might be that 
the size of the halogen determines the positioning of the compound which influences the 
interaction of the COOH groups and/or the carbonyl group with the protein.162 The activatory 
potency of 4O, 4U and 4V was comparable to that of the 3 kDa peptide PIFtide, and the 
activation efficacy of the small compounds was also within the same range. Therefore, the 
degree of potency is now sufficient to perform studies in a cellular setting since PIFtide itself 
has been used for the same purpose previously.1 Our small molecule compounds contain 
extended pi-system which are participating in extended hydrophobic and Van der Waals 
interactions and may additionally contribute to a potential cation-pi interaction with Lys115 
(docking not shown). 
A successful application of a prodrug approach was demonstrated by introducing an 
acetoxymethyl ester function to the corresponding malonic acid analogues. This was used to 
overcome various undesirable chemical properties of acidic compounds and to enhance their 
bioavailability. Increase in the lipophilicity of the parent hydrophilic compounds resulted in 
good membrane permeability and intracellular accumulation after esterase-catalyzed cleavage. 
In agreement, we observed that the prodrug disappeared concomitantly with increasing 
amount of the malonic acid analogue. In spite of the serum instability of 5H a promising 
strategy for an efficient drug delivery and a promising starting point for the generation of 
cellular efficacy could be achieved. As demonstrated in previous reports, the stability of the 
prodrug toward serum esterases such as acetylcholin esterase can be fine tuned by variation of 
the acyl group; for instance, exchange to a pivaloyl function might increase serum stability 
while still permitting intracellular cleavage.163-165 
Further experiments aiming to analyze the compounds´ effect on the intracellular PDK1-
dependent signaling pathways were additionally possible using the prodrug form. Especially, 
we were able to demonstrate the proof of mechanism applying the prodrug 5H in HEK293 
cells followed by western blot analysis. As expected, the intracellularly released compound 
4H blocked the PIF pocket of PDK1 for interaction with the substrate S6K without affecting 
the substrate PKB. This approach enabled with additional experiments to suggest these 
compound series (IV) for treatment of cancer and diabetes type-2.  
                                                                                                                                           Results 
 88 
The binding mode was elucidated by cocrystallization and X-ray analysis. Indeed it was 
very similar to III (Figure 33) binding mode with one of the carboxyl group (being located in 
the same pocket space) overlapping with the carboxyl group in III. The additional carboxyl 
function exclusively formed a salt bridge with Arg131 suggesting that this electrostatic 
interaction was mainly responsible for the observed increase in affinity. Maximum activation 
was higher on average than observed with the 3,5-diphenylpent-2-enoic acids, indicating that 
stronger allosteric changes must occur which can now be analyzed by comparing with co-
crystals formed with weaker activators (not within the scope of this work). Thus, our 
compounds allow for the first time to investigate the conformational changes underlying the 
allosteric activation mechanism. Fixation of Arg 131 by strong electrostatic interactions is 
crucial for the activation mechanism not only for binding affinity. This is also corroborated by 
the mono carboxyl analogues of selected malonic acid derivatives, which display both weaker 
binding and lower activation efficacy (4H compared to 6H in Table 11). Moreover, via chiral 
HPLC we were able to obtain specific chiral forms of the compound 4H. Retesting for their 
effect on PDK1 and with the help of the cocrystal structure we suggested the S-Enantiomer as 
the bioactive chiral form.  
In conclusion, we have shown that modifying the lead compounds I and III by 
introduction of an additional carboxyl group has clearly improved the activity and selectivity 
profile of the PDK1 activators. Finally the cocrystal structure has proven the importance and 
the influence of the second carboxyl group. Furthermore, we have provided an efficient 
prodrug strategy to deliver the highly polar compounds to the cellular cytoplasm, thus 
rendering them applicable to cellular studies. Thus, we were able to provide the proof of 
mechanism. 
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3.3. Evaluation of 3,5-diphenylpent-2-enoic acids´ inhibitory effect 
toward PKCζ: allosteric kinase inhibition targeting the PIF-
binding pocket 
3.3.1. Introduction 
Regarding the specificity of the 3,5-diphenylpent-2-enoic acid class, III (presented in  3.1) 
against a panel of AGC kinases, we found out a tendency to affect the activity of the zeta 
isoform of the PKC family (PKCζ). Thereby, compounds with the substitution pattern of the 
phenyl moiety A with expanded aromatic systems (Table 5, chapter  3.1.3.1) stood out. 
Interestingly, we have noticed that the PIF pocket-directed compounds are able not only to 
stabilize an active conformation of individual kinases, e.g. PDK1, but they are also able to 
inhibit kinase activity. These results induced us to invest more effort in this project in order to 
obtain further insight into the impact of explored aromatic systems on the inhibition of PKCζ. 
Especially since PKCζ constitutes an interesting target containing the unique feature to 
activate the eukaryotic transcription factor NF-κB which is involved in the transcriptional 
activation of proinflammatoric and anti-apoptotic genes.87, 95 The direct inhibition of NF-κB 
would trigger toxic effects because of its numerous functionalities to the conservation of cell 
integrity in all tissues (chapter  1.11).104, 105 In contrast, PKCζ performs the activating 
interaction only in selected cells and tissues (e.g. lung tissue). Hence, the inhibition of PKCζ 
provides a promising strategy to treat chronic inflammatory diseases as well as different types 
of cancer without influencing a ubiquitous inhibition of NF-κB. Also the PKCζ knockout 
studies (chapter  1.11) have been suggested PKCζ as a qualified target revealing viable mice 
with nearly normal developed organs only with the exception of a deficiency for the 
activation of NF-κB that was observed e.g. in lymph cells and in lung.84, 90, 91  
Usually, the drug design of protein kinase inhibitors is focused on the ATP-binding 
domain. But due to the existence of 11 isoenzymes of the PKC family the search for selective 
PKCζ’s ATP-directed compounds has been proved to be more challenging. Moreover, the 
binding affinity for PKCζ’s substrate, ATP, is measured as KM = 3.3 µM. This value is 
relatively low and thus implies that the ATP-competitive inhibitors should have a Ki - value in 
a subnanomolar range to reach a significant inhibition in vivo. Consequently, there are no 
ATP-competitive inhibitors described so far.  
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Here we will present the structure optimization of 3,5-diphenylpent-2-enoic acids 
expanding the aromatic systems using the PIF pocket strategy as already presented for PDK1 
in the previous chapters  3.1 and  3.2. First, the space availability in PKCζ’s PIF pocket will be 
investigated varying the aromatic moieties in order to increase the inhibition effect and 
selectivity. Although the PIF pocket of PDK1 was relatively well filled by 2Z as presented in 
the cocrystal structure in Figure 24, we suppose that the flexibility and ability to undergo an 
induced fit might differ between the two PIF pockets (PDK1 vs PKCζ). Secondly, we will 
establish an adequate high-throughput screening assay which allows determination of the 
inhibitory activity toward PKCζ in cells.  
 
3.3.2. Synthesis 
To develop small molecule inhibitors with enhanced activity toward PKCζ compounds 
15Z and 16Z (Figure 36) were chosen as leads for the design and synthesis. Thus, the 
preparation of the new structures was performed according to our previous procedure as 
presented in the optimization study of the class of 3,5-diphenylpent-2-enoic acids as 
activators of PDK1 (chapter  3.1.2).20, 75 
 
Figure 36: Allosteric inhibitors design concept 
 
 
 
 
For substituents Ar2 and Ar3 see Table 14 and Table 15. 
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The synthetic pathway affording the final compounds 26E-33E and 26Z-33Z is depicted 
in Scheme 13. In pursuing our aim to further explore the aromatic systems we could retain the 
synthetic steps as already done in Scheme 5 expanding only the phenyl moieties. Thus, in the 
first step of the synthesis the corresponding, commercially available, benzaldehydes and 
acetophenones derivatives reacted together in a classical aldol condensation. This step was 
followed by a chemoselective reduction of the double bond of the individual chalcones. Via 
Horner-Wittig reaction using phosphonoacetate we introduced the acrylic acid side chain. 
This reaction led to E/Z mixtures which we were able to separate by flash chromatography. In 
the last step the pure geometric isomers were afforded by hydrolysis. More details of the 
synthetic route are described in chapter  3.1.2. 
 
Scheme 13a: Synthesis of compounds 26E-34E and 26Z-34Z 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a: Ar = aryl, heteroaryl; (i) bromomethyl-methylether, NaH, DME, 0 °C, 1 h; (ii) Method A: NaOH, EtOH, 1 h, 
rt; (iii) Method B: 3,5-bis(ethoxycarbonyl)-1,4-dihydro-2,6-dimethylpyridine, toluene, silica gel, 70 °C, 16 h; 
(iv) Method C: triethyl phosphonoacetate, NaH, DME, 80 °C, 4 h; (v) 10 % HCl, methanol, reflux, 2 h; (vi) 
Method D: NaOH, EtOH, rt, 3 h. For substituents Ar2 and Ar3 see Table 14 andTable 15. 
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The only one exception constituted the substances 34 (Scheme 13). The nucleophilic 
alcohol function of the aldehyde had to be protected for the synthetic pathway. For this 
purpose, we chose the methoxymethyl (MOM) group accordingly to the method already 
described for 2-(3-oxo-1,3-diphenylpropyl)malonic acid (4M) in  3.2.2. 152 With the obtained 
6-(methoxymethoxy)-2-naphthaldehyde (34e) and the 1-(naphthalen-2-yl)ethanone we were 
able to synthesize the corresponding chalcone 34c which was converted to the desired E and Z 
ethyl 5-(6-hydroxynaphthalen-2-yl)-3-(naphthalen-2-yl)pent-2-enoates (34Ea1 and 34Za1) in 
two steps. Afterwards the cleavage of the protecting group was performed under acidic 
conditions furnishing 34Ea2 and 34Za2 which were in turn hydrolysed into the target 
molecules 34E and 34Z.152 
 
3.3.3. Biological results and Discussion 
3.3.3.1. Biological characterization in vitro of the synthesized PKCζ 
inhibitors 
The activity of the compounds toward PKCζ was determined by performing our 
previously described radioactivity kinase assay.74 The radioactivity incorporation of 32P 
phosphate from [γ-32P]ATP into PKCζ‘s substrate myelin basic protein (MBP) was here 
measured (in duplicates) and was done by our collaborator group under the supervision of Dr. 
Ricardo M. Biondi. The biological results for the new compounds are shown in Table 14 and 
Table 15 (cell free), whereas the percent inhibition values were determined at concentrations 
50 and 200 µM and were compared to the control values with DMSO. To enable a better 
comparison of the structure-activity relationships we added also the SARs of the starting 
compounds 15 and 16 into the same table.  
In our aim to investigate the spatial limitations of PKCζ’s PIF pocket we extended our 
library with several compounds. These can be divided into two groups according to the Ar 
residues (Ar2 and Ar3). On the one hand; in the first group (I) we chose para-chlorophenyl as 
Ar2 introducing different aromatic substituents on the Ar3 moiety as presented in Table 14. 
This strategy arises from our previous results with the PIF-binding pocket of PDK1 which 
revealed that ring substitutions with halogens improved the enzyme activity within this series 
(Table 3). Consequently, we decided to investigate the impact of the nature of the p-
chlorophenyl moiety on the potency and selectivity toward PKCζ. On the other hand; our ITC 
study with the 3,5-diphenylpent-2-enoic acids disclosed compound 16Z as enthalpically 
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favourable what can be attributed to the CH-pi interactions most likely due to the high pi-
electron density of the unsubstituted fused rings combined with the large surface. Thus, in the 
second group (II) we varied the Ar2 moiety focussing Ar3 by naphthyl group (Table 15). 
In contrast to the results obtained with the first 3,5-diphenylpent-2-enoic acid series when 
tested toward PDK1 (chapter  3.1.3.1) and despite the restricted bond rotation by the double 
bond, the new geometric isomers (26-34Z & 26-34E) did not display a discernible trend to the 
difference in intrinsic potency toward PKCζ. Already the parental compound 16 showed this 
characteristic. The isomer carrying the carboxyl group cis relatively to the Ar3 moiety as well 
as the isomer with the opposite conformation disclosed a relatively similar inhibition efficacy 
toward PKCζ. Nevertheless, the E- and Z-isomers of compounds 29-32 still differed in their 
PKCζ‘s activity. The cis isomers (29-31Z) displayed high inhibition potency. The 
corresponding trans isomers (29-31E) exhibited even an increase of activation potency of 
PKCζ. The only exceptions represented the quinoline derivatives (32Z and 32E) influencing 
PKCζ with an opposite effect. 32Z prompted an activation effect on PKCζ and 32E triggered 
an inhibition.  
Among the group I, compounds bearing a naphthyl moiety (26 and 27) showed a similar 
inhibitory activity as the parental compound 16. The inhibition was in the range of 90 % when 
tested at 200 µM as well as at 50 µM. The maximum inhibitory effect reached by the para-
methoxy derivatives (28Z and 28E) did not exceed 76 % at 200 µM and decreased completely 
already at 50 µM (28Z). The introduction of a biphenyl group on Ar3 led in case of the E 
isomer to the absence of inhibitory effect turning out to be a weak PKCζ activator.  
These results suggest that an aromatic residue with fused rings as Ar3 is favored for the 
inhibitory effect whereas the para substitution patterns led to an abolishment of the inhibition 
up to activation of the enzyme. Moreover, the contribution to the biological activity of both 
isomers (cis and trans of 26 and 27) may be a result of additional space surrounding the 
hydrophobic PIF pocket which allowed greater flexibility of positioning of the naphthyl 
group. We can suppose that both arrangements of the naphthyl group in the PIF pocket 
enabled good electrostatic interactions of the carboxylic side chain with the corresponding 
amino acid (Lys301 that is equivalent to Arg131 in PDK1) what has to be investigated by co-
crystallization experiments. 
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Table 14: Group I: Inhibition of recombinant PKCζ and of the NF-κB pathway in U937 cells 
 
 
 
 
 
 
Cpd Ar2 Ar3 
PKCζ 
cell free 
 
% inhibition 
 
NF-κB 
reporter gene assay (U937 cells) 
 
% inhibition 
   
200 µM 50 µM 40 µM 10-1 µM 
15Z 
15E 
 
 100 
60           
90 
ne 
59 
87 
nd 
nd 
16Z 
16E 
  
100 
100           
85 
70 
nd 
84 
nd 
nd 
26Z 
26E 
 
 99 
86           
93 
82 
100 
100 
nd 
82 @ 5 µM 
27Z 
27E 
  95 
99           
89 
93 
100 
100 
nd 
nd 
28Z 
28E 
 
 
76 
55           
ne 
10 
18 
26 
nd 
nd 
29Z 
29E 
 
 92 
act           
nd 
act 
 
nd 
nd 
77 @ 5 µM 
78 @ 5 µM 
 
                nd: not determined; ne: no effect; act: compound showed an activation of the enzyme 
 
 
Group II includes compounds with extended aromatic residues on both Ar moieties 
leading to generally lower inhibitory potency than the analogues from group I. The good 
potency of compounds 26 and 27 prompted us to synthesize analogues with two naphthyl 
groups to figure out the variability of the PIF pocket shape. Indeed, the twofold naphthyl 
substitution resulted in good inhibition, but did not exceed the values of the mononaphthyl 
derivatives 26 and 27. Moreover, the inhibition of 90 % at 50 µM was only achieved by the 
cis isomer, the compound with the opposite conformation reached only 25 %. These results 
seem to demonstrate that enlarging the target compound size only the cis conformation might 
reach the position to interact with the hydrophobic moiety and amino acids relevant for the 
carboxyl moiety of the binding site. In order to further explore the ligand space and the 
structural features of the PIF pocket we introduced also a 6-hydroxynaphthalen as Ar2 (34) 
and we transformed the naphthyl group into a quinoline (32). Compound 34 influenced the 
Cl
Cl
Cl O
Cl
Ar3
COOH
Ar2
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PKCζ activity by a less inhibition in comparison to the twofold naphthyl derivative (30) but 
with this substitution pattern, having a polar group, again both isomers affected the kinase. 
The cis quinoline derivative triggered activation and the trans isomer showed a moderate 
inhibition.  
 
Table 15: Group II: Inhibition of recombinant PKCζ and of the NF-κB pathway in U937 cells 
 
 
 
 
Cpd Ar2 Ar3 
PKCζ 
cell free 
 
% inhibition 
 
NF-κB 
reporter gene assay (U937 cells) 
 
% inhibition 
   
200 µM 50 µM 40 µM conc 
15Z 
15E 
 
 100 
60           
90 
ne 
59 
87 
nd 
nd 
16Z 
16E 
  
100 
100           
85 
70 
nd 
84 
nd 
nd 
30Z 
30E 
  nd 
nd 
89 
25 
nd 
nd 
83 @ 5 µM 
98 @ 5 µM 
31Z 
31E 
  81 
8.0           
60 
nd 
nd 
nd 
67 @ 10 µM  
67 @ 10 µM 
32Z 
32E 
  act 
63          
nd 
nd 
nd 
nd 
13 @ 10 µM  
1 @ 10 µM 
33Z 
33E 
  20 
act 
nd 
nd 
 
nd 
nd 
9 @ 1 µM  
4 @ 1 µM 
34Z 
34E 
  85 
82 
nd 
nd 
 
nd 
nd 
nd 
nd 
     conc: concentration; nd: not determined; ne: no effect; act: compound showed an activation of the enzyme; 
 
 
To further investigate larger aromatic systems we synthesized 5-(4-phenoxyphenyl)-3-
phenylpent-2-enoic acid isomers (31Z and 31E), whereas 31Z reached a moderate inhibition 
and 31E showed hardly any effect. Moreover, we examine the influence of 5-(biphenyl-4-yl)-
3-(naphthalen-2-yl)pent-2-enoic acid on the PKCζ activity which exhibited only 20 % 
inhibition as cis isomer (33Z) and triggered a weak activation as trans isomer (33E). 
O
N
HO
Ar3
COOH
Ar2
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However, the inhibitory potency among the compounds bearing extended aromatic functions 
on both Ar residues dropped in accordance with the para substitution of Ar2. This fact is in 
contrast to the results of group I which revealed the p-chlorophenyl derivatives (26 and 27) as 
the most potent PKCζ inhibitors in vitro in this study. It appears that the inductive effect of 
the halogen plays an important role in the hydrophobic subregion of the binding pocket. 
However, compounds 26, 27 and 30Z appear to be the best inhibitors in this series proving the 
fused rings (naphthyl) as a promising feature of the core structure to reach good affinity for 
the PIF pocket. 
In order to examine the selectivity of the new PIF-binding pocket-directed compounds we 
screened them additionally against a panel of AGC kinases (Group of Ricardo M. Biondi). 
Since we observed both an inhibitory and an activatory effect toward PKCζ, it was 
particularly interesting to know which effect the series would exert by binding to other AGC 
kinases. As already mentioned, by binding the PIF pocket the target compounds are able to 
stabilize the active conformation of the respective kinase or even lead to inhibition of the 
kinase activity. Table 16 shows the specificity of selected 3,5-diphenylpent-2-enoic acids. It 
should be noted that in contrast to the Table 14 and Table 15 the values are not given in 
percentage inhibition, but in percentage activation potency whereas the DMSO control were 
set at 100 % in order to simplify the comparison.  
Within the investigated series we focused on analogues with the most impact on PKCζ 
activity. It becomes apparent that compounds with the highest inhibitory efficacy toward 
PKCζ revealed to be only slight (26E, 26Z, 27E, 27Z) PDK1 activators. This fact we had 
already observed with the parental compounds. But it should be noted that these exhibited an 
elevated activation and the E isomers did not show any activity effect. Introduction of a 
chlorine atom and changing the position of the naphthyl moiety indicates that this substitution 
is more tolerated by the hydrophobic PIF pocket subregions of PKCζ and lead to loss of 
affinity toward PDK1. Moreover, compounds 26Z and 27Z turned out to have not only a good 
inhibition effect toward PKCζ but also a relatively good specificity toward its PIF pocket over 
the PIF pockets of the closely related AGC kinases. Both analogues influenced only slightly 
PDK1 and MSK, whereby 27Z affected additionally the AGC kinases S6K1 and SGK. 
Nevertheless, our strategy seems to be along a right direction, especially since we are looking 
for allosteric modulators of PIF pocket that is in contrast to the ATP binding site less 
conserved and stands out through differences in the amino acid sequences among the AGC 
kinases (Figure 20, chapter  1.13). While the mentioned analogues possess a specific PIF 
pocket affinity, the cis isomer of 3,5-di(naphthalen-2-yl)pent-2-enoic acid displayed an 
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inhibitory effect toward almost all closely related AGC kinases we tested. The data shown for 
31E and 31Z has not been yet completely investigated and thus these are not meaningful 
enough for the specificity.  
Interestingly, the compounds affected several of the investigated AGC kinases with a 
contrary effect at 200 µM in comparison with the values of 50 µM concentration. This 
anomaly can be attributed to ATP-competitive inhibition which might occur at high 
concentrations of the target molecules. From this perspective further investigations such as 
mutant studies and cocrystallization are necessary to provide the binding of the compounds in 
the PIF pocket. 
 
Table 16: In vitro specificity of selected analogues against a panel of AGC kinases 
 
 
Cpd. 
 
[µM] PDK1 (%) 
S6K1 
(%) 
PKCζ 
  (%) 
PKCι 
  (%) 
SGK 
(%) 
PKA 
(%) 
PRK2 
(%) 
RSK 
(%) 
MSK 
(%) 
26Z 50 225 60 7 90 60 72 148 230 30 
 
200 17 25 1 10 2 10 160 50 10 
26E 50 170 70 18 80 80 150 170 160 50 
 
200 58 100 14 30 40 50 114 60 80 
27Z 50 280 37 11 73 40 120 170 130 15 
 200 26 30 5 15 2 50 140 10 10 
27E 50 220 45 7 62 30 24 160 80 15 
 200 7 15 1 7 1 35 190 20 10 
30Z 50 70 34 11 48 16 nd 135 42 4 
 200 nd nd nd 3 nd nd nd nd nd 
31Z 50 nd nd 40 18 nd nd nd nd nd 
 200 109 12 19 0 52 nd 54 6 nd 
34Z 50 150 nd nd 67 nd nd nd nd nd 
 200 32 2 15 3 7 nd ne 6 4 
34E 50 nd nd nd 52 nd nd nd nd nd 
 200 19 2 18 4 6 nd 30 5 4 
     Values in % catalytic activity (DMSO-treated control = 100%)                                       nd: not determined 
 
 
A further essential item which has to be discussed is the comparison of the activity of the 
compounds toward the closely related atypical kinases PKCζ and PKCι. Interestingly, in the 
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presence of the compounds 26Z and 26E at 50 µM the basal activity of PKCι was hardly 
affected, suggesting high specificity for the PKCζ PIF pocket. There is also a certain 
selectivity given for compounds 27Z and 27E whereby these showed a slight inhibition of 
PKCι. In contrast, the remaining compounds seem not to be specific toward the target kinase.  
Altogether, the above data suggest compound 26Z as the most potent and specific toward 
PKCζ in vitro. Thereby, an increase in lipophilicity by an inductive effect (-I) due to a para-
phenyl substitution (Ar2) by a halogen and a naphthyl group (Ar3) proved to be important for 
enhancement of both potency and selectivity. Additionally, the results confirmed that the PIF 
pocket of PKCζ could transduce inhibition. Nevertheless, we could also observe activation 
potency with the investigated molecules. The difference was already caused by screening of 
the compounds with the opposite conformation.  
 
3.3.3.2. Biological characterization of 3,5-diphenylpent-2-enoic acids in U937 
cells 
Since we observed inhibition potency screening compounds from our library toward 
PKCζ in our routinary radioactivity kinase assay, we were interested to investigate their 
activity in cells on the target protein. For this purpose, we chose the human lymphoma cell 
line U937 because these cells displayed PKCζ expression in immunoblotting experiments 
(Figure 37A) and antisense oligonucleotides to PKCζ in turn was shown to control the 
HIVinduced NF-κB activity (Figure 37B).106, 166 Additionally, Filamenco et al. performed 
immunoblotting experiments with lymphoma U937 cell line which revealed PKCζ in a central 
position in the TNFα induced NF-κB activation pathway.107 
In order to analyze the effect of the synthesized compounds in this cell model we 
developed a luciferase reporter gene assay according to the principle of the canonical TNFα 
induced NF-κB activation pathway (Figure 17). The assay was established under the 
supervision of Dr. M. Engel by me and mainly by Nadja Weber who performed afterwards 
the screenings. 
Firstly, we transfected the lymphoma U937 cells with plasmid containing luciferase 
coding sequence. This plasmid expressed luciferase under control by NF-κB response 
elements as showed on the assay principle in Figure 38. Secondly, we validated the reporter 
gene assay with specific inducers to find out if the system would respond as expected. 
Therefore, we chose TNFα, C6 ceramide, an activator lipid of PKCζ and bacterial 
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lipopolysaccharides (LPS). We observed a strong induction of NF-κB activity using TNFα. 
C6 ceramide in turn influenced NF-κB weakly and LPS not at all. 
 
Figure 37: A: Immunoblotting experiment: PKC isoenzymes in U937 cells166  
                  B: Antisense oligonucleotides to PKC-ζ inhibit the HIV-mediated NF-kB  
                       activation in U937 cells166 
 
A                                                                            B 
 
 
 
 
 
 
 
 
 
 
 
A) Top panel: Within the group of classical PKC isoenzymes, only PKC-γ was detected in U937 cell lysates (U), 
while PKC-α, -βI and -βII, and -γ were present in the rat brain homogenate (B). 
Bottom panel: PKC-δ and PKC−ε were present in rat brain (B) but not in U937 cells (U). The aPKC isoenzyme, 
PKC-ζ, was detected in both U937 cell lysates (U) and rat brain homogenate (B). 
B) HIV infected U937 cells were co-transfected with a NF-κB reporter gene plasmid (3 kB Cona Luc) and sense 
or antisense oligonucleotides to PKC-ζ. 
 
 
In the next step we verified the inhibition of NF-κB activation induced by 
TNFα treatment using known ATP-competitive protein kinase inhibitors. Among others we 
tested the broad range kinase inhibitor Staurosporine which inhibited the NF-κB activation as 
expected. Moreover, we used UCN01 that inhibited only at high concentrations. Additionally, 
we chose known PI3K kinase pathway inhibitors, because many AGC kinases which also 
posses a PIF pocket are activated in the PI3 kinase pathway. Obtaining no inhibition effect 
with the known inhibitors LY294002 and Wortmannin, we were able to demonstrate that 
PI3K and PDK1 are not expressed and do not influence the assay.  
Under these established conditions the luciferase transfected U937 cell line was incubated 
with the synthesized compounds for three hours and was activated with TNFα for further two 
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hours. Subsequently, the luciferase activity was measured based on light production (Figure 
38).  
 
Figure 38: Luciferase reporter gene assay principle in U937 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assay principle: TNFα treatment of the cells leads to stimulation of the transcriptions factor NF-κB (essential 
contribution from PKCζ) inducing an anti-apoptotic signal whereby light is produced by oxidation of luciferin. 
An inhibitor induces apoptosis and leads to decrease of the lightproduction. 
 
 
As already described the stimulation of the cells with TNFα affected a sharp activation of 
NF-κB, so that we could determine the inhibition effect of tested compounds in comparison to 
DMSO as control. However, in Table 14 and Table 15 we summarized the cell data of our 
new developed target molecules which were incubated in duplicates and at different 
concentrations (40-1 µM). Several of the synthesized 3,5-diphenylpent-2-enoic acids inhibited 
the reporter gene activity. Comparing the potency of the compounds in the cell assay with the 
radioactivity assay it was obvious that compounds 26 and 27 did not only affected the target 
protein activity in vitro but also decreased the NF-κB activation, even totally at 40 µM in 
cells. Moreover, both geometric isomers of 29, 30 and 31 decreased also the reporter gene 
activity being incubated in U937 cells. These results show a good correlation of the inhibition 
effect in luciferase activity with the PKCζ inhibitory efficacy in cell free assay, but only for 
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the cis derivatives of 29, 30 and 31. The corresponding E isomers which had any inhibitory 
effect on PKCζ in vitro, triggered NF-κB inhibition. This fact indicates a non specific 
inhibition in cells. The remaining compounds did not affect the NF-κB activation in cells 
showing a good correlation to the results of the cell free assay. 
Another interesting point of view constitutes the disadvantages of the compounds. On the 
one hand, there is the carboxyl moiety that makes the cell permeability difficult and the 
hydrophobic aromatic moieties which are facing each other. Nevertheless, diffusion through 
biological membranes enabled the compounds to enter the cells. On the other hand, the high 
hydrophobicity of the compounds led to binding to the serum albumin what we found out 
performing the luciferase assay with and without bovine serum albumin. In further studies an 
important approach is to create the compound scaffold more drug-like via exchange of the 
naphthyl moiety with benzimidazole or –thiazole groups, especially since we know from our 
ITC experiments with PDK1 that fused rings are favored for enthalpy.  
Summarizing, the presented results suggest that the target molecules are able to bind the 
PKCζ PIF pocket in the cells. Furthermore, having the compounds 26 and 27 we present the 
most potent inhibitors in the reporter gene assay as well as in the kinase activity assay. 
Interestingly, we observed stronger inhibition of the compounds in cells than in the cell free 
assay. This might be due to the big advantage of allosteric inhibitors over the ATP site-
directed compounds whereby the ATP concentration is often responsible of an increase of the 
IC50. In conclusion there is again no activity difference between the isomers in cells. 
 
 
3.3.4. Conclusion 
This study demonstrates that analogues of 3,5-diphenylpent-2-enoic acids which were first 
identified as activators of PDK1 (chapter  3.1) have also a potential as PKCζ modulators when 
extended on the phenyl moieties (A, B, Figure 36). Biological evaluation revealed that 
introduction of p-chlorophenyl as Ar2 and 2- or 3-naphthyl as Ar3 (26, 27) led to potent PKCζ 
inhibitors. These results provide herein new insights on inhibition efficacy on AGC kinases 
that can occur by binding the PIF pocket. We were already successful in development of 
allosteric PKCζ inhibitors with an SAR study of 4-benzimidazolyl-3-phenylbutanoic acids as 
PIF pocket-directed compounds recently published by Dr. W. Fröhner et al.167 Though, 
additional PIF pocket mutant study indicated that this class of compounds mediated their 
effects via the PIF pocket.154, 167  
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In addition to the ability of the compounds to induce inhibition of the kinase targeting the 
PIF pocket both geometric isomers, 26Z, 26E and 27Z, 27E, turned out to be active 
substances. This is in contrast to the current results with PDK1 and applies especially to the 
most potent compounds 26 and 27. Nevertheless, these results were confirmed also in the 
developed U937 cell assay. Thus we succeeded in proving the PKCζ inhibition also in cells 
for 26Z, 26E and 27Z, 27E. With these most potent compounds in vitro as well as in cells we 
found also specific compounds as showed in our screening with several related AGC kinases. 
We achieved compounds with decreased activation potency toward PDK1 in comparison with 
the parental compounds and even a high degree of selectivity toward the PKCι isoforms.  
Further studies for the new described 3,5-diphenylpent-2-enoic acids such as the mutant 
study and cocrystallization are underway to confirm the binding site and the localization of 
the compounds. Having this evidence we could continue with further modifications to 
improve the affinity, selectivity and drug like features. Especially the cocrystal structure is of 
major importance since the here presented compound class bearing a double bond at the 
carboxylic side chain showed with both isomers good PIF pocket affinity. However, within 
the published the 4-benzimidazolyl-3-phenylbutanoic acid series two pure enantiomers 
showed also the characteristic displaying activity toward PKCζ, but these compounds are able 
to reach the relevant electrostatic interactions only via single bond rotation what is not 
possible with the double bond. 
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4 Discussion 
Previous work revealed a new allosteric regulatory site in PDK1, termed PIF pocket that 
is required for the recognition and phosphorylation of its substrates. It was found later that it 
serves as an important regulatory site in other AGC kinases as well, where the hydrophobic 
motif (HM), a C-terminal extension to the catalytic domain, folds back and binds into their 
own PIF pocket, thereby regulating the conformational transition between the active and 
inactive conformation and thus the activity of the kinases.12, 26 In contrast to other AGC 
kinases the PIF pocket of PDK1 is characterized by the lack of the HM and revealed as the 
docking site for the intramolecular HMs of PDK1’s substrates. Hence, this docking 
interaction of PDK1 with it substrates triggers an intrinsic activity of PDK1 enabling ATP 
binding and phosphorylation of its substrates. Additional mutation and knock-in studies 
confirmed PDK1 as an upstream master kinase that controls the phosphorylation and 
activation of its substrate enzymes. These include S6K, SGK, RSK, MSK and the atypical 
PKCs. Only the phosphorylation of PKB does not depend on the interaction of the PIF pocket 
of PDK1.11, 32 
Supported by all these results the PIF pocket of PDK1 was suggested as a new allosteric 
target site for drug development. It is particularly interesting since the inhibition of PDK1 has 
gained high interest due to its crucial role in transducing the PI3K signaling pathway, where 
several of the substrates comprising PKB, RSK and S6K regulate processes which are 
essential for tumor cells, such as cell growth and survival. Deregulation of this signaling 
pathway leads in the majority of cases to cancer and also triggers diabetes type-2, 
autoimmune diseases, inflammation, neurological and metabolic disorders.21 Hence, proper 
regulation of PDK1 is critical for prevention of too high activity of its substrates. For that 
reason, targeted inhibition of PDK1 has emerged as an attractive strategy in treatment of a 
wide range of human cancers.17, 35, 36 Particularly, because the in vivo results suggested an 
incomplete inhibition of PDK1 in cancers where PTEN is mutated. Mice with 10-20 % of 
PDK1 protein were healthy although they were smaller. However, when they were crossed 
with knockout mice in a PTEN deficient background, they had spontaneous tumors, the mice 
with less PDK1 activity had less tumors and extended lifespan.17 As binding of ATP is 
essential for kinase activity, most therapeutic efforts have been focused on inactivation of 
PDK1 via ATP-competitive, small molecular weight compounds (Type I inhibitors) which 
block the enzymatic activity and thus interfere the phosphorylation of the cellular 
substrates.16, 35, 37-39, 41, 42 But, this approach has two main drawbacks. On the one site, due to 
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relative structural conservation of ATP binding sites for several protein kinases and resulting 
cross reactions with many different kinases, the risk of dose limiting off-target effects 
increases and it is a challenge to find a new candidate for clinical trails. In fact, not only in 
case of PDK1 the most ATP-competitive inhibitors show limited selectivity (e.g. 
staurosporine, UCN01)62, 63 Moreover, in general these inhibitors compete with the ATP for 
the same binding site.63, 168 On the other hand, this strategy proved inappropriate for several 
kinases because of the fact that therapeutic inactivation of essential protein kinases exerts a 
selective pressure resulting in development of mutations and thus inhibitor resistance.6 A 
prominent example is Gleevec. These observations prompted the search for new paths which 
have to be taken in order to succeed in specific and lasting regulation of kinase activity. 
Currently, the trend toward multi-kinase target strategy is increased in an attempt to become 
enhanced antitumor efficacy and safety profiles compared to single target drugs.64 Moreover, 
the focus turned from the ATP binding site to intrinsic and unique regulation mechanisms of a 
protein kinase. In fact, increasing interest was observed based on many publications which 
included characterization of novel allosteric sites as drugable sites in kinases. Several focused 
on type II inhibitors, which do not really belong to allosteric inhibitors occupying at least 
partially the ATP binding site and acting only in some extent in a different non-competitive 
manner.65 However, due to similar hydrophobic regions adjacent to the ATP binding site 
among the protein kinases these inhibitors exhibited again a lack of specificity. The next class 
of compounds presented in research studies are type III inhibitors. Type III inhibitors tend to 
exhibit the highest degree of kinase selectivity using an allosteric site, distant to the ATP 
binding site and exploiting regulatory mechanisms which are unique to a particular kinase.65 
Only few kinases from the kinome can be targeted by these allosteric, selective and potent 
inhibitors so far. Therefore, the development of further strategies remains urgent and provided 
us the motivation to identify first small compounds which bind to the PIF pocket. For this 
purpose, we defined a pharmacophore based on the crystals of the PIF pocket of PDK1 and of 
the closed PKA within the C-terminal HM and performed a virtual screening of a commercial 
compound data base. Selected compounds were subsequently tested on the activity of PDK1 
and other AGC kinases. Two compound classes (I, II), (Scheme 14) revealed as activators of 
PDK1 and provided first evidence with further biochemical experiments that small 
compounds directed to the PIF pocket can be developed. 
In this thesis a medicinal chemistry approach was used. Starting from compound class I 
the aim was to overcome its structural drawbacks in order to improve the activity and 
selectivity. Since no cocrystal structure was available, the rational drug design approach was 
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used. The goal was to discover new classes of PDK1 activators. In such manner, starting from 
the compound 1 we modified the structure by displacement of the chiral centre and the 
sulfanyl moiety to become more drug-like target molecules. Nevertheless, the general 
characteristic scaffold including two aromatic rings connected by a carbon chain with an 
attached carboxyl side chain should be maintained. 
 
Scheme 14: Screening hits and designed, synthesized and evaluated classes through   
                    medicinal chemistry approach used 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The structural refinement led to the series of 3,5-diphenylpent-2-enoic acids. Performing 
the radioactive kinase activity assay, it was apparent that the main potency showed mostly the 
cis isomers of the new synthesized 3,5-diphenylpent-2-enoic acids. Introduction of para-
halogen substituents on the phenyl ring A revealed to increase the PDK1 activity and the 
potency was improved even more with compounds carrying additionally to the para-halogen 
one more halogen in meta or ortho position. In contrast, an ethyl substitution led to an 
abolishment of PDK1 activity. The same pattern could be observed by introduction of fluorine 
atoms on the phenyl moiety B. Furthermore, the replacement of the phenyl moiety A with 
different aromatic systems in order to explore the requirements of the PIF pocket led to a 
moderate potency toward PDK1. Only the naphthyl analogue (16Z) stood out showing the 
highest increase of potency. Derivatization of the backbone chain inserting polar groups (O, 
S) and the scaffold rigidification resulted in a significantly decrease of PDK1 activity.  
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Choosing compound 2Z (Scheme 14), one of the first isolated analogue of the 3,5-
diphenylpent-2-enoic acid series with good potency toward PDK1, the PIF pocket of PDK1 
was proved as the binding site in a mutagenesis study. The cocrystal structure of 2Z bound to 
the PIF pocket confirmed the compound as truly allosteric. Moreover, the cocrystal structure 
confirmed the interaction of the carboxyl moiety of the cis compounds with the phosphate 
binding site is essential to prompt the activation of PDK1.  
The next particular part of this study provides the ITC approach. The relationships 
between the structural properties, binding affinity and allosteric activation with PIF pocket-
directed small weight molecules could be evaluated for the first time. The ITC results again 
confirmed the main potency of the cis isomers obtaining a typical binding isotherm. In 
contrast, the trans isomers did not show a typical curve shape. The similar results for all 
tested compounds let suppose that the phosphate binding site accommodated all analogues in 
the same way. Thereby, the phenyl ring B of the cis analogues might bind into the subpocket 
on the PDK1 PIF pocket enabling good interactions with the carboxyl moiety. Furthermore, 
the ITC analysis revealed that there is no agreement between the estimated Kd- and the AC50-
values (Figure 27) from the radioactivity assay. For this reason, the attention was directed 
toward the influences of structural features on the affinity toward PDK1. There are three 
crucial aspects to be considered in terms of affinity and activity. In an agreement with the 
cocrystal analysis the edge-to-face CH-pi interaction of the phenyl ring B with the amino acid 
F157 plays a crucial role in stabilizing the ligand protein binding, particularly since such 
hydrophobic interaction is found to be most favorable formation in solution. Thus, it was 
apparent why substitution of this phenyl ring led to an abolishment of activity toward PDK1. 
The next interesting issue represented the fact that in contrast to the in vitro activity assay 
results which did not show major differences between the activation potency of the halogen 
substituted derivatives, the dichloro analogues (7Z and 8Z) emerged with distinct 
thermodynamic properties. 7Z broke the general correlation between Kd and AC50 and 
exhibited the biggest loss of the binding entropy compared to 2Z. The behavior can be 
attributed to the meta-chloro substituent which seemed to impede the hydrophobic 
interactions with the PIF pocket. In contrast, 8Z displayed the lowest Kd that correlated with 
the AC50 value. But the ortho-chlorine substitution of 8Z indicated an “antagonist” like 
behavior since its potency to allosterically activate PDK1 was striking due to the decrease to 
about half of the Amax of 2Z. In the end, although entropically driven ligand protein binding is 
usually attributed to structural features 8Z displayed the entropy-driven binding and 7Z did 
not. This fact may be due to the differences in the position of these compounds within the PIF 
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pocket. Subsequently, extended aromatic system led to enthalpy-entropy compensation. These 
compounds showed Kd values similar to the halogen derivatives although these interacted 
differently to the PIF pocket. The highest ∆H/∆G ratios showed the naphtyl analogue (16Z) 
and the indol derivative (17Z) resulting from increase of enthalpy relative to entropy of 
binding. This might be attributed to the CH-pi interaction resulting from the pi-electron density 
of bicyclic rings combined with larger surface. In comparison with the cocrystal structure of 
2Z putative interaction of extended pi-electron system of 16Z and 17Z was provided (Figure 
24). In conclusion, the ITC approach resulted in a broad thermodynamic binding spectrum 
from mainly entropy-driven to predominantly enthalpy-driven binding. Among the 3,5-
diphenylpent-2-enoic acid series with comparable size, the increase of the binding enthalpy is 
accompanied by a loss of entropy to about the same degree leading to little or no change in 
binding affinity. This compensation effect was obvious when comparing the halogen 
derivatives with the extended aromatic derivatives. In general, with the ITC method that is 
proved as a method to guide the lead evaluation and optimization in drug development, 16Z 
and 17Z were provided as compounds with the most ideal thermodynamic lead profile, since 
the enthalpic term strongly predominates the binding free energy. Thus, additional 
information about structural requirements was achieved in order to use them for further 
improvement of the affinity and activity toward the PIF pocket of PDK1.  
Since a crucial point in development of PDK1 modulators is selectivity, the effect of the 
3,5-diphenylpent-2-enoic acid series was tested on some related AGC kinases. Analyzing the 
results a slight inhibition of some compounds toward S6K and SGK and a tendency to 
stronger inhibition of PKCζ was observed. This effect was exploited for a new approach to 
develop PKCζ selective inhibitors.  
The 3,5-diphenylpent-2-enoic acids proved as activators of PDK1 targeting the PIF 
pocket. But these compounds turned out to have low affinity rendering further studies 
difficult. In order to discover even more potent and selective PDK1 activators, the lead 
scaffold (2Z) was modified combining the short carboxyl side chain with the carbonyl 
function from the previous lead compound 1. Additional aim to improve the activity of the 
compounds was to mimic the two negative charges of the phosphate groups present in natural 
ligands. For this purpose, we chose the malonic acid moiety as the short side chain. In the 
end, the synthesis of 2-(3-oxo-1,3-diphenyl-propyl)malonic acids (IV), (Scheme 14) as a new 
class of PDK1 activators and evaluation of its impact on the activatory potency toward 
PDK1’s PIF pocket led to further increase of the PDK1 activation in both higher levels and 
lower AC50 in comparison to 2Z. There was a significant contribution of the dicarboxyl 
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moiety to the affinity and activity to the PIF pocket particularly when compared to the 
corresponding mono acid derivatives (Scheme 14). These were achieved via decarboxylation 
of the malonic acid derivatives and caused generally increased potency than 2Z, but did not 
reach the pronounced increase of the activity like the malonic analogues did.  
Supported by the results with the previous compound class, the focus was directed again 
toward compounds substituted with halogens on the phenyl moieties. In fact, the para 
substitution on ring A led in comparison to the structure class III to higher potency and lower 
AC50 in the following order Cl < Br < I. The iodine analogue revealed as a particular good 
activator (AC50 = 0.4 µM) and even improved by replacement of the phenyl ring B by a 
naphthyl group. An extraordinary high effect was observed also with the para-trifluoromethyl 
derivative. The introduction of condensed phenyl rings instead of phenyl ring B resulted also 
in potent activators. Concerning the selectivity the series showed not only high potency 
toward PDK1 but in most cases also a high selectivity over the closed related AGC kinases. 
Going back to the monoacid derivatives (VI) that exhibited generally reduced potency 
than the malonic acid compounds it should be mentioned that both the para-iodo and the 
para-trifluoromethyl analogues were characterized by very good potency. Nevertheless, the 
focus was directed toward the malonic acid series in order to further succeed with potent and 
selective PDK1 activators. 
In an effort to verify the binding site PIF pocket mutants experiments were done and 
proved the PIF pocket as the target site. These results were confirmed by displacement 
experiments utilizing the Alpha-Screen technology. 
Furthermore, a prodrug strategy was adapted and investigated to overcome the membrane 
transport barrier that emerged due to the high polar malonic acid moiety. Therefore, the 
compounds were converted to bisacetoxymethyl esters and their cellular conversion in the L6 
skeletal muscle cell line which displays esterase activity was evaluated. As expected, the 
prodrug derivatives remained inactive in our cell free kinase assay. The cell results data in 
turn revealed that the hydrolysis of the prodrug esters was occurring upon enzymatic activity 
leading to a good cell permeability and to intracellular accumulation, despite the serum 
instability of the prodrug. However, this prodrug concept provided a promising starting point 
for further development of PDK1 activators with efficient drug delivery and subsequently 
good cellular efficacy. Moreover, with the developed prodrugs the proof of mechanism could 
be demonstrated using a western blot analysis of pretreated HEK293 cells. In this manner, the 
influence of PDK1 PIF pocket-directed compounds toward the phosphorylation of the 
relevant kinases was investigated. These include S6K, SGK and RSK which require the PIF 
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pocket of PDK1 for docking interaction with their HM. The exception remains PKB. In fact, 
an inhibition of S6K without an influence of PKB activity was obtained. Accordingly, with 
further experiments these compounds could be proposed for treatment of cancer and diabetes 
type-2.  
To gain insight into the mode of binding of the malonic acid derivatives cocrystals were 
generated. Their X-ray analysis revealed in comparison to the compound class III additional 
crucial interaction of the malonic moiety with the PIF pocket of PDK1 via a salt bridge. This 
salt bridge is essential for the allosteric activation mechanism as it became apparent due to 
increased affinity and activity toward PDK1. Finally, performing a chiral separation using 
HPLC and having the cocrystal results the S-enantiomer of the para-trifluoromethyl analogue 
could be suggested as the bioactive chiral form. 
Altogether, the optimization approach starting with compound 1 was successful in 
improvement of the activity and selectivity profile of the PDK1 activators. With both 
compound series the importance of the carboxyl moiety and malonic acid moiety respectively, 
which mimic the phosphate group of the natural ligand, was confirmed as crucial for the 
affinity to the PIF pocket of PDK1. Moreover, the evidence that compounds blocking the PIF 
pocket might be able to prevent phosphorylation of PDK1’s substrates was provided.  
Discovering the PIF pocket’s function in the molecular mechanism of kinase activation it 
became apparent that this site mediates conformational transition between active and inactive 
conformations in many AGC kinases. Therefore, the system provides the opportunity to 
influence the kinase activation both with an activity increase or inhibition depending on 
which conformation is stabilized. In fact, the optimization approach of the screening hit 1 
revealed several compounds of the 3,5-diphenylpent-2-enoic acid series not only as PDK1 
activators but they caused also an inhibitory effect toward PKCζ. Thereby, compounds with 
expanded aromatic systems stood out. These results are interesting since the development of 
PKCζ inhibitors arose interest due to its unique feature to activate the eukarytic transcription 
factor NF-κB which plays a crucial role in the transcriptional activation of proinflommatoric 
and anti-apoptotic genes.86, 87 There are several advantages to inhibit PKCζ instead of NF-κB 
in order to treat inflammatory diseases. Firstly, PKCζ performs the activating interaction only 
in selected cells and tissues. Secondly, knock-out studies revealed mice with nearly normal 
developed organs. Because there are not even ATP-competitive inhibitors described so far, 
the allosterical inhibition using the PIF pocket opened a promising strategy to develop 
selective inhibitors of PKCζ. All these facts led to a new project. In an effort to investigate the 
impact of explored aromatic system on the PKCζ activity the 3,5-diphenylpent-2-enoic acid 
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series was enlarged with the focus on improvement of the inhibitory effect. The biphenyl 
derivative (15Z) and the naphthyl derivative (16Z) served as leads in the aim to investigate 
the spatial limitations of PKCζ‘s PIF pocket. Two groups of derivatives were obtained. The 
first is characterized by the para-chlorophenyl moiety on the phenyl ring A position with 
varied aromatic substituents on phenyl ring B. For the second group the naphthyl function 
was set as phenyl ring B whereas the phenyl ring A was varied. The biological evaluation 
revealed several interesting characteristics. The geometric isomers of the potent analogues did 
not show a difference in intrinsic potency toward PKCζ in most cases. These included (E and 
Z)-5-(4-chlorophenyl)-3-(naphthalen-2-yl)pent-2-enoic acid (26) and (E and Z)-5-(4-
chlorophenyl)-3-(naphthalen-1-yl)pent-2-enoic acid (27) and indicated that the arrangements 
of the naphthyl group of both isomers enabled good electrostatic interactions of the carboxylic 
side chain with the relevant amino acid of the PIF pocket. Further derivatives demonstrated 
that enlarging the target compound size only the cis conformation might reach good inhibition 
potency toward PKCζ. Moreover, further para substitution on the phenyl ring A led to a 
decrease of the PKCζ effect and indicated the inductive effect of the halogen moiety as 
promising feature of the core structure to reach good affinity for the PIF pocket. This also 
applied for the naphthyl moiety on the phenyl ring B position.  
Regarding the selectivity the most potent compounds turned out to be also specific toward 
PKCζ. The particular challenge represented the aim to obtain molecules which specifically 
target the PIF pocket of PKCζ but not of PDK1, especially since the lead compounds were 
found as PDK1 activators. The other challenge was to obtain selectivity toward the most 
closed PKC isoform PKCι. Both compounds 26 and 27 revealed to have these features. These 
in vitro results increased the motivation to investigate the activity of the compounds in cells. 
Since the human lymphoma cell line U937 is known for the PKCζ expression, and PKCζ 
revealed to be involved in TNFα induced NF-κB activation pathway, this cell line provided as 
a model to develop a luciferase reporter gene assay in order to find out the influence of the 
compounds on the TNFα induced NF-κB activation. Again, 26 and 27 confirmed their in vitro 
inhibition toward PKCζ also in cells. Nevertheless, due to the handicap of the derivatives, 
namely the limited cell membrane permeability due to the polar carboxyl moiety, the obtained 
results were attributable to diffusion through biological membranes. Interestingly, the cell 
results revealed stronger inhibition than in the cell free assay. This might be due to the 
advantage of allosteric inhibitors over the ATP site-directed compounds, whereby the ATP 
concentration is often responsible for an increase of the IC50. Moreover, the isomers of the 
compounds showed again no activity differences in cells.  
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Altogether, to reach good potency and selectivity toward PDK1 an increase in 
lipophilicity by an inductive effect in para-phenyl position (ring A) by a halogen and a 
naphthyl moiety as phenyl ring B are important. Additionally, the luciferase reporter gene 
assay results proved these molecules as PKCζ's PIF pocket inhibitors in cells. However, 
mutant analysis and cocrystals would provide evidence about the targeting site and 
localization of the developed molecules.  
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5 Summary and Conclusion 
       The aim of the present thesis was the design and synthesis of small molecule compounds 
which act via an allosteric mode by binding to the PIF pocket of two AGC kinases, primarily, 
PDK1 and potentially the atypical PKC isoform PKCζ. Based on the hit compound 1 derived 
from previous work of our group new compound classes (Scheme 15) were to be developed 
using structure based drug design. Our efforts were focused on selectivity toward a panel of 
related AGC kinases and on enhancement of potency of allosteric modulators to the 
nanomolar range in order to confirm the druggability of the PIF pocket. With potent allosteric 
modulators we could suggest an interesting alternative to traditional ATP-competitive drugs.  
Chapter  3.1 deals with the synthesis and biological evaluation of 3,5-diphenylpent-2-enoic 
acids. This new compound class resulted from an effort to obtain more drug-like structure 
replacing the chiral center and the sulfanyl moiety of the hit compound 1. The phenyl moiety 
was systematically modified to identify most favorable lead structure for further optimization. 
Since in the previous work the attention was focused on the ring substituents, here we 
examined in addition the structural features of the target site on PDK1 by extension and 
rigidification of the 3,5-diphenylpent-2-enoic acid scaffold.  
The structure-activity relationships clearly revealed that the obtained geometric isomers of 
the 3,5-diphenylpent-2-enoic acids exhibited different intrinsic activation potency toward 
PDK1. The analogues with the cis configuration were the active substances, whereas the 
compounds with the opposite configuration hardly displayed any potency. Among the cis 
isomers, the halogenated derivatives generally induced a stronger activation of PDK1, 
especially dihalogen substituted compounds. Similarly, bicyclic aromatic substituents turned 
out to improve potency toward PDK1. However, scaffold rigidification did not further 
increase the activity, suggesting that the some flexibility of the compounds was necessary to 
optimally accommodate to the hydrophobic surface of the PIF pocket. At the same time, polar 
groups inserted in the backbone chain of the molecules were poorly tolerated, leading to a 
substantial reduction of potency.  
The binding site of modulators was finally confirmed using PDK1 mutated at the PIF 
pocket, and by cocrystallography with the selected compound 2Z. It could be shown that 2Z 
binds to the PIF pocket proving that the compounds were truly allosteric. Furthermore, the 
cocrystal structure emphasized the importance of the carboxyl moiety which seems to mimic 
the phosphate group of phosphoserine/threonine residues from the natural ligands. These 
results were confirmed by further experiments using isothermal titration calorimetry. Again, 
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only the cis isomers were observed as PIF pocket binding compounds. Moreover, the ITC 
study as an increasingly important method in drug development provided additional 
information about structure-dependent binding thermodynamics, useful for further 
improvement of the affinity and potency toward the PIF pocket. Compounds 16Z and 17Z 
(Scheme 15) showed the most ideal thermodynamic profile that might be attributable to their 
extended pi-electron system and thus were selected as new lead structures. Both analogues 
turned out to compensate the loss of entropy gain by increased enthalpy resulting from 
additional CH-pi interactions with the PIF pocket.  
To obtain informations about selectivity, the 3,5-diphenylpent-2-enoic acids were tested 
toward a panel of selected, closely related AGC kinases. Interestingly, besides activation of 
the PDK1, inhibition of other AGC kinases, in particular PKCζ were pursued further and 
refined in Chapter  3.3. 
 
Scheme 15: Selected compounds of the optimization approach 
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In Chapter  3.2, rational optimization of the new structure 2Z, also considering the 
previous hit compound 1 is described. We created a chimeric compound containing the 
carbonyl function from 1 and the shorter carboxyl side chain from 2Z. In addition, the design 
concept was aimed to better mimic the phosphate moiety of the natural ligands by 
introduction of a second carboxyl group. These modifications led to 2-(3-oxo-1,3-
diphenylpropyl)malonic acids which revealed to be very potent PDK1 activators reaching 
even submicromolar affinity. This compound class also showed a remarkable selectivity 
toward PDK1 when tested against a panel of related AGC kinases. Together with the 
mutagenesis study that confirmed the PIF pocket as binding site, we confirmed that specific 
modulators of even a single kinase can be developed using the less conserved, regulatory PIF 
pocket as a target site. Finally, the cocrystal structure of PDK1 in complex with 4A 
corroborated the importance of the second carboxyl group with respect to potency and 
selectivity.  
Separating the racemic mixture of 4H by chiral HPLC and including the cocrystal 
structure we were able to suggest the S-enantiomer as the eutomer with the higher biological 
activity. The absolute conformation could be not determined due to limited amounts of 
material.  
A prodrug approach allowed to investigate the activity of the highly polar compounds in 
cells, for which the bicacetoxymethyl ester of the most potent malonic acid analogue 4H was 
synthesized (Scheme 15). In fact, the corresponding prodrug 5H displayed good cellular 
delivery and was readily converted to the active malonic acid form 4H upon enzymatic 
hydrolysis. This prodrug concept, combined with the high activity and selectivity of 4H, the 
opened up the possibility to provide the proof of mechanism in cellular studies: indeed, the 
intracellular released 4H blocked the PIF pocket of PDK1 for interaction with the substrate 
kinase S6K that requires the PIF pocket to become phosphorylated. As expected, the only one 
substrate PKB whose phosphorylation does not depend on PDK1’s PIF pocket was not 
affected. Due to the essential role of S6K in insulin resistance the PIF pocket-directed 
compound 4H might be applicable as a novel therapeutic for the treatment of diabetes type-2. 
Moreover, Chapter  3.2 deals with a further compound class, the 5-oxo-3,5-
diphenylpentanoic acids that were relatively easy to accessible via decarboxylation of the 
corresponding malonic acid derivatives. These monoacids exhibited generally reduced 
potency toward PDK1 than the corresponding dicarboxylic derivatives confirming the 
importance of the second carboxyl moiety for affinity and activity. Nevertheless, this series 
could be exploited to analyze the relative contribution of the second carboxylate group to the 
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overall potency toward PDK1. Combination of various fused aromatic rings with the mono-
carboxyl group proved to retain the activity as observed with 6Q, 6S and 6U (Scheme 15). 
These findings could be utilized for further optimization in order to render the molecules 
more drug-like.  
The elaboration of the 3,5-diphenylpent-2-enoic acid structure with regard to inhibition 
efficacy on AGC kinases is described in Chapter  3.3. Since we found out that particularly 15Z 
and 16Z did not only trigger the PDK1 activity but also induced PKCζ inhibition, the interest 
arose to optimize their scaffold in an effort to obtain more potent and selective inhibitors. For 
this purpose, the phenyl moieties were furthermore extended in order to investigate the spatial 
limitations of PKCζ’s PIF pocket.  
The biological evaluation demonstrated that the geometric isomers of the new synthesized 
analogues were still inhibiting PKCζ whereas allosteric activation of PDK1 was abolished 
indicating that the PIF pockets of PDK1 and PKCζ differ in their flexibility toward sterically 
demanding ligands. This was particularly the case with the most potent naphthyl analogues 
26Z, 26E and 27Z, 27E. Enlarging the scaffold e.g. by two naphthyl groups (30) led to 
differences of potency between the isomers, so that only the cis isomers reached a good 
inhibitory effect. Further derivatizations of the aromatic moieties introducing polar groups 
abolished the potency toward PKCζ.  
The specifity profile of the most potent PKCζ inhibitors was examined toward selected 
AGC kinases, with a main focus on PDK1 and the closely related PKC isoform PKCι. In fact, 
26Z, 26E and 27Z, 27E turned out to have not only good efficacy toward PKCζ but also a 
decent specificity toward the other AGC kinases. 26Z and 26E did not even affect the most 
closely related isoenzyme PKCι, indicating a remarkable selectivity for PKCζ. In contrast, the 
remaining compounds were found to be not very specific. Altogether, the biological 
evaluation highlighted 26Z as the most potent and specific inhibitor of PKCζ in vitro.  
In order to analyze the effect of the new PKCζ inhibitors in cells, we used a luciferase 
reporter gene assay. Again, we observed no activity difference between the isomers. 
Moreover, a good correlation of the effect in cells with the PKCζ inhibitory efficacy in cell 
free assay - particularly with the most potent compounds - was observed.  
Altogether, our 3,5-diphenylpent-2-enoic acid series confirmed that PIF pocket-directed 
compounds are able besides stabilizing an active conformation of PDK1 also to allosterically 
inhibit PKCζ’s activity. In further work, the actual binding mode of the inhibitors on PKC 
will be elucidated using cocrystallography.  
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In summary, this work describes the ligand- and structure-based design of truly allosteric 
compounds targeting the PIF pocket, a regulatory site on AGC protein kinases’ catalytic 
domain. Compounds with such an alternative mode of action are still poorly represented. 
Since the PIF pocket is less conserved than the ATP binding site,we expect for the PIF 
pocket-directed modulators a distinct pharmacological profile, based on higher selectivity and 
a more subtle modulation of downstream signaling in particular of PDK1.  
Extensive SAR studies to PDK1 and PKCζ confirmed that the relevant structural 
requirements for PIF pocket-directed small molecules are two aromatic moieties connected by 
an aliphatic carbon chain, bearing a two atom membered side chain with a free carboxylic or 
dicarboxylic group. A V-shaped conformation of the aryl groups toward each other is required 
to achieve complemtarity to the PIF-binding pocket. Moreover, the SAR results allowed for 
the first time to investigate conformational changes of the allosteric activation mechanism. 
We provided the evidence that it is possible to exploit the PIF pocket on the AGC kinases for 
the development of reversible allosteric activators and inhibitors. In the case of PDK1, the 
small molecules stabilize the active conformation leading to an increase of PDK1 activity. In 
contrast, the same molecules induced inhibition of the kinase targeting the PIF pocket of 
PKCζ.  
Furthermore, with allosteric activators directed to the PIF pocket of PDK1 we provided 
for the first time the proof of mechanism and the evidence that specific activators of a single 
kinase can be developed. Concerning further optimization of the potency, the most active 
compounds found in this work could serve as new lead structures. This may finally improve 
the biological activity in cells and enable the investigation of PDK1 activators in vivo using a 
suitable animal model. 
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6 Experimental Section 
6.1. Chemistry 
6.1.1. General descriptions  
Solvents and reagents were obtained from commercial suppliers and were used without 
further purification. Flash column chromatography was carried out using silica-gel 40 (35/40-
63/70 µM) with petroleum ether/ethyl acetate mixtures as eluents, and the reaction progress 
was determined by TLC analysis on Alugram® SIL G/UV254 (Macherey-Nagel). 
Visualization was accomplished with UV light and KMnO4 solution. 1H-NMR and 13C 
spectra were recorded at 500 MHz using a Bruker DRX-500 spectrometer. 1H shifts are 
referenced to the residual protonated solvent signal (δ 2.50 for DMSO-d6 and δ 7.26 for 
CDCl3) and 13C shifts are referenced to the deuterated solvent signal (δ 39.5 for DMSO-d6 
and δ 77.2 for CDCl3). Chemical shifts are given in parts per million (ppm), and all coupling 
constants (J) are given in hertz (Hz). The purities of the tested compounds were determined 
by HPLC coupled with mass spectrometry and were higher than 95% for all compounds. 
Mass spectrometric analysis (HPLC-ESI-MS) was performed on a TSQ quantum (Thermo 
Electron Corporation) instrument equipped with an ESI source and a triple quadrupole mass 
detector (Thermo Finnigan, San Jose, CA). The MS detection was carried out at a spray 
voltage of 4.2 kV, a nitrogen sheath gas pressure of 4.0 x 105 Pa, an auxiliary gas pressure of 
1.0 x 105 Pa, a capillary temperature of 400 °C, capillary voltage of 35 V and source CID of 
10 V. All samples were injected by autosampler (Surveyor®, Thermo Finnigan) with an 
injection volume of 10 µL. A RP C18 NUCLEODUR ® 100-3 (125 x 3 mm) column 
(Macherey-Nagel) was used as stationary phase. The solvent system consisted of water 
containing 0.1 % TFA (A) and 0.1 % TFA in acetonitril (B). HPLC-Method: flow rate 400 
µL/min. The percentage of B started at an initial of 5 %, was increased up to 100 % during 16 
min, kept at 100 % for 2 min and flushed back to the 5 % in 2 min. All masses were reported 
as those of the protonated parent ions. Melting points were determined on a Mettler FP1 
melting point apparatus and are uncorrected. 
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6.1.2. Synthetic procedures 
 
Method A:  Claisen-Schmitt condensation 
The corresponding benzaldehyde (1 eq) was dissolved in EtOH (2 mL / 1 mmol), a 3 M 
NaOHaq solution (3 eq) and the corresponding acetophenone (1 eq) were added and the 
resulting mixture was stirred at rt for 2 h forming a precipitate. The solid was separated by 
vacuum filtration and was washed three times with 10 mL ice water. The crude product was 
purified by recrystallization from MeOH.  
 
Method B:  Selective silica gel-catalyzed 1,4-reduction 
The corresponding chalcone (1 eq) was stirred under the nitrogen atmosphere with 3,5-
bis(ethoxycarbonyl)-1,4-dihydro-2,6-dimethylpyridine (HEH, 1.5 eq) in the presence of silica 
gel (0.2 g / 0.1 mmol) in toluene (2 mL / 1 mmol) at 70 °C in the dark for 17 h. After removal 
of toluene under vacuum, the crude mixture was purified by flash column chromatography on 
silica gel. 
 
Method C:  Horner-Wadsworth-Emmons reaction 
Triethyl phosphonoacetate (1-3 eq) was added dropwise at 20 °C to a slurry of sodium 
hydride (abs. 60 % in oil) (1-3 eq) in anhydrous 1,2-dimethoxyethane under nitrogen. The 
reaction mixture was stirred at rt for 1 h until the gas evolution had ceased and the appropriate 
reduced chalcone (1 eq) was added. After stirring at 80 °C for 4 hours the resultant solution 
was poured into ice water (50 mL) and then extracted with dichloromethane (3 x 20 mL). The 
extract was washed with brine (20 mL), dried over anhydrous MgSO4 and evaporated in 
vacuo to afford a crude which was purified by flash column chromatography to obtain the 
corresponding geometric isomers of the ethyl acrylate derivatives.  
 
Method D:  Hydrolysis I 
A solution of the corresponding ester (1 eq) and NaOHaq (3eq) in EtOH was refluxed for 4 
hours. After the completion of reaction, the cooled mixture was poured into water (30 mL), 
acidified to pH 2 with 10 % HCl and extracted with ethyl acetate (3 x 20 mL). The organic 
layers were collected, washed with brine (20 mL), dried over MgSO4 and evaporated to afford 
a residue, which was purified by crystallization to afford the acids. 
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Method E:  Rap-Stoermer reaction 
The corresponding salicylaldehyde (1 eq) and 2-bromoacetophenone (1 eq) were dissolved in 
ethanol and then treated with potassium carbonate (2.2 eq). The resultant mixture was heated 
at 80 °C for 1 hour, and the reaction mixture was taken up in water (50 mL) and extracted 
with dichloromethane (3 x 20 mL). The combined organic extracts were washed with brine 
(20 mL), dried over MgSO4 and concentrated under reduced pressure. The resultant oil was 
subjected to silica gel chromatography to give the appropriate product.  
 
Method F:  Catalytic transfer hydrogenation  
To a solution of the corresponding (E)-ethyl 3-(benzofuran-2-yl)-3-phenylacrylate (1eq) in 
ethanol (10 mL) was added Pd/C (10 %) and a solution of sodium hypophosphite (1.5 eq) in 7 
mL of water. The mixture was stirred at 50 °C for 1.5 hours. After the completion of the 
reaction the catalyst was filtered off and the crude hydrolyzed (50 mL), extracted with 
dichloromethane (3 x 20 mL), dried over MgSO4 and evaporated. The resultant oil was 
subjected to silica gel chromatography to give the appropriate product. 
 
Method G: Synthesis of MOM-ether 
Bromomethyl-methylether (1 eq) was added dropwise to a stirred suspension of the 
corresponding hydroxyl derivative (1.5 eq) and sodium hydride (1 eq) in dimethoxyethane at 
0 °C. The mixture was stirred for 1h at room temperature. After the complete addition water 
was carefully added and it was exracted with ethylacetate (3x), dried over MgSO4 and 
concentrated in vacuo. 
 
Method H:  Michael Addition Reaction I 
The corresponding chalcone (1 eq) and magnesium oxide (0.1 g / 0.1 mmol) were dissolved in 
toluene and diethyl malonate (1 eq) was added. The reaction was stirred at rt for 2 hours. The 
magnesium oxide was separated by vacuum filtration and was washed three times with 10 mL 
dichloromethane. The solvent was evaporated and the crude product was crystallized from 
diethyl ether and hexane. 
 
Method I:  Michael Addition Reaction II 
The corresponding chalcone (1 eq) and diethyl malonate (1.1 eq) were dissolved in ethanol 
and potassium carbonate (2 eq) was added. The mixture was heated at reflux for 2 hours. The 
reaction was quenched with H2O (50 mL) and extracted with CH2Cl2 (3 x 20 mL). The 
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organic layer was washed with brine, dried with MgSO4 and evaporated under vacuum. The 
crude product was crystallized from methylene chloride and hexane. 
 
Method J:  Michael Addition Reaction III 
The corresponding chalcone (1 eq) and diethyl malonate (1 eq) were dissolved in methanol 
and sodium hydride (cat) was added. The mixture was heated at reflux for 2 hours. The 
reaction was quenched with H2O (50 mL) and extracted with CH2Cl2 (3 x 20 mL). The 
organic layer was washed with brine, dried with MgSO4 and evaporated under vacuum. The 
crude product was crystallized from methylene chloride and hexane. 
 
Method K: Deprotection of MOM-ether 
A solution of the corresponding MOM derivative was treated with 10 % HCl (2 mL) in 
methanol (10 mL) and the resulting mixture was refluxed for 2h. After cooling the solvent 
was removed, the residue was extracted with ethyl acetate (3x) and dried with MgSO4. Then 
the crude product was concentrated to obtain the product (quant, without further purification). 
 
Method L:  Hydrolysis II 
A solution of the corresponding malon ester (1 eq) and NaOHaq (3eq) in EtOH was refluxed 
for 4 hours. After the completion of reaction, the cooled mixture was poured into water (30 
mL), acidified to pH 2 with 10 % HCl and extracted with ethyl acetate (3 x 20 mL). The ethyl 
acetate extracts were collected and further extracted with aqueous sodium bicarbonate 
solution (4 x 20 mL). The bicarbonate extractions were made acidic with 10 % HCl which 
was added until a pH of 2 was obtained. The white solids were formed which were further 
extracted with ethyl acetate (3×50 mL.). The organic solution was dried over MgSO4 and 
evaporated to afford a residue, which was purified by crystallization to afford the acids. 
 
Method M:  Esterification 
To a stirred solution of the corresponding malonic acid derivative (1 eq) and NEt3 (5 eq) in 
anhydrous DMF (5 mL), bromomethyl acetate (3 eq) was added. After being stirred for 4h at 
rt, the mixture was hydrolized, extracted with ethyl acetate (3 x), washed with brine, dried 
over MgSO4, filtered and concentrated at reduced pressure. The residue was purified by flash 
column chromatography. 
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Method N:  Decarboxylation 
The corresponding malonic acid derivative (1 eq) was pyrolytic treated in an oil bath at 160 
°C for 1 hour and the heating was stopped after the CO2 evolution ceased. The crude acid was 
dissolved in acetone/methanol and precipitated with dichloromethane to afford the acid. 
 
6.1.3. Analytical data 
6.1.3.1. Compounds described in Chapter  3.1. 
5-(4-Chlorophenyl)-3-phenylpent-2-enoic acids, (2E & 2Z): 
 
3-(4-Chlorophenyl)-1-phenylprop-2-en-1-one, (2c):  
Synthesized according to Method A using 4-chlorobenzaldehyde 2d (9.36 g, 67.0 mmol) and 
acetophenone (8.0 g, 67.0 mmol); pale yellow solid; yield: 15.3 g (94 %); Mp 113-114 °C; 
1H NMR (CDCl3, 500 MHz): δ = 7.39 (d, 3J = 8.5 Hz, 2H), 7.47-7.51 (m, 3H), 7.58-7.60 (m, 
3H), 7.75 (d, 3J = 15.7 Hz, 1H), 8.00-8.03 (m, 2H). 13C NMR (CDCl3, 125 MHz): δ = 128.4, 
128.7, 129.2, 129.5, 132.1, 132.9, 133.4, 136.4, 138.0, 144.7, 189.9. 
 
3-(4-Chlorophenyl)-1-phenylpropan-1-one, (2b): 
Synthesized according to Method B using compound 2c (0.636 g, 2.62 mmol), HEH (1.0 g, 
3.93 mmol) and silica gel (5.26 g); white solid; yield: 0.49 g (81 %); Mp 99-100 °C;  
1H NMR (CDCl3, 500 MHz): δ = 2.95 (t, 3J = 7.6, 2H), 3.21 (t, 3J = 7.6, 2H), 7.17-7.19 (m, 
2H), 7.19 (m, 2H), 7.44-7.47 (m, 2H), 7.55-7.58 (m, 1H), 7.96-7.94 (m, 2H). 13C NMR 
(CDCl3, 125 MHz): δ = 29.6, 40.4, 128.2, 129.8, 128.9, 130.1, 132.1, 133.4, 137.0, 
139.0,  199.1. 
 
Ethyl 5-(4-chlorophenyl)-3-phenylpent-2-enoate, (2a):  
Synthesized according to Method C using compound 2b (0.346 g, 1.41 mmol), NaH (0.17 g, 
4.23 mmol) and triethyl phosphonoacetate (0.96 mL, 4.23 mmol); 
2Ea: colourless oil; yield: 0.19 g (42 %); 1H NMR (CDCl3, 500 MHz): δ = 1.30 (t, 3J = 7.2 
Hz, 3H), 2.68-2.72 (m, 2H), 3.36-3.39 (m,  3J
  
= 8.3 Hz, 2H), 4.20 (q, 3J 
 
= 7.2 Hz, 2H), 6,06 
(s, 1H), 7.12-7.15 (m, 2H), 7.21-7.23 (m, 2H), 7.38-7.40 (m, 3H), 7.42-7.45 (m, 2H). 13C 
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NMR (CDCl3, 125 MHz): δ = 14.3, 32.9, 34.4, 59.9, 118.1, 126.7, 128.3, 128.7, 129.0, 129.9, 
131.6, 139.9, 140.9, 158.9, 165.9. 
2Za: colourless oil; yield: 0.17 g (38 %); 1H NMR (CDCl3, 500 MHz): δ = 1.06 (t, 3J = 7.2 
Hz, 3H), 2.65-2.68 (m, 2H), 2.69-2.72 (m, 2H), 4.98 (q, 3J = 7.2 Hz, 1H), 5.87 (s, 1H), 7.05 
(d, 3J = 8.2 Hz, 2H), 7.17 (d, 3J = 7.8 Hz, 2H), 7.23 (d, 3J = 8.2 Hz, 2H), 7.37-7.34 (m, 3H). 
13C NMR (CDCl3, 125 MHz): δ = 13.9, 33.1, 41.8, 59.9, 118.1, 127.2, 127.8, 127.9, 128.5, 
129.6, 131.9, 139.2, 139.6, 157.8, 164.9. 
 
(E)-5-(4-Chlorophenyl)-3-phenylpent-2-enoic acid, (2E):  
Synthesized according to Method D using compound 2Ea (0.16 g, 0.51 mmol) and NaOHaq 
(1.1 mL, 5.1 mmol); white solid; yield: 0.105 g (72 %); Mp 117-118 °C;  
1H NMR (CDCl3, 500 MHz): δ = 2.70-2.74 (m, 2H), 3.37-3.41 (m, 2H), 6,11 (s, 1H), 7.12 (d, 
3J = 8.5 Hz, 2H), 7.22 (d, 3J = 8.2 Hz, 2H ), 7.39-7.42 (m, 3H), 7.44-7.48 (m, 2H); 13C NMR 
(CDCl3, 125 MHz): δ = 17.2, 33.5, 60.2, 126.9, 127.6, 128.0, 128.1, 129.5, 131.2, 141.3, 
144.8, 148.8, 180.5; NOESY experiment (1H NMR (CDCl3, 500 MHz) showed a cross peak 
between the signal at 7.44-7.48 (m, 2H) and the signal at 6,11 (s, 1H). LC/MS (+ESI): m/z = 
287.6 [MH+], Rt = 14.13 (≥ 99 %). 
(Z)-5-(4-Chlorophenyl)-3-phenylpent-2-enoic acid, (2Z):  
Synthesized according to Method D using compound 2Za (0.139 g, 0.44 mmol) and NaOHaq 
(1.1 mL, 4.4 mmol); white solid; yield: 0.093 g (74 %); Mp 114-115 °C;  
1H NMR (CDCl3, 500 MHz): δ = 2.64-2.67 (m, 2H), 2.71-2.77 (m, 2H), 5.87 (s, 1H), 7.04 (d, 
3J = 8.5 Hz, 2H ), 7.18 (m, 2H), 7.24 (d, 3J = 8.5 Hz, 2H), 7.34 (m, 3H); 13C NMR (CDCl3, 
125 MHz): δ = 15.9, 32.8, 60.2, 127.1, 127.6, 128.0, 129.7, 131.8, 139.8, 142.4, 145.3, 170.5; 
NOESY experiment (1H NMR (CDCl3, 500 MHz) showed a cross peak between the signals at 
2.64-2.67 (m, 2H) and at 2.71-2.77 (m, 2H), and the signal at 5.87 (s, 1H). LC/MS (+ESI): 
m/z = 287.5 [MH+], Rt = 13.56 (≥ 99 %). 
 
 
5-(3-Chlorophenyl)-3-phenylpent-2-enoic acids (3E & 3Z): 
 
3-(3-Chlorophenyl)-1-phenylprop-2-en-1-one, (3c):  
Synthesized according to Method A using 3-chlorobenzaldehyde 3d (0.8 mL, 7.11 mmol) and 
acetophenone (0.83 mL, 7.11 mmol); pale yellow solid; yield: 1.62 g (94 %); Mp 110-111 °C; 
1H NMR (CDCl3, 500 MHz): δ = 7.39-7.44 (m, 2H), 7.50-7.55 (m, 4H), 7.60-7.64 (m, 2H), 
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7.73 (d, 3J = 15.3 Hz, 1H), 8.02 (d, 3J = 8.5 Hz, 1H). 13C NMR (CDCl3, 125 MHz): δ = 123.2, 
126.8, 127.9, 128.5, 128.7, 130.2, 130.3, 133.0, 134.9, 137.9, 143.0, 190.1. 
 
3-(3-Chlorophenyl)-1-phenylpropan-1-one, (3b):  
Synthesized according to Method B using compound 3c (0.60 g, 2.47 mmol), HEH (0.94 g, 
3.70 mmol) and silica gel (4.94 g); white solid; yield: 0.57 g (89 %); Mp 82-84 °C;  
1H NMR (CDCl3, 500 MHz): δ = 3.03-3.07 (m, 2H), 3.29-3.32 (m, 2H), 7.27-7.32 (m, 4H), 
7.46 (t, 3J = 7.9 Hz, 2H), 7.57 (t, 3J = 7.6 Hz, 1H), 7.96 (d, 3J = 7.9 Hz, 2H). 13C NMR 
(CDCl3, 125 MHz): δ = 29.7, 40.0, 126.3, 126.7, 128.0, 128.6, 128.6, 129.7, 133.2, 134.3, 
136.8, 143.3, 198.7. 
 
Ethyl 5-(3-chlorophenyl)-3-phenylpent-2-enoate, (3a):  
Synthesized according to Method C using compound 3b (0.40 g, 1.63 mmol), NaH (0.20 g, 
4.89 mmol) and triethyl phosphonoacetate (0.97 mL, 4.89 mmol); 
3Ea: colourless oil; yield: 0.22 g (43 %); 1H NMR (CDCl3, 500 MHz): δ = 1.32 (t, 3J = 6.9 
Hz, 3H), 2.69-2.74 (m, 2H), 3.37-3.41 (m, 2H), 4.21 (q, 3J = 7.2 Hz, 2H), 6.07 (s, 1H), 7.16-
7.20 (m, 4H), 7.42-7.46 (m, 5H). 13C NMR (CDCl3, 125 MHz): δ = 14.3, 32.7, 34.7, 59.9, 
118.1, 126.1, 126.7, 128.6, 128.7, 129.0, 129.5, 133.9, 140.9, 141.3, 143.5, 158.8, 166.3. 
3Za: colourless oil; yield: 0.19 g (38 %); 1H NMR (CDCl3, 500 MHz): δ = 1.07 (t, 3J = 7.2 
Hz, 3H), 2.66-2.70 (m, 2H), 2.74-2.79 (m, 2H), 3.98 (q, 3J = 7.2 Hz, 2H), 5.88 (s, 1H), 7.05 
(d, 3J = 7.2 Hz, 1H), 7.11 (s, 1H), 7.16-7.21 (m, 4H), 7.30-7.37 (m, 3H). 13C NMR (CDCl3, 
125 MHz): δ = 13.9, 33.5, 41.7, 59.9, 118.0, 126.3, 126.5, 127.8, 128.0, 128.4, 129.7, 134.2, 
139.6, 142.8, 157.7, 165.8. 
  
(E)-5-(3-Chlorophenyl)-3-phenylpent-2-enoic acid, (3E): 
Synthesized according to Method D using compound 3Ea (0.2 g, 0.63 mmol) and NaOHaq 
(2.1 mL, 6.3 mmol); white solid; yield: 0.158 g (88 %); Mp 98-100 °C;  
1H NMR (CDCl3, 500 MHz): δ = 2.72-2.77 (m, 2H), 3.40-3.43 (m, 2H), 6.13 (s, 1H), 7.09 (d, 
3J = 7.2 Hz, 1H ), 7.19-7.15 (m, 3H), 7.41-7.45 (m, 3H), 7.46-7.50 (m, 2H); 13C NMR 
(CDCl3, 125 MHz): δ = 33.0, 34.8, 117.0, 126.6, 126.7, 126.8, 128.6, 129.5, 129.6, 134.0, 
140.7, 143.3, 162.0, 170.8; LC/MS (+ESI): m/z = 288.6 [MH+]; Rt = 14.06 (≥ 97 %). 
(Z)-5-(3-Chlorophenyl)-3-phenylpent-2-enoic acid, (3Z): 
Synthesized according to Method D using compound 3Za (0.17 g, 0.54 mmol) and NaOHaq 
(1.8 mL, 5.4 mmol); white solid; yield: 0.135 g (87 %); Mp 102-104 °C;  
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1H NMR (CDCl3, 500 MHz) δ = 2.63-2.67 (m, 2H), 2.74-2.77 (m, 2H), 5.85 (s, 1H), 6.98 (td, 
4J = 1.6, 3J = 7.2 Hz, 1H ), 7.09-7.10 (m, 1H), 7.15-7.18 (m, 3H), 7.18-7.21 (m, 1H), 7.31-
7.33 (m, 1H), 7.33-7.36 (m, 2H); 13C NMR (CDCl3, 125 MHz): δ = 33.3, 42.0, 117.0, 126.0, 
126.4, 127.2, 128.1, 128.2, 128.4, 128.6, 129.7, 138.8, 142.6, 160.6, 170.1; LC/MS (+ESI): 
m/z = 288.6 [MH+]; Rt = 13.43 (≥ 99 %). 
 
 
5-(4-Fluorophenyl)-3-phenylpent-2-enoic acids (4E & 4Z): 
 
3-(4-Fluorophenyl)-1-phenylprop-2-en-1-one, (4c): 
Synthesized according to Method A using 4-fluorobenzaldehyde 4d (2.0 g, 16.11 mmol) and 
acetophenone (1.88 mL, 16.11 mmol); yellow solid; yield: 3.35 g (92 %); Mp 88-90 °C; 
1H NMR (CDCl3, 500 MHz): δ = 7.09-7.13 (m, 2H), 7.44-7.52 (m, 3H), 7.57-7.65 (m, 3H), 
7.77 (d, 3J = 15.8 Hz, 1H), 8.00-8.02 (m, 2H). 13C NMR (CDCl3, 125 MHz): δ = 116.1 (d, 2J 
(C, F) = 21.9 Hz, CH), 121.8, 128.4, 128.6, 130.3 (d, 3J (C, F)
 
= 8.2 Hz, CH), 131.1 (d, 4J (C,  
F)
 
= 3.7 Hz, CH), 132.8, 138.1, 143.4, 164,0 (d, 1J (C, F) = 252.0 Hz, Cquat), 190.3. 
 
3-(4-Fluorophenyl)-1-phenylpropan-1-one, (4b): 
Synthesized according to Method B using compound 4c (0.50 g, 2.21 mmol), HEH (0.84 g, 
3.31 mmol) and silica gel (4.42 g); pale yellow oil; yield: 0.476 g (94 %);  
1H NMR (CDCl3, 500 MHz): δ = 3.05 (t, 3J = 7.6, 2H), 3.29 (t, 3J = 7.6, 2H), 6.99-6.95 (m, 
2H), 7.22-7.19 (m, 2H), 7.46 (t, 3J = 7.6 Hz, 2H), 7.58-7.54 (m, 1H), 7.95 (d, 3J = 8.5 Hz, 
2H). 13C NMR (CDCl3, 125 MHz): δ = 29.2, 40.4, 115.2 (d, J (C, F) = 21.1 Hz, CH), 127.9, 
128.6, 129.8 (d, J (C, F)
 
= 7.7 Hz, CH), 133.1, 136.7, 136.8, 161,0 (d, J (C, F) = 243.8 Hz, 
Cquat), 198.9. 
 
Ethyl 5-(4-fluorophenyl)-3-phenylpent-2-enoate, (4a):  
Synthesized according to Method C using compound 4b (0.40 g, 1.75 mmol), NaH (0.21 g, 
5.26 mmol) and triethyl phosphonoacetate (1.2 mL, 5.42 mmol); 
4Ea: colourless oil; yield: 0.193 g (37%); 1H NMR (CDCl3, 500 MHz): δ = 1.06 (t, 3J = 7.2 
Hz, 3H), 2.65-2.75 (m, 4H), 3.98 (q, 3J = 7.2 Hz, 2H), 5.87 (s, 1H), 6.93-6.97 (m, 2H), 7.06-
7.09 (m, 2H), 7.16-7.18 (m, 2H), 7.31-7.38 (m, 3H). 13C NMR (CDCl3, 125 MHz): δ = 13.9, 
32.9, 42.1, 59.8, 115.0, 115.1 (d, J (C, F) = 22.1 Hz, CH), 117.9, 127.2, 127.7, 127.8, 127.9, 
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129.6 (d, J (C, F) = 7.7 Hz, CH), 136.4, 139.7, 158.0, 161.0 (d, J (C, F) = 243.8 Hz, Cquat), 
165.8. 
4Za: colourless oil; yield: 0.189 g (36 %); 1H NMR (CDCl3, 500 MHz): δ = 1.29 (t, 3J = 7.2 
Hz, 3H), 2.69-2.72 (m, 2H), 3.36-3.39 (m, 2H), 4.20 (q, 3J = 7.2 Hz, 2H), 6.06 (s, 1H), 6.92-
6.96 (m, 2H), 7.15-7.18 (m, 2H), 7.46-7.35 (m, 5H). 13C NMR (CDCl3, 125 MHz): δ = 14.3, 
31.1, 34.3, 59.9, 115.0 (d, J (C, F) = 21.1 Hz, CH), 117.9, 126.7, 128.6, 129.0, 129.8 (d, J (C, 
F) = 7.7 Hz, CH), 137.1, 140.9, 159.1, 161.0 (d, J (C, F) = 243.8 Hz, Cquat), 166.3. 
 
(E)-5-(4-Fluorophenyl)-3-phenylpent-2-enoic acid, (4E): 
Synthesized according to Method D using compound 4Ea (0.185 g, 0.62 mmol) and NaOHaq 
(2.1 mL, 6.2 mmol); white solid; yield: 0.150 g (90 %); Mp 95-98 °C;  
1H NMR (CDCl3, 500 MHz): δ = 2.72-2.75 (m, 2H), 3.38-3.42 (m, 2H), 6.12 (s, 1H), 6.92-
6.96 (m, 2H), 7.13-7.16 (m 2H), 7.41-7.42 (m, 3H), 7.46-7.48 (m, 2H); 13C NMR (CDCl3, 
125 MHz): δ = 33.4, 34.4, 115.0 (d, J (C, F) = 21.1 Hz, CH), 116.9, 126.8, 128.7, 129.4, 
129.8 (d, J (C, F) = 8.6 Hz, CH), 136.9, 140.8, 149.5, 161.0 (d, J (C, F) = 240.9 Hz, Cquat), 
170.9; LC/MS (+ESI): m/z = 271.5 [MH+]; Rt = 13.24 (≥ 99 %). 
(Z)-5-(4-Fluorophenyl)-3-phenylpent-2-enoic acid, (4Z):  
Synthesized according to Method D using compound 4Za (0.18 g, 0.60 mmol) and NaOHaq 
(2.0 mL, 5.4 mmol); white solid; yield: 0.135 g (83 %); Mp 90-92 °C; 
1H NMR (CDCl3, 500 MHz): δ = 2.63-2.67 (m, 2H), 2.73-2.77 (m, 2H), 5.87 (s, 1H), 6.93-
7.07 (m, 2H), 7.16-7.23 (m, 2H), 7.34-7.39 (m, 5H); 13C NMR (CDCl3, 125 MHz): δ = 34.3, 
42.4, 116.0 (d, J (C, F) = 21.1 Hz, CH), 117.9, 127.2, 128.2, 128.6, 129.6, 132.0 (, J (C, F) = 
7.7 Hz, CH), 141.5, 160.4, 161.5 (d, J (C, F) = 264.9 Hz, Cquat), 168.2; LC/MS (+ESI): m/z = 
271.5 [MH+]; Rt = 12.73 (≥ 98 %). 
 
 
5-(4-Bromophenyl)-3-phenylpent-2-enoic acids, (5E & 5Z): 
 
3-(4-Bromophenyl)-1-phenylprop-2-en-1-one, (5c):  
Synthesized according to Method A using 4-bromobenzaldehyde 5d (2.0 g, 10.81 mmol) and 
acetophenone (1.26 mL, 10.81 mmol); yellow solid; yield: 2.80 g (90 %); Mp 121-123 °C; 
1H NMR (CDCl3, 500 MHz): δ = 7.50-7.61 (m, 8H), 7.74 (d, 3J = 15.7 Hz, 1H), 8.01 (dd, 4J = 
1.4, 3J = 7.2 Hz, 2H). 13C NMR (CDCl3, 125 MHz): δ = 122.6, 124.8, 128.5, 128.7, 129.8, 
132.2, 132.9, 133.8, 138.0, 143.4, 190.2. 
                                                                                                                    Experimental Section 
 126 
3-(4-Bromophenyl)-1-phenylpropan-1-one, (5b): 
Synthesized according to Method B using compound 5c (0.50 g, 1.74 mmol), HEH (0.661 g, 
2.61 mmol) and silica gel (3.48 g); pale yellow solid; yield: 0.479 g (95 %); Mp 73-75 °C;  
1H NMR (CDCl3, 500 MHz): δ = 3.03 (t, 3J = 7.6 Hz, 2H), 3.28 (t, 3J = 7.6 Hz, 2H), 7.13 (d, 
3J = 8.5 Hz, 2H), 7.30 (d, 3J = 8.5 Hz, 2H), 7.46 (t, 3J 
 
= 7.2 Hz, 2H), 7.58-7.55 (m, 1H), 7.94 
(dd, 4J 
 
= 1.3, 3J 
 
= 7.2 Hz, 2H). 13C NMR (CDCl3, 125 MHz): δ = 29.4, 40.0, 119.9, 128.0, 
128.6, 130.2, 131.5, 133.2, 136.7, 140.2, 198.8. 
 
Ethyl 5-(4-bromophenyl)-3-phenylpent-2-enoate, (5a): 
Synthesized according to Method C using compound 5b (0.40 g, 1.38 mmol), NaH (0.166 g, 
4.15 mmol) and triethyl phosphonoacetate (0.94 mL, 4.15 mmol); 
5Ea: colourless oil; yield: 0.226 g (46 %); 1H NMR (CDCl3, 500 MHz): δ = 1.30 (t, 3J = 7.2 
Hz, 3H), 2.67-2.70 (m, 2H), 3.36-3.92 (m, 2H), 4.20 (q, 3J = 7.2 Hz, 2H), 6.06 (s, 1H), 7.08 
(d, 3J = 8.5 Hz, 2H), 7.38-7.45 (m, 7H). 13C NMR (CDCl3, 125 MHz): δ = 14.3, 32.8, 34.5, 
59.9, 118.1, 119.7, 126.7, 128.7, 129.1, 130.3, 131.3, 140.9, 158.9, 166.2. 
5Za: colourless oil; yield: 0.205 g (41 %); 1H NMR (CDCl3, 500 MHz): δ = 1.06 (t, 3J = 7.2 
Hz, 3H), 2.63-2.75 (m, 4H), 3.98 (q, 3J = 7.2 Hz, 2H), 5.87 (s, 1H), 7.00 (d, 3J = 8.5 Hz, 1H), 
7.16-7.18 (m, 2H), 7.31-7.40 (m, 5H). 13C NMR (CDCl3, 125 MHz): δ = 12.2, 33.4, 42.0, 
60.1, 118.3, 120.2, 127.4, 128.0, 128.2, 130.3, 131.7, 139.8, 140.0, 158.0, 166.1. 
 
(E)-5-(4-Bromophenyl)-3-phenylpent-2-enoic acid, (5E):  
Synthesized according to Method D using compound 5Ea (0.20 g, 0.56 mmol) and NaOHaq 
(0.56 mL, 1.68 mmol); white solid; yield: 0.162 g (88 %); Mp 137-140 °C; 1H NMR (CDCl3, 
500 MHz): δ = 2.70-2.73 (m, 2H), 3.38-3.40 (m, 2H), 6.12 (s, 1H), 7.07 (d, 3J = 8.2 Hz, 2H), 
7.37 (d, 3J = 8.5 Hz, 2H), 7.41-7.45 (m, 3H), 7.45-7.47 (m, 2H); 13C NMR (CDCl3, 125 
MHz): δ = 33.2, 34.5, 116.8, 126.8, 128.8, 129.5, 130.2, 131.4, 131.7, 140.2, 140.7, 162.1, 
169.9; LC/MS (+ESI): m/z = 332.3 [MH+]; Rt = 14.53 (≥ 99 %). 
(Z)-5-(4-Bromophenyl)-3-phenylpent-2-enoic acid, (5Z):  
Synthesized according to Method D using compound 5Za (0.18 g, 0.50 mmol) and NaOHaq 
(0.5 mL, 1.5 mmol); white solid; yield: 0.148 g (90 %); Mp 120-122 °C;  
1H NMR (CDCl3, 500 MHz): δ = 2.62-2.65 (m, 2H), 2.73-2.76 (m, 2H, 3J = 8.3 Hz, 2H), 5.85 
(s, 1H), 6.98 (d, 3J = 8.5 Hz, 2H), 7.11 (d, 3J = 8.5 Hz, 2H), 7.29-7.42 (m, 5H); 13C NMR 
(CDCl3, 125 MHz): δ = 33.1, 35.7, 116.9, 127.4, 128.5, 130.0, 130.5, 131.6, 133.1, 139.5, 
141.4, 160.8, 169.9; LC/MS (+ESI): m/z = 332.3 [MH+]; Rt = 13.93 (≥ 99 %). 
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3-Phenyl-5-(4-(trifluoromethyl)phenyl)pent-2-enoic acids, (6E & 6Z): 
 
3-(4-(Trifluoromethylphenyl)-1-phenylprop-2-en-1-one, (6c):  
Synthesized according to Method A using 4-trifluoromethylbenzaldehyde 6d (2.00 g, 11.5 
mmol) and acetophenone (1.34 mL, 11.5 mmol); yellow solid; yield: 3.05 g (94 %); Mp 129-
131 °C;  
1H NMR (CDCl3, 500 MHz): δ =  7.50-7.55 (m, 2H), 7.58-7.63 (m, 2H), 7.68 (d, 3J = 8.5 Hz, 
2H), 7.74 (d, 3J = 8.5 Hz, 2H), 7.81 (d, 3J = 15.8 Hz, 1H), 8.02-8.04 (m, 2H). 13C NMR 
(CDCl3, 125 MHz) : δ = 124.3, 125.9 (q, J(C, F) = 3.7, CH), 128.5, 128.6, 128.7, 129.4, 131.9 
(d, J(C-F) = 32.6), 132.1, 133.2, 138.1 (d, J (C, F)
 
= 61.4 Hz, CH), 142.7, 190.6.  
 
1-Phenyl-3-(4-(trifluoromethyl)phenyl)propan-1-one, (6b):  
Synthesized according to Method B using compound 6c (0.50 g, 1.81 mmol), HEH (0.687 g, 
2.71 mmol) and silica gel (3.62 g); pale yellow oil; yield: 0.438 g (87 %);  
1H NMR (CDCl3, 500 MHz): δ = 3.14 (t, 3J = 7.6 Hz, 2H), 3.32 (t, 3J = 7.6 Hz, 2H), 7.37 (d, 
3J = 7.9 Hz, 2H), 7.46 (t, J = 7.9 Hz, 2H), 7.54-7.56 (m, 3H), 7.95 (d, 3J 
 
= 8.2 Hz, 2H). 13C 
NMR (CDCl3, 125 MHz): δ = 29.8, 39.8, 125.2, 125.4, 127.9, 128.7, 128.8, 133.2, 136.7, 
145.1, 145.4, 190.8. 
 
Ethyl 3-phenyl-5-(4-(trifluoromethyl)phenyl)pent-2-enoate, (6a):  
Synthesized according to Method C using compound 6b (0.35 g, 1.26 mmol), NaH (0.151 g, 
3.77 mmol) and triethyl phosphonoacetate (0.86 mL, 3.77 mmol); 
6Ea: colourless oil; yield: 0.19 g (43 %); 1H NMR (CDCl3, 500 MHz): δ = 1.30 (t, 3J = 7.2 
Hz, 3H), 2.79-2.81 (m, 2H), 3.40-3.44 (m, 2H), 4.20 (q, 3J = 7.2 Hz, 2H), 6.07 (s, 1H), 7.31 
(d, 3J = 8.2 Hz, 2H), 7.39-7.45 (m, 5H), 7.50 (d, 3J = 8.2 Hz, 2H); 13C NMR (CDCl3, 125 
MHz): δ = 14.3, 32.6, 34.9, 59.9, 118.2, 125.0, 125.2 (d, J (C, F) = 3.9 Hz, CH), 126.7, 128.4, 
128.5, 128.6, 128.8, 129.1, 140.8, 145.5, 158.8, 166.3; 
6Za: colourless oil; yield: 0.162 g (36 %); 1H NMR (CDCl3, 500 MHz): δ = 1.06 (t, 3J = 7.2 
Hz, 3H), 2.73-2.79 (m, 4H), 3.98 (q, 3J = 7.2 Hz, 2H), 5.89 (s, 1H), 7.18 (d, 3J = 8.2 Hz, 2H), 
7.23 (d, 3J = 8.2 Hz, 2H), 7.32-7.39 (m, 3H), 7.52 (d, 3J = 7.9 Hz, 2H); 13C NMR (CDCl3, 125 
MHz): δ = 13.9, 33.6, 41.5, 59.9, 118.1, 125.2, 125.3 (d, J (C, F) = 3.9 Hz, CH), 125.4, 127.2, 
127.9, 128.0, 128.4, 128.6, 139.4, 144.9, 157.5, 165.8; 
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(E)-3-Phenyl-5-(4-(trifluoromethyl)phenyl)pent-2-enoic acid, (6E):  
Synthesized according to Method D using compound 6Ea (0.19 g, 0.54 mmol) and NaOHaq 
(1.80 mL, 5.45 mmol); white solid; yield: 0.163 g (95 %); Mp 127-129 °C;  
1H NMR (CDCl3, 500 MHz): δ = 2.80-2.83 (m, 2H), 3.41-3.45 (m, 2H), 6.13 (s, 1H), 7.30 (d, 
3J = 8.2 Hz, 2H), 7.41-7.48 (m, 5H), 7.51 (d, 3J = 8.2 Hz, 2H); 13C NMR (CDCl3, 125 MHz): 
δ =  32.9, 34.9, 117.0, 125.2 (d, J (C, F) = 3.7 Hz, CH), 126.7, 128.3, 128.6, 128.8, 128.8, 
129.1, 129.5, 140.6, 145.3 (d, J (C, F) = 1.9 Hz, CH), 162.0, 170.9; LC/MS (+ESI): m/z = 
321.5 [MH+]; Rt = 14.27 (≥ 99 %). 
(Z)-3-Phenyl-5-(4-(trifluoromethyl)phenyl)pent-2-enoic acid, (6Z):  
Synthesized according to Method D using compound 6Za (0.15 g, 0.43 mmol) and NaOHaq 
(1.4 mL, 4.31 mmol); white solid; yield: 0.113 g (82 %); Mp 125-127 °C;  
1H NMR (CDCl3, 500 MHz): δ = 2.70-2.78 (m, 4H), 5.85 (s, 1H), 7.14-7.16 (m, 2H), 7.19-
7.29 (m, 2H), 7.30-7.37 (m, 3H), 7.49-7.54 (m, 2H); 13C NMR (CDCl3, 125 MHz): δ = 33.5, 
34.9, 125.3 (d, J (C, F) = 3.7 Hz, CH), 125.9, 127.2, 127.5, 128.1, 128.5, 128.6, 128.8, 130.0, 
133.5, 144.6, 160.6, 170.0; LC/MS (+ESI): m/z = 321.5 [MH+]; Rt = 13.74 (≥ 95 %). 
 
 
5-(3,4-Dichlorophenyl)-3-phenylpent-2-enoic acids, (7E & 7Z): 
 
3-(3,4-Dichlorophenyl)-1-phenylprop-2-en-1-one, (7c):  
Synthesized according to Method A using 3,4-dichlorobenzaldehyde 7d (2.00 g, 11.4 mmol) 
and acetophenone (1.33 mL, 11.4 mmol); pale yellow solid; yield: 3.00 g (94 %); Mp 110-113 
°C;  
1H NMR (CDCl3, 500 MHz): δ = 7.44-7.53 (m, 5H), 7.59-7.62 (m, 1H), 7.69 (d, 3J = 15.8 Hz, 
1H), 7.72 (d, 3J = 1.9 Hz, 1H), 8.00-8.03 (m, 2H). 13C NMR (CDCl3, 125 MHz): δ = 123.5, 
127.5, 128.5, 128.7, 129.7, 131.0, 133.1, 133.3, 134.4, 134.9, 137.8, 141.9, 189.9. 
 
3-(3,4-Dichlorophenyl)-1-phenylpropan-1-one, (7b): 
Synthesized according to Method B using compound 7c (0.50 g, 1.80 mmol), HEH (0.685 g, 
2.70 mmol) and silica gel (3.60 g); pale yellow oil; yield: 0.416 g (83 %);  
1H NMR (CDCl3, 500 MHz): δ = 3.03 (t, 3J = 7.2 Hz, 2H), 3.28 (t, 3J = 7.2 Hz, 2H), 7.09 (dd, 
4J = 1.9, 4J = 8.5 Hz, 1H), 7.35-7.34 (m, 2H), 7.46 (t, 3J = 7.2 Hz, 2H), 7.59-7.55 (m, 1H), 
7.96-7.94 (m, 2H). 13C NMR (CDCl3, 125 MHz): δ = 29.9, 39.7, 127.9, 128.0, 128.7, 130.0, 
130.3, 130.4, 132.3, 133.2, 136.6, 141.5, 198.4. 
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Ethyl 5-(3,4-dichlorophenyl)-3-phenylpent-2-enoate, (7a): 
Synthesized according to Method C using compound 7b (0.35 g, 1.25 mmol), NaH (0.15 g, 
3.76 mmol) and triethyl phosphono-acetate (0.85 mL, 3.76 mmol); 
7Ea: colourless oil; yield: 0.204 g (47 %); 1H NMR (CDCl3, 500 MHz): δ = 1.30 (t, 3J = 7.2 
Hz, 3H), 2.67-2.71 (m, 2H), 3.36-3.39 (m, 2H), 4.20 (q, 3J = 7.2 Hz, 2H), 6.06 (s, 1H), 7.04 
(dd, 4J = 1.9, 3J = 8.2 Hz, 1H), 7.28 (d, 4J = 2.2, 3J = 8.2 Hz, 1H), 7.30 (d, 3J = 8.2 Hz, 1H), 
7.38-7.44 (m, 5H); 13C NMR (CDCl3, 125 MHz): δ = 14.3, 32.5, 34.1, 60.0, 118.3, 126.7, 
128.1, 128.7, 129.1, 129.8, 130.1, 130.5, 132.0, 140.7, 141.6, 158.6, 166.3. 
7Za: colourless oil; yield: 0.178 g (41 %); 1H NMR (CDCl3, 500 MHz): δ = 1.01 (t, 3J = 6.9 
Hz, 3H), 2.75-2.63 (m, 4H), 3.98 (q, 3J = 6.9 Hz, 2H), 5.87 (s, 1H), 6.96 (dd, 4J = 2.2, 3J = 8.2 
Hz, 2H), 7.17 (d, 3J = 8.2 Hz, 2H), 7.20 (s, 1H), 7.32-7.38 (m, 4H); 13C NMR (CDCl3, 125 
MHz): δ = 13.9, 32.9, 41.5, 59.9, 118.2, 127.2, 127.8, 127.9, 128.0, 130.1, 130.2, 130.3, 
132.3, 139.3, 141.0, 157.3, 165.8. 
 
(E)-5-(3,4-Dichlorophenyl)-3-phenylpent-2-enoic acid, (7E):  
Synthesized according to Method D using compound 7Ea (0.10 g, 0.29 mmol) and NaOHaq 
(0.96 mL, 2.86 mmol); white solid; yield: 0.09 g (95 %); Mp 120-123 °C;  
1H NMR (CDCl3, 500 MHz): δ = 2.70-2.73 (m, 2H), 3.38-3.41 (m, 2H), 6.13 (s, 1H), 7.02 
(dd, 4J = 1.9, 3J = 8.2 Hz, 1H ), 7.27 (d, 4J = 2.2 Hz, 1H), 7.31 (d, 3J = 8.2 Hz, 1H), 7.41-7.46 
(m, 5H); 13C NMR (CDCl3, 125 MHz): δ = 32.8, 34.2, 117.0, 126.7, 128.0, 128.8, 129.6, 
130.0, 130.2, 130.4, 132.1, 140.5, 141.4, 170.4, 196.6; LC/MS (+ESI): m/z = 322.6 [MH+]; Rt 
= 14.88 (≥ 99 %). 
(Z)-5-(3,4-Dichlorophenyl)-3-phenylpent-2-enoic acid, (7Z):  
Synthesized according to Method D using compound 7Za (0.10 g, 0.29 mmol) and NaOHaq 
(0.96 mL, 2.86 mmol); white solid; yield: 0.085 g (91 %); Mp 130-134 °C;  
1H NMR (CDCl3, 500 MHz): δ = 2.62-2.65 (m, 2H), 2.74-2.77 (m, 2H), 5.86 (s, 1H), 6.93 
(dd, 4J = 2.2, 3J =8.2 Hz, 2H ), 7.16-7.21 (m, 2H), 7.31-7.39 (m, 4H); 13C NMR (CDCl3, 125 
MHz): δ = 32.5, 35.5, 116.8, 125.8, 126.9, 127.5, 127.9, 128.0, 128.2, 130.2, 133.3, 139.9, 
140.4, 160.3, 169.9; LC/MS (+ESI): m/z = 322.7 [MH+]; Rt = 14.32 (≥ 99 %). 
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5-(2,4-Dichlorophenyl)-3-phenylpent-2-enoic acids, (8E &8Z): 
 
3-(2,4-Dichlorophenyl)-1-phenylprop-2-en-1-one, (8c): 
Synthesized according to Method A using 2,4-dichlorobenzaldehyde 8d (2.0 g, 11.43 mmol) 
and acetophenone (1.33 mL, 11.43 mmol); yellow solid; yield: 3.1 g (94 %); Mp 175-178 °C; 
1H NMR (CDCl3, 500 MHz): δ = 7.39 (dd, 4J = 2.2, 3J = 8.5 Hz, 1H), 7.46-7.53 (m, 4H), 
7.59-7.62 (m, 1H), 7.69 (d, 3J = 8.2 Hz, 1H), 8.00-8.10 (m, 2H), 8.10 (d, 3J = 15.8 Hz, 1H). 
13C NMR (CDCl3, 125 MHz): δ = 125.1, 127.6, 127.9, 128.5, 128.6, 128.7, 130.1, 133.1, 
136.0, 136.5, 137.8, 139.3, 190.1. 
 
3-(2,4-Dichlorophenyl)-1-phenylpropan-1-one, (8b): 
Synthesized according to Method B using compound 8c (0.50 g, 1.80 mmol), HEH (0.685 g, 
2.70 mmol) and silica gel (3.60 g); pale green oil; yield: 0.363 g (72 %);  
1H NMR (CDCl3, 500 MHz): δ = 3.15 (t, 3J = 7.6 Hz, 2H),  3.29 (t, 3J = 7.6 Hz, 2H), 7.17 (dd, 
4J = 2.2, 3J = 8.2 Hz, 1H), 7.26 (d, 3J = 8.2 Hz, 2H), 7.37 (d, 3J = 2.2 Hz, 1H), 7.46 (t, 3J 
 
= 
7.6 Hz, 2H), 7.54-7.59 (m, 1H), 7.95-7.97 (m, 2H). 13C NMR (CDCl3, 125 MHz): δ = 27.7, 
38.1, 127.3, 128.0, 128.6, 129.3, 131.7, 132.7, 133.2, 134.6, 136.6, 137.4, 198.6. 
 
Ethyl 5-(2,4-dichlorophenyl)-3-phenylpent-2-enoate, (8a): 
Synthesized according to Method C using compound 8b (0.30 g, 1.07 mmol), NaH (0.13 g, 
3.22 mmol) and triethyl phosphonoacetate (0.73 mL, 3.22 mmol); 
8Ea: colourless oil; yield: 0.147 g (39 %); 1H NMR (CDCl3, 500 MHz): δ = 1.29 (t, 3J = 7.2 
Hz, 3H), 2.83-2.86 (m, 2H), 3.35-3.38 (m, 2H), 4.20 (q, 3J = 7.2 Hz, 2H), 6.10 (s, 1H), 7.14 
(dd, 3J = 2.2, 3J = 8.2 Hz, 1H), 7.23 (d, 3J = 8.2 Hz, 2H), 7.31 (d, 3J = 2.2 Hz, 1H), 7.37-7.41 
(m, 3H), 7.48-7.50 (m, 2H); 13C NMR (CDCl3, 125 MHz): δ = 14.3, 30.9, 32.3, 60.0, 118.1, 
126.7, 127.0, 128.6, 129.0, 129.1, 131.5, 132.3, 134.4, 137.7, 140.6, 158.6, 166.3. 
8Za: colourless oil; yield: 0.179 g (48 %); 1H NMR (CDCl3, 500 MHz): δ = 1.07 (t, 3J = 7.2 
Hz, 3H), 2.70-2.79 (m, 4H), 3.99 (q, 3J = 7.2 Hz, 2H), 5.91 (s, 1H), 7.05 (d, 3J = 8.2 Hz, 1H), 
7.15 (dd, 4J = 2.2, 3J =8.2 Hz, 1H), 7.19-7.21 (m, 2H), 7.31-7.38 (m, 4H). 13C NMR (CDCl3, 
125 MHz): δ = 13.9, 31.4, 39.8, 59.9, 118.0, 127.1, 127.3, 127.9, 128.0, 129.3, 131.1, 132.6, 
134.5, 137.0, 139.4, 157.6, 165.9. 
 
 
 
                                                                                                                    Experimental Section 
 131 
(E)-5-(2,4-Dichlorophenyl)-3-phenylpent-2-enoic acid, (8E):  
Synthesized according to Method D using compound 8Ea (0.10 g, 0.31 mmol) and NaOHaq 
(0.32 mL, 0.93 mmol); white solid; yield: 0.09 g (87 %); Mp 118-120 °C;  
1H NMR (CDCl3, 500 MHz): δ = 2.85-2.89 (m, 2H), 3.40-3.72 (m, 2H), 6.16 (s, 1H), 7.14 
(dd, 4J = 2.2, 3J = 8.2 Hz, 2H), 7.19 (d, 3J = 8.2 Hz, 2H), 7.32 (d, 3J = 1.9 Hz, 1H), 7.40-7.41 
(m, 3H), 7.51-7.53 (m, 2H); 13C NMR (CDCl3, 125 MHz): δ = 31.1, 32.4, 116.8, 125.9, 126.8, 
127.1, 128.7, 129.1, 129.6, 131.5, 132.5, 137.1, 137.5, 140.0, 169.9; LC/MS (+ESI): m/z = 
322.2 [MH+]; Rt = 13.12 (≥ 93 %). 
(Z)-5-(2,4-Dichlorophenyl)-3-phenylpent-2-enoic acid, (8Z):  
Synthesized according to Method D using compound 8Za (0.10 g, 0.31 mmol) and NaOHaq 
(0.32 mL, 0.93 mmol); white solid; yield: 0.09 g (87 %); Mp 122-124 °C;  
1H NMR (CDCl3, 500 MHz): δ = 2.67-2.74 (m, 4H), 5.88 (s, 1H), 7.03 (d, 3J = 8.2 Hz, 1H ), 
7.14 (dd, 3J = 2.2, 4J =8.2 Hz, 1H), 7.19-7.21 (m, 2H), 7.33-7.39 (m, 4H); 13C NMR (CDCl3, 
125 MHz): δ = 32.5, 40.2, 116.9, 127.1, 127.3, 128.2, 128.4, 129.4, 131.1, 132.7, 134.5, 
138.7, 141.4, 160.5, 176.5; LC/MS (+ESI): m/z = 322.7 [MH+]; Rt = 14.63 (≥ 98 %). 
 
 
5-(4-Bromo-2-fluorophenyl)-3-phenylpent-2-enoic acids, (9E & 9Z): 
 
3-(4-Bromo-2-fluorophenyl)-1-phenylprop-2-en-1-one, (9c):  
Synthesized according to Method A using 4-bromo-2-fluoro-benzaldehyde 9d (1.50 g, 7.39 
mmol) and acetophenone (0.86 mL, 7.39 mmol); yellow solid; yield: 1.81 g (80 %); Mp 166-
168 °C;  
1H NMR (CDCl3, 500 MHz): δ = 7.33-7.36 (m, 2H), 7.51 (t, 3J = 7.6 Hz, 3H), 7.56-7.63 (m, 
1H), 7.63 (d, 3J = 15.8 Hz, 1H), 7.82 (d, 3J = 16.1 Hz, 1H), 8.03-8.00 (m, 2H). 13C NMR 
(CDCl3, 125 MHz): δ = 119.9 (d, J (C, F) = 24.9 Hz, CH), 120.1 (d, J (C, F) = 1.6 Hz, CH), 
122.2, 124.6 (d, J (C, F) = 9.6 Hz, CH), 125.0 (d, J (C, F) = 3.8 Hz, CH), 128.0 (d, J (C, F) = 
7.7 Hz, CH), 128.6, 128.7, 130.6 (d, J (C, F) = 3.8 Hz, CH), 133.0, 136.3, 161.0 (d, J (C, F) = 
252.0 Hz, Cquat), 190.2. 
 
3-(4-Bromo-2-fluorophenyl)-1-phenylpropan-1-one, (9b): 
Synthesized according to Method B using compound 9c (0.50 g, 1.64 mmol), HEH (0.623 g, 
2.46 mmol) and silica gel (3.28 g); pale green oil; yield: 0.395 g (78 %);  
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1H NMR (CDCl3, 500 MHz): δ = 3.06 (t, 3J = 7.6 Hz, 2H), 3.28 (t, 3J = 7.6 Hz, 2H), 7.15-7.21 
(m, 3H), 7.46 (t, 3J = 7.9 Hz, 2H), 7.54-7.59 (m, 1H), 7.91-7.97 (m, 2H). 13C NMR (CDCl3, 
125 MHz): δ = 23.5, 38.4, 118.8, 119.0, 120.0 (d, J (C, F) = 9.6 Hz, CH), 127.3, (t, J (C, F) = 
2.9 Hz, CH), 128.0, 128.6, 132.0 (d, J (C, F) = 5.8 Hz, CH), 133.2, 136.6, 161.0 (d, J (C, F) = 
249.5 Hz, Cquat), 198.6. 
 
Ethyl 5-(4-bromo-2-fluorophenyl)-3-phenylpent-2-enoate, (9a): 
Synthesized according to Method C using compound 9b (0.30 g, 0.98 mmol), NaH (0.117 g, 
2.93 mmol) and triethyl phosphonoacetate (0.67 mL, 3.05 mmol); 
9Ea: colourless oil; yield: 0.145 g (39 %); 1H NMR (CDCl3, 500 MHz): δ = 1.30 (t, 3J = 6.9 
Hz, 3H), 2.73-2.76 (m, 2H), 3.35-3.38 (m, 2H), 4.19 (q, 3J = 6.9 Hz, 2H), 6.09 (s, 1H), 7.10-
7.18 (m, 3H), 7.37-7.39 (m, 3H), 7.45-7.47 (m, 2H). 13C NMR (CDCl3, 125 MHz): δ = 14.3, 
28.0, 31.1, 60.0, 118.2, 118.6 (d, J (C, F) = 24.9 Hz, CH), 119.7 (d, J (C, F) = 9.6 Hz, CH), 
126.7, 127.1 (d, J (C, F) = 3.9 Hz, CH), 127.4, 128.6, 129.1, 131.9, 132.0, 140.6, 158.4, 160.5 
(d, J (C, F) = 249.5 Hz, Cquat). 
9Za: colourless oil; yield: 0.154 g (42 %); 1H NMR (CDCl3, 500 MHz): δ = 1.06 (t, 3J = 7.2 
Hz, 3H), 2.66-2.75 (m, 4H), 3.98 (q, 3J = 7.2 Hz, 2H), 5.87 (s, 1H), 6.96 (t, 3J = 8.2 Hz, 1H), 
7.18 (d, 3J = 8.8 Hz, 4H), 7.31-7.38 (m, 3H). 13C NMR (CDCl3, 125 MHz): δ = 13.9, 27.1, 
40.1, 60.0, 118.1, 118.9, 119.0, 119.5 (d, J (C, F) = 9.6 Hz, CH), 126.8, 127.1, 127.2, 127.3, 
127.9 (d, J (C, F) = 9.6 Hz, CH), 131.5 (d, J (C, F) = 5.8 Hz, CH), 139.4, 158.5 (d, J (C, F) = 
299.4 Hz, Cquat), 165.8. 
 
(E)-5-(4-Bromo-2-fluorophenyl)-3-phenylpent-2-enoic acid, (9E):  
Synthesized according to Method D using compound 9Ea (0.10 g, 0.26 mmol) and NaOHaq 
(0.27 mL, 0.79 mmol); white solid; yield: 0.075 g (82 %); Mp 110-113 °C;  
1H NMR (CDCl3, 500 MHz): δ = 2.76-2.79 (m, 2H), 3.37-3.41 (m, 2H), 6.14 (s, 1H), 7.08 (d, 
3J = 8.2 Hz, 1H), 7.14-7.19 (m, 2H), 7.40-7.41 (m, 3H), 7.48-7.50 (m, 2H); 13C NMR (CDCl3, 
125 MHz): δ = 28.1, 31.4, 117.0, 118.7, 118.9, 119.9, 126.7, 127.2 (d, J (C, F) = 2.8 Hz, CH), 
127.3, 128.7, 129.5, 131.9 (d, J (C, F) = 6.4 Hz, CH), 160.9 (d, J (C, F) = 250.2 Hz, Cquat), 
161.6, 170.9; LC/MS (+ESI): m/z = 350.3 [MH+]; Rt = 12.90 (≥ 98 %). 
(Z)-5-(4-Bromo-2-fluorophenyl)-3-phenylpent-2-enoic acid, (9Z):  
Synthesized according to Method D using compound 9Za (0.10 g, 0.26 mmol) and NaOHaq 
(0.27 mL, 0.79 mmol); white solid; yield: 0.078 g (85 %); Mp 82-84 °C;  
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1H NMR (CDCl3, 500 MHz): δ = 2.65-2.68 (m, 2H), 2.74-2.78 (m, 2H), 5.86 (s, 1H), 7.18-
7.22 (m, 3H), 7.27-7.38 (m, 4H); 13C NMR (CDCl3, 125 MHz): δ = 27.0, 28.0, 35.6, 40.5, 
116.9, 118.8 (d, J (C, F) = 5.5 Hz, CH), 119.2 (d, J (C, F) = 9.2 Hz, CH), 120.1, 126.0, 127.5 
(d, J (C, F) = 3.7 Hz, CH), 128.5, 131.4 (d, J (C, F) = 5.5 Hz, CH), 141.4, 161.0 (d, J (C, F) = 
258.4 Hz, Cquat), 169.8; LC/MS (+ESI): m/z = 350.3 [MH+]; Rt = 14.00 (≥ 99 %). 
 
 
5-(4-Ethylphenyl)-3-phenylpent-2-enoic acids, (10E &10Z): 
 
3-(4-Ethylphenyl)-1-phenylprop-2-en-1-one, (10c):  
Synthesized according to Method A using 4-ethylbenzaldehyde 10d (2.00 g, 14.9 mmol) and 
acetophenone (1.79 g, 14.9 mmol); yellow oil; yield: 2.60 g (74 %);  
1H NMR (CDCl3, 500 MHz): δ = 1.04 (t, 3J = 7.6 Hz, 3H), 2.47 (q, 3J = 7.6 Hz, 2H), 7.02-
7.04 (m, 2H), 7.26-7.32 (m, 3H), 7.34-7.37 (m, 3H), 7.58 (d, 3J = 15.8 Hz, 1H), 7.77-7.81 (m, 
2H). 13C NMR (CDCl3, 125 MHz): δ = 15.3, 28.8, 121.2, 128.4, 128.5, 128.6, 131.6, 132.4, 
132.6, 138.4, 145.0, 147.4, 190.7. 
 
3-(4-Ethylphenyl)-1-phenylpropan-1-one, (10b):  
Synthesized according to Method B using compound 10c (0.50 g, 2.11 mmol), HEH (0.84 g, 
3.17 mmol) and silica gel (4.22 g); pale yellow oil; yield: 0.284 g (57 %);  
1H NMR (CDCl3, 500 MHz): δ = 1.23 (t, 3J = 7.6 Hz, 3H), 2.63 (q, 3J = 7.6 Hz, 2H), 3.05 (t, 
3J = 7.6 Hz, 2H), 3.30 (t, 3J = 7.6 Hz, 2H), 7.14 (d, 3J = 8.2 Hz, 2H), 7.18 (d, 3J = 8.2 Hz, 2H), 
7.46 (t, 3J = 7.2 Hz, 2H), 7.54-7.57 (m, 1H), 7.95-7.98 (m, 2H). 13C NMR (CDCl3, 125 MHz): 
δ = 15.6, 28.4, 29.7, 40.6, 127.9, 128.0, 128.3, 128.6, 133.0, 136.9, 138.4, 142.0, 199.3. 
 
Ethyl 5-(4-ethylphenyl)-3-phenylpent-2-enoate, (10a):  
Synthesized according to Method C using compound 10b (0.25 g, 1.05 mmol), NaH (0.126 g, 
3.15mmol) and triethyl phosphonoacetate (0.72 mL, 3.15 mmol); 
10Ea: colourless oil; yield: 0.143 g (44 %); 1H NMR (CDCl3, 500 MHz): δ = 1.25 (d, 3J = 7.6 
Hz, 3H), 1.30 (t, 3J = 7.2 Hz, 3H), 2.61 (q, 3J = 7.6 Hz, 2H), 2.69-2.72 (m, 2H), 3.37-3.40 (m, 
2H), 4.21 (q, 3J = 7.2 Hz, 2H), 6.07 (s, 1H), 7.10 (d, 3J = 8.2 Hz, 2H), 7.15 (d, 3J = 8.2 Hz, 
2H), 7.38-7.41 (m, 3H), 7.46-7.48 (m, 2H). 13C NMR (CDCl3, 125 MHz): δ = 14.3, 15.7, 
28.5, 33.3, 34.8, 59.9, 117.8, 126.7, 127.8, 128.4, 128.6, 128.9, 138.8, 141.1, 141.8, 159.5, 
166.3. 
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10Za: colourless oil; yield: 0.133 g (41 %); 1H NMR (CDCl3, 500 MHz): δ = 1.06 (t, 3J = 7.2 
Hz, 3H), 1.22 (t, 3J = 7.6 Hz, 3H), 2.60 (q, 3J = 7.6 Hz, 2H), 2.72-2.76 (m, 4H), 3.98 (q, 3J = 
7.2 Hz, 2H), 5.90 (s, 1H), 7.05 (d, 3J = 7.9 Hz, 2H), 7.10 (d, 3J = 7.9 Hz, 2H), 7.20-7.18 (m, 
2H), 7.38-7.30 (m, 3H). 13C NMR (CDCl3, 125 MHz): δ = 13.9, 15.6, 28.4, 33.4, 42.1, 59.8, 
117.6, 127.2, 127.7, 127.9, 128.2, 138.1, 139.9, 142.0, 158.6,  166.0. 
 
(E)-5-(4-Ethylphenyl)-3-phenylpent-2-enoic acid, (10E):  
Synthesized according to Method D using compound 10Ea (0.10 g, 0.32 mmol) and NaOHaq 
(1.07 mL, 3.24 mmol); white solid; yield: 0.085 g (94 %); Mp 98-100 °C;  
1H NMR (CDCl3, 500 MHz): δ = 1.22 (t, 3J = 7.6 Hz, 3H), 2.62 (q, 3J = 7.6 Hz, 2H), 2.72-
2.76 (m, 2H), 3.39-3.42 (m, 2H), 6.13 (s, 1H), 7.11 (d, 3J = 8.2 Hz, 2H), 7.15 (d, 3J = 8.2 Hz, 
2H), 7.40-7.41 (m, 3H), 7.48-7.50 (m, 2H); 13C NMR (CDCl3, 125 MHz): δ = 15.7, 28.5, 
33.6, 34.9, 116.7, 126.8, 127.8, 128.3, 128.7, 129.3, 140.9, 141.9, 145.5, 162.6, 170.8; LC/MS 
(+ESI): m/z = 289.4 [MH+]; Rt = 14.68 (≥ 97 %). 
(Z)-5-(4-Ethylphenyl)-3-phenylpent-2-enoic acid, (10Z):  
Synthesized according to Method D using compound 10Za (0.10 g, 0.32 mmol) and NaOHaq 
(1.07 mL, 3.24 mmol); white solid; yield: 0.083 g (92 %); Mp 96-98 °C;  
1H NMR (CDCl3, 500 MHz): δ = 1.15 (t, 3J = 7.6 Hz, 3H), 2.54 (q, 3J = 7.6 Hz, 2H), 2.64-
2.68 (m, 2H), 3.34 (m, 2H), 6.05 (s, 1H), 7.03 (d, 3J = 8.2 Hz, 2H), 7.07 (d, 3J = 8.2 Hz, 2H), 
7.33-7.35 (m, 3H), 7.41-7.43 (m, 2H); 13C NMR (CDCl3, 125 MHz): δ = 15.7, 28.5, 33.6, 
34.8, 116.5, 126.8, 127.8, 128.2, 128.3, 128.7, 129.3, 140.9, 141.9, 162.2, 170.8; LC/MS 
(+ESI): m/z = 289.4 [MH+]; Rt = 14.15 (≥ 97 %). 
 
 
5-(4-Chlorophenyl)-3-(3-fluorophenyl)pent-2-enoic acids, (11E & 11Z): 
 
(E)-3-(4-Chlorophenyl)-1-(2-fluorophenyl)prop-2-en-1-one, (11c):  
Synthesized according to Method A using 4-chlorobenzaldehyde (2.00 g, 14.3 mmol) and 2-
fluoroacetophenone (1.74 mL, 14.3 mmol); pale yellow solid; yield: 1.85 g (49 %); 
1H NMR (CDCl3, 500 MHz) δ 7.18 (t, J  = 8.5 Hz, 2H), 7.40 (d, J  = 8.5 Hz, 2H), 7.47 (d, J  = 
15.4 Hz, 1H), 7.57 (d, J 
 
= 8.5 Hz, 2H), 7.76 (d, J 
 
= 15.8 Hz, 1H), 8.06 (d, J 
 
= 8.5 Hz, 2H); 
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3-(4-Chlorophenyl)-1-(2-fluorophenyl)propan-1-one, (11b):  
Synthesized according to Method B using 11c (1.0 g, 3.85 mmol), HEH (1.46 g, 5.75 mmol) 
and silica gel (7.67 g); colourless solid; yield: 0.75 g (75 %);  
1H NMR (CDCl3, 500 MHz) δ 3.04 (t, J  = 7.2 Hz, 2H), 3.30 (dt, J  = 3.1, 7.6 Hz, 2H), 7.12-
7.3 (m, 6H), 7.50-7.55 (m, 1H), 7.88 (dd, J 
 
= 1.6, 8.5 Hz, 1H). 13C NMR (CDCl3, 125 MHz) δ 
29.2, 44.9, 116.6 (d, 2JC-F = 23.4 Hz), 124.5 (d, 4JC-F = 2.9 Hz), 125.5 (d, 3JC-F = 13.4 Hz), 
128.5, 129.8, 130.6 (d, 4JC-F = 2.9 Hz), 131.8, 134.6 (d, 3JC-F = 9.6 Hz), 139.6, 161.9 (d, 1JC-F 
= 254.3 Hz), 197.1. 
 
Ethyl 5-(4-chlorophenyl)-3-(2-fluorophenyl)pent-2-enoate, (11a):  
Synthesized according to Method C using 11b (0.60 g, 2.28 mmol), NaH (0.28 g, 6.85 mmol) 
and triethyl phosphonoacetate (1.51 mL, 6.85 mmol); 
11Ea: colourless oil; yield: 0.14 g (19 %); 1H NMR (CDCl3, 500 MHz) δ 1.30 (t, J = 7.2 Hz, 
3H), 2.66-2.70 (m, 2H), 3.32-3.35 (m, 2H), 4.19 (q, J = 7.2 Hz, 2H), 5.94 (s, 1H), 7.07-7.11 
(m, 3H), 7.14 (d, J =  8.5 Hz, 1H), 7.17-7.21 (m, 3H), 7.31-7.35 (m, 1H). 13C NMR (CDCl3, 
125 MHz) δ 14.3, 33.7, 33.9, 60.1, 116.1 (d, 2JC-F = 23.0 Hz), 117.9, 119.4, 122.0 (d, 4JC-F 
=2.9 Hz), 124.2 (d, 4JC-F = 3.8 Hz), 128.3, 129.8, 129.9, 130.2, 139.7, 155.1, 167.9 (d, 1JC-F = 
250.5 Hz), 169.4. 
11Za: colourless oil; yield: 0.18 g (24 %); 1H NMR (CDCl3, 500 MHz) δ 1.07 (t, J = 7.2 Hz, 
3H), 2.69-2.74 (m, 4H), 4.00 (q, J = 7.2 Hz, 2H), 5.98 (s, 1H), 7.06-7.14 (m, 5H), 7.23 (d, J = 
8.5 Hz, 2H), 7.29-7.33 (m, 1H).  
 
(E)-5-(4-Chlorophenyl)-3-(3-fluorophenyl)pent-2-enoic acid, (11E):  
Synthesized according to Method D using (E)-ethyl 11Ea (0.14 g, 0.42 mmol) and NaOHaq 
(1.4 mL, 4.20 mmol); white solid; yield: 0.09 g (70 %);  
1H NMR (CDCl3, 500 MHz) δ 2.69-2.72 (m, 2H), 3.34-3.38 (m, 2H), 6.01 (s, 1H), 7.08-7.21 
(m, 7H), 7.37-7.38 (m, 1H). MS (+ESI): m/z = 306 (M+H). 
(Z)-5-(4-Chlorophenyl)-3-(3-fluorophenyl)pent-2-enoic acid, (11Z): 
 Synthesized according to Method D using 11Za (0.18 g, 0.55 mmol) and NaOHaq (1.8 mL, 
5.5 mmol); white solid; yield: 0.07 g (40 %);  
1H NMR (CDCl3, 500 MHz) δ 2.60-2.63 (m, 2H), 2.67-2.70 (m, 2H), 5.91 (s, 1H), 6.93-7.10 
(m, 4H), 7.17-7.23 (m, 4H); MS (+ESI): m/z = 306 (M+H). 
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5-(4-Chlorophenyl)-3-(3-flurorphenyl)pent-2-enoic acids, (12E & 12Z):  
 
(E)-3-(4-Chlorophenyl)-1-(3-fluorophenyl)prop-2-en-1-one, (12c):  
Synthesized according to Method A using 4-chlorobenzaldehyde (1.02 g, 7.24 mmol) and 3-
fluoroacetophenone (1.0 g, 7.24 mmol); pale yellow solid; yield: 1.68 g (45 %); 
1H NMR (CDCl3, 500 MHz) δ 7.18 (t, J  = 8.5 Hz, 2H), 7.40 (d, J  = 8.5 Hz, 2H), 7.47 (d, J  = 
15.4 Hz, 1H), 7.57 (d, J 
 
= 8.5 Hz, 2H), 7.76 (d, J 
 
= 15.8 Hz, 1H), 8.06 (d, J 
 
= 8.5 Hz, 2H); 
13C NMR (CDCl3, 125 MHz) δ 116.5 (d, 2JC-F = 23.0 Hz), 124.5 (d, 4JC-F = 3.8 Hz), 126.0 (d, 
3JC-F = 6.7 Hz), 126.9, 129.2, 129.7, 131.0 (d, 4JC-F = 2.9 Hz), 133.2, 134.1 (d, 3JC-F = 8.6 
Hz), 136.6, 143.2, 161.2 (d, 1JC-F = 253.3 Hz), 188.7. 
 
3-(4-Chlorophenyl)-1-(3-fluorophenyl)propan-1-one, (12b):  
Synthesized according to Method B using 3-(4-chlorophenyl)-1-(3-fluorophenyl)prop-2-en-1-
one (1.0 g, 3.85 mmol), HEH (1.46 g, 5.75 mmol) and silica gel (7.67 g); colourless solid; 
yield: 0.88 g (88 %);  
1H NMR (CDCl3, 500 MHz) δ 3.03 (t, J  = 7.6 Hz, 2H), 3.23 (t, J  = 7.6 Hz, 2H), 7.17 (d, J  =  
8.5 Hz, 1H), 7.23-7.28 (m, 3H), 7.40-7.48 (m, 1H), 7.60-7.63 (m, 1H), 7.71 (d, J 
 
= 7.9 Hz, 
1H). 13C NMR (CDCl3, 125 MHz) δ 29.3, 40.3, 114.7 (d, 2JC-F = 22.1 Hz), 120.1 (d, 2JC-F = 
21.1 Hz), 123.7, 128.6, 129.8, 130.3 (d, 3JC-F = 7.7 Hz), 131.9, 138.8 (d, 3JC-F = 5.8 Hz), 
139.4, 162.8 (d, 1JC-F = 248.5 Hz), 197.5. 
 
Ethyl 5-(4-chlorophenyl)-3-(3-fluorophenyl)pent-2-enoate, (12a):  
Synthesized according to Method C using 12b (0.60 g, 2.28 mmol), NaH (0.28 g, 6.85 mmol) 
and triethyl phosphonoacetate (1.51 mL, 6.85 mmol); 
12Ea: colourless oil; yield: 0.34 g (45 %); 1H NMR (CDCl3, 500 MHz) δ 1.29 (t, J = 7.0 Hz, 
3H), 2.69-2.71 (m, 2H), 3.33-3.36 (m, 2H), 4.19 (q, J = 7.0 Hz, 2H), 6.05 (s, 1H), 7.04 (t, J =  
8.5 Hz, 1H), 7.10-7.14 (m, 3H), 7.20-7.23 (m, 3H), 7.33-7.36 (m, 1H). 13C NMR (CDCl3, 125 
MHz) δ 14.3, 32.8, 34.3, 60.1, 113.7 (d, 2JC-F = 23.0 Hz), 115.8 (d, 2JC-F = 22.1 Hz), 119.0, 
122.4 (d, 4JC-F = 2.9 Hz), 128.3, 129.9, 130.2 (d, 3JC-F = 8.6 Hz), 131.7, 139.6, 143.2 (d, 3JC-F 
= 6.7 Hz), 157.4, 160.0 (d, 1JC-F = 253.3 Hz),166.0. 
12Za: colourless oil; yield: 0.3 g (40 %); 1H NMR (CDCl3, 500 MHz) δ 1.07 (t, J = 7.2 Hz, 
3H), 2.65-2.72 (m, 4H), 3.99 (q, J = 7.2 Hz, 2H), 5.88 (s, 1H), 6.87-6.89 (m, 1H), 6.94 (d, J = 
7.6 Hz, 1H), 7.00-7.01 (m, 1H), 7.04 (d, J = 8.5 Hz, 2H), 7.24 (d, J = 8.2 Hz, 2H), 7.30-7.35 
(m, 1H). 13C NMR (CDCl3, 125 MHz) δ 13.9, 33.0, 41.6, 60.0, 114.4 (d, 2JC-F = 22.1 Hz), 
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114.7, 118.7, 123.0 (d, 4JC-F = 2.9 Hz), 128.6, 129.5, 129.6, 132.0, 156.2 (d, 4JC-F = 1.9 Hz), 
161.4 (d, 1JC-F = 2465.7 Hz), 162.6, 163.2. 165.5. 
 
(E)-5-(4-Chlorophenyl)-3-(3-fluorophenyl)pent-2-enoic acid, (12E):  
Synthesized according to Method D using 12Ea (0.25 g, 0.75 mmol) and NaOHaq (2.5 mL, 
7.5 mmol); white solid; yield: 0.16 g (72 %);  
1H NMR (CDCl3, 500 MHz) δ 2.71-2.74 (m, 2H), 3.34-3.38 (m, 2H), 6.11 (s, 1H), 7.09-7.16 
(m, 4H), 7.21-7.24 (m, 3H), 7.36-7.40 (m, 1H). 13C NMR (CDCl3, 125 MHz) δ 33.1, 34.4, 
113.8 (d, 2JC-F = 22.1 Hz), 116.3 (d, 2JC-F = 21.1 Hz), 117.9, 122.5 (d, 4JC-F = 2.9 Hz), 128.5, 
129.8, 130.3 (d, 3JC-F = 8.6 Hz), 131.9, 139.4, 143.0, 160.5, 164.6 (d, 1JC-F = 261.0 Hz), 
170.5; MS (+ESI): m/z = 306 (M+H). 
(Z)-5-(4-Chlorophenyl)-3-(3-flurorphenyl)pent-2-enoic acid, (12Z): 
Synthesized according to Method D using 12Za (0.25 g, 0.87 mmol) and NaOHaq (2.5 mL, 
7.5 mmol); white solid; yield: 0.11 g (40 %);  
1H NMR (CDCl3, 500 MHz) δ 2.64-2.67 (m, 2H), 2.71-2.74 (m, 2H), 5.86 (s, 1H), 6.91-7.10 
(m, 4H), 7.24-7.27 (m, 3H), 7.31-7.34 (m, 1H). 13C NMR (CDCl3, 125 MHz) δ 32.9, 41.9, 
114.2, 114.9 (d, 2JC-F = 21.1 Hz), 117.5, 122.9, 128.6, 129.6, 129.7, 131.7, 132.1, 141.1, 
143.0, 159.3, 168.3 (d, 1JC-F = 255.3 Hz); MS (+ESI): m/z = 306 (M+H). 
 
 
5-(4-Chlorophenyl)-3-(4-fluorophenyl)pent-2-enoic acids, (13E & 13Z):  
 
(E)-3-(4-Chlorophenyl)-1-(4-fluorophenyl)prop-2-en-1-one, (13c):  
Synthesized according to Method A using 4-chlorobenzaldehyde (2.00 g, 14.3 mmol) and 4-
fluoroacetophenone (1.74 mL, 14.3 mmol); pale yellow solid; yield: 3.44 g (92 %); 
1H NMR (CDCl3, 500 MHz) δ 7.18 (t, J  = 8.5 Hz, 2H), 7.40 (d, J  = 8.5 Hz, 2H), 7.47 (d, J  = 
15.4 Hz, 1H), 7.57 (d, J 
 
= 8.5 Hz, 2H), 7.76 (d, J 
 
= 15.8 Hz, 1H), 8.06 (d, J 
 
= 8.5 Hz, 2H); 
13C NMR (CDCl3, 125 MHz) δ 115.8 (d, 2JC-F = 22.1 Hz), 121.9, 129.3, 129.6, 131.1 (d, 3JC-F 
= 9.6 Hz), 133.2, 134.4, 136.6, 143.5, 165.6 (d, 1JC-F = 255.3 Hz), 188.5. 
 
3-(4-Chlorophenyl)-1-(4-fluorophenyl)propan-1-one, (13b):  
Synthesized according to Method B using 13c (1.0 g, 3.85 mmol), HEH (1.46 g, 5.75 mmol) 
and silica gel (7.67 g); colourless solid; yield: 0.82 g (82 %);  
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1H NMR (CDCl3, 500 MHz) δ 3.05 (t, J  = 7.5 Hz, 2H), 3.26 (t, J  = 7.5 Hz, 2H), 7.13 (d, J  = 
8.5 Hz, 2H), 7.18 (d, J 
 
= 8.8 Hz, 2H), 7.27 (d, J 
 
= 8.5 Hz, 2H), 7.98 (t, J 
 
= 8.8 Hz, 2H). 
 
Ethyl 5-(4-chlorophenyl)-3-(4-fluorophenyl)pent-2-enoate, (13a): 
Synthesized according to Method C using 13b (0.60 g, 2.28 mmol), NaH (0.28 g, 6.85 mmol) 
and triethyl phosphonoacetate (1.51 mL, 6.85 mmol); 
13Ea: colourless oil; yield: 0.301 g (30 %); 1H NMR (CDCl3, 500 MHz) δ 1.30 (t, J = 7.2 Hz, 
3H), 2.67-2.71 (m, 2H), 3.33-3.37 (m, 2H), 4.20 (q, J = 7.2 Hz, 2H), 6.01 (s, 1H), 7.06 (t, J = 
8.5 Hz, 2H), 7.10 (d, J = 8.5 Hz, 2H), 7.22 (d, J = 8.5 Hz, 2H), 7.39-7.42 (m, 2H). 13C NMR 
(CDCl3, 125 MHz) δ 14.3, 32.8, 34.3, 60.0, 115.5 (d, 2JC-F = 22.1 Hz), 118.1, 128.3, 128.5 (d, 
4JC-F = 7.7 Hz), 129.8, 131.7, 136.8 (d, 3JC-F = 6.7 Hz), 157.8, 163.2 (d, 1JC-F = 248.5 Hz), 
166.1. 
13Za: colourless oil; yield: 0.299 g (39 %); 1H NMR (CDCl3, 500 MHz) δ 1.10 (t, J = 6.9 Hz, 
3H), 2.63-2.66 (m, 2H), 2.70-2.73 (m, 2H), 3.99 (q, J = 6.9 Hz, 2H), 5.87 (s, 1H), 7.02-7.07 
(m, 4H), 7.13-7.16 (m, 2H), 7.23 (d, J = 8.5 Hz, 2H). 13C NMR (CDCl3, 125 MHz) δ 14.0, 
33.1, 41.8, 59.9, 115.0 (d, 2JC-F = 21.1 Hz), 118.4, 128.6, 129.6 (d, 3JC-F = 7.7 Hz), 131.9, 
135.3, 139.0, 156.8, 164.4 (d, 1JC-F = 246.6 Hz), 165.7. 
 
(E)-5-(4-Chlorophenyl)-3-(4-fluorophenyl)pent-2-enoic acid, (13E): 
Synthesized according to Method D using 13Ea (0.3 g, 0.90 mmol) and NaOHaq (3.01 mL, 
9.01 mmol); white solid; yield: 0.19 g (69 %);  
1H NMR (CDCl3, 500 MHz) δ 2.70-2.72 (m, 2H), 3.35-3.38 (m, 2H), 6.07 (s, 1H), 7.08-7.12 
(m, 4H), 7.22 (d, J = 8.5 Hz, 2H), 7.42-7.45 (m, 2H). 13C NMR (CDCl3, 125 MHz) δ 33.1, 
34.4, 111.4 (d, 4JC-F = 2.9 Hz), 113.9, 115.8 (d, 2JC-F = 21.1 Hz), 128.4, 128.6, 129.8, 131.9, 
135.3, 139.5, 143.2, 157.2 (d, 2JC-F = 250.5 Hz), 162.5, 169.3; MS (+ESI): m/z = 306 (M+H). 
(Z)-5-(4-Chlorophenyl)-3-(4-flurorphenyl)pent-2-enoic acid, (13Z): 
Synthesized according to Method D using 13Za (0.29 g, 0.87 mmol) and NaOHaq (2.9 mL, 
8.7 mmol); white solid; yield: 0.09 g (35 %);  
1H NMR (CDCl3, 500 MHz) δ 2.61-2.65 (m, 2H), 2.72-2.75 (m, 2H), 5.85 (s, 1H), 6.98-7.04 
(m, 4H), 7.22 (d, J = 8.5 Hz, 2H), 7.23-7.27 (m, 2H). 13C NMR (CDCl3, 125 MHz) δ 33.0, 
42.1, 115.1 (d, 2JC-F = 21.1 Hz), 117.2, 127.7, 128.6 (d, 3JC-F = 7.7 Hz), 129.1 (d, 3JC-F = 9.6 
Hz), 129.6, 129.8, 138.2, 138.8, 159.8, 164.8 (d, 1JC-F = 250.5 Hz), 167.6, 169.3; MS (+ESI): 
m/z = 306 (M+H). 
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(E)-5-(4-Chlorophenyl)-3-(pyridin-2-yl)pent-2-enoic acid, (14E): 
 
(E)-3-(4-Chlorophenyl)-1-(acetylpyridin)prop-2-en-1-one, (14c):  
Synthesized according to Method A using 4-chlorobenzaldehyde (2.00 g, 14.3 mmol) and 
acetylpyridine (1.60 mL, 14.3 mmol); pale yellow solid; yield: 1.2 g (34 %); 
1H NMR (CDCl3, 500 MHz) δ 7.39 (d, J  = 8.5 Hz, 2H), 7.48-7.51 (m, 1H), 7.66 (d, J  = 8.8 
Hz, 2H), 7.86-7.90 (m, 2H), 8.19 (td, J 
 
= 0.9, 7.9 Hz, 1H), 8.28 (d, J 
 
= 16.1 Hz, 1H), 8.73-
8.75 (m, 1H); 
 
3-(4-Chlorophenyl)-1-(acetylpyridin)propan-1-one, (14b):  
Synthesized according to Method B using 14c (1.0 g, 4.1 mmol), HEH (1.56 g, 5.75 mmol) 
and silica gel (8.20 g); pale yellow solid; yield: 0.56 g (52 %);  
1H NMR (CDCl3, 500 MHz) δ 3.04 (t, J  = 7.6 Hz, 2H), 3.55 (t, J  = 7.6 Hz, 2H), 7.19-7.25 
(m, 4H), 7.45-7.48 (m, 1H), 7.82 (dt, J 
 
= 7.6 Hz, 1H), 8.03 (td, J 
 
= 1.3, 7.9 Hz, 1H), 8.66-
8.70 (m, 1H). 
 
Ethyl 5-(4-chlorophenyl)-3-(pyridin-2-yl)pent-2-enoate, (14a): 
Synthesized according to Method C using 14b (0.56 g, 2.28 mmol), NaH (0.28 g, 6.85 mmol) 
and triethyl phosphonoacetate (1.30 mL, 6.85 mmol); 
14Ea: colourless oil; yield: 0.15 g (21 %); 1H NMR (CDCl3, 500 MHz) δ 1.32 (t, J = 7.2 Hz, 
3H), 2.75-2.79 (m, 2H), 3.47-3.50 (m, 2H), 4.21 (q, J = 7.2 Hz, 2H), 6.51 (s, 1H), 7.16-7.21 
(m, 4H), 7.22-7.27 (m, 1H), 7.50 (d, J = 7.9 Hz, 1H), 7.70 (dt, J = 1.6, 7.9 Hz, 1H), 8.65-8.67 
(m, 1H). 
14Za: colourless oil; yield: 0.08 g (11 %); 1H NMR (CDCl3, 500 MHz) δ 1.09 (t, J = 7.2 Hz, 
3H), 2.77-2.79 (m, 2H), 3.01-3.04 (m, 2H), 4.05 (q, J = 7.2 Hz, 2H), 6.30 (s, 1H), 7.06-7.08 
(m, 1H), 7.16-7.27 (m, 5H), 7.54 (dt, J = 1.6, 7.9 Hz, 1H), 8.49-8.51 (m, 1H). 
 
(E)-5-(4-Chlorophenyl)-3-(pyridin-2-yl)pent-2-enoic acid, (14E):  
Synthesized according to Method D using 13Ea (0.15 g, 0.46 mmol) and NaOHaq (0.5 mL, 
1.4 mmol); yellow solid; yield: 0.09 g (68 %);  
1H NMR (CDCl3, 500 MHz) δ 2.76-2.79 (m, 2H), 3.49-3.52 (m, 2H), 6.51 (s, 1H), 7.13 (d, J = 
8.5 Hz, 2H), 7.20 (d, J = 7.9 Hz, 2H), 7.26-7.33 (m, 1H), 7.51 (d, J = 7.9 Hz, 1H), 7.74 (dt, J 
= 1.6, 7.9 Hz, 1H), 8.69-8.70 (m, 1H). 13C NMR (CDCl3, 125 MHz) δ 31.4, 34.6, 118.8, 
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121.6, 123.9, 128.3, 129.9, 137.0, 139.8, 141.4, 149.4, 157.2, 159.8, 164.2. MS (+ESI): m/z = 
288 (M+H). 
 
 
5-(Biphenyl-4-yl)-3-phenylpent-2-enoic acids, (15E & 15Z):  
 
3-(Biphenyl-4-yl)-1-phenylprop-2-en-1-one, (15c): 
Synthesized according to Method A using 2-biphenylcarboxaldehyde 15d (2.00 g, 10.9 mmol) 
and acetophenone (1.28 g, 10.9 mmol); pale yellow solid; yield: 1.90 g (63 %); Mp 102-104 
°C;  
1H NMR (CDCl3, 500 MHz): δ = 7.37-7.41 (m, 1H), 7.47 (t, 3J = 7.6 Hz, 2H), 7.52 (t, 3J = 7.6 
Hz, 2H), 7.56-7.65 (m, 6H), 7.73 (d, 3J = 8.2 Hz, 2H), 7.86 (d, 3J = 15.8 Hz, 1H), 8.03-8.06 
(m, 2H). 13C NMR (CDCl3, 125 MHz): δ = 121.9, 127.0, 127.6, 127.9, 128.5, 128.6, 128.9, 
129.0, 132.8, 133.8, 138.3, 140.1, 143.3, 144.4, 190.2. 
 
3-(Biphenyl-4-yl)-1-phenylpropan-1-one, (15b): 
Synthesized according to Method B using compound 15c (0.50 g, 1.76 mmol), HEH (0.686 g, 
2.63 mmol) and silica gel (3.52 g); pale yellow solid; yield: 0.446 g (88 %);  
1H NMR (CDCl3, 500 MHz): δ = 3.13 (t, 3J = 7.6 Hz, 2H), 3.35 (t, 3J = 7.6 Hz, 2H), 7.31-7.35 
(m, 3H), 7.42-7.48(m, 4H), 7.55-7.59 (m, 5H), 7.97-8.00 (m, 2H). 13C NMR (CDCl3, 125 
MHz): δ = 29.7, 40.4, 126.9, 127.0, 127.2, 128.0, 128.6, 128.7, 128.9, 133.1, 136.9, 139.1, 
140.4, 140.9, 199.1. 
 
Ethyl 5-(biphenyl-4-yl)-3-phenylpent-2-enoate, (15a): 
Synthesized according to Method C using compound 15b (0.35 g, 1.22 mmol), NaH (0.147 g, 
3.67mmol) and triethyl phosphonoacetate (0.83 mL, 3.67 mmol); 
15Ea: colourless oil; yield: 0.171 g (39 %); 1H NMR (CDCl3, 500 MHz): δ = 1.31 (t, 3J = 7.2 
Hz, 3H), 2.77-2.81 (m, 2H), 3.42-3.46 (m, 2H), 4.22 (q, 3J = 7.2 Hz, 2H), 6.09 (s, 1H), 7.30-
7.37 (m, 3H), 7.38-7.48 (m, 5H), 7.49-7.51 (m, 4H), 7.56-7.59 (m, 2H); 13C NMR (CDCl3, 
125 MHz): δ = 14.3, 33.1, 34.8, 59.9, 157.9, 126.7, 126.9, 127.0, 127.1, 128.6, 128.7, 128.9, 
129.0, 138.9, 140.7, 141.0, 141.1, 159.3, 166.3. 
15Za: colourless oil; yield: 0.194 g (45 %); 1H NMR (CDCl3, 500 MHz): δ = 1.07 (t, 3J = 7.2 
Hz, 3H), 2.73-2.82 (m, 4H), 3.99 (q, 3J = 7.2 Hz, 2H), 5.93 (s, 1H), 7.20-7.22 (m, 4H), 7.31-
7.39 (m, 4H), 7.42 (t, 3J = 7.5 Hz, 2H), 7.49-7.51 (m, 2H), 7.56-7.59 (m, 2H). 13C NMR 
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(CDCl3, 125 MHz): δ = 13.9, 33.4, 42.0, 59.8, 117.8, 127.0, 127.1, 127.2, 127.3, 127.7, 127.9, 
128.7, 138.6, 139.0, 139.8, 139.9, 140.9, 158.3, 166.0. 
 
(E)-5-(Biphenyl-4-yl)-3-phenylpent-2-enoic acid, (15E):  
Synthesized according to Method D using compound 15Ea (0.16 g, 0.45 mmol) and NaOHaq 
(1.50 mL, 4.49 mmol); white solid; yield: 0.125 g (85 %); Mp 139-141 °C;  
1H NMR (CDCl3, 500 MHz): δ = 2.79-2.83 (m, 2H), 3.44-3.48 (m, 2H), 6.15 (s, 1H), 7.29-
7.32 (m, 3H), 7.39-7.44 (m, 5H), 7.50-7.52 (m, 4H), 7.55-7.57 (m, 2H); 13C NMR (CDCl3, 
125 MHz): δ = 33.5, 34.9, 116.8, 126.6, 126.8, 127.0, 127.1, 128.7, 128.7, 128.9, 129.4, 
139.0, 140.5, 140.8, 141.1, 162.3, 170.7; LC/MS (+ESI): m/z = 329.8 [MH+]; Rt = 12.60 (≥ 97 
%). 
(Z)-5-(Biphenyl-4-yl)-3-phenylpent-2-enoic acid, (15Z):  
Synthesized according to Method D using compound 15Za (0.185 g, 0.52 mmol) and NaOHaq 
(1.75 mL, 5.19 mmol); white solid; yield: 0.145 g (85 %); Mp 185-188 °C; 1H NMR (CDCl3, 
500 MHz): δ = 2.72-2.75 (m, 2H), 2.78-2.83 (m, 2H), 5.91 (s, 1H), 7.20 (t, 3J = 7.9 Hz, 4H), 
7.30-7.39 (m, 4H), 7.42 (t, 3J = 7.9 Hz, 2H), 7.50 (d, 3J = 8.2 Hz, 2H), 7.56-7.58 (m, 2H); 13C 
NMR (CDCl3, 125 MHz): δ = 33.4, 42.3, 116.6, 127.0, 127.1, 127.2, 127.2, 128.1, 128.1, 
128.7, 128.8, 139.1, 139.7, 140.9, 141.5, 160.9, 173.7; LC/MS (+ESI): m/z = 329.8 [MH+]; Rt 
= 14.70 (≥ 96 %). 
 
 
5-(Naphthalen-2-yl)-3-phenylpent-2-enoic acids, (16E & 16Z): 
 
3-(Naphthalen-2-yl)-1-phenylprop-2-en-1-one, (16c). 
Synthesized according to Method A using 2-naphthaldehyde 16d (2.00 g, 12.8 mmol) and 
acetophenone (1.49 g, 12.8 mmol); pale yellow solid; yield: 2.85 g (86 %); Mp 158-160 °C;  
1H NMR (CDCl3, 500 MHz): δ = 7.51-7.55 (m, 4H), 7.59-7.62 (m, 1H), 7.65 (d, 3J = 15.4 Hz, 
1H), 7.80 (dd, 4J = 1.7, 3J = 8.5 Hz, 1H), 7.85-7.90 (m, 3H), 7.98 (d, 3J = 15.4 Hz, 1H), 8.04-
8.08 (m, 3H). 13C NMR (CDCl3, 125 MHz): δ = 122.3, 123.7, 126.8, 127.4, 127.8, 128.5, 
128.6, 128.7, 130.6, 132.4, 132.8, 133.4, 134.4, 138.3, 144.9, 190.5. 
 
3-(Naphthalen-2-yl)-1-phenylpropan-1-one, (16b): 
Synthesized according to Method B using compound 16c (0.50 g, 1.936 mmol), HEH (0.735 
g, 2.90 mmol) and silica gel (3.86 g); white solid; yield: 0.426 g (85 %); Mp 68-70 °C;  
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1H NMR (CDCl3, 500 MHz): δ = 3.25 (t, 3J = 8.5 Hz, 2H), 3.40 (t, 3J = 8.5 Hz, 2H), 7.39-7.48 
(m, 5H), 7.56 (m, 1H), 7.70 (s, 1H), 7.78-7.82 (m, 3H), 7.98 (dd, 4J = 1.26, 3J = 8.5 Hz, 2H). 
13C NMR (CDCl3, 125 MHz): δ = 30.2, 40.3, 125.3, 126.0, 126.5, 127.1, 127.4, 127.6, 128.0, 
128.1, 128.6, 132.1, 133.1, 133.6, 136.9, 138.8, 187.9. 
 
Ethyl 5-(naphthalen-2-yl)-3-phenylpent-2-enoate, (16a): 
Synthesized according to Method C using compound 16b (0.35 g, 1.34 mmol), NaH (0.161 g, 
4.03mmol) and triethyl phosphonoacetate (0.91 mL, 4.03 mmol); 
16Ea: colourless oil; yield: 0.178 g (40 %); 1H NMR (CDCl3, 500 MHz): δ = 1.29 (t, 3J = 7.2 
Hz, 3H), 2.89-2.92 (m, 2H), 3.48-3.52 (m, 2H), 4.20 (q, 3J = 7.2 Hz, 2H), 6.08 (s, 1H), 7.39-
7.50 (m, 8H), 7.63 (s, 1H), 7.75-7.80 (m, 3H). 13C NMR (CDCl3, 165 MHz): δ = 14.3, 33.0, 
35.3, 59.9, 118.0, 125.1, 125.8, 126.4, 126.8, 127.4, 127.5, 127.6, 127.8, 128.6, 129.0, 132.1, 
133.6, 139.1, 141.1, 159.3, 166.4. 
16Za: colourless oil; yield: 0.188 g (42 %); 1H NMR (CDCl3, 500 MHz): δ = 1.06 (t, 3J = 7.2 
Hz, 3H), 2.83-2.90 (m, 4H), 3.98 (q, 3J = 7.2 Hz, 2H), 5.94 (s, 1H), 7.21 (dd, 4J = 1.7, 4J = 8.2 
Hz, 2H), 7.23-7.28 (m, 2H), 7.32-7.47 (m, 5H), 7.56 (s, 1H), 7.76 (d, 3J = 7.9 Hz, 2H), 7.80 
(d, 3J = 7.9 Hz, 1H). 13C NMR (CDCl3, 125 MHz): δ = 13.9, 34.0, 41.9, 59.8, 117.8, 125.3, 
126.0, 126.4, 127.0, 127.3, 127.4, 127.6, 127.8, 127.9, 128.0, 132.1, 133.6, 138.3, 139.8, 
158.4, 165.9. 
 
(E)-5-(Naphthalen-2-yl)-3-phenylpent-2-enoic acid, (16E): 
Synthesized according to Method D using compound 16Ea (0.17 g, 0.51 mmol) and NaOHaq 
(1.70 mL, 5.14 mmol); white solid; yield: 0.143 g (93 %); Mp 147-150 °C;  
1H NMR (CDCl3, 500 MHz): δ = 2.91-2.94 (m, 2H), 3.49-3.53 (m, 2H), 6.14 (s, 1H), 7.38-
7.44 (m, 6H), 7.51-7.53 (m, 2H), 7.62 (s, 1H), 7.74-7.79 (m, 3H); 13C NMR (CDCl3, 125 
MHz): δ = 33.3, 35.4, 116.5, 125.2, 126.5, 126.8, 127.2, 127.4, 127.9, 128.4, 128.7, 128.7, 
129.4, 130.9, 132.1, 138.6, 138.7, 162.4, 170.9; LC/MS (+ESI): m/z = 303.6 [MH+]; Rt = 
14.54 (≥ 99 %). 
(Z)-5-(Naphthalen-2-yl)-3-phenylpent-2-enoic acid, (16Z):  
Synthesized according to Method D using compound 16Za (0.180 g, 0.54 mmol) and NaOHaq 
(1.80 mL, 5.45 mmol); white solid; yield: 0.150 g (92 %); Mp 117-120 °C;  
1H NMR (CDCl3, 500 MHz): δ = 2.84-2.89 (m, 4H), 5.92 (s, 1H), 7.21 (dd, 4J = 1.7, 3J = 8.2 
Hz, 2H), 7.30-7.47 (m, 6H), 7.47-7.52 (m, 1H), 7.55 (s, 1H), 7.74-7.82 (m, 2H); 13C NMR 
(CDCl3, 125 MHz): δ = 34.1, 42.5, 116.9, 125.6, 126.3, 126.7, 127.2, 127.5, 127.7, 127.9, 
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128.3, 128.4, 128.5, 128.7, 133.8, 138.3, 139.4, 159.8, 173.3; LC/MS (+ESI): m/z = 303.5 
[MH+]; Rt = 14.02 (≥ 98 %). 
 
 
5-(1H-Indol-3-yl)-3-phenylpent-2-enoic acids, (17E & 17Z): 
 
3-(1H-Indol-3-yl)-1-phenylprop-2-en-1-one, (17c): 
Indole-3-aldehyde 17d (1 g, 6.89 mmol) was dissolved in EtOH (14 mL). Then the 
acetophenone (0.8 mL, 6.89 mmol) and afterwards piperidine (0.37 mL, 3.82 mmol) were 
added. The resulting solution was refluxed for 16 h. The reaction mixture was neutralized 
with 10 % HCl to pH 7. The formed precipitate was collected by vacuum filtration and 
purified by recrystallization from MeOH to give 17c. Deep yellow solid; yield: 1.18 g (68 %); 
Mp 161-163 °C;  
1H NMR (CDCl3, 500 MHz): δ = 7.29-7.33 (m, 2H), 7.44-7.46 (m, 1H), 7.50-7.54 (m, 2H), 
7.56-7.62 (m, 3H), 8.01-8.06 (m, 1H), 8.06-8.08 (m, 2H), 8.12 (d, 3J = 15.5 Hz, 1H), 8.84 (s, 
NH). 13C NMR (CDCl3, 125 MHz): δ = 112.0, 114.5, 117.9, 120.7, 121.8, 123.5, 125.4, 
128.3, 128.5, 130.3, 132.3, 137.3, 139.0, 139.0, 191.9. 
 
3-(1H-Indol-3-yl)-1-phenylpropan-1-one, (17b): 
Synthesized according to Method B using compound 17c (1.0 g, 4.04 mmol), HEH (1.53 g, 
6.06 mmol) and silica gel (8.08 g); white solid; yield: 0.85 g (84 %); Mp 127-130 °C;  
1H NMR (CDCl3, 500 MHz): δ = 3.23 (t, 3J = 7.6 Hz, 2H), 3.39 (t, 3J = 7.6 Hz, 2H), 7.05-7.06 
(m, 1H), 7.14 (dt, 4J 
 
= 0.9, 3J 
 
= 7.2 Hz, 1H), 7.21 (dt, 4J = 1.3, 4J = 8.2 Hz, 1H), 7.36 (d, 3J 
 
= 
8.2 Hz, 1H), 7.43-7.47 (m, 2H), 7.53-7.57 (m, 1H), 7.64 (d, 3J = 8.5 Hz, 1H), 7.96-7.99 (m, 
2H). 13C NMR (CDCl3, 125 MHz): δ = 19.7, 39.3, 111.1, 115.5, 118.7, 119.3, 121.5, 122.0, 
127.3, 128.0, 128.5, 132.9, 136.3, 137.0, 199.9. 
 
Ethyl 5-(1H-indol-3-yl)-3-phenylpent-2-enoate, (17a):  
Synthesized according to Method C using compound 17b (0.50 g, 2.0 mmol), NaH (0.250 g, 
6.01mmol) and triethyl phosphonoacetate (1.2 mL, 6.01 mmol); 
17Ea: pale brown oil; yield: 0.175 g (27 %); 1H NMR (CDCl3, 500 MHz): δ = 1.29 (t, 3J = 
7.2 Hz, 3H), 2.87-2.91 (m, 2H), 3.49-3.52 (m, 2H), 4.19 (q, 3J = 7.2 Hz, 2H), 6.09 (s, 1H), 
7.00-7.01 (m, 1H), 7.10 (dt, 4J = 1.3, 3J = 8.2 Hz, 1H), 7.17 (dt, 4J = 1.3, 3J = 8.2 Hz, 1H), 
7.33 (d, 3J = 8.2 Hz, 2H), 7.37-7.41 (m, 3H), 7.48-7.50 (m, 2H), 7.63 (d, 3J = 7.9 Hz, 1H), 
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7.91 (s, NH). 13C NMR (CDCl3, 125 MHz): δ = 14.3, 24.7, 31.9, 59.9, 110.9, 116.1, 117.7, 
119.0, 119.1, 121.3, 121.8, 126.7, 127.4, 128.5, 128.9, 136.2, 141.2, 159.8, 166.4. 
17Za: pale brown oil; yield: 0.189 g (30 %); 1H NMR (CDCl3, 500 MHz): δ = 1.07 (t, 3J = 6.9 
Hz, 3H), 2.82-2.90 (m, 4H), 3.99 (q, 3J = 6.9 Hz, 2H), 5.94 (s, 1H), 6.96 (s, 1H), 7.10 (dt, 4J = 
0.9, 3J = 7.9 Hz, 1H), 7.19-7.23 (m, 3H), 7.31-7.38 (m, 4H), 7.51 (d, 3J = 7.9 Hz, 1H), 7.93 (s, 
NH). 13C NMR (CDCl3, 125 MHz): δ = 13.9, 23.3, 40.8, 59.8, 111.1, 115.1, 117.5, 118.6, 
119.2, 121.2, 121.9, 127.2, 127.9, 128.0, 128.5, 136.2, 140.0, 159.1, 166.1. 
 
(E)-5-(1H-Indol-3-yl)-3-phenylpent-2-enoic acid, (17E):  
Synthesized according to Method D using compound 17Ea (0.20 g, 0.63 mmol) and NaOHaq 
(0.65 mL, 1.89 mmol); white solid; yield: 0.135 g (73 %); Mp 157-160 °C;  
1H NMR (CD3OD, 500 MHz): δ = 2.72-2.75 (m, 2H), 3.39-3.43 (m, 2H), 6.05 (s, 1H), 6.95 
(dt, 3J = 0.9, 8.2 Hz, 1H), 7.05 (dt, 4J = 0.9, 4J =7.9 Hz, 1H), 7.11-7.12 (d, 3J = 2.2 Hz, 1H), 
7.31 (d, 3J = 8.2 Hz, 1H), 7.39-7.46 (m, 3H), 7.57-7.60 (m, 3H), 10.76 (s, NH), 12.29 (s, OH); 
13C NMR (CD3OD, 125 MHz): δ = 34.3, 40.9, 120.8, 123.6, 127.5, 127.6, 128.0, 130.3, 
131.6, 136.1, 136.6, 138.2, 138.5, 145.8, 150.1, 168.0, 176.8; LC/MS (+ESI): m/z = 292.5 
[MH+]; Rt = 12.37 (≥ 96 %). 
(Z)-5-(1H-Indol-3-yl)-3-phenylpent-2-enoic acid, (17Z):  
Synthesized according to Method D using compound 17Za (0.20 g, 0.63 mmol) and NaOHaq 
(0.65 mL, 1.89 mmol); white solid; yield: 0.135 g (73 %); Mp 160-162 °C;  
1H NMR (CD3OD, 500 MHz): δ = 2.68-2.71 (m, 2H), 2.79-2.82 (m, 2H), 5.89 (s, 1H), 7.05 (t, 
3J = 7.9 Hz, 1H), 6.95 (dt, 4J = 0.9, 3J = 7.6 Hz, 1H), 7.05 (dt, 4J = 0.9, 3J = 7.6 Hz, 1H), 7.10-
7.11 (d, 4J = 2.2 Hz, 1H), 7.23-7.25 (m, 2H), 7.29-7.38 (m, 4H), 7.41 (d, 3J = 7.9 Hz, 1H), 
10.78 (s, NH), 11.85 (s, OH); 13C NMR (CD3OD, 125 MHz): δ = 24.6, 42.3, 112.2, 115.1, 
118.7, 119.2, 119.5, 122.3, 123.0, 128.5, 128.6, 128.7, 128.9, 138.2, 141.4, 160.7, 169.8; 
LC/MS (+ESI): m/z = 292.5 [MH+]; Rt = 11.93 (≥ 94 %). 
 
 
4-(4-Chlorophenoxy)-3-phenylbut-2-enoic acids, (18Z & 18E): 
 
2-(4-Chlorophenoxy)-1-phenylethanone, (18b): 
4-Chlorophenol 18c (0.774 g, 6.02 mmol) was refluxed with 2-bromoacetophenone (1.0 g, 
5.02 mmol) in DMF (10 mL) with potassium carbonate (3.5 g, 25.1 mmol) for 2 hours. The 
reaction mixture was taken up in water (50 mL) and extracted with dichloromethane (3 x 20 
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mL). The combined organic layers were washed with water (20 mL) and brine (20 mL), dried 
over MgSO4 and the solvent was removed under reduced pressure. The crude product was 
purified by flash column chromatography on silica gel [PE / EtOAc (10:1)]; pale yellow solid; 
yield: 1.22 g (99 %);  
1H NMR (CDCl3, 500 MHz): δ = 5.26 (s, 2H), 6.85-6.89 (m, 2H), 7.22-7.25 (m, 2H ), 7.51 (t, 
3J = 7.4 Hz, 2H), 6.09-6.42 (m, 1H), 7.97-8.00 (m, 2H); 13C NMR (CDCl3, 125 MHz): δ = 
71.0, 116.2, 126.6, 128.0, 128.9, 129.4, 133.9, 134.5, 156.7, 194.1. 
 
Ethyl 4-(4-chlorophenoxy)-3-phenylbut-2-enoate, (18a):  
Synthesized according to Method C using compound 18b (0.60 g, 2.43 mmol), NaH (0.29 g, 
7.30 mmol) and triethyl phosphonoacetate (1.61 mL, 7.30 mmol); 
18Za: colourless oil; yield: 0.135 g (18 %); 1H NMR (CDCl3, 500 MHz): δ = 1.01 (t, 3J = 6.9 
Hz, 3H), 3.94 (q, 3J = 6.9 Hz, 2H), 4.63 (d, 3J = 1.9 Hz, 2H), 6.19 (t, 3J = 1.9 Hz, 1H), 6.77-
6.82 (m, 2H), 7.16-7.20 (m, 4H), 7.28-7.35 (m, 3H). 13C NMR (CDCl3, 125 MHz): δ = 13.9, 
60.1, 71.1, 116.1, 117.4, 126.4, 127.5, 128.2, 128.4, 129.5, 136.6, 152.4, 156.5, 165.6. 
18Ea: colourless oil; yield: 0.40 g (52 %); 1H NMR (CDCl3, 500 MHz): δ = 1.32 (t, 3J = 7.2 
Hz, 3H), 4.25 (q, 3J = 7.2 Hz, 2H), 5.56 (s, 1H), 6.25 (s, 1H), 6.81-6.83 (m, 2H), 7.17-7.21 
(m, 2H), 7.35-7.38 (m, 3H), 7.46-7.48 (m, 2H). 13C NMR (CDCl3, 125 MHz): δ = 14.2, 60.5, 
64.4, 116.3, 120.5, 125.9, 127.2, 128.4, 129.2, 129.3, 138.2, 153.5, 157.0, 165.6. 
 
(Z)-4-(4-Chlorophenoxy)-3-phenylbut-2-enoic acid, (18Z):  
Synthesized according to Method D using compound 18Za (0.15 g, 0.47 mmol) and NaOHaq 
(1.6 mL, 4.7 mmol); white solid; yield: 0.10 g (74 %); Mp 115-117 °C;  
1H NMR (CDCl3, 500 MHz): δ = 5.48 (s, 2H), 6.21 (s, 1H), 6.71-6.74 (m, 2H), 7.10-7.13 (m, 
2H ), 7.28-7.33 (m, 3H), 7.38-7.42 (m, 2H); 13C NMR (CDCl3, 125 MHz): δ = 64.5, 116.3, 
119.2, 126.1, 127.3, 128.5, 129.3, 129.7, 137.8, 156.7, 156.9, 170.4; LC/MS (+ESI): m/z = 
289.4 [MH+]; Rt = 13.26 (≥ 95 %). 
(E)-4-(4-Chlorophenoxy)-3-phenylbut-2-enoic acid, (18E):  
Synthesized according to Method D using compound 18Ea (0.06 g, 0.18 mmol) and NaOHaq 
(0.61 mL, 1.8 mmol); white solid; yield: 0.05 g (86 %); Mp 110-112 °C;  
1H NMR (CDCl3, 500 MHz): δ = 3.43 (s, 2H), 6.61 (s, 1H), 7.00 (d, 3J = 9.1 Hz, 2H), 7.25-
7.27 (m, 1H ), 7.28 (d, 3J = 8.8 Hz, 2H), 7.33-7.36 (m, 2H), 7.53-7.55 (m, 2H); 13C NMR 
(CDCl3, 125 MHz): δ = 38.0, 115.8, 118.1, 127.4, 127.9, 128.3, 128.4, 129.6, 135.4, 141.2, 
155.7, 177.4; LC/MS (+ESI): m/z = 289.4 [MH+]; Rt = 13.01 (≥ 99 %). 
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(Z)-4-(4-Chlorophenylthio)-3-phenylbut-2-enoic acid, (19Z):  
 
2-(4-Chlorophenylthio)-1-phenylethanone, (19b):  
2-Bromoacetophenone (1.0 g, 6.91 mmol), 4-chlorothiophenol 19c (1.37 g, 6.91 mmol) and 5 
% benzyltriethylammonium chloride (0.078 g, 0.35 mmol) were dissolved in 20 mL 
dichloromethane. Under vigorous stirring sodium hydroxide (0.61 g, 15.21 mmol) in 2 mL 
water was added and the stirring maintained for 16 hours. The mixture was diluted with water 
(50 mL), the dichloromethane organic layer (60 mL) separated and washed successively with 
brine (20 mL), dried over MgSO4 and evaporated. The resultant oil was further purified by 
column chromatography on silica gel [PE / EtOAc (12:1)]; pale yellow solid; yield 0.74 g (41 
%); Mp 82-84 °C;  
1H NMR (CDCl3, 500 MHz): δ = 4.26 (s, 2H), 7.24-7.28 (m, 2H), 7.31-7.34 (m, 2H ), 7.46-
7.50 (m, 2H), 7.58-7.62 (m, 1H), 7.92-7.97 (m, 2H). 
 
(Z)-Ethyl 4-(4-chlorophenylthio)-3-phenylbut-2-enoate, (19Za):  
Synthesized according to Method C using compound 19b (0.50 g, 1.90 mmol), NaH (0.228 g, 
5.71 mmol) and triethyl phosphonoacetate (1.26 mL, 5.71 mmol); pale yellow oil; yield: 
0.401 g (63 %);  
1H NMR (CDCl3, 500 MHz): δ = 1.23 (t, 3J = 7.2 Hz, 3H), 3.77 (s, 2H), 4.14 (q, 3J = 7.2 Hz, 
2H), 6.69 (s, 1H), 7.27-7.31 (m, 3H), 7.32-7.36 (m, 4H), 7.38-7.42 (m, 2H). 13C NMR 
(CDCl3, 125 MHz): δ = 14.1, 37.8, 61.0, 124.8, 125.8, 127.7, 128.6, 129.2, 130.5, 132.6, 
134.3, 136.1, 140.1, 170.3. 
 
(Z)-4-(4-Chlorophenylthio)-3-phenylbut-2-enoic acid, (19Z):  
Synthesized according to Method D using compound 19Za (0.20 g, 0.60 mmol) and NaOHaq 
(1.0 mL, 3 mmol); white solid; yield: 0.11 g (60 %); Mp 137-139 °C;  
1H NMR (CDCl3, 500 MHz): δ = 3.76 (s, 2H), 6.66 (s, 1H), 6.71-6.74 (m, 2H), 7.20-7.35 (m, 
9H); 13C NMR (CDCl3, 125 MHz): δ = 37.3, 125.6, 125.7, 127.9, 128.7, 129.3, 130.7, 133.1, 
134.0, 134.8, 139.7, 176.2; LC/MS (+ESI): m/z = 305.6 [MH+]; Rt = 13.84 (≥ 99 %). 
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(E/Z)-3-(5-Chlorobenzofuran-2-yl)-3-phenylacrylic acid, (20E/Z): 
 
Benzofuran-2-yl-(4-chlorophenyl)methanone, (20b):  
Synthesized according to Method E using compound 20c (2.0 g, 12.77 mmol), 2-
bromoacetophenone (1.85 g, 12.77 mmol) and K2CO3 (3.53 g, 25.54 mmol); white solid, 
yield: 1.85 g (57 %);  
1H NMR (CDCl3, 500 MHz): δ = 7.44-7.48 (m, 2H), 7.53-7.58 (m, 13), 7.64-7.68 (m, 1H), 
7.70 (d, 3J = 2.2 Hz, 1H), 8.03-8.06 (m, 2H); 13C NMR (CDCl3, 125 MHz): δ = 113.7, 115.4, 
122.6, 126.5, 128.2, 128.6, 128.7, 129.5, 129.6, 133.2, 136.9, 154.2, 184.1. 
 
(E/Z)-Ethyl 3-(5-chlorobenzofuran-2-yl)-3-phenylacrylate, (20E/Za):  
Synthesized according to Method C using compound 20b (0.60 g, 2.34 mmol), NaH (0.187 g, 
4.68 mmol) and triethyl phosphonoacetate (1.08 mL, 4.91 mmol); pale yellow oil; yield: 
0.702 g (92 %; 3:1, E/Z);  
1H NMR (CDCl3, 500 MHz): δ = 1.12 (t, 3J = 7.2 Hz, 1H, Z), 1.24 (t, 3J = 7.2 Hz, 3H, E)), 
4.06 (q, 3J = 7.2 Hz, 0.6H, Z), 4.24 (q, 3J = 7.2 Hz, 2H, E), 6.27 (s, 1H, E), 6.36 (s, 0.3H, Z), 
6.78 (s, 0.3H, Z), 6.83 (s, 1H, E), 7.45-7.26 (m, 10H), 7.55 (d, 3J = 2.2 Hz, 1H). 13C NMR 
(CDCl3, 125 MHz): δ = 13.9, 14.2, 60.2, 60.7, 109.5, 110.6, 112.3, 116.8, 121.0, 121.1, 125.5, 
126.4, 128.0, 128.4, 128.5, 128.6, 129.6, 128.4, 141.5, 143.9, 153.4, 154.2, 165.6, 165.9. 
 
(E/Z)-3-(5-Chlorobenzofuran-2-yl)-3-phenylacrylic acid, (20E/Z):  
Synthesized according to Method D using compound 20E/Za (0.20 g, 0.63 mmol) and 
NaOHaq (2.1 mL, 6.3 mmol); pale yellow solid; yield: 0.147 g (78 %; 3:1, E/Z); Mp 164-166 
°C;  
1H NMR (CDCl3, 500 MHz): δ = 6.27 (s, 1H, E), 6.39 (s, 0.3H, Z), 6.78 (s, 0.3H, Z), 6.88 (s, 
1H, E), 7.26-7.47 (m, 10H), 7.55 (d, 4J = 1.8 Hz, 1H); 13C NMR (CDCl3, 125 MHz): δ = 
110.4, 110.4, 111.6, 112.5, 115.5, 119.4, 121.1, 121.3, 125.8, 126.8, 128.0, 128.6, 128, 7, 
128.8, 129.4, 129.6, 130.0, 138.3, 144.2, 153.5, 156.6, 170.3, 207.6, 210.0; LC/MS (+ESI): 
m/z = 299.4 [MH+]; Rt (E) = 13.39, Rt (Z) = 14.33; (≥ 99 %). 
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(E/Z)-3-(5-Methylbenzofuran-2-yl)-3-phenylacrylic acid, (21E/Z): 
 
Benzofuran-2-yl-(p-tolyl)methanone, (21b): 
Synthesized according to Method E using compound 21c (1.0 g, 7.35 mmol), 2-
bromoacetophenone (1.06 g, 7.35 mmol) and K2CO3 (2.03 g, 14.69 mmol); pale yellow solid, 
yield: 1.1 g (64 %);  
1H NMR (CDCl3, 500 MHz): δ = 2.47 (s, 3H), 7.31 (dd, 4J = 1.9, 3J =8.2 Hz, 1H), 7.46 (s, 1H 
), 7.49-7.55 (m, 4H), 7.61-7.66 (m, 1H), 8.03-8.06 (m, 2H); 13C NMR (CDCl3, 125 MHz): δ = 
21.3, 112.1, 116.4, 122.7, 128.5, 129.4, 130.0, 132.8, 133.6, 137.3, 152.4, 154.6, 184.4. 
 
(E/Z)-Ethyl 3-(5-methylbenzofuran-2-yl)-3-phenylacrylate, (21E/Za):  
Synthesized according to Method C using compound 21b (0.60 g, 2.54 mmol), NaH (0.204 g, 
5.10 mmol) and triethyl phosphonoacetate (1.18 mL, 5.33 mmol); pale yellow oil; yield: 
0.721 g (93 %; 2.5:1, E/Z);  
1H NMR (CDCl3, 500 MHz): δ = 1.12 (t, 3J = 7.0 Hz, 1.2H, Z), 1.25 (t, 3J = 7.0 Hz, 3H, E)), 
2.41 (s, 1.2H, Z), 2.44 (s, 3H, E), 4.06 (q, 3J = 7.0 Hz, 0.8H, Z), 4.26 (q, 3J = 7.0 Hz, 2H, E), 
6.20 (s, 1H, E), 6.35 (s, 0.4H, Z), 6.77 (s, 0.4H, Z), 6.81 (s, 1H, E), 7.17-7.14 (m, 1.4H), 7.24 
(s, 0.4H), 7.32-7.45 (m, 10H). 13C NMR (CDCl3, 125 MHz): δ = 13.9, 14.2, 21.2, 21.3, 60.0, 
60.7, 110.0, 110.8, 111.3, 115.6, 120.0, 121.2, 126.7, 127.6, 127.9, 128.3, 128.4, 128.7, 128.8, 
129.4, 132.4, 132.7, 136.2, 138.9, 141.8, 144.6, 152.9, 153.5, 153.9, 155.6, 165.8, 166.3. 
 
(E/Z)-3-(5-Methylbenzofuran-2-yl)-3-phenylacrylic acid, (21E/Z): 
Synthesized according to Method D using compound 21E,Za (0.25 g, 0.63 mmol) and 
NaOHaq (2.73 mL, 8.2 mmol); pale yellow solid; yield: 0.189 g (83 %; 2.5:1, E/Z); Mp 200-
204 °C;  
1H NMR (CDCl3, 500 MHz): δ = 2.41 (s, 1.3H, Z), 2.44 (s, 3H, E), 6.21 (s, 1H, E), 6.37 (s, 
0.4H, Z), 6.76 (s, 0.4H, Z), 6.88 (s, 1H, E), 7.13-7.19 (m, 1.5H), 7.24 (s, 0.4H), 7.33-7.46 (m, 
10H); 13C NMR (CDCl3, 125 MHz): δ = 21.1, 21.3, 110.0, 110.9, 111.0, 111.2, 114.2, 118.4, 
121.2, 121.3, 126.9, 127.1, 127.9, 128.5, 128.6, 128.9, 129.2, 129.8, 132.6, 133.6, 137.9, 
138.8, 143.1, 143.8, 144.6, 145.4, 146.6, 152.2, 152.4, 154.3, 154.8, 169.7, 169.9; LC/MS 
(+ESI): m/z = 279.5 [MH+]; Rt = 14.09 (≥ 98 %). 
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3-(5-Chlorobenzo[b]thiophen-2-yl)-3-phenylacrylic acids, (22Z & 22E):  
 
1-Benzothiophen-2-yl-(4-chlorophenyl)methanone, (22b):  
To a cold solution (ice bath) containing 5-chloro-2-nitrobenzaldehyde (0.2 g, 1.31 mmol) and 
anhydrous potassium carbonate (0.221 g, 1.60 mmol) in DMF was added dropwise a solution 
of thioacetophenone (0.243 g, 1.31 mmol). The mixture was stirred from 0 °C to rt within 3 
hours. The mixture was then poured into ice water, extracted with dichloromethane and dried 
over MgSO4. The oily crude product was purified by column chromatography on silica gel 
[PE / EtOAc (10:1)]; pale yellow solid; yield 0.31 g (87 %);  
1H NMR (CDCl3, 500 MHz): δ = 7.45 (dd, 4J = 1.9, 3J = 8.8 Hz, 1H), 7.53-7.56 (m, 2H), 
7.63-7.67 (m, 1H), 7.79 (s, 1H), 7.83-7.86 (m, 2H), 7.91-7.94 (m, 2H); 13C NMR (CDCl3, 125 
MHz): δ = 124.0, 124.9, 125.3, 126.7, 127.9, 128.6, 129.3, 130.9, 131.3, 132.7, 137.5, 144.9, 
189.3. 
 
Ethyl 3-(5-chlorobenzo[b]thiophen-2-yl)-3-phenylacrylate, (22E/Za): 
Synthesized according to Method C using compound 22b (0.17 g, 0.62 mmol), NaH (0.05 g, 
1.24 mmol) and triethyl phosphonoacetate (0.29 mL, 1.24 mmol); 
22Za: pale yellow oil; yield: 0.086 g (41 %); 1H NMR (CDCl3, 500 MHz): δ = 1.17 (t, 3J = 
6.9 Hz, 3H), 4.14 (q, 3J = 6.9 Hz, 2H), 6.39 (s, 1H), 7.27 (s, 1H), 7.27-7.32 (m, 2H), 7.34-7.41 
(m, 5H), 7.71-7.74 (m, 2H). 13C NMR (CDCl3, 125 MHz): δ = 14.0, 60.5, 120.4, 123.2, 123.4, 
125.2, 125.4, 128.2, 128.5, 128.7, 130.6, 138.8, 139.0, 140.4, 141.9, 147.9, 165.5. 
22Ea: pale yellow oil; yield: 0.077 g (36 %); 1H NMR (CDCl3, 500 MHz): δ = 1.11 (t, 3J = 
6.9 Hz, 3H), 4.04 (q, 3J = 6.9 Hz, 2H), 6.46 (s, 1H), 6.90 (s, 1H), 7.29-7.31 (m, 3H), 7.35-7.46 
(m, 3H), 7.59 (d, 4J = 1.9 Hz, 1H) 7.69 (d, 3J = 8.5 Hz, 1H). 13C NMR (CDCl3, 125 MHz): δ = 
13.9, 60.2, 118.0, 123.3, 123.8, 126.3, 126.9, 128.0, 128.4, 128.6, 135.0, 137.4, 138.0, 140.7, 
146.5, 156.8, 165.3. 
 
(Z)-3-(5-Chlorobenzo[b]thiophen-2-yl)-3-phenylacrylic acid, (22Z):  
Synthesized according to Method D using compound 22Za (0.075 g, 0.22 mmol) and NaOHaq 
(0.75 mL, 2.28 mmol); pale yellow solid; yield: 0.05 g (74 %); Mp 210-212 °C;  
1H NMR ((CD3)2SO, 500 MHz): δ = 6.48 (s, 1H), 7.38-7.41 (m, 2H), 7.41-7.43 (m, 4H), 7.43-
7.46 (m, 1H), 7.97 (d, 4J = 2.2 Hz, 1H), 8.00 (d, 3J = 8.5 Hz, 1H); 13C NMR ((CD3)2SO, 125 
MHz): δ = 122.3, 123.1, 123.8, 124.6, 124.8, 125.8, 127.7, 128.5, 129.4, 129.5, 138.4, 139.4, 
140.4, 141.9, 166.3; LC/MS (+ESI): m/z = 315.4 [MH+]; Rt = 14.14 (≥ 99 %). 
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(E)-3-(5-Chlorobenzo[b]thiophen-2-yl)-3-phenylacrylic acid, (22E):  
Synthesized according to Method D using compound 22Ea (0.085 g, 0.26 mmol) and NaOHaq 
(0.9 mL, 2.61 mmol); pale yellow solid; yield: 0.06 g (74 %); Mp 208-210 °C;  
1H NMR (CDCl3, 500 MHz): δ = 6.26 (s, 1H), 7.16-7.29 (m, 7H), 7.58-7.61 (m, 2H); 13C 
NMR (CDCl3, 125 MHz): δ = 120.9, 123.3, 123.5, 125.3, 125.5, 128.4, 128.6, 129.9, 130.7, 
139.3, 140.9, 140.5, 142.1, 148.0, 167.8; LC/MS (+ESI): m/z = 315.4 [MH+]; Rt = 14.70 (≥ 99 
%). 
 
 
3-(5-Chlorobenzofuran-2-yl)-3-phenylpropanoic acid, (23): 
 
Ethyl 3-(5-chlorobenzofuran-2-yl)-3-phenylpropanoate, (23a):  
Synthesized according to Method F using compound 20E/Z (0.4 g, 1.22 mmol), sodium 
hypophosphite (0.194 g, 1.83 mmol) and Pd/C (0.13 g, 0.12 mmol); pale yellow oil; yield: 
0.249 g (88 %); 1H NMR (CDCl3, 500 MHz): δ = 1.16 (t, 3J = 7.2 Hz, 3H), 2.95-3.01 (m, 1H), 
3.17-3.24 (m, 1H), 4.03-4.13 (m, 2H), 4.69 (t, 3J = 7.9 Hz, 1H), 6.45 (s, 1H), 7.16-7.32 (m, 
4H), 7.38-7.49 (m, 4H); 13C NMR (CDCl3, 125 MHz): δ = 14.1, 41.8, 60.6, 102.8, 111.0, 
120.6, 122.6, 123.9, 127.4, 127.8, 128.2, 128.7, 129.8, 140.4, 153.2, 159.3, 171.0. 
 
3-(5-Chlorobenzofuran-2-yl)-3-phenylpropanoic acid, (23).  
Synthesized according to Method D using compound 23a (0.2 g, 0.61 mmol) and NaOHaq (2.0 
mL, 6.01 mmol); white solid; yield: 0.14 g (76 %); Mp 135-138 °C;  
1H NMR (CDCl3, 500 MHz): δ = 3.03-3.06 (m, 1H), 3.25-3.29 (m, 1H), 4.67 (t, 3J = 7.6 Hz, 
1H), 6.45 (s, 1H), 7.15-7.30 (m, 4H), 7.39-7.47 (m, 4H); 13C NMR (CDCl3, 125 MHz): δ = 
38.9, 41.4, 102.9, 112.0, 117.8, 120.6, 122.7, 123.8, 127.4, 127.7, 127.8, 128.4, 128.9, 154.8, 
160.5; LC/MS (+ESI): m/z = 301.6 [MH+]; Rt = 13.45 (≥ 99 %). 
 
 
3-(5-Methylbenzofuran-2-yl)-3-phenylpropanoic acid, (24): 
 
Ethyl 3-(5-methylbenzofuran-2-yl)-3-phenylpropanoate, (24a):  
Synthesized according to Method F using compound 21E/Z (0.2 g, 0.65 mmol), sodium 
hypophosphite (0.103 g, 0.98 mmol) and Pd/C (0.07 g, 0.065 mmol); white oil; yield: 0.182 g 
(91 %); 
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1H NMR (CDCl3, 500 MHz): δ = 1.15 (t, 3J = 7.2 Hz, 3H), 2.40 (s, 3H), 2.95-3.00 (m, 1H), 
3.17-3.22 (m, 1H), 4.02-4.12 (m, 2H), 4.67 (t, 3J = 7.9 Hz, 1H), 6.37 (s, 1H), 7.02 (dd, 4J = 
1.6, 3J = 9.1 Hz, 1H), 7.23-7.33 (m, 7H); 13C NMR (CDCl3, 125 MHz): δ = 14.1, 21.2, 39.5, 
41.8, 60.6, 102.6, 110.5, 120.5, 124.8, 127.2, 127.9, 128.5, 128.6, 132.0, 140.4, 153.2, 159.4, 
171.1. 
 
3-(5-Methylbenzofuran-2-yl)-3-phenylpropanoic acid, (24):  
Synthesized according to Method D using compound 24a (0.15 g, 0.48 mmol) and NaOHaq 
(1.6 mL, 4.86 mmol); white solid; yield: 0.101 g (75 %); Mp 124-127 °C;  
1H NMR (CDCl3, 500 MHz): δ = 2.40 (s, 3H), 2.99-3.04 (m, 1H), 3.23-3.28 (m, 1H), 4.64 (t, 
3J = 8.2 Hz, 1H), 6.37 (s, 1H), 7.01 (dd, 4J = 1.6, 3J =8.8 Hz, 1H), 7.23-7.33 (m, 8H); 13C 
NMR (CDCl3, 125 MHz): δ = 21.3, 38.8, 41.5, 102.7, 110.6, 120.1, 120.5, 124.9, 125.7, 
127.3, 127.8, 128.5, 128.8, 132.1, 153.3, 158.9, 175.6; LC/MS (+ESI): m/z = 281.5 [MH+]; Rt 
= 13.03 (≥ 99 %). 
 
 
(E)-2-(2-(4-Chlorobenzyl)-2,3-dihydro-1H-inden-1-ylidene)acetic acid, (25E): 
 
2-(4-Chlorobenzylidene)-2,3-dihydro-1H-inden-1-one, (25c):  
Synthesized according to Method A using 4-chlorobenzaldehyde 2d (1.06 g, 7.57 mmol) and 
1-indanone (1.0 g, 7.57 mmol); white solid; yield: 1.6 g (83 %); Mp 156-160 °C;  
1H NMR (CDCl3, 500 MHz): δ = 4.02 (s, 2H), 7.42-7.45 (m, 3H), 7.55-7.64 (m, 5H), 7.91 (d, 
3J = 7.6 Hz, 1H). 13C NMR (CDCl3, 125 MHz): δ = 32.3, 124.5, 126.2, 127.8, 129.2, 131.8, 
132.4, 133.9, 134.8, 135.1, 135.6, 137.9, 149.4, 194.0. 
 
2-(4-Chlorobenzyl)-2,3-dihydro-1H-inden-1-one, (25b):  
Synthesized according to Method B using compound 25c (0.435 g, 1.71 mmol), HEH (0.650 
g, 2.56 mmol) and silica gel (3.42 g); white solid; yield: 0.359 g (82 %); Mp 80-82 °C;  
1H NMR (CDCl3, 500 MHz): δ = 2.68-2.73 (m, 1H), 2.81-2.86 (m, 1H), 2.95-3.00 (m, 1H), 
3.16-3.21 (m, 1H), 3.32-3.36 (m, 1H), 7.15-7.19 (m, 2H), 7.25-7.29 (m, 2H), 7.36-7.42 (m, 
2H), 7.58 (dt, 4J = 1.2, 3J = 7.2 Hz, 1H), 7.78 (d, 3J = 7.2 Hz, 1H). 13C NMR (CDCl3, 125 
MHz): δ = 32.0, 36.2, 48.7, 124.0, 126.6, 127.5, 128.6, 130.3, 132.2, 134.9, 136.5, 138.0, 
153.4, 207.3. 
 
                                                                                                                    Experimental Section 
 152 
(E)-Ethyl 2-(2-(4-chlorobenzyl)-2,3-dihydro-1H-inden-1-ylidene)acetate, (25Ea):  
Synthesized according to Method C using compound 25b (0.30 g, 1.17 mmol), NaH (0.234 g, 
3.51 mmol) and triethyl phosphonoacetate (0.70 mL, 3.51 mmol); pale yellow oil; yield: 
0.126 g (33 %);1H NMR (CDCl3, 500 MHz): δ = 1.33 (t, 3J = 7.2 Hz, 3H), 2.22 (t, 3J = 11.0 
Hz, 1H), 2.72 (d, 3J = 17.0 Hz, 1H), 2.95 (m, 1H), 3.17 (dd, 4J = 3.5, 3J = 13.2 Hz, 1H), 4.09-
4.17 (m, 1H), 4.25 (q, 3J = 7.2 Hz, 2H), 6.32 (d, 3J = 1.6 Hz, 1H), 7.24-7.30 (m, 6H), 7.35 (t, 
3J = 7.6 Hz, 1H) 7.59 (d, 3J = 7.6 Hz, 1H).13C NMR (CDCl3, 125 MHz): δ = 14.4, 35.6, 40.7, 
44.2, 59.9, 108.1, 122.0, 125.2, 126.0, 127.0, 128.2, 128.3, 130.6, 131.0, 131.9, 139.2, 139.2, 
165.8. 
 
(E)-2-(2-(4-Chlorobenzyl)-2,3-dihydro-1H-inden-1-ylidene)acetic acid, (25E): 
Synthesized according to Method D using compound 25Ea (0.10 g, 0.30 mmol) and NaOHaq 
(1.0 mL, 3.06 mmol); white solid; yield: 0.07 g (79 %); Mp 216-219 °C;  
1H NMR ((CD3)2SO, 500 MHz): δ = 2.23 (dd, 3J = 11.0 Hz, 1H), 2.68 (d, 3J = 17.0 Hz, 1H), 
2.94 (dd, 3J = 7.2 Hz, 1H), 3.08 (dd, 4J = 2.8, 3J = 12.9 Hz, 1H), 3.98-4.04 (m, 1H), 6.39 (s, 
1H), 7.26-7.32 (m, 1H), 7.34-7.41 (m, 6H), 7.77 (d, 3J = 7.9 Hz, 1H); 13C NMR ((CD3)2SO, 
125 MHz): δ = 34.9, 40.1, 43.4, 109.2, 122.0, 125.9, 126.9, 128.1, 130.6, 130.9, 138.7, 139.4, 
146.7, 164.8, 167.4; Mp 115-118 °C; LC/MS (+ESI): m/z = 299.5 [MH+]; Rt = 14.6 (≥ 96 %). 
 
 
6.1.3.2. Compounds described in Chapter  3.2. 
2-(3-(4-Chlorophenyl)-3-oxo-1-phenylpropyl)malonic acid, (4A): 
 
(E)-1-(4-Chlorophenyl)-3-phenylprop-2-en-1-one, (1A):  
Synthesized according to Method A using benzaldehyde (2.0 g, 18.8 mmol) and 4’-
chloroacetophenone (2.91 g, 18.8 mmol); pale yellow solid; yield: 4.2 g (93 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 7.42-7.43 (m, 3H), 7.47-7.50 (m, 3H), 7.63-7.65 (m, 
2H), 7.82 (d, J = 15.8 Hz, 1H), 7.96 (d, J = 8.8 Hz, 2H). 13C-NMR (125 MHz, CDCl3): 
δ (ppm) = 121.5, 128.5, 128.9, 129.0, 129.9, 130.7, 134.7, 136.5, 139.2, 145.3, 189.2. 
 
Diethyl 2-(3-(4-chlorophenyl)-3-oxo-1-phenylpropyl)malonate, (2A):  
Synthesized according to Method H using 1A (1.0 g, 4.12 mmol) and diethyl malonate (0.62 
mL, 4.12 mmol) and magnesium oxide (0.41 g) ; white solid; yield: 1.5 g (89 %);  
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1H-NMR (500 MHz, CDCl3): δ (ppm) = 1.01 (t, J = 7.2 Hz, 3H), 1.23 (t, J = 7.2 Hz, 3H),  
3.38 (dd, J = 9.2, 9.2 Hz, 1H), 3.53 (dd, J = 4.4, 4.4 Hz, 1H), 3.80 (d, J = 9.7 Hz, 1H), 3.95 
(q, J = 7.2 Hz, 2H), 4.12-4.25 (m, 3H), 7.14-7.19 (m, 1H), 7.22-7.25 (m, 4H),  7.39 (d, J = 
8.8 Hz, 2H), 7.83 (d, J = 8.8 Hz, 2H). 13C-NMR (125 MHz, CDCl3): δ (ppm) = 13.7, 14.0, 
40.9, 42.6, 57.5, 61.4, 61.7, 127.2, 128.2, 128.4, 128.8, 129.5, 135.1, 139.4, 140.2, 167.6, 
168.3, 196.4. 
 
2-(3-(4-Chlorophenyl)-3-oxo-1-phenylpropyl)malonic acid, (4A):  
Synthesized according to Method L using 2A (0.9 g, 2.22 mmol) and NaOHaq (7.5 mL); white 
solid; yield: 0.5 g (64 %); mp 143-145 °C.  
1H-NMR (500 MHz, CD3OD): δ (ppm) = 3.33 (dd, J = 3.5, 16.7 Hz, 1H), 3.60 (dd, J = 10.1, 
10.1 Hz, 1H), 3.73 (d, J = 3.5, 16.7 Hz, 1H), 3.87 (dt, J = 3.8, 10.4 Hz, 1H), 7.11 (t, J = 7.2 
Hz, 1H), 7.19 (t, J = 7.2 Hz, 2H), 7.27 (d, J = 7.2 Hz, 2H), 7.54 (d, J = 8.5 Hz, 2H), 7.87 (d, 
J = 8.5 Hz,, 2H), 12.67 (s, 2H). 13C-NMR (125 MHz, CD3OD): δ (ppm) = 40.4, 42.4, 57.2, 
126.4, 127.8, 128.3, 128.7, 129.6, 135.2, 137.9, 141.0, 169.0, 169.6, 196.4; LC/MS (+ESI): 
m/z = 347.2 [MH+]; Rt = 4.17 (≥ 97 %). 
 
Bis(acetoxymethyl) 2-(3-(4-chlorophenyl)-3-oxo-1-phenylpropyl)malonate, (5A): 
Synthesized according to Method M 4A (0.5 g, 1.44 mmol), bromomethyl acetate (0.42 mL, 
4.32 mmol) and triethylamine (1.0 mL, 7.2 mmol); white solid; yield: 0.46 g (65 %); mp 92-
93 °C;  
1H-NMR (500 MHz, CD3OD):δ (ppm) = 1.99 (s, 3H), 2.10 (s, 3H), 3.47 (dd, J = 8.9 Hz, 1H), 
3.54 (dd, J = 4.72 Hz, 1H), 3.96 (d, J = 9.1 Hz, 1H), 4.17-4.21 (m, 1H), 5.67 (q, J = 5.7 Hz, 
2H), 5.76 (q, J = 5.7 Hz, 2H), 7.19-7.23 (m, 1H), 7.25-7.28 (m, 4H), 7.41 (d, J = 8.5 Hz, 2H), 
7.83 (d, J = 8.5 Hz, 2H); 13C-NMR (125 MHz, CD3OD): δ (ppm) = 20.5, 20.53, 40.42, 42.1, 
56.3, 79.4, 79.8, 127.5, 128.1, 128.6, 128.9, 129.5, 134.9, 139.6, 139.64, 166.0, 166.5, 169.1, 
169.3, 196.0; LC/MS (+ESI): m/z = 491.2 [MH+]; Rt = 5.24 (≥ 97 %).  
 
5-(4-Chlorophenyl)-5-oxo-3-phenylpentanoic acid, (6A):  
Synthesized according to Method N using 4A (0.30 g, 0.86 mmol); white solid; yield: 0.19 g 
(75 %); mp 135-137 °C;  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 2.73 (dd, J = 7.6, 7.6 Hz, 1H), 2.85 (dd, J = 6.9, 6.9 
Hz, 1H), 3.28-3.37 (m, 2H), 3.81-3.87 (m, 1H), 7.18-7.22 (m, 1H), 7.24-7.31 (m, 4H), 7.39 
(d, J = 8.8 Hz, 2H), 7.82 (d, J = 8.8 Hz, 2H); 13C-NMR (125 MHz, CDCl3): δ (ppm) = 37.2. 
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40.1, 44.5, 127.0, 127.3, 128.7, 128.9, 129.5, 135.1, 139.6, 142.8, 176.9, 196.9; LC/MS 
(+ESI): m/z = 303.2 [MH+]; Rt = 4.69 (≥ 98 %).  
 
 
2-(3-(3-Chlorophenyl)-3-oxo-1-phenylpropyl)malonic acid, (4B):  
 
(E)-1-(3-Chlorophenyl)-3-phenylprop-2-en-1-one, (1B):  
Synthesized according to Method A using benzaldehyde (3.4 g, 32.34 mmol) and 3’-
chloroacetophenone (5.0 g, 32.34 mmol); pale yellow solid; yield: 6.48 g (83 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 7.43-7.45 (m, 4H), 7.47 (d, J = 15.4 Hz, 1H), 7.55-
7.57 (m, 1H), 7.65-7.67 (m, 2H), 7.82 (d, J = 15.4 Hz, 1H), 7.88-7.90 (m, 1H), 7.99 (t, J = 
1.7 Hz, 1H). 13C-NMR (125 MHz, CDCl3): δ (ppm) = 121.5, 126.5, 128.4, 128.6, 129.0, 
129.9, 130.8,  132.7, 134.5, 134.9, 139.8, 145.7, 189.2. 
 
Diethyl 2-(3-(3-chlorophenyl)-3-oxo-1-phenylpropyl)malonate, (2B):  
Synthesized according to Method H using 1B (2.0 g, 8.25 mmol) and diethyl malonate (1.26 
mL, 8.25 mmol) and magnesium oxide (0.82 g); white solid; yield: 2.66 g (80 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 1.02 (t, J = 7.2 Hz, 3H), 1.25 (t, J = 7.2 Hz, 3H), 
3.43 (dd, J = 9.2, 9.2 Hz, 1H), 3.53 (dd, J = 4.45, 4.5 Hz, 1H),  3.80 (d, J = 9.5 Hz, 1H), 3.97 
(q, J = 7.2 Hz, 2H), 4.13-4.24 (m, 3H), 7.16-7.19 (m, 1H), 7.24-7.27 (m, 4H),  7.36 (t, J = 8.2 
Hz, 1H), 7.48-7.50 (m, 1H), 7.77-7.79 (m, 1H), 7.84 (t, J = 1.6 Hz, 1H). 13C-NMR (125 MHz, 
CDCl3): δ (ppm) = 13.8, 14.0, 40.7, 42.7, 57.4, 61.4, 61.7, 126.2, 127.2, 128.2, 128.4, 129.9, 
132.9, 134.9, 138.4, 167.7, 168.3, 182.9. 
 
2-(3-(3-Chlorophenyl)-3-oxo-1-phenylpropyl)malonic acid, (4B): 
Synthesized according to Method L using 2B (2.0 g, 4.96 mmol) and NaOHaq (8.3 mL); white 
solid; yield: 1.3 g (76 %); mp 155-158 °C.  
1H-NMR (500 MHz, CD3OD): δ (ppm) = 3.50 (d, J = 7.6 Hz, 2H), 3.84 (d, J = 10.4 Hz, 1H),  
4.00-4.05 (m, 1H), 7.14 (t, J = 7.2 Hz, 1H), 7.21 (t, J = 7.6 Hz, 2H), 7.27 (d, J = 7.2 Hz, 2H), 
7.44 (t, J = 7.9 Hz, 1H), 7.55 (d, J = 8.8 Hz, 1H), 7.8-7.83 (m, 2H). 13C-NMR (125 MHz, 
CD3OD): δ (ppm) = 42.7, 44.1, 58.8, 127.6, 128.1, 128.6, 129.0, 129.3, 129.6, 131.4, 134.0, 
140.1, 142.1, 171.4, 171.8, 199.0; LC/MS (+ESI): m/z = 347.2 [MH+]; Rt = 4.08 (≥ 96 %).  
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5-(3-Bromophenyl)-5-oxo-3-phenylpentanoic acid, (6B):  
Synthesized according to Method N using 4B (0.75g, 2.16 mmol); white solid; yield: 0.49 g 
(75 %); mp 118-120 °C;  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 2.73 (dd, J = 7.6, 7.6 Hz, 1H),  2.85 (dd, J = 7.2, 7.2 
Hz, 1H), 3.29-3.38 (m, 2H),  3.82-3.88 (m, 1H), 7.21 (t, J = 6.9 Hz, 1H), 7.25-7.31 (m, 3H), 
7.37 (t, J = 7.6 Hz, 1H), 7.50-7.52 (m, 2H), 7.76 (d, J = 8.8 Hz, 1H), 7.84-7.86 (t, J = 1.6 Hz, 
1H); 13C-NMR (125 MHz, CDCl3): δ (ppm) = 37.1, 39.9, 44.0, 126.2, 126.4, 127.4, 127.5, 
128.0, 130.6, 132.7, 133.5, 138.4, 143.6, 156.9, 190.2; LC/MS (+ESI): m/z = 303.1 [MH+]; Rt 
= 4.62 (≥ 98 %).  
 
 
2-(1,3-Bis(4-chlorophenyl)-3-oxopropyl)malonic acid, (4C):  
 
(E)-1,3-Bis(4-chlorophenyl)prop-2-en-1-one, (1C):  
Synthesized according to Method A using 4-chlorobenzaldehyde (3.0 g, 21.34 mmol) and 4’-
chloroacetophenone (2.77 mL, 21.34 mmol); pale yellow solid; yield: 5.60 g (95 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 7.38 (d, J = 8.2 Hz, 2H), 7.45 (d, J = 15.8 Hz, 1H), 
7.48 (d, J = 8.8 Hz, 2H), 7.57 (d, J = 8.2 Hz, 2H), 7.76 (d, J = 15.8 Hz, 1H), 7.98 (d, J = 8.8 
Hz, 2H). 13C-NMR (125 MHz, CDCl3): δ (ppm) = 121.9, 128.9, 129.3, 129.6, 129.9, 133.2, 
126.3, 126.6, 139.4, 143.8, 188.8. 
 
Dimethyl 2-(1,3-Bis(4’-chlorophenyl)-3-oxopropyl)malonate, (2C):  
Synthesized according to Method J using 1C (2.0 g, 7.2 mmol) and diethyl malonate (1.10 
µL, 14.4 mmol) and sodium hydride (cat.); white solid; yield: 2.32 g (74 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 3.40 (dd, J = 9.2, 9.2 Hz, 1H), 3.51 (dd, J = 4.4, 4.4 
Hz, 1H), 3.53 (s, 3H), 3.72 (s, 3H), 3.81 (d, J = 9.1 Hz, 1H), 7.20 (q, J = 8.8 Hz, 4H), 7.40 (d, 
J = 8.8 Hz, 2H), 7.82 (d, J = 8.8 Hz, 2H). 13C-NMR (125 MHz, CDCl3): δ (ppm) = 40.1, 
42.1, 52.5, 52.7, 56.9, 128.7, 128.9, 129.4, 129.5, 133.1, 134.9, 138.7, 139.7, 167.9, 168.5, 
196.1. 
 
2-(1,3-Bis(4-chlorophenyl)-3-oxopropyl)malonic acid, (4C):  
Synthesized according to Method L using 2C (2.0 g, 4.57 mmol) and NaOHaq (7.62 mL); 
white solid; yield: 0.11 g (74 %); mp 140-142 °C.  
                                                                                                                    Experimental Section 
 156 
1H-NMR (500 MHz, CD3OD): δ (ppm) = 3.53 (d, J = 6.9 Hz, 2H), 3.84 (d, J = 10.4 Hz, 1H), 
4.03-4.07 (m, 1H), 7.24 (d, J = 8.5 Hz, 2H), 7.30 (d, J = 8.5 Hz, 2H), 7.49 (d, J = 8.8 Hz, 
2H), 7.92 (d, J = 8.8 Hz, 2H). 13C-NMR (125 MHz, CD3OD): δ (ppm) = 42.0, 43.8, 58.6, 
129.3, 130.0, 130.9, 131.3, 133.8, 136.8, 140.6, 141.0, 171.3, 171.6, 198.8. LC/MS (+ESI): 
m/z = 382.8 [MH+]; Rt = 4.08 (≥ 98 %).  
 
3,5-Bis(4-chlorophenyl)-5-oxopentanoic acid, (6C): 
Synthesized according to Method N using 4C (0.70 g, 1.84 mmol); white solid; yield: 0.5 g 
(80 %); mp 149-151 °C; 1H-NMR (500 MHz, CDCl3): δ (ppm) = 2.68 (dd, J = 7.9 Hz, 1H), 
2.83 (dd, J = 6.9 Hz, 1H), 3.24-3.35 (m, 2H), 3.79-3.85 (m, 1H), 7.18 (d, J = 8.5 Hz, 2H), 
7.25 (d, J = 8.5 Hz, 2H), 7.40 (d, J = 8.8 Hz, 2H), 7.81 (d, J = 8.8 Hz, 2H); 13C-NMR (125 
MHz, CDCl3): δ (ppm) = 36.5, 40.0, 44.3, 128.7, 128.8, 129.0, 129.4, 132.7, 135.0, 139.8, 
141.3, 176.7, 196.4; LC/MS (+ESI): m/z = 339.2 [MH+]; Rt = 4.97 (≥ 98 %).  
 
 
2-(3-(4-Bromophenyl)-3-oxo-1-phenylpropyl)malonic acid, (4D):  
 
(E)-1-(4-Bromophenyl)-3-phenylprop-2-en-1-one, (1D):  
Synthesized according to Method A using benzaldehyde (2.55 mL, 25.1 mmol) and 4’-
bromoacetophenone (5.0 g, 25.1 mmol); pale yellow solid; yield: 5.84 g (81 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 7.40-7.43 (m, 3H), 7.48 (d, J = 15.6 Hz, 1H), 7.63-
7.66 (m, 4H), 7.81 (d, J = 15.6 Hz, 1H), 7.89 (d, J = 8.5 Hz, 2H). 13C-NMR (125 MHz, 
CDCl3): δ (ppm) = 121.5, 127.9, 128.5, 129.0, 130.0, 130.7, 131.9, 134.7, 136.9, 145.4, 189.3. 
 
Diethyl 2-(3-(4-bromophenyl)-3-oxo-1-phenylpropyl)malonate, (2D): 
Synthesized according to Method H using 1D (2.0 g, 6.96 mmol) and diethyl malonate (1.06 
mL, 6.96 mmol) and magnesium oxide (0.70 g) ; white solid; yield: 2.56 g (82 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 1.01 (t, J = 7.2 Hz, 3H), 1.23 (t, J = 7.2 Hz, 3H), 
3.39 (dd, J = 9.2, 9.2 Hz, 1H), 3.52 (dd, J = 4.4, 4.4 Hz, 1H), 3.94 (d, J = 9.5 Hz, 1H), 3.95 
(q, J = 7.2 Hz, 2H), 4.11-4.25 (m, 3H), 7.15-7.19 (m, 1H), 7.22-7.25 (m, 4H), 7.56 (d, J = 8.8 
Hz, 2H), 7.75 (d, J = 8.8 Hz, 2H). 13C-NMR (125 MHz, CDCl3): δ (ppm) = 13.7, 14.0, 40.9, 
42.6, 57.5, 61.4, 61.7, 127.2, 128.2, 128.4, 129.6, 131.8, 135.5, 140.2, 167.6, 168.3, 190.6, 
196.6. 
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2-(3-(4-Bromophenyl)-3-oxo-1-phenylpropyl)malonic acid, (4D):  
Synthesized according to Method L using 2D (2.0 g, 4.47 mmol) and NaOHaq (7.45 mL); 
white solid; yield: 1.27 g (72 %); mp 159-161 °C. 
1H-NMR (500 MHz, (CD3)2SO): δ (ppm) = 3.29-3.33 (m, 1H), 3.59 (dd, J = 10.1. 10.1 Hz, 
1H), 3.74 (d, J = 10.7 Hz, 1H), 3.83-3.88 (m, 1H), 7.11 (t, J = 7.2 Hz, 1H), 7.18 (t, J = 7.2 
Hz, 2H), 7.26 (d, J = 7.2 Hz, 2H), 7.70 (d, J = 86 Hz, 2H), 7.78 (d, J = 8.6 Hz, 2H). 13C-
NMR (125 MHz, (CD3)2SO): δ (ppm) = 40.4, 42.3, 57.2, 126.4, 127.1, 127.8, 128.3, 129.7, 
131.6, 135.5, 141.0, 168.9, 169.9, 197.1; LC/MS (+ESI): m/z = 392.6 [MH+]; Rt = 4.2 (≥ 98 
%). 
 
5-(4-Bromophenyl)-5-oxo-3-phenylpentanoic acid, (6D): 
Synthesized according to Method N using 4D (0.5 g, 1.28 mmol); white solid; yield: 0.39 g 
(89 %); 
1H-NMR (500 MHz, CD3OD): δ (ppm) = 2.64-2.71 (m, 1H), 2.78-2.85 (m, 1H), 3.39 (d, J = 
6.9 Hz, 2H), 3.75-3.81 (m, 1H),  7.16 (t, J = 6.9 Hz, 1H), 7.23-7.29 (m, 4H), 7.63 (d, J = 8.8 
Hz, 2H), 7.83 (d, J = 8.8 Hz, 2H), 13C-NMR (125 MHz, CD3OD): δ (ppm) = 37.2, 40.1, 44.4, 
127.0, 127.3, 128.3, 128.7, 129.6, 131.9, 135.5, 142.8, 176.8, 197.1; LC/MS (+ESI): m/z = 
348.2 [MH+]; Rt = 4.74 (≥ 98 %). 
 
 
2-(3-(4-Bromophenyl)-1-(4-chlorophenyl)-3-oxopropyl)malonic acid, (4E):  
 
(E)-1-(4-Bromophenyl)-3-(4-chlorophenyl)prop-2-en-1-one, (1E):  
Synthesized according to Method A using 4-chlorobenzaldehyde (3.53 mL, 25.11 mmol) and 
4-bromoacetophenone (5.0 g, 25.11 mmol); pale yellow solid; yield: 6.51 g (81 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 7.39 (d, J = 8.5 Hz, 2H), 7.44 (d, J = 15.5 Hz, 1H), 
7.57 (d, J = 8.5 Hz, 2H), 7.65 (d, J = 8.5 Hz, 2H), 7.76 (d, J = 15.5 Hz, 1H), 7.88 (d, J = 8.5 
Hz, 2H). 13C-NMR (125 MHz, CDCl3): δ (ppm) = 121.9, 128.0, 129.3, 129.6, 130.0, 132.0, 
133.2, 136.7, 136.8, 143.8, 189.0. 
 
Dimethyl 2-(3-(4-bromophenyl)-1-(4-chlorophenyl)-3-oxopropyl)malonate, (2E):  
Synthesized according to Method J using 1E (3.0 g, 9.32 mmol) and diethyl malonate (1.56 
mL, 10.26 mmol) and sodium hydride (cat.); white solid; yield: 3.20 g (76 %);  
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1H-NMR (500 MHz, CDCl3): δ (ppm) = 3.39 (dd, J = 9.1, 9.1 Hz, 1H), 3.50 (dd, J = 4.7, 4.7 
Hz, 1H), 3.53 (s, 3H), 3.73 (s, 3H), 3.80 (d, J = 9.1 Hz, 1H), 4.11-4.16 (m, 1H), 7.21 (q, J = 
8.5 Hz, 4H), 7.57 (d, J = 8.5 Hz, 2H), 7.75 (d, J = 8.8 Hz, 2H). 13C-NMR (125 MHz, CDCl3): 
δ (ppm) = 40.1, 42.1, 52.5, 52.7, 56.9, 128.4, 128.7, 129.4, 129.6, 131.9, 133.1, 135.3, 138.7, 
167.9, 168.5, 196.2. 
 
2-(3-(4-Bromophenyl)-1-(4-chlorophenyl)-3-oxopropyl)malonic acid, (4E):  
Synthesized according to Method L using 2E (2.0 g, 4.41 mmol) and 10M NaOHaq (4.4 mL); 
white solid; yield: 1.2 g (64 %); mp 154-155 °C;  
1H-NMR (500 MHz, (CD3)2SO): δ (ppm) = 3.32 (dd, J = 3.5, 17.3 Hz, 1H), 3.62 (dd, J = 
10.1 Hz, 1H),  3.74 (d, J = 10.7 Hz, 1H), 3.82 (dt, J = 3.8, 10.4 Hz, 1H), 7.26 (d, J = 8,5 Hz, 
2H), 7.31 (d, J = 8.5 Hz, 2H), 7.70 (d, J = 8.8 Hz, 2H), 7.79 (d, J = 8.8 Hz, 2H), 12.60 (s, 
OH), 13,00 (s, OH). 13C-NMR (125 MHz, (CD3)2SO): δ (ppm) = 30.6, 42.2, 57.0, 127.3, 
127.8, 129.74, 130.3, 131.1, 131.7, 135.4, 140.1, 168.9, 169.4, 197.0. LC/MS (+ESI): m/z = 
426.9 [MH+]; Rt = 4.56 (≥ 99 %).  
 
 
2-(3-(4-Iodophenyl)-3-oxo-1-phenylpropyl)malonic acid, (4F):  
 
(E)-1-(4-Iodophenyl)-3-phenylprop-2-en-1-one, (1F):  
Synthesized according to Method A using benzaldehyde (1.03 g, 10.2 mmol) and 4’-
iodoacetophenone (2.5g, 10.2 mmol); pale beige solid; yield: 1.6 g (47 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 7.42-7.44 (m, 3H),  7.46 (d, J = 15.5 Hz, 1H), 7.62-
7.67 (m, 2H), 7.73 (d, J = 8.2 Hz, 2H), 7.82 (d, J = 15.5 Hz, 1H), 7.87 (d, J = 8.5 Hz, 2H). 
13C-NMR (125 MHz, CDCl3): δ (ppm) = 100.6, 121.4, 128.5, 129.0, 129.9, 130.7, 134.7, 
137.4, 137.9, 145.3, 189.6. 
 
Dimethyl 2-(3-(4-iodophenyl)-3-oxo-1-phenylpropyl)malonate, (2F):  
Synthesized according to Method J using 1F (1.0 g, 2.99 mmol) and diethyl malonate (0.50 
mL, 3.29 mmol) and sodium hydride (cat.); pale yellow solid; yield: 0.96 g (69 %); 
1H-NMR (500 MHz, CDCl3): δ (ppm) = 3.41 (dd, J = 4.8, 16.7 Hz, 1H), 3.50 (s, 3H), 3.52 
(dd, J = 4.8, 16.7 Hz, 1H),  3.72 (s, 3H), 3.83 (d, J = 9.4 Hz, 1H),  4.12-4.17 (m, 1H), 7.16-
7.20 (m, 1H), 7.21-7.27 (m, 4H), 7.60 (d, J = 8.5 Hz, 2H), 7.79 (d, J = 8.5 Hz, 2H). 13C-NMR 
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(125 MHz, CDCl3): δ (ppm) = 40.8, 42.2, 52.4, 52.7, 57.2, 127.9, 128.5, 129.5, 137.9, 140.2, 
142.8, 145.1, 158.8, 177.0, 177.3, 199.6. 
 
2-(3-(4-Iodophenyl)-3-oxo-1-phenylpropyl)malonic acid, (4F):  
Synthesized according to Method L using 2F (0.6 g, 1.29 mmol) and 10M NaOHaq (1.3 mL); 
white solid; yield: 0.48 g (86 %); mp 174-175 °C;  
1H-NMR (500 MHz, (CD3)2SO): δ (ppm) = 3.28 (dd, J = 3.6, 17.1 Hz, 1H),  3.58 (dd, J = 
10.5 Hz, 1H),  3.73 (d, J = 10.7 Hz, 1H), 3.84 (dt, J = 3.6, 10.3 Hz, 1H), 7.11 (t, J = 7.3 Hz, 
1H), 7.19 (t, J = 7.9 Hz, 2H), 7.26 (d, J = 7.3 Hz, 2H), 7.61 (d, J = 8.5 Hz, 2H), 7.87 (d, J = 
8.5 Hz, 2H), 12.61 (s, OH), 12.90 (s, OH). 13C-NMR (125 MHz, (CD3)2SO): δ (ppm) = 40.4, 
42.3, 57.3, 101.6, 126.4, 127.8, 128.3, 129.4, 135.8, 137.5, 141.0, 168.9, 169.9, 197.4; LC/MS 
(+ESI): m/z = 439.1 [MH+]; Rt = 4.32 (≥ 99 %).  
 
5-(4-Iodophenyl)-5-oxo-3-phenylpentanoic acid, (6F): 
Synthesized according to Method N using 4F (0.11 g, 0.25 mmol); white solid; yield: 0.60 g 
(71 %). mp 183-184 °C;  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 2.73 (dd, J = 7.3, 16.0 Hz, 1H), 2.85 (dd, J = 7.3, 
16.0 Hz, 1H), 3.28 (dd, J = 7.2, 16.7 Hz, 1H), 3.34 (dd, J = 7.2, 16.7 Hz, 1H), 3.81-3.87 (m, 
1H), 7.20 (tt, J = 1.3, 7.2 Hz, 1H), 7.24-7.31 (m, 4H), 7.59 (d, J = 8.6 Hz, 2H), 7.79 (d, J = 
8.6 Hz, 2H). 13C-NMR (125 MHz, (CD3)2SO): δ (ppm) = 37.1, 40.2, 43.8, 101.6, 126.1, 
127.4, 129.5, 135.8, 137.5, 172.7, 197.9; LC/MS (+ESI): m/z = 396.0 [MH+]; Rt = 4.85 (≥ 98). 
 
 
2-(1-(4-Chlorophenyl)-3-(4-iodophenyl)-3-oxopropyl)malonic acid, (4G):  
 
(E)-3-(4-Chlorophenyl)-1-(4-iodophenyl)prop-2-en-1-one, (1G):  
Synthesized according to Method A using 4-chlorobenzaldehyde (1.14 mL, 8.13 mmol) and 
4’-iodooacetophenone (2.0 g, 8.13 mmol); pale beige solid; yield: 2.65 g (89 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 7.39 (d, J = 8.5, 2H), 7.42 (d, J = 15.8, 1H), 7.57 (d, 
J = 8.5, 2H), 7.71 (d, J = 8.5, 2H), 7.77 (d, J = 15.8, 1H), 7.85 (d, J = 8.5 Hz, 2H). 13C-NMR 
(125 MHz, CDCl3): δ (ppm) = 100.8, 121.8, 129.2, 129.6, 129.9, 133.2, 136.7, 137.3, 138.0, 
143.8, 189.3. 
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Diethyl 2-(1-(4-chlorophenyl)-3-(4-iodophenyl)-3-oxopropyl)malonate, (2G):  
Synthesized according to Method I using 1G (2.0 g, 4.07 mmol) and diethyl malonate (0.68 
mL, 4.47 mmol) and potassium carbonate (1.12 g, 8.14 mmol) ; pale beige solid; yield: 0.86 g 
(40 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 1.05 (t, J = 7.2 Hz, 3H), 1.25 (t, J = 7.2 Hz, 3H),  
3.35 (dd, J = 9.5, 9.5 Hz, 1H), 3.49 (dd, J = 4.1, 4.1 Hz, 1H), 3.76 (d, J = 9.8 Hz, 1H), 3.98 
(q, J = 7.2 Hz, 2H), 4.09-4.25 (m, 3H), 7.18 (d, J = 8.8 Hz, 2H), 7.22 (d, J = 8.8 Hz, 2H), 
7.59 (d, J = 8.8 Hz, 2H), 7.79 (d, J = 8.8 Hz, 2H). 13C-NMR (125 MHz, CDCl3): δ (ppm) = 
13.8, 14.0, 40.1, 42.3, 57.2, 61.5, 61.8, 101.2, 128.6, 129.5, 129.6, 133.0, 133.9, 138.0, 138.8, 
167.5, 168.1, 196.6. 
 
2-(1-(4-Chlorophenyl)-3-(4-iodophenyl)-3-oxopropyl)malonic acid, (4G):  
Synthesized according to Method L using 2G (0.59 g, 1.11 mmol) and 10M NaOHaq (2 mL); 
pale yellow solid; yield: 0.35 g (67 %); mp 167-168 °C;  
1H-NMR (500 MHz, (CD3)2SO): δ (ppm) = 3.31 (dd, J = 3.5, 17.0 Hz, 1H), 3.59 (dd, J = 9.9 
Hz, 1H), 3.73 (d, J = 10.8 Hz, 1H), 3.82 (dt, J = 3.5, 10.42 Hz, 1H), 7.26 (d, J = 8.5 Hz, 2H), 
7.29 (d, J = 8.5 Hz, 2H), 7.62 (d, J = 8.5 Hz, 2H), 7.88 (d, J = 8.5 Hz, 2H), 12.62 (s, OH), 
12.89 (s, OH). 13C-NMR (125 MHz, (CD3)2SO): δ (ppm) = 39.8, 42.1, 57.0, 101.8, 127.8, 
129.4, 130.3, 131.0, 135.6, 137.5, 140.1, 168.9, 169.5, 197.3; LC/MS (+ESI): m/z = 473.1 
[MH+]; Rt = 4.66 (≥ 95 %). 
 
3-(4-Chlorophenyl)-5-(4-iodophenyl)-5-oxopentanoic acid, (6G):  
Synthesized according to Method N using 4G (0.15 g, 0.32 mmol); white solid; yield: 0.12 g 
(88 %); mp 145-147 °C;  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 2.67 (dd, J = 7.9 Hz, 1H), 2.82 (dd, J = 6.6 Hz, 1H), 
3.25 (dd, J = 7.2 Hz, 1H), 3.32 (dd, J = 6.6 Hz, 1H), 3.79-3.85 (m, 1H), 7.18 (d, J = 8.4 Hz, 
2H), 7.25 (d, J = 8.4 Hz, 2H), 7.59 (d, J = 8.8 Hz, 2H), 7.80 (d, J = 8.8 Hz, 2H); 13C-NMR 
(125 MHz, CDCl3): δ (ppm) = 36.5, 40.0, 44.2, 101.3, 128.7, 128.8, 129.4, 132.7, 135.9, 
138.0, 141.3, 176.2, 197.0; LC/MS (+ESI): m/z = 429.1 [MH+]; Rt = 5.16 (≥ 99 %). 
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2-(3-Oxo-1-phenyl-3-(4-(trifluoromethyl)phenyl)propyl)malonic acid, (4H):  
 
(E)-3-Phenyl-1-(4-(trifluoromethyl)phenyl)prop-2-en-1-one, (1H):  
Synthesized according to Method A using benzaldehyde (1.62 mL, 15.95 mmol) and 1-(4’-
(trifluoromethyl)phenyl)ethanone (3.0 g, 15.95 mmol); pale yellow solid; yield: 3.05 g (70 
%);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 7.49-7.43 (m, 3H), 7.50 (d, J = 15.8 Hz, 1H), 7.67-
7.65 (m, 2H), 7.77 (d, J = 8.0 Hz, 2H), 7.84 (d, J = 15.8 Hz, 1H), 8.10 (d, J = 8.0 Hz, 2H). 
13C-NMR (125 MHz, CDCl3): δ (ppm) = 121.6, 123.6 (q, 1JC-F = 272.9 Hz), 125.69 (q, 3JC-F 
= 4.3 Hz), 128.6, 128.8, 129.0, 130.9, 133.9 (q, 2JC-F = 32.3 Hz), 134.5, 141.1, 146.1, 189.7. 
 
Diethyl 2-(3-oxo-1-phenyl-3-(4-(trifluoromethyl)phenyl)propyl)malonate, (2H):  
Synthesized according to Method H using 1H (1.5 g, 5.42 mmol) and diethyl malonate (0.82 
mL, 5.92 mmol) and magnesium oxide (0.54 g) ; white solid; yield: 1.8 g (76 %);  
1H-NMR (500 MHz, (CD3)2SO): δ (ppm) = 0.85 (t, J = 7.2 Hz, 3H), 1.16 (t, J = 7.2 Hz, 3H),  
3.46 (dd, J = 3.8, 17.0 Hz, 1H), 3.69 (dd, J = 3.8,  17.0 Hz, 1H), 3.83 (q, J = 7.2 Hz, 2H), 
3.90-3.98 (m, 2H), 4.08-4.18 (m, 2H), 7.15 (t, J = 7.6 Hz, 1H), 7.22 (d, J = 7.6 Hz, 2H), 7.29 
(d, J = 7.8 6z, 2H), 7.87 (d, J = 8.2 Hz, 2H), 8.05 (d, J = 8.2 Hz, 2H). 13C-NMR (125 MHz, 
(CD3)2SO): δ (ppm) = 13.4, 13.7, 40.4, 56.7, 60.6, 61.2, 116.2, 116.4, 125.6 (q, 3JC-F = 3.7 
Hz), 126.8, 127.9, 128.2, 128.5, 140.2, 167.7, 168.4, 197.2. 
 
2-(3-Oxo-1-phenyl-3-(4-(trifluoromethyl)phenyl)propyl)malonic acid, (4H):  
Synthesized according to Method L using 2H (1.76 g, 4.03 mmol) and NaOHaq (6.71 mL); 
white solid; yield: 1.25 g (82 %); mp 128-130 °C;  
1H-NMR (500 MHz, CD3OD): δ (ppm) = 3.53 (d, J = 9.7 Hz 1H), 3.56 (d, J = 6.9 Hz, 1H), 
3.83 (d, J = 10.9 Hz, 1H), 4.02-4.08 (m, 1H), 7.14 (t, J = 7.2 Hz, 1H), 7.21 (t, J = 7.6 Hz, 
2H), 7.27 (d, J = 7.9 Hz, 2H), 7.75 (d, J = 8.2 Hz, 2H), 8.05 (d, J = 8.2 Hz, 2H). 13C-NMR 
(125 MHz, CD3OD): δ (ppm) = 42.6, 44.3, 58.7, 125.2 (q, 1JC-F = 272.2 Hz), 126.7 (q, 3JC-F = 
3.7 Hz), 128.0, 129.3, 129.6, 129.8, 135.2 (d, 2JC-F = 32.9 Hz), 141.3, 142.0 (d, 4JC-F = 1.8 
Hz), 171.5, 171.8, 199.2; LC/MS (+ESI): m/z = 381.2 [MH+]; Rt = 4.35 (≥ 96 %).  
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Bis(acetoxymethyl) 2-(3-oxo-1-phenyl-3-(4 (trifluoromethyl)-phenyl)propyl)-malonate, 
(5H):  
Synthesized according to Method M using 4H (0.2 g, 0.52 mmol), bromo methylacetate 
(0.206 mL, 2.10 mmol) and triethylamine (0.44 mL, 3.12 mmol); white solid; yield: 0.17 g 
(62 %); mp 89-90 °C;  
1H-NMR (500 MHz, CD3OD): δ (ppm) = 1.98 (s, 3H), 2.09 (s, 3H), 3.50 (dd, J = 8.8 Hz, 
1H), 3.60 (dd, J = 4.2 Hz, 1H), 3.96 (d, J = 9.1 Hz, 1H), 4.17-4.21 (m, 1H), 5.55 (q, J = 5.7 
Hz, 2H), 5.76 (d, J = 5.7Hz, 2H), 7.18-7.21 (m, 1H), 7.23-7.28 (m, 4H), 7.69 (d, J = 8.2 Hz, 
2H), 7.98. 13C-NMR (125 MHz, CD3OD): δ (ppm) = 20.5, 20.6, 40.4, 40.5, 56.5, 79.4, 79.8, 
118.0, 125.6 (q, 3JC-F = 4.6 Hz), 127.6, 128.1, 128.4, 128.7, 164.9, 165.8, 166.0, 166.5, 169.2, 
169.3, 196.4; LC/MS (+ESI): m/z = 525.3 [MH+]; Rt = 5.31 (≥ 99 %).  
 
5-Oxo-3-phenyl-5-(4-(trifluoromethyl)phenyl)pentanoic acid, (6H):  
Synthesized according to Method N 4H (0.10 g, 0.26 mmol); white solid; yield: 0.70 g (68%); 
mp 99-101 °C;  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 2.75 (dd, J = 7.0, 16.1 Hz, 1H), 2.87 (dd, J = 7.0, 
16.1 Hz, 1H), 3.36 (dd, J = 6.8, 17.0 Hz, 1H), 3.42 (dd, J = 6.8, 17.0 Hz, 1H), 3.83-3.89 (m, 
1H), 7.20 (tt, J = 1.6, 6.9 Hz, 1H), 7.22-7.31 (m, 4H), 7.69 (d, J = 8.2 Hz, 2H), 7.90 (d, J = 
8.2 Hz, 2H). 13C-NMR (125 MHz, CDCl3): δ (ppm) = 37.2, 39.9, 44.8, 114.8, 115.3, 116.0, 
116.5,  125.7 (q, 3JC-F = 3.7 Hz), 127.1, 127.3, 128.4, 128.8, 175.6, 199.4. LC/MS (+ESI): m/z 
= 337.2 [MH+]; Rt = 4.80 (≥ 99 %). 
 
 
2-(1-(4-Chlorophenyl)-3-oxo-3-(4-(trifluoromethyl)phenyl)propyl) malonic acid, (4I):  
 
(E)-3-(4-Chlorophenyl)-1-(4-(trifluoromethyl)phenyl)prop-2-en-1-one, (1I):  
Synthesized according to Method A using 4-chlorobenzaldehyde (1.12 g, 7.97 mmol) and 1-
(4’-(trifluoromethyl)phenyl)ethanone (1.5 g, 7.97 mmol); pale beige solid; yield: 1.90 g (77 
%);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 7.41 (d, J = 8.5 Hz, 2H), 7.46 (d, J = 15.8 Hz, 1H), 
7.58 (q, J = 8.5 Hz, 2H), 7.77 (d, J = 8.2 Hz, 2H), 7.78 (d, J = 15.8 Hz, 1H), 8.10 (d, J = 
8.2Hz, 2H). 13C-NMR (125 MHz, CDCl3): δ (ppm) = 122.0, 123.7 (q, 1JC-F = 273.1 Hz), 
125.7 (q, 3JC-F = 3.7 Hz), 128.8, 129.4, 129.7, 133.0, 134.3, 136.9, 140.9, 144.5, 189.3. 
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Dimethyl 2-(1-(4-chlorophenyl)-3-oxo-3-(4-(trifluoromethyl)phenyl)propyl)malonate, 
(2I): 
Synthesized according to Method J using 1I (1.0 g, 3.22 mmol), diethyl malonate (0.54 mL, 
3.54 mmol) and sodium hydride (cat.); white solid; yield: 1.35 g (95%);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 3.45 (dd, J = 9.1, 17.0 Hz, 1H), 3.54 (s, 3H), 3.59 
(dd, J = 4.4, 17.0 Hz, 1H), 3.74 (s, 3H), 3.81 (d, J = 9.1 Hz, 1H), 4.13-4.17 (m, 1H), 7.18-
7.24 (q, J = 8.5 Hz, 4H), 7.70 (d, J = 8.2 Hz, 2H), 7.99 (d, J = 8.2 Hz, 2H). 13C-NMR (125 
MHz, CDCl3): δ (ppm) = 40.0, 42.4, 52.6, 52.8, 56.9, 122.4, 125.7 (q, 3JC-F = 3.7 Hz), 128.4, 
128.8, 129.4, 133.2, 134.7, 138.6, 139.2, 167.8 , 168.5, 196.4. 
 
2-(1-(4-Chlorophenyl)-3-oxo-3-(4-(trifluoromethyl)phenyl)propyl) malonic acid, (4I):  
Synthesized according to Method L using 2I (0.8 g, 1.18 mmol) and 10M NaOHaq (1.8 mL); 
white solid; yield: 0.41 g (55 %); mp 147-148 °C;  
1H-NMR (500 MHz, (CD3)2SO): δ (ppm) = 3.49 (dd, J = 3.8, 17 .9 Hz, 1H), 3.67 (dd, J = 
3.8, 9.8 Hz, 1H), 3.76 (d, J = 10.7 Hz, 1H), 3.85 (dt, J = 3.8, 10.4 Hz, 1H), 7.30 (q, J = 8.5 
Hz, 4H), 7.87 (d, J = 8.5 Hz, 2H), 8.05 (d, J = 8.5 Hz, 2H). 13C-NMR (125 MHz, (CD3)2SO): 
δ (ppm) = 40.0, 42.6, 57.0, 124.0 (q, 1JC-F = 272.9 Hz,) 125.7(q, 3JC-F = 4.3 Hz), 127.8, 128.6, 
130.3, 131.1, 139.5, 140.0, 140.7, 168.9, 169.5, 197.4; LC/MS (+ESI): m/z = 415.1 [MH+]; Rt 
= 4.68 (≥ 98 %).  
 
3-(4-Chlorophenyl)-5-oxo-5-(4-(trifluoromethyl)phenyl)pentanoic acid, (6I).: 
Synthesized according to Method N using 4I (0.10 g, 0.24 mmol); white solid; yield: 0.75 g 
(84 %); 
1H-NMR (500 MHz, (CD3)2SO): δ (ppm) = 2.70 (dd, J = 7.4, 16.1 Hz, 1H), 2.85 (dd, J = 7.4, 
16.1 Hz, 1H), 3.34 (dd, J = 7.0, 17.1 Hz, 1H), 3.40 (dd, J = 7.0, 17.1 Hz, 1H), 3.82-3.88 (m, 
1H), 7.20 (d, J = 8.5 Hz, 2H), 7.27 (d, J = 8.5 Hz, 2H), 7.70 (d, J = 8.2 Hz, 2H), 7.99 (d, J = 
8.2 Hz, 2H). 13C-NMR (125 MHz, (CD3)2SO): δ (ppm) = 36.5, 39.8, 44.6, 122.4, 125.7 (q, 
3JC-F = 4.3 Hz), 128.3, 128.7, 128.72, 128.9, 132.8, 139.3, 141.1, 175.4, 196.8; LC/MS 
(+ESI): m/z = 371.2 [MH+]; Rt = 5.06 (≥ 95 %).  
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2-(1-(2-Chlorophenyl)-3-oxo-3-(4-(trifluoromethyl)phenyl)propyl) malonic acid, (4J):  
 
(E)-3-(2-Chlorophenyl)-1-(4-(trifluoromethyl)phenyl)prop-2-en-1-one, (1J): 
Synthesized according to Method A using 2-chlorobenzaldehyde (1.64 g, 11.7 mmol) and 1-
(4’-(trifluoromethyl)phenyl)ethanone (1.3 mL, 11.7  mmol); pale beige solid; yield: 1.28 g (35 
%);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 7.32-7.38 (m, 2H), 7.43 (d, J = 15.8 Hz, 1H), 7.46 
(d, J = 8.2 Hz, 1H), 7.75-7.79 (m, 3H), 8.10 (d, J = 7.9 Hz, 2H), 8.20 (d, J = 15.8 Hz, 1H). 
 
Dimethyl 2-(1-(2-chlorophenyl)-3-oxo-3-(4-(trifluoromethyl)phenyl)propyl)malonate, 
(2J):  
Synthesized according to Method J using 1J (0.64 g, 2.10 mmol), diethyl malonate (0.35 mL, 
2.30 mmol) and sodium hydride (cat.); white solid; yield: 0.511 g (55%);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 3.60 (s, 3H), 3.68-3.71 (m, 5H), 4.08 (d, J = 8.2 Hz, 
1H), 4.63-4.68 (m, 1H), 7.12-7.19 (m, 2H), 7.27 (dd, J = 2.2, 7.2 Hz, 1H), 7.35 (dd, J = 2.2, 
7.2 Hz, 2H), 7.70 (d, J = 8.2 Hz, 2H), 8.03 (d, J = 8.8Hz, 2H). 13C-NMR (125 MHz, CDCl3): 
δ (ppm) = 37.2, 40.6, 52.6, 54.7, 60.3, 122.4, 122.6 (q, 1JC-F = 269.4 Hz), 125.7 (q, 3JC-F = 3.7 
Hz) , 126.9, 128.4, 128.5, 130.2, 134.0, 134.3, 134.5, 137.4, 139.3, 168.1, 168.6, 196.6. 
 
2-(1-(2-Chlorophenyl)-3-oxo-3-(4-(trifluoromethyl)phenyl)propyl) malonic acid, (4J): 
Synthesized according to Method L using 2J (0.45 g, 1.10 mmol) and 10M NaOHaq (1.1 mL); 
white solid; yield: 0.33 g (71 %); mp 149-151 °C;  
1H-NMR (500 MHz, (CD3)2SO): δ (ppm) = 3.56 (dd, J = 4.7, 4.7 Hz, 1H), 3.63 (dd, J = 9.1, 
9.1 Hz, 1H), 3.85 (d, J = 9.8 Hz, 1H), 4.39-4.44 (m, 1H), 7.16 (t, J = 8.8 Hz, 1H), 7.23 (t, J = 
8.5 Hz, 1H), 7.32 (d, J = 9.1 Hz, 1H), 7.51 (d, J = 8.8 Hz, 1H), 7.86 (d, J = 8.2 Hz, 2H), 8.06 
(d, J = 8.2 Hz, 2H). 13C-NMR (125 MHz, (CD3)2SO): δ (ppm) = 36.5, 42.2, 56.1, 123.8 (q, 
1JC-F = 272.2 Hz,) 125.7 (q, 3JC-F = 3.7 Hz), 127.1, 128.2, 128.8, 129.4, 132.4, 132.6, 133.6, 
138.6, 139.7, 169.0, 169.6, 197.3; LC/MS (+ESI): m/z = 415.2 [MH+]; Rt = 4.46 (≥ 99 %). 
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2-(3-(4-Ethylphenyl)-3-oxo-1-phenylpropyl)malonic acid, (4K):  
 
(E)-1-(4-Ethylphenyl)-3-phenylprop-2-en-1-one, (1K):  
Synthesized according to Method A using benzaldehyde (3.43 mL, 34.0 mmol) and 4’-
ethylacetophenone (5.0 g, 34.0 mmol); pale yellow solid; yield: 6.9 g (85 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 1.28 (t, J = 7.6 Hz, 3H), 2.74 (d, J = 7.6 Hz, 2H), 
7.33 (d, J = 8.5 Hz, 2H), 7.41-7.44 (m, 3H), 7.54 (d, J = 15.8 Hz, 1H), 7.64-7.66 (m, 2H), 
7.81 (d, J = 15.8 Hz, 1H), 7.97 (d, J = 8.2 Hz, 2H). 13C-NMR (125 MHz, CDCl3): δ (ppm) = 
15.2, 28.9, 122.2, 128.1, 128.4, 128.7, 128.9, 130.4, 130.1, 135.9, 144.4, 149.8, 190.1. 
 
Diethyl 2-(3-(4-ethylphenyl)-3-oxo-1-phenylpropyl)malonate, (2K):  
Synthesized according to Method H using 1K (2.0 g, 8.46 mmol) and diethyl malonate (1.28 
mL, 8.46 mmol) and magnesium oxide (0.85 g); white solid; yield: 1.85 g (55 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 1.01 (t, J = 7.2 Hz, 3H), 1.24 (t, J = 7.2 Hz, 6H),  
2.69 (q, J = 7.6 Hz, 2H), 3.42-3.43 (dd, J = 9.1, 9.1 Hz, 1H), 3.50 (dd, J = 4.7, 4.7 Hz, 1H), 
3.82 (d, J = 9.5 Hz, 1H), 3.95 (q, J = 7.2 Hz, 2H), 4.18-4.25 (m, 3H), 7.16 (t, J = 7.2 Hz, 
1H), 7.21-7.27 (m, 6H),  7.82 (d, J = 8.2 Hz, 2H). 13C-NMR (125 MHz, CDCl3): δ (ppm) = 
13.7, 14.1, 15.1, 28.9, 40.8, 42.5, 57.6, 61.3, 61.6, 127.1, 128.0, 128.2, 128.3, 128.3, 134.6, 
140.6, 149.9, 167.7, 168.4, 197.1. 
 
2-(3-(4-Ethylphenyl)-3-oxo-1-phenylpropyl)malonic acid, (4K):  
Synthesized according to Method L using 2K (2.7 g, 7.33 mmol) and NaOHaq (1.1 mL, 12.2 
mmol); white solid; yield: 1.5 g (60 %); mp 127-128 °C. 
1H-NMR (500 MHz, DMSO-d6): δ (ppm) = 1.17 (t, J = 7.6 Hz, 3H),  2.64 (q, J = 7.6 Hz, 
2H),  3.27 (q, J = 3.5, 16.7 Hz, 1H), 3.59 (dd, J = 10.4. 10.4 Hz, 1H), 3.74 (d, J = 10.7 Hz, 
1H), 3.86-3.90 (m, 1H), 7.11 (t, J = 7.2 Hz, 1H), 7.19 (t, J = 7.9 Hz, 2H), 7.27 (d, J = 6.9 Hz, 
2H), 7.30 (d, J = 7.9 Hz, 2H), 7.78 (d, J = 8.2 Hz, 2H), 12.78 (s, 2H, OH). 13C-NMR (125 
MHz, DMSO-d6): δ (ppm) = 15.0, 28.0, 30.6, 40.4, 42.2, 57.3, 126.3, 127.8, 127.9, 128.3, 
134.3, 141.2, 149.4, 169.0, 169.6, 197.3; LC/MS (+ESI): m/z = 341.2 [MH+]; Rt = 4.23 (≥ 95 
%). 
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5-(4-Ethylphenyl)-5-oxo-3-phenylpentanoic acid, (6K): 
Synthesized according to Method N using 4K (0.2 g, 0.67 mmol); white solid; yield: 0.11 g 
(56 %); mp 118-119 °C;  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 1.24 (t, J = 7.6 Hz, 3H), 2.67-2.74 (m, 3H), 2.86 (dd, 
J = 6.6, 6.9 Hz, 1H), 3.33 (d, J = 8.2 Hz, 2H), 3.83-3.89 (m, 1H), 7.18-7.20 (m, 1H), 7.28-
7.30 (m, 6H), 7.83 (d, J = 8.2 Hz, 2H), 10.25 (s, 1H, OH); 13C-NMR (125 MHz, CDCl3): 
δ (ppm) = 15.1, 28.9, 37.2, 40.0, 44.4, 126.9, 127.3, 128.1, 128.3, 128.6, 134.5, 143.1, 150.1, 
173.5, 197.7; LC/MS (+ESI): m/z = 297.2 [MH+]; Rt = 4.76 (≥ 97 %). 
 
 
2-(1-(4-Chlorophenyl)-3-(4-ethylphenyl)-3-oxopropyl)malonic acid, (4L):  
 
(E)-3-(4-Chlorophenyl)-1-(4-ethylphenyl)prop-2-en-1-one, (1L):  
Synthesized according to Method A using 4-chlorobenzaldehyde (1.90 g, 12.19 mmol) and 4-
ethylacetophenone (3.0 g, 12.19 mmol); pale yellow solid; yield: 3.90 g (83 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 1.28 (t, J =7.9 Hz, 3H), 2.73 (q, J = 7.9 Hz, 2H), 
7.33 (d, J = 8.2 Hz, 2H), 7.39 (d, J = 8.5 Hz, 2H), 7.50 (d, J = 15.8 Hz, 1H), 7.57 (d, J = 8.8 
Hz, 2H), 7.75 (d, J = 15.8 Hz, 1H), 7.95 (d, J = 8.2 Hz, 2H). 13C-NMR (125 MHz, CDCl3): 
δ (ppm) = 15.2, 29.0, 122.6, 128.2, 128.7, 129.2, 129.5, 133.5, 135.7, 136.3, 142.1, 150.0, 
189.7. 
 
Dimethyl 2-(1-(4-chlorophenyl)-3-(4-ethylphenyl)-3-oxopropyl)malonate (2L):  
Synthesized according to Method J using 1L (3.0 g, 11.10 mmol) and diethyl malonate (1.85 
mL, 12.19 mmol) and sodium hydride (cat.); pale yellow solid; yield: 3.40 g (76 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 1.24 (t, J =7.8 Hz, 3H), 2.69 (q, J = 7.8 Hz, 2H), 
3.42 (dd, J = 8.8, 16.7 Hz, 1H),  3.48 (dd, J = 4.7, 16.7 Hz, 1H),  3.53 (s, 3H), 3.73 (s, 3H), 
3.82 (d, J = 9.5 Hz, 1H),  4.14-4.19 (m, 1H), 7.19-7.23 (m, 4H), 7.25 (d, J = 8.5 Hz, 2H), 
7.81 (d, J = 8.2 Hz, 2H). 13C-NMR (125 MHz, CDCl3): δ (ppm) = 15.1, 28.9, 40.2, 42.0, 52.5, 
52.7, 57.1, 128.1, 128.3, 128.6, 129.5, 132.9, 134.4, 139.1, 150.2, 168.0, 168.5, 196.8. 
 
2-(1-(4-Chlorophenyl)-3-(4-ethylphenyl)-3-oxopropyl)malonic acid, (4L):  
Synthesized according to Method L using 2L (2.0 g, 4.96 mmol) and 10M NaOHaq (5.0 mL, 
14.89 mmol); white solid; yield: 1.53 g (83 %); mp 153-154 °C; 
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1H-NMR (500 MHz, (CD3)2SO): δ (ppm) = 1.17 (t, J =7.6 Hz, 3H), 2.65 (q, J = 7.6 Hz, 2H), 
3.28  (dd, J = 3.5, 16.7 Hz, 1H), 3.60 (dd, J = 10.4, 16.7 Hz, 1H), 3.75 (d, J = 10.7 Hz, 1H), 
3.86 (dt, J = 3.5, 10.4 Hz, 1H), 7.26 (d, J = 8.5 Hz,  2H), 7.30-7.32 (m, 4H), 7.79 (d, J = 8.2 
Hz, 2H), 12.80 (s, 2OH). 13C-NMR (125 MHz, (CD3)2SO): δ (ppm) = 15.0, 28.0, 42.1, 46.4, 
57.1, 127.7, 127.9, 128.0, 132.3, 131.0, 134.2, 140.2, 149.5, 168.9, 169.5, 197.2; LC/MS 
(+ESI): m/z = 375.1 [MH+]; Rt = 4.55 (≥ 95 %). 
 
 
2-(1-(4-Chlorophenyl)-3-(4-hydroxyphenyl)-3-oxopropyl)malonic acid, (4M):  
 
1-(4-(Methoxymethoxy)phenyl)ethanone, (0M): 
Synthesized according to Method G using bromomethyl-methylether (0.87 mL, 11.01 mmol), 
4-hydroxyacetophenone (1.0 g, 7.34 mmol) and sodium hydride (0.44 g, 11.01 mmol); yellow 
solid; yield: 1.25 g (95%).  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 2.55 (s, 3H), 3.47 (s, 3H), 5.22 (s, 2H), 7.06 (d, J = 
8.8 Hz, 2H), 7.92 (d, J = 8.8 Hz, 2H). 13C-NMR (125 MHz, CDCl3): δ (ppm) = 26.3, 56.2, 
94.0, 115.7, 130.4, 131.2, 161.0, 196.8. 
 
(E)-3-(4-Chlorophenyl)-1-(4-(methoxymethoxy)phenyl)prop-2-en-1-one, (1M):  
Synthesized according to Method A using 4-chlorobenzaldehyde (0.78 mL, 5.5 mmol) and 1-
(4-(methoxymethoxy)phenyl)ethanone (1.0 g, 5.5 mmol); pale yellow solid; yield: 0.84g (50 
%);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 3.50 (s, 3H), 5.26 (s, 2H), 7.12 (d, J = 8.8 Hz, 2H), 
7.39 (d, J = 8.2 Hz, 2H), 7.50 (d, J = 15.5 Hz, 1H), 7.57 (d, J = 8.2 Hz, 2H), 7.74 (d, J = 15.5 
Hz, 1H), 8.02 (d, J = 8.8 Hz, 2H). 13C-NMR (125 MHz, CDCl3): δ (ppm) = 56.3, 94.1, 115.9, 
122.3, 129.2, 129.5, 130.7, 131.8, 133.5, 136.2, 142.6, 161.1, 188.5. 
 
Dimethyl 2-(1-(4-chlorophenyl)-3-(4-(methoxymethoxy)phenyl)-3-oxopropyl)-malonate, 
(2M):  
Synthesized according to Method J using 1M (0.4 g, 1.32 mmol) and diethyl malonate (0.22 
mL, 1.45 mmol) and sodium hydride (cat.); white solid; yield: 0.45 g (88 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 3.38 (dd, J = 9.1, 9.1 Hz, 1H), 3.46 (d, J = 4.7 Hz, 
1H), 3.47 (s, 3H), 3.52 (s, 3H), 3.72 (s, 3H), 3.82 (d, J = 9.1 Hz, 1H), 4.13-4.17 (m, 1H), 5.21 
(s, 2H), 7.04 (d, J = 8.8 Hz, 2H), 7.19-7.27 (m, 4H), 7.86 (d, J = 8.8 Hz, 2H). 13C-NMR (125 
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MHz, CDCl3): δ (ppm) = 40.25, 41.8, 52.5, 52.7, 56.2, 57.0, 94.0, 115.7, 128.6, 129.5, 130.2, 
130.6, 132.9, 139.0, 161.2, 168.0, 168.5, 195.7. 
 
Dimethyl 2-(1-(4-chlorophenyl)-3-(4-hydroxyphenyl)-3-oxopropyl)malonate, (3M):  
Synthesized according to Method K using 2M (0.3 g, 0.71mmol) and 2 mL 10 % HCl;yellow 
oil; yield: 0.30 g (quant, without further purification);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 3.37 (dd, J = 9.1 Hz, 1H), 3.46 (d, J = 4.6 Hz, 1H), 
3.53 (s, 3H), 3.73 (s, 3H), 3.81 (d, J = 9.1 Hz, 1H), 4.14-4.17 (m, 2H), 6.82 (d, J = 8.8 Hz, 
2H), 7.18-7.22 (m, 4H), 7.82 (d, J = 8.8 Hz, 2H).13C-NMR (125 MHz, CDCl3): δ (ppm) = 
40.3, 41.7, 52.6, 52.8, 57.1, 115.3, 128.6, 129.5, 130.7, 133.0, 137.4, 138.9, 139.8, 168.1, 
168.6, 195.4. 
 
2-(1-(4-Chlorophenyl)-3-(4-hydroxyphenyl)-3-oxopropyl)malonic acid, (4M):  
Synthesized according to Method L using 3M (0.25 g, 0.64 mmol) and 10M NaOHaq (1.1 
mL); white solid; yield: 0.15 g (63 %); mp 151-152 °C;  
1H-NMR (500 MHz, (CD3)2SO): δ (ppm) = 3.18 (dd, J = 3.3, 16.7 Hz, 1H),  3.53 (dd, J = 
10.3, 16.7 Hz, 1H),  3.73 (d, J = 11.0 Hz, 1H), 3.85 (dt, J = 3.3, 10.3 Hz, 1H), 6.79 (d, J = 
8,8 Hz, 2H), 7.28 (q, J = 8.5 Hz, 4H), 7.75 (d, J = 8.8 Hz, 2H), 10.3 (s, OH), 12.60 (s, OH), 
12.98 (s, OH). 13C-NMR (125 MHz, (CD3)2SO): δ (ppm) = 40.0, 41.6, 57.1, 115.1, 127.7, 
128.1, 130.3, 130.4, 130.9, 140.3, 162.0, 169.0, 196.5, 195,7; LC/MS (+ESI): m/z = 363.2 
[MH+]; Rt = 3.30 (≥ 96 %). 
 
 
2-(3-Oxo-3-(4-phenoxyphenyl)-1-phenylpropyl)malonic acid, (4N):  
 
(E)-3-(4-Chlorophenyl)-1-(4-phenoxyphenyl)prop-2-en-1-one, (1N):  
Synthesized according to Method A using 4-chlorobenzaldehyde (5.0 g, 23.56 mmol) and 4’-
phenoxyacetophenone (5.0 g, 23.56 mmol); pale yellow solid; yield: 5.1 g (72 %).  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 7.06 (d, J = 8.5 Hz, 2H), 7.10 (d, J = 8.5 Hz, 2H),  
7.21 (t, J = 7.2 Hz, 1H), 7.39-7.43 (m, 5H), 7.54 (d, J = 15.8 Hz, 1H), 7.63-7.66 (m, 2H), 
8.82 (d, J = 15.8 Hz, 1H), 8.04 (d, J = 8.5 Hz, 2H). 13C-NMR (125 MHz, CDCl3): δ (ppm) = 
117.5, 120.1, 121.8, 124.5, 128.4, 128.9, 130.0, 130.4, 130.8, 132.8, 134.9, 144.4, 155.6, 
161.8, 188.8. 
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Diethyl 2-(3-oxo-3-(4-phenoxyphenyl)-1-phenylpropyl)malonate, (2N): 
Synthesized according to Method H using 1N (2.0 g, 6.66 mmol) and diethyl malonate (1.01 
mL, 6.66 mmol) and magnesium oxide (0.67 g); white solid; yield: 2.52 g (82 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 1.01 (t, J = 6.9 Hz, 3H),  1.24 (t, J = 6.9 Hz, 3H),  
3.39 (dd, J = 9.1, 9.1 Hz, 1H), 3.49 (dd, J = 4.4, 4.4 Hz, 1H), 3.81 (d, J = 9.8 Hz, 1H), 3.96 
(q, J = 7.2 Hz, 2H), 4.14-4.23 (m, 3H), 6.95 (d, J = 8.9 Hz, 2H), 7.05 (d, J = 8.9 Hz, 1H), 
7.15-7.27 (m, 6H), 7.38 (t, J = 7.6 Hz, 1H),  7.88 (d, J = 9.1 Hz, 2H). 13C-NMR (125 MHz, 
CDCl3): δ (ppm) = 13.7, 14.0, 41.0, 42.4, 57.6, 61.3, 61.6, 117.3, 120.1, 124.6, 127.1, 128.2, 
128.4, 130.0, 130.4, 131.5, 140.4, 125.5, 161.9, 167.7, 168.4, 196.1 
 
2-(3-Oxo-3-(4-phenoxyphenyl)-1-phenylpropyl)malonic acid, (4N): 
Synthesized according to Method L using 2N (2.0 g, 4.34 mmol) and NaOHaq (7.3 mL); white 
solid; yield: 1.26 g (72 %); mp 131-134 °C.  
1H-NMR (500 MHz, CD3OD): δ (ppm) = 3.44 (m, 2H), 3.86 (d, J = 10.4 Hz, 1H), 4.05-4.10 
(m, 1H), 6.97 (d, J = 8.5 Hz, 2H), 7.08 (d J = 7.2 Hz, 2H), 7.16 (t, J = 7.9 Hz, 1H), 7.20-7.30 
(m, 5H), 7.44 (t, J = 7.6 Hz, 2H), 7.92 (d, J = 8.2 Hz, 2H); 13C-NMR (125 MHz, CD3OD): 
δ (ppm) = 42.8, 43.8, 58.9, 118.2, 121.3, 125.8, 128.0, 129.3, 129.6, 131.2, 131.7, 133.0, 
142.2, 156.9, 163.6, 171.4, 171.8, 199.0; LC/MS (+ESI): m/z = 405.2 [MH+]; Rt = 4.59 (≥ 95 
%). 
 
5-Oxo-5-(4-phenoxyphenyl)-3-phenylpentanoic acid, (6N): 
Synthesized according to Method N using 4N (0.3 g, 0.74 mmol); white solid; yield: 0.25 g 
(93 %); mp 135-136 °C;  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 2.71 (dd, J = 7.9, 7.9 Hz, 1H), 2.86 (dd, J = 6.8, 6.8 
Hz, 1H), 3.27-3.35 (m, 2H), 3.82-3.88 (m, 1H),  6.96 (d, J = 9.1 Hz, 1H), 7.05 (d, J = 8.5 Hz, 
2H), 7.20 (t, J = 7.2 Hz, 2H), 7.25-7.30 (m, 4H), 7.39 (t, J = 7.6 Hz, 2H), 7.88 (d, J = 8.8 Hz, 
2H). 13C-NMR (125 MHz, CDCl3): δ (ppm) = 37.1, 39.7, 44.0, 117.1, 119.9, 124.4, 126.6, 
127.0, 128.4, 129.8, 130.1, 131.3, 142.8, 155.2, 161.8, 175.7, 196.4; LC/MS (+ESI): m/z = 
361.2 [MH+]; Rt = 5.05 (≥ 99 %). 
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2-(3-(4-Iodophenyl)-1-(naphthalen-2-yl)-3-oxopropyl)malonic acid, (4O):  
 
(E)-1-(4-Iodophenyl)-3-(naphthalen-2-yl)prop-2-en-1-one, (1O):  
Synthesized according to Method A using 2-naphthaldehyde (1.90 g, 12.19 mmol) and 4’-
iodoacetophenone (3.0 g, 12.19 mmol); pale yellow solid; yield: 3.90 g (83 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 7.51-7.56 (m, 2H),  7.58 (d, J = 15.6 Hz, 1H), 7.76 
(d, J = 8.5 Hz, 2H), 7.76-7.80 (m, 1H), 7.82-7.89 (m, 3H), 7.88 (d, J = 8.5 Hz, 2H), 7.98 (d, J 
= 15.6 Hz, 1H), 8.04 (s, 1H). 13C-NMR (125 MHz, CDCl3): δ (ppm) = 100.6, 121.6, 123.6, 
126.8, 127.5, 127.8, 128.7, 128.8, 129.9, 130.8, 132.2, 133.4, 134.5, 137.6, 137.9, 145.5, 
189.6. 
 
Dimethyl 2-(3-(4-iodophenyl)-1-(naphthalen-2-yl)-3-oxopropyl)malonate, (2O):  
Synthesized according to Method J using 1O (1.5 g, 3.90 mmol) and diethyl malonate (0.59 
mL, 3.90 mmol) and sodium hydride (cat.); pale yellow solid; yield: 1.10 g (55 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 3.47 (s, 3H), 3.53 (dd, J = 8.8, 16.9 Hz, 1H), 3.59 
(dd, J = 4.7, 16.9 Hz, 1H),  3.73 (s, 3H), 3.95 (d, J = 9.1 Hz, 1H),  4.31-4.36 (m, 1H), 7.39 
(dd, J = 1.9, 8.5 Hz, 1H), 7.41-7.45 (m, 2H), 7.60 (d, J = 8.5 Hz, 2H), 7.67 (ds, J = 1.26 Hz, 
1H), 7.74-7.77 (m, 3H), 7.78 (d, J = 8.5 Hz, 2H). 13C-NMR (125 MHz, CDCl3): δ (ppm) = 
40.8, 42.2, 52.4, 52.7, 57.2, 101.1, 125.9, 126.0, 126.1, 127.6, 127.8, 128.3, 129.5, 132.6, 
133.3, 136.0, 137.8, 137.9, 168.0, 168.7, 196.5. 
 
2-(3-(4-Iodophenyl)-1-(naphthalen-2-yl)-3-oxopropyl)malonic acid, (4O):  
Synthesized according to Method L using 2O (0.7 g, 1.36 mmol) and 10M NaOHaq (4.4 mL); 
white solid; yield: 0.5 g (75 %); mp 150-151 °C;  
1H-NMR (500 MHz, (CD3)2SO): δ (ppm) = 3.41 (dd, J = 3.5, 17.02 Hz, 1H),  3.71 (dd, J = 
10.4 Hz, 1H),  3.85 (d, J = 10.7 Hz, 1H), 4.02 (dt, J = 3.8, 10.4 Hz, 1H), 7.41-7.46 (m, 2H), 
7.50 (dd, J = 1.6, 8.5 Hz, 1H), 7.74-7.77 (m, 2H), 7.79-7.82 (m, 2H), 7.86 (d, J = 8.5 Hz, 
21H), 12.84 (s, 2OH). 13C-NMR (125 MHz, (CD3)2SO): δ (ppm) = 40.2, 40.5, 57.3, 101.7, 
125.5, 125.8, 126.7, 126.9, 127.2, 127.3, 127.4, 129.5, 131.8, 132.6, 134.4, 135.7, 137.5, 
138.7, 168.9, 169.6, 192.4; LC/MS (+ESI): m/z = 489.2 [MH+]; Rt = 5.05 (≥ 97 %). 
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2-(3-Oxo-1-(4-phenylthiophen-2-yl)-3-(4-(trifluoromethyl)phenyl)propyl)malonic acid, 
(4P):  
 
(E)-3-(4-Phenylthiophen-2-yl)-1-(4-(trifluoromethyl)phenyl)prop-2-en-1-one, (1P):  
Synthesized according to Method A using 4-phenylthiophene-2-carbaldehyde (0.50 g, 2.66 
mmol) and 1-(4’-(trifluoromethyl)phenyl)ethanone (0.49 g, 2.66 mmol); yellow solid; yield: 
0.86 g (90 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 7.31 (d, J = 15.3, 1H), 7.34 (tt, J = 1.3, 7.6, 1H), 
7.43 (t, J = 7.9, 2H), 7.58 (dt, J = 8.2, 3H), 7.66 (ds, J = 1.3 Hz, 1H), 7.78 (d, J =lo. 8.2 Hz, 
2H), 7.99 (d, J = 15.3 Hz, 1H), 8.10 (d, J = 7.9 Hz, 2H). 13C-NMR (125 MHz, (CD3)2SO): 
δ (ppm) = 117.0, 117.2, 120.4,  125.6 (q, 3JC-F = 3.7 Hz), 125.9, 127.6, 128.9, 129.1, 131.3, 
132.4, 132.5, 134.1, 137.6, 139.9, 142.4, 188.1. 
 
Diethyl 2-(3-oxo-1-(4-phenylthiophen-2-yl)-3-(4-(trifluoromethyl)phenyl)propyl) 
malonate, (2P):  
Synthesized according to Method H using 1P (0.5 g, 1.39 mmol) and diethyl malonate (0.37 
mL, 1.53 mmol) and magnesium oxide (0.14 g) ; yellow oil; yield: 0.67 g (93 %);  
1H-NMR (500 MHz, (CD3)2SO): δ (ppm) = 0.99 (t, J = 7.1 Hz, 3H), 1.16 (t, J = 7.1 Hz, 3H), 
3.31 (s, 3H), 3.56 (dd, J = 4.1, 17.8 Hz, 1H), 3.80 (dd, J = 9.5, 17.8 Hz, 1H), 3.95-3.98 (m, 
2H), 3.99 (m, 2H), 4.12-4.18 (m, 2H), 4.27 (dt, J = 4.1, 9.1 Hz, 1H), 7.26 (tt, J = 1.3, 7.3 Hz, 
1H), 7.37 (t, J = 7.6 Hz, 2H), 7.45 (ds, J = 1.3 Hz, 1H), 7.60 (dd, J = 1.3, 8.2 Hz, 2H), 7.62 
(ds, J = 1.6 Hz, 1H), 7.89 (d, J = 8.5 Hz, 2H), 8.13 (d, J = 8.5 Hz, 2H). 13C-NMR (125 MHz, 
(CD3)2SO): δ (ppm) = 13.5, 13.7, 35.4, 43.1, 57.0, 60.9, 61.3, 119.4, 122.5, 124.6, 125.61, 
125.63, 125.7, 126.9, 128.7, 128,71, 135.0, 138.5, 140.4, 144.0, 167.0, 167.4, 196.9. 
 
2-(3-Oxo-1-(4-phenylthiophen-2-yl)-3-(4-(trifluoromethyl)phenyl)propyl)malonic acid, 
(4P): 
Synthesized according to Method L using 2P (0.4 g, 0.77 mmol) and 10M NaOHaq (0.8 mL); 
white solid; yield: 0.21 g (59 %); mp 162-163 °C;  
1H-NMR (500 MHz, (CD3)2SO): δ (ppm) = 3.53 (dd, J = 3.8, 17.3 Hz, 1H),  3.79 (dd, J = 
9.5, 17.3 Hz, 1H), 3.80  (d, J = 9.8 Hz, 1H), 4.20 (dt, J = 4.1, 9.5 Hz, 1H), 7.26 (t, J = 7.3 Hz, 
1H), 7.37 (t, J = 7.6 Hz, 2H), 7.41 (ds, J = 1.3 Hz, 1H), 7.58-7.60 (m, 3H), 7.88 (d, J = 8.2 
Hz, 2H), 8.12 (d, J = 8.2 Hz, 2H), 12.92 (s, 2OH). 13C-NMR (125 MHz, (CD3)2SO): δ (ppm) 
= 35.5, 43.3, 57.7, 119.2, 124.3, 125.6, 126.9, 128.6, 128.7, 135.0, 138.9, 140.3, 144.8, 168.9, 
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169.2, 175.0, 183.1, 194.0, 194.2, 197.1; LC/MS (+ESI): m/z = 463.2 [MH+]; Rt = 4.92 (≥ 95 
%). 
 
 
2-(3-(Naphthalen-2-yl)-3-oxo-1-phenylpropyl)malonic acid, (4Q):  
 
(E)-1-(Naphthalen-2-yl)-3-phenylprop-2-en-1-one, (1Q):  
Synthesized according to Method A using benzaldehyde (2.99 mL, 29.4 mmol) and 2-
acetylnaphthalene (5.0 g, 29.4 mmol); pale yellow solid; yield: 6.1 g (80 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 7.44-7.46 (m, 3H), 7.56-7.63 (m, 2H), 7.68-7.72 (m, 
3H), 7.87-7.96 (m, 3H), 7.95 (d, J = 7.9 Hz, 1H), 8.11 (d, J = 8.5 Hz, 1H), 8.55 (s, 1H). 13C-
NMR (125 MHz, CDCl3): δ (ppm) = 122.1, 124.5, 126.8, 127.8, 128.4, 128.5, 128.6, 129.0, 
129.5, 129.9, 130.5, 132.6, 135.0, 135.5, 135.6, 144.7, 190.3. 
 
Diethyl 2-(3-(naphthalen-2-yl)-3-oxo-1-phenylpropyl)malonate, (2Q):  
Synthesized according to Method H using 1Q (2.0 g, 7.74 mmol) and malonate diethyl 
malonate (1.17 mL, 7.74 mmol) and magnesium oxide (0.77 g) ; white solid; yield: 2.76 g (85 
%);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 1.02 (t, J = 7.2 Hz, 3H), 1.25 (t, J = 7.2 Hz, 3H), 
3.60 (dd, J = 9.5, 9.5 Hz, 1H), 3.67 (dd, J = 4.4, 4.4 Hz, 1H), 3.87 (d, J = 9.5 Hz, 1H), 3.97 
(q, J = 6.9 Hz, 2H), 4.19-4.28 (m, 3H), 7.17 (t, J = 7.2 Hz, 1H), 7.23-7.30 (m, 4H), 7.52-7.60 
(m, 2H), 7.84 (d, J = 8.5 Hz, 2H), 7.93-7.96 (m, 2H), 8.44 (s, 1H). 13C-NMR (125 MHz, 
CDCl3): δ (ppm) = 13.7, 14.0, 41.0, 42.7, 57.6, 61.3, 61.6, 123.9, 126.7, 127.1, 127.7, 128.2, 
128.4, 128.4, 129.6, 129.8, 132.5, 134.2, 135.5, 140.5, 153.0, 167.6 , 167.8 , 197.5.  
 
2-(3-(Naphthalen-2-yl)-3-oxo-1-phenylpropyl)malonic acid, (4Q):  
Synthesized according to Method L using 2Q (2.0 g, 4.78 mmol) and NaOHaq (8.0 mL); white 
solid; yield: 1.5 g (87 %); mp 147-149 °C.  
1H-NMR (500 MHz, DMSO-d6): δ (ppm) = 3.44 (dd, J = 3.5, 16.7 Hz, 2H), 3.74-3.80 (m, 
2H),  3.93-3.98 (m, 1H), 7.10 (t, J = 7.6 Hz, 1H), 7.20 (t, J = 7.9 Hz, 2H), 7.31 (d, J = 8.5 
Hz, 2H), 7.60-7.67 (m, 2H), 7.86 (dd, J = 1.9, 8.8 Hz, 1H), 7.96 (dd, J = 2.5, 7.9 Hz, 1H), 
8.07 (d, J = 7.9 Hz, 1H), 8.59 (s, 1H). 13C-NMR (125 MHz, DMSO-d6): δ (ppm) = 40.6, 42.4, 
57.4, 123.3, 126.4, 126.8, 127.5, 127.8, 128.1, 128.3, 128.5, 129.4, 129.6, 132.0, 133.8, 134.8, 
141.2, 168.9, 169.7, 197.7; LC/MS (+ESI): m/z = 363.2 [MH+]; Rt = 4.26 (≥ 95 %). 
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Bis(acetoxymethyl) 2-(3-(naphthalen-2-yl)-3-oxo-1-phenylpropyl)malonate, (5Q):  
Synthesized according to Method M using 4Q (0.3 g, 0.83 mmol), bromo methylacetate (0.24 
mL, 2.48 mmol) and triethylamine (0.57 mL, 4.14 mmol); white solid; yield: 0.12 g (30 %); 
mp 100-102 °C;  
1H-NMR (500 MHz, DMSO-d6): δ (ppm) = 1.97 (s, 3H), 2.10 (s, 3H), 3.61-3.71 (m, 2H), 4.02 
(d, J = 9.1 Hz, 1H), 4.27-4.32 (m, 1H), 5.58 (q, J = 5.7 Hz, 2H), 5.76-5.78 (m, 2H), 7.19 (t, J 
= 7.2 Hz, 1H), 7.24-7.31 (m, 4H), 7.53-7.61 (m, 2H), 7.85 (d, J = 8.5 Hz, 2H), 7.92-7.97 (m, 
2H), 8.43 (s, 1H); 13C-NMR (125 MHz, DMSO-d6): δ (ppm) = 20.5, 20.54, 40.6, 42.2, 56.6, 
79.4, 79.8, 123.7, 126.8, 127.4, 127.7, 128.2, 128.4, 128.51, 128.58, 129.6, 129.9, 132.5, 
134.0, 135.6, 139.8, 166.1, 166.6, 169.2, 169.3, 197.1; LC/MS (+ESI): m/z = 507.3 [MH+]; Rt 
= 5.33 (≥ 96 %).  
 
5-(naphthalen-2-yl)-5-oxo-3-phenylpentanoic acid, (6Q): 
Synthesized according to Method N using 4Q (0.55 g, 1.52 mmol); white solid; yield: 0.30 g 
(61 %); mp 169-170 °C;  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 2.77 (dd, J = 7.6, 7.9 Hz, 1H), 2.92 (dd, J = 6.9, 6.9 
Hz, 1H), 3.45-3.55 (m, 2H), 3.91-3.96 (m, 1H), 7.20-7.22 (m, 1H), 7.29-7.31 (m, 4H), 7.52 (t, 
J = 8.2 Hz, 1H), 7.59 (t, J = 8.2 Hz, 1H), 7.86 (d, J = 8.8 Hz, 1H), 7.92-7.98 (m, 2H), 8.42 (s, 
1H); 13C-NMR (125 MHz, CDCl3): δ (ppm) = 37.4, 40.1, 44.6, 123.8, 126.8, 126.9, 127.4, 
127.7, 128.4, 128.5, 128.7, 129.6, 129.8, 132.5, 134.2, 135.6, 143.1, 176.5, 198.0; LC/MS 
(+ESI): m/z = 319.2 [MH+]; Rt = 4.80 (≥ 96 %).  
 
 
2-(3-(6-Methoxynaphthalen-2-yl)-3-oxo-1-phenylpropyl)malonic acid, (4R):  
 
(E)-1-(6-Methoxynaphthalen-2-yl)-3-phenylprop-2-en-1-one, (1R):  
Synthesized according to Method A using benzaldehyde (1.52 mL, 14.98 mmol) and 2-acetyl-
6-methoxynaphthalene (3.0 g, 14.98 mmol); pale beige solid; yield: 4.0 g (93 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 3.95 (s, 3H), 7.18 (d, J = 2.2, 1H), 7.22 (dd, J = 2.5, 
11.3, 1H), 7.43-7.45 (m, 3H), 7.67-7.71 (m, 3H), 7.81 (d, J = 8.5 Hz, 1H), 7.86-7.89 (m, 2H), 
8.10 (dd, J = 1.60, 1.89, 8.5 Hz, 1H), 8.48 (s, 1H). 13C-NMR (125 MHz, CDCl3): δ (ppm) = 
55.4, 105.8, 119.7, 122.1, 125.2, 127.3, 127.9, 128.4, 128.9, 129.8, 130.4, 131.1, 133.5, 135.1, 
137.2, 144.3, 159.7, 189.8. 
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Diethyl 2-(3-(6-methoxynaphthalen-2-yl)-3-oxo-1-phenylpropyl)malonate (2R):  
Synthesized according to Method H using 1R (2.0g, 6.94 mmol) and diethyl malonate (1.05 
mL, 6.94 mmol) and magnesium oxide (0.694 g) ; pale beige solid; yield: 2.10 g (68 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 1.01 (t, J = 7.2 Hz, 3H), 1.25 (t, J = 7.2 Hz, 3H),  
3.56 (dd, J = 9.1, 9.1 Hz, 1H), 3.64 (dd, J = 4.4, 4.4 Hz, 1H), 3.87 (d, J = 9.8 Hz, 1H), 3.94 
(s, 3H), 3.96 (q, J = 7.2 Hz, 2H), 4.16-4.27 (m, 3H), 7.12-7.30 (m, 7H), 7.71 (d, J = 8.8 Hz, 
1H), 7.83 (d, J = 9.1 Hz, 1H), 7.91 (dd, J = 1.9, 8.5 Hz, 1H), 8.37 (d, J = 1.6 Hz, 1H). 13C-
NMR (125 MHz, CDCl3): δ (ppm) = 13.7, 14.0, 41.0, 42.5, 55.4, 57.6, 61.3, 61.6, 105.7, 
119.6, 124.6, 127.0, 127.1, 127.8, 128.3, 128.4, 129.7, 131.1, 132.2, 137.2, 140.6, 159.7, 
167.8, 168.4, 197.1. 
 
2-(3-(6-Methoxynaphthalen-2-yl)-3-oxo-1-phenylpropyl)malonic acid, (4R):  
Synthesized according to Method L using 2R (1.0 g, 2.22 mmol) and 10M NaOHaq (5 mL); 
pale yellow solid; yield: 0.74 g (85 %); mp 164-165 °C.  
1H-NMR (500 MHz, (CD3)2SO): δ (ppm) = 3.38 (dd, J = 3.5, 16.7 Hz, 1H), 3.71-3.79 (m, 
2H), 3.95 (s, 3H), 3.96 (dt, J = 3.5, 10.7 Hz, 1H), 7.10 (t, J = 7.2 Hz, 1H), 7.20 (t, J = 7.6 Hz, 
2H), 7.25 (dd, J = 2.2, 8.8 Hz, 1H), 7.31 (d, J = 7.2 Hz, 2H), 7.37 (d, J = 2.2 Hz, 1H), 7.83 
(q, J = 8.8 Hz, 2H), 7.98 (d, J = 8.8 Hz, 1H), 8.51 (s, 1H), 12.53 (s, OH), 12.92 (s, OH). 13C-
NMR (125 MHz, (CD3)2SO): δ (ppm) = 40.6, 42.3, 55.4, 57.5, 106.0, 119.5, 124.0, 126.4, 
126.9, 127.3, 127.9, 128.4, 129.6, 131.1, 131.9, 136.8, 141.3, 159.3, 169.1, 169.8, 197.3; 
LC/MS (+ESI): m/z = 393.2 [MH+]; Rt = 4.25 (≥ 96 %). 
 
5-(6-Hydroxynaphthalen-2-yl)-5-oxo-3-phenylpentanoic acid, (6R):  
A mixture of 4R (0.15 g, 0.45 mmol) in glacial acetic acid (5 mL) was treated with 48% 
aqueous HBr (2 mL) and heated to 150 °C for 2 h. The solvent and acid were then distilled off 
and the residue hydrolyzed, acidified to pH 2 with 10 % HCl and extracted with ethyl acetate 
(3 x 20 mL). The organic layers were collected, washed with brine (20 mL), dried over 
MgSO4 and evaporated to afford a residue, which was purified by flash column 
chromatography on silica gel; pale yellow solid; yield: 0.10 g (67 %); 
1H-NMR (500 MHz, (CD3)2SO): δ (ppm) = 2.59 (dd, J = 8.5 Hz, 1H), 2.73 (dd, J = 6.3 Hz, 
1H), 3.43 (dd, J = 6.3Hz, 1H), 3.52 (dd, J = 8.5 Hz, 1H), 3.69-3.74 (m, 1H), 7.12-7.18 (m, 
3H), 7.25 (t, J = 7.6 Hz, 2H), 7.32 (d, J = 8.2 Hz, 2H), 7.71 (d, J = 8.8 Hz, 1H), 7.82 (dd, J = 
1.9, 8.8 Hz, 1H), 7.94 (d, J = 9.8 Hz, 1H), 8.51 (d, J = 1.6 Hz, 1H), 10.19 (s, OH), 12.20 (s, 
OH). 13C-NMR (125 MHz, (CD3)2SO): δ (ppm) = 37.3, 40.3, 43.6, 108.6, 119.4, 123.7, 126.1, 
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126.2, 126.4, 127.4, 128.0, 129.9, 131.1, 131.4, 136.7, 143.9, 157.7, 172.8, 197.7; LC/MS 
(+ESI): m/z = 335.2 [MH+]; Rt = 3.99 (≥ 96 %). 
 
 
2-(1,3-Di(naphthalen-2-yl)-3-oxopropyl)malonic acid, (4S):  
 
(E)-1,3-Di(naphthalen-2-yl)prop-2-en-1-one, (1S):  
Synthesized according to Method A using 2-naphthaldehyde (10.9 g, 64.03 mmol) and 1-
(naphthalen-2-yl)ethanone (11.9 g, 64.03 mmol); yellow solid; yield: 18.8 g (95 %); 
1H-NMR (500 MHz, CDCl3): δ (ppm) = 7.52-7.55 (m, 2H),  7.56-7.65 (m, 2H), 7.82 (d, J = 
15.8 Hz, 1H), 7.86-7.92 (m, 5H), 7.97 (d, J = 8.8 Hz, 1H), 8.02-8.07(m, 2H), 8.08 (s, 1H), 
8.14 (dd, J = 1.6, 8.5 Hz, 1H), 8.59 (s, 1H). 13C-NMR (125 MHz, CDCl3): δ (ppm) = 117.7, 
122.2, 123.7, 124.5, 126.8, 127.4, 127.81, 127.84, 128.4, 128.6, 128.7, 128.8, 129.5, 129.9, 
130.7, 132.5, 132.6, 133.4, 134.4, 35.5, 135.7, 144.9, 190.2. 
 
Diethyl 2-(1,3-di(naphthalen-2-yl)-3-oxopropyl)malonate, (2S):  
Synthesized according to Method H using 1S (2.0 g, 6.48 mmol) and diethyl malonate (0.98 
mL, 6.48 mmol) and magnesium oxide (0.65 g) ; white solid; yield: 1.32 g (43 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 0.95 (t, J = 7.1 Hz, 3H), 1.25 (t, J = 7.1 Hz, 3H), 
3.72 (dd, J = 9.1, 16.7 Hz, 1H), 3.77 (dd, J = 4.9, 16.7 Hz, 1H), 3.90-3.96 (m, 2H), 3.98 (d, J 
= 9.7 Hz, 1H), 4.18-4.27 (m, 2H), 4.41-4.46 (m, 1H), 7.39-7.44 (m, 2H), 7.47 (dd, J = 1.5, 
8.5 Hz, 1H), 7.53 (t, J = 7.9 Hz, 1H), 7.58 (t, J = 8.2 Hz, 1H), 7.73-7.77 (m, 4H), 7.83-7.85 
(m, 2H), 7.93-7.95 (m, 2H), 8.47 (s, 1H).  13C-NMR (125 MHz, CDCl3): δ (ppm) = 13.5, 13.8, 
40.8, 42.4, 57.4, 61.1, 61.4, 123.6, 125.4, 125.7, 126.1, 126.4, 126.9, 127.3, 127.5, 127.6, 
127.9, 128.1, 128.2, 129.3, 129.6, 132.2, 132.3, 133.0, 133.9, 135.3, 137.8, 167.5, 168.2, 
197.1. 
 
2-(1,3-Di(naphthalen-2-yl)-3-oxopropyl)malonic acid, (4S):  
Synthesized according to Method L using 2S (1.0 g, 2.13 mmol) and 10M NaOHaq (5.0 mL, 
6.39 mL); white solid; yield: 0.6 g (68 %); mp 174-175 °C;  
1H-NMR (500 MHz, (CD3)2SO): δ (ppm) = 3.61 (dd, J = 3.8, 16.85 Hz, 1H),  3.85 (dd, J = 
9.8, 16.85 Hz, 1H), 3.92  (d, J = 10.4 Hz, 1H), 4.17 (dt, J = 3.8, 10.1 Hz, 1H), 7.39-7.45 (m, 
2H), 7.53 (dd, J = 1.9, 8.5 Hz, 1H), 7.59 (dt, J = 1.3, 8.2, 1H), 7.64 (dt, J = 1.3, 8.2 Hz, 1H), 
7.76 (d, J = 8,5 Hz, 1H), 7.78-7.80 (m, 3H), 7.86 (dd, J = 1.6, 8.8 Hz, 1H), 7.93-7.95 (m, 
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2H), 8.06 (d, J = 8.2 Hz, 1H), 8.58 (s, 1H), 12.78 (s, 2OH).13C-NMR (125 MHz, (CD3)2SO): 
δ (ppm) = 40.7, 42.4, 57.5, 123.3, 125.4, 125.7, 126.7, 126.8, 126.9, 127.1, 127.2, 127.4, 
127.5, 128.1, 128.5, 129.4, 129.7, 131.8, 132.0, 133.7, 134.9, 138.8, 169.0, 169.7, 197.8; 
LC/MS (+ESI): m/z = 413.2 [MH+]; Rt = 4.67 (≥ 98 %). 
 
3,5-di(naphthalen-2-yl)-5-oxopentanoic acid, (6S):  
Synthesized according to Method N 4S (0.25 g, 0.61 mmol); pale beige solid; yield: 0.17 g 
(76 %); mp 151-153 °C;  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 2.86 (dd, J = 7.9, 16.1 Hz, 1H), 2.99 (dd, J = 6.9, 
16.1 Hz, 1H), 3.53-3.63 (m, 2H), 4.08-4.13 (m, 1H), 7.39-7.46 (m, 3H), 7.53 (dt, J = 0.9, 8.2 
Hz, 1H), 7.59 (dt, J = 1.3, 8.4 Hz, 1H), 7.74 (ds, J = 1.3 Hz, 1H), 7.76-7.79 (m, 3H), 7.84 (d, 
J = 8.8 Hz, 2H), 7.91 (d, J = 8.2 Hz, 1H), 7.96 (dd, J = 1.9, 8.8 Hz, 1H), 8.43 (s, 1H). 13C-
NMR (125 MHz, CDCl3): δ (ppm) = 37.4, 40.2, 44.6, 123.8, 125.6, 125.7, 125.9, 126.1, 
126.7, 126.8, 127.6, 127.73, 127.75, 128.45, 128.48, 129.6, 129.8, 132.4, 132.5, 133.5, 134.1, 
135.6, 140.5, 176.8, 198.0; LC/MS (+ESI): m/z = 369.2 [MH+]; Rt = 5.20 (≥ 95 %). 
 
 
2-(3-(1H-Indol-3-yl)-3-oxo-1-phenylpropyl)malonic acid, (4T): 
 
(E)-1-(1H-Indol-3-yl)-3-phenylprop-2-en-1-one, (1T):  
Synthesized according to Method A using benzaldehyde (1.59 mL, 15.7 mmol) and 3-
acetylindole (2.5 g, 15.7 mmol); gold-colored solid; yield: 2.40 g (62 %);  
1H-NMR (500 MHz, (CD3)2SO): δ (ppm) = 7.21-7.27 (m, 2H), 7.40-7.44 (m, 3H), 7.48 (d, J 
= 7.6, 1H), 7.64 (d, J = 15.8, 1H), 7.83-7.86 (m, 3H), 7.83-7.84 (m, 1H), 8.74 (s, 1H), 12.1 (s, 
NH). 13C-NMR (125 MHz, (CD3)2SO): δ (ppm) = 112.1, 117.7, 121.6, 121.7, 121.8, 123.1, 
124.6, 125.9, 128.3, 128.8, 129.7, 135.2, 136.8, 139.5, 183.5. 
 
Dimethyl 2-(3-(1H-indol-3-yl)-3-oxo-1-phenylpropyl)malonate, (2T):  
Synthesized according to Method J using 1T (0.70 g, 2.83 mmol), diethyl malonate (0.48 mL, 
2.83 mmol) and sodium hydride (cat.); pale yellow solid; yield: 0.60 g (56 %);  
1H-NMR (500 MHz, (CD3)2SO): δ (ppm) = 3.10 (dd, J = 3.9, 15.7 Hz, 1H),  3.37 (s, 3H), 
3.30 (dd, J = 10.1, 15.7 Hz, 1H),  3.67 (s, 3H), 3.96 (d, J = 10.4 Hz, 1H), 3.99 (dt, J = 3.7, 
10.1 Hz, 1H), 7.10-7.13 (m, 2H), 7.18 (dd, J = 1.2, 6.9 Hz, 1H), 7.20 (t, J = 7.6 Hz, 2H), 7.31 
(d, J = 8.5 Hz, 2H), 7.42 (d, J = 7.9 Hz, 1H), 8.07 (d, J = 7.9 Hz, 1H), 8.25 (d, J = 3.1 Hz, 
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1H), 11.9 (s, NH). 13C-NMR (125 MHz, (CD3)2SO): δ (ppm) = 46.3, 47.7, 57.2, 57.7, 62.2, 
117.2, 121.8, 126.5, 126.9, 128.0, 130.4, 131.9, 133.2, 133.5, 139.0, 141.7, 145.9, 173.0, 
173.5, 197.5. 
 
2-(3-(1H-Indol-3-yl)-3-oxo-1-phenylpropyl)malonic acid, (4T):  
Synthesized according to Method L using 2T (0.44 g, 1.16 mmol) and NaOHaq (2 mL, 5.80 
mmol); pale yellow solid; yield: 0.29 g (71 %); mp 169-171 °C;  
1H-NMR (500 MHz, (CD3)2SO): δ (ppm) = 3.05 (dd, J = 3.5, 15.8 Hz, 1H),  3.47 (dd, J = 
10.7 Hz, 1H), 3.71 (d, J = 10.7 Hz, 1H), 3.94 (dt, J = 3.5, 10.7 Hz, 1H), 7.07 (t, J = 7.6 Hz, 
1H), 7.08-7.12 (m, 4H), 7.30 (d, J = 7.7 Hz, 2H), 7.39 (d, J = 8.2 Hz, 1H), 8.06 (d, J = 7.9 
Hz, 1H), 8.23 (d, J = 2.8 Hz, 1H), 11.84 (s, NH), 12.51 (s, OH), 12.88 (s, OH). 13C-NMR 
(125 MHz, (CD3)2SO): δ (ppm) = 46.3, 47.7, 57.2, 57.7, 62.2, 117.2, 121.8, 126.5, 126.9, 
128.0, 130.4, 131.9, 133.2, 133.5, 139.0, 141.7, 145.9, 173.0, 173.5, 197.5; LC/MS (+ESI): 
m/z = 352.2 [MH+]; Rt = 3.23 (≥ 95 %). 
 
 
2-(3-Oxo-3-(phenanthren-2-yl)-1-phenylpropyl)malonic acid, (4U): 
 
(E)-1-(Phenanthren-2-yl)-3-phenylprop-2-en-1-one, (1U):  
Synthesized according to Method A using benzaldehyde (0.46 mL, 4.54 mmol) and 2-
acetylphenanthrene (1.0 g, 4.54 mmol); pale yellow solid; yield: 1.20 g (86 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 7.41-7.48 (m, 3H), 7.66-7.74 (m, 5H), 7.84 (q, J = 
8.8 Hz, 2H), 7.89-7.93 (m, 2H), 8.29 (dd, J = 1.89, 8.5 Hz, 1H), 8.57 (d, J = 1.89 Hz, 1H), 
8.73 (d, J = 7.9 Hz, 1H), 8.78 (d, J = 8.8 Hz, 1H). 13C-NMR (125 MHz, CDCl3): δ (ppm) = 
122.1, 123.2, 123.3, 125.6, 127.0, 127.3, 127.7, 127.9, 128.5, 128.7, 129.0, 129.7, 130.6, 
131.5, 133.0, 133.3, 135.0, 136.0, 144.9, 190.1. 
 
Diethyl 2-(3-oxo-3-(phenanthren-2-yl)-1-phenylpropyl)malonate, (2U):  
Synthesized according to Method H using 1U (1.0g, 3.24 mmol) and diethyl malonate (0.49 
mL, 3.24 mmol) and magnesium oxide (0.324 g) ; white solid; yield: 1.20 g (79 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 1.02 (t, J = 7.2 Hz, 3H), 1.27 (t, J = 7.2 Hz, 3H),  
3.62 (dd, J = 9.1, 9.1 Hz, 1H), 3.71 (dd, J = 4.4, 4.4 Hz, 1H), 3.89 (d, J = 9.4 Hz, 1H), 3.97 
(q, J = 7.2 Hz, 2H), 4.18-4.30 (m, 3H), 7.17 (tt, J = 1.4, 7.6 Hz, 1H), 7.25 (t, J = 7.9 Hz, 2H), 
7.31 (dd, J = 1.2, 8.2 Hz, 2H), 7.64-7.70 (m, 2H), 7.78 (q, J = 8.8 Hz, 2H), 7.91 (dd, J = 1.9, 
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7.2 Hz, 1H), 8.14 (dd, J = 1.9, 8.8 Hz, 1H), 8.45 (d, J = 1.9 Hz, 1H), 8.68-8.71 (m, 2H). 13C-
NMR (125 MHz, CDCl3): δ (ppm) = 13.8, 14.0, 41.0, 42.8, 57.6, 61.3, 61.7, 123.1, 123.3, 
125.1, 127.0, 127.1, 127.4, 127.7, 127.8, 128.3, 128.4, 128.7, 129.5, 129.7, 131.4, 133.0, 
133.4, 134.6, 140.5, 167.8, 168.4, 197.4. 
 
2-(3-Oxo-3-(phenanthren-2-yl)-1-phenylpropyl)malonic acid, (4U):  
Synthesized according to Method L using 2U (0.6 g, 1.28 mmol) and 10M NaOHaq (5 mL); 
white solid; yield: 0.45 g (85 %); mp 170-171 °C;  
1H-NMR (500 MHz, (CD3)2SO): δ (ppm) = 3.49 (dd, J = 3.5, 10.9 Hz, 1H), 3.77-3.82 (m, 
2H), 3.98 (dt, J = 3.5, 10.9 Hz, 1H), 7.11 (t, J = 7.2 Hz, 1H), 7.21 (t, J = 7.6 Hz, 2H), 7.33 (d, 
J = 7.2 Hz, 2H), 7.70-7.76 (m, 2H), 7.95 (q, J = 8.8 Hz, 2H), 8.02-8.39 (m, 1H), 8.07 (dd, J = 
1.9, 8.8 Hz, 1H), 8.59 (d, J = 1.9 Hz, 1H), 8.86-8.90 (m, 2H). 13C-NMR (125 MHz, 
(CD3)2SO): δ (ppm) = 40.7, 42.6, 57.5, 123.4, 123.6, 124.8, 126.5, 127.2, 127.7, 127.8, 127.9, 
128.0, 128.5, 128.6, 129.6, 131.0, 132.1, 132.5, 132.6, 134.5, 141.3, 169.0, 169.8, 197.7; 
LC/MS (+ESI): m/z = 413.2 [MH+]; Rt = 4.78 (≥ 98 %). 
 
5-Oxo-5-(phenanthren-2-yl)-3-phenylpentanoic, (6U):  
Synthesized according to Method M using 4U (0.15 g, 0.36 mmol); white solid; yield: 0.105 g 
(79 %); mp 199-201 °C;  
1H-NMR (500 MHz, (CD3)2SO): δ (ppm) = 2.62 (dd, J = 8.5 Hz, 1H), 2.76 (dd, J = 6.6 Hz, 
1H), 3.58 (dd, J = 6.6 Hz, 1H), 3.64 (dd, J = 7.6 Hz, 1H), 3.73-3.79 (m, 1H), 7.15 (t, J = 7.6 
Hz, 1H), 7.26 (t, J = 7.9 Hz, 2H), 7.35 (d, J = 8.2 Hz, 2H), 7.71-7.76 (m, 2H), 7.96 (q, J = 
8.8 Hz, 2H), 8.01-8.04 (m, 1H), 8.13 (dd, J = 1.9, 8.8 Hz, 1H), 8.66 (ds, J = 1.9 Hz, 1H), 8.87 
(d, J = 9.1 Hz, 1H), 8.90 (d, J = 8.8 Hz, 1H), 12.15 (s, OH). 13C-NMR (125 MHz, (CD3)2SO): 
δ (ppm) = 37.2, 40.4, 44.1, 116.2, 123.3, 123.5, 124.8, 126.1, 127.1, 127.2, 127.5, 127.6, 
127.9, 128.1, 128.5, 129.0, 129.4, 131.0, 132.4, 132.6, 134.5, 143.9, 198.2; LC/MS (+ESI): 
m/z = 369.2 [MH+]; Rt = 5.35 (≥ 95 %). 
 
 
2-(3-(9H-Carbazol-2-yl)-3-oxo-1-phenylpropyl)malonic acid, (4V):  
 
(E)-1-(9H-Carbazol-2-yl)-3-phenylprop-2-en-1-one, (1V):  
Synthesized according to Method A using benzaldehyde (0.51 g, 4.78 mmol) and 2-
acetylcarbazole (1.0 g, 4.78 mmol); yellow solid; yield: 0.75 g (53 %);  
                                                                                                                    Experimental Section 
 179 
1H-NMR (500 MHz, CDCl3): δ (ppm) = 7.22 (t, J = 7.9 Hz, 1H), 7.45-7.51 (m, 4H), 7.58 (d, 
J = 8.2 Hz, 1H), 7.78 (d, J = 15.6 Hz, 1H), 7.91-7.93 (m, 2H), 8.01 (dd, J = 1.6, 8.2 Hz, 1H), 
8.06 (d, J = 15.6 Hz, 1H),8.23 (d, J = 7.9 Hz, 1H), 8.27-8.30 (m, 2H), 11.55 (s, NH). 13C-
NMR (125 MHz, CDCl3): δ (ppm) = 111.3, 111.6, 119.1, 120.11, 120.13, 121.1, 121.5, 122.6, 
126.2, 127.0, 128.7, 128.9, 130.4, 134.7, 134.8, 139.2, 141.3, 143.3, 189.1. 
 
Dimethyl 2-(3-(9H-carbazol-2-yl)-3-oxo-1-phenylpropyl)malonate, (2V):  
Synthesized according to Method H using 1V (0.5 g, 1.68 mmol) and diethyl malonate (0.28 
mL, 1.85 mmol) and magnesium oxide (0.17 g) ; white solid; yield: 0.43 g (60 %);  
1H-NMR (500 MHz, (CD3)2SO): δ (ppm) = 3.37 (s, 3H), 3.46 (dd, J = 3.6, 17.1 Hz, 1H), 3.69 
(s, 3H), 3.77 (dd, J = 9.1, 9.1 Hz, 1H), 4.00-4.08 (m, 2H), 7.13 (t, J = 7.3 Hz, 1H), 7.19-7.24 
(m, 3H), 7.32 (d, J = 7.3 Hz, 2H), 7.46 (d, J = 8.2 Hz , 1H), 7.54 (d, J = 8.2 Hz, 1H), 7.72 
(dd,  J = 1.5, 8.2 Hz, 1H), 8.90 (s, 1H), 8.19 (t, J = 7.9 Hz, 2H), 11.5 (s, NH). 13C-NMR (125 
MHz, (CD3)2SO): δ (ppm) = 41.1, 42.6, 52.4, 52.6, 57.4, 110.9, 111.0, 119.5, 119.9, 120.0, 
121.1, 122.4, 127.2, 127.3, 128.1, 128.5, 134.2, 139.0, 140.4, 141.0, 168.2, 168.8, 197.6. 
 
2-(3-(9H-Carbazol-2-yl)-3-oxo-1-phenylpropyl)malonic acid, (4V):  
Synthesized according to Method L using 2V (0.30 g, 0.78 mmol) and 10M NaOHaq (0.9 mL, 
2.31 mL); white solid; yield: 0.15 g (48 %); mp 181-182 °C;  
1H-NMR (500 MHz, (CD3)2SO): δ (ppm) = 3.40 (dd, J = 3.3, 16.75 Hz, 1H),  3.74 (dd, J = 
10.3, 16.75 Hz, 1H), 3.81  (d, J = 10.3 Hz, 1H), 3.96 (dt, J = 3.0, 10.7 Hz, 1H), 7.11 (t, J = 
7.3 Hz, 1H), 7.19-7.22 (m, 3H), 7.32 (d, J = 7.3 Hz, 2H), 7.46 (d, J = 7.9 Hz, 1H), 7.53 (d, J 
= 7.9 Hz, 1H), 7.71 (dd, J = 1.2, 7.9 Hz, 1H), 7.99 (ds, J = 0.6 Hz, 1H), 8.17-8.20 (m, 2H), 
11.5 (s, NH), 12.71 (s, 2OH). 13C-NMR (125 MHz, (CD3)2SO): δ (ppm) = 40.6, 42.5, 57.4, 
110.8, 111.2, 118.2, 119.0, 119.9, 121.0, 121.4, 126.0, 126.3, 126.9, 127.8, 128.4, 133.7, 
139.0, 141.2, 141.3, 169.0, 169.7, 197.6; LC/MS (+ESI): m/z = 402.2 [MH+]; Rt = 4.30 (≥ 96 
%). 
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6.1.3.3. Compounds described in Chapter  3.3. 
5-(4-Chlorophenyl)-3-(naphthalen-2-yl)pent-2-enoic acids, (26E & 26Z):  
 
(E)-1-(4-Chlorophenyl)-3-(naphthalen-2-yl)prop-2-en-1-one, (26c): 
Synthesized according to Method A using 4-chlorobenzaldehyde (5.0 g, 35.57 mmol) and 2-
acetylnaphthalene (6.05 g, 35.57 mmol); pale yellow solid; yield: 9.32 g (90 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 7.41 (d, J = 8.2 Hz, 2H), 7.56-7.63 (m, 4H), 7.67 (d, 
J = 15.8 Hz, 1H), 7.82 (d, J = 15.8 Hz, 1H), 7.90 (d, J = 8.2 Hz, 1H), 7.94 (d, J = 9.8 Hz, 
1H), 8.00 (d, J = 8.2 Hz, 1H), 8.10 (d, J = 8.5 Hz, 1H), 8.53 (s, 1H). 13C-NMR (125 MHz, 
CDCl3): δ (ppm) = 122.5, 124.4, 126.8, 127.8, 128.5, 128.6, 129.2, 129.5, 129.6, 129.9, 132.5, 
133.5, 135.4, 135.5, 136.4, 143.2, 189.9. 
 
1-(4-Chlorophenyl)-3-(naphthalen-2-yl)propan-1-one, (26b): 
Synthesized according to Method B using 26c (1.0 g, 3.41 mmol), HEH (1.30 g, 5.12 mmol) 
and silica gel (6.82 g); colourless oil; yield: 0.87 g (87 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 3.11 (t, J = 7.9 Hz, 2H), 3.42 (t, J = 7.9 Hz, 2H), 
7.22 (d, J = 8.5 Hz, 2H), 7.27 (d, J = 8.5 Hz, 2H), 7.55 (t, J = 7.5 Hz, 1H), 7.59 (t, J = 7.5 
Hz, 1H), 7.89 (t, J = 8.8 Hz, 2H), 7.94 (d, J = 8.2 Hz, 1H), 8.01 (dd, J = 1.8, 8.5 Hz, 1H), 
8.53 (s, 1H). 13C-NMR (125 MHz, CDCl3): δ (ppm) = 29.5, 40.2, 117.4, 123.8, 127.8, 128.4, 
128.5, 128.6, 129.5, 129.6, 129.8, 131.9, 132.5, 134.1, 135.6, 139.8, 198.7. 
 
Ethyl 5-(4-chlorophenyl)-3-(naphthalen-2-yl)pent-2-enoate, (26a): 
Synthesized according to Method C using 26b (0.75 g, 2.54 mmol), NaH (0.31 g, 7.63 mmol) 
and triethyl phosphonoacetate (1.58 mL, 7.87 mmol); 
26Ea: colourless oil; yield: 0.55 g (59 %); 1H-NMR (500 MHz, CDCl3): δ (ppm) = 1.33 (t, J 
= 7.2 Hz, 3H), 2.74-2.77 (m, 2H), 3.48-3.52 (m, 2H), 4.22 (q, J = 7.2 Hz, 2H), 6.20 (s, 1H), 
7.15 (d, J =  8.5 Hz, 2H), 7.22 (d, J =  8.2 Hz, 2H), 7.51-7.54 (m, 2H), 7.56 (dd, J =  1.9, 8.5 
Hz, 1H), 7.84-7.88 (m, 3H), 7.90 (d, J = 1.6 Hz, 1H). 13C-NMR (125 MHz, CDCl3): δ (ppm) 
= 14.3, 32.8, 34.5, 60.0, 118.4, 124.3, 126.2, 126.6, 126.8, 127.6, 128.3, 128.4, 128.5, 129.9, 
131.7, 133.2, 133.5, 138.1, 139.9, 158.9, 166.3. 
26Za: colourless oil; yield: 0.38 g (41 %); 1H-NMR (500 MHz, CDCl3): δ (ppm) = 1.00 (t, J 
= 7.2 Hz, 3H), 2.68-2.71 (m, 2H), 2.82-2.86 (m, 2H), 3.97 (q, J = 7.2 Hz, 2H), 5.97 (s, 1H), 
7.05 (d, J =  8.5 Hz, 2H), 7.23 (d, J =  8.5 Hz, 2H), 7.30 (dd, J =  1.9, 8.5 Hz, 1H), 7.47-7.51 
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(m, 2H), 7.64 (d, J =  1.6 Hz, 1H), 7.82-7.86 (m, 3H). 13C-NMR (125 MHz, CDCl3): δ (ppm) 
= 13.9, 32.2, 41.9, 59.9, 118.4, 125.9, 126.0, 126.1, 126.2, 127.5, 127.7, 128.1, 128.5, 129.7, 
131.9, 132.9, 133.0, 137.1, 139.2, 157.7, 165.8. 
 
(E)-5-(4-Chlorophenyl)-3-(naphthalen-2-yl)pent-2-enoic acid, (26E): 
Synthesized according to Method D using 26Ea (0.4 g, 1.09 mmol) and NaOHaq (1.10 mL, 
3.29 mmol); white solid; yield: 0.20 g (54 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 2.77-2.80 (m, 2H), 3.51-3.54 (m, 2H), 6.27 (s, 1H), 
7.15 (d, J =  8.5 Hz, 2H), 7.23 (d, J =  8.5 Hz, 2H), 7.53-7.56 (m, 2H), 7.58 (dd, J =  1.9, 8.5 
Hz, 1H), 7.86-7.91 (m, 3H), 7.94 (d, J =  1.6 Hz, 1H). 13C-NMR (125 MHz, CDCl3): δ (ppm) 
= 33.1, 34.6, 117.1, 117.2, 117.5, 124.2, 126.5, 126.7, 127.0, 127.6, 128.4, 128.5, 129.8, 
131.8, 133.1, 133.7, 137.9, 139.7, 162.0. 
(Z)-5-(4-Chlorophenyl)-3-(naphthalen-2-yl)pent-2-enoic acid, (26Z): 
Synthesized according to Method D using 26Za (0.3 g, 0.82 mmol) and NaOHaq (1.40 mL, 
4.11 mmol); white solid; yield: 0.22 g (80 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 2.65-2.68 (m, 2H), 2.82-2.85 (m, 2H), 5.92 (s, 1H), 
7.02 (d, J =  8.2 Hz, 2H), 7.22 (d, J =  8.2 Hz, 2H), 7.42-7.45 (m, 2H), 7.52 (dd, J =  1.9, 8.5 
Hz, 1H), 7.62 (s, 1H), 7.76-7.78 (m, 3H). 13C-NMR (125 MHz, CDCl3): δ (ppm) = 33.1, 34.6, 
117.1, 117.2, 124.3, 125.9, 126.1, 126.3, 126.4, 127.7, 128.1, 128.6, 129.6, 129.8, 132.0, 
133.0, 136.4, 138.9, 160.5. 
 
 
5-(4-Chlorophenyl)-3-(naphthalen-1-yl)pent-2-enoic acids, (27E & 27Z):  
 
(E)-3-(4-Chlorophenyl)-1-(naphthalen-1-yl)prop-2-en-1-one, (27c): 
Synthesized according to Method A using 4-chlorobenzaldehyde (5.0 g, 35.57 mmol) and 1-
acetylnaphthalene (5.40 mL, 35.57 mmol); yellow solid; yield: 7.10 g (68 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 7.35 (d, J = 16.1 Hz, 1H), 7.44 (d, J = 7.9 Hz, 2H), 
7.57 (d, J = 7.9 Hz, 2H), 7.59-7.67 (m, 4H), 7.85 (d, J = 7.2 Hz, 1H), 7.99 (d, J = 7.9 Hz, 
1H), 8.08 (d, J = 8.2 Hz, 1H), 8.41 (d, J = 8.2 Hz, 1H). 13C-NMR (125 MHz, CDCl3): 
δ (ppm) = 124.4, 125.6, 126.5, 127.2, 127.4, 127.7, 128.4, 129.2, 129.6, 130.4, 131.8, 133.1, 
133.8, 136.6, 136.8, 144.2, 195.2. 
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3-(4-Chlorophenyl)-1-(naphthalen-1-yl)propan-1-one, (27b): 
Synthesized according to Method B using 27c (1.0 g, 3.41 mmol), HEH (1.30 g, 5.12 mmol) 
and silica gel (6.82 g); colourless oil; yield: 0.57 g (57 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 3.07 (t, J = 7.2 Hz, 2H), 3.32 (t, J = 7.2 Hz, 2H), 
7.15 (d, J = 7.9 Hz, 2H), 7.22 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 8.5 Hz, 1H), 7.46-7.53 (m, 
2H), 7.77 (dd, J = 1.3, 7.2 Hz, 1H), 7.84 (d, J = 7.9 Hz, 1H), 7.94 (d, J = 8.2 Hz, 1H), 8.50 
(dd, J = 8.8 Hz, 1H). 
 
Ethyl 5-(4-chlorophenyl)-3-(naphthalen-1-yl)pent-2-enoate, (27a): 
Synthesized according to Method C using 27b (0.58 g, 1.97 mmol), NaH (0.29 g, 5.91 mmol) 
and triethyl phosphonoacetate (1.20 mL, 6.11 mmol); 
27Ea: colourless oil; yield: 0.30 g (42 %); 1H-NMR (500 MHz, CDCl3): δ (ppm) = 0.78 (t, J 
= 7.2 Hz, 3H), 2.69-2.85 (m, 4H), 3.81 (q, J = 7.2 Hz, 2H), 6.21 (s, 1H), 7.05 (d, J = 8.5 Hz, 
2H), 7.18-7.23 (m, 3H), 7.39-7.49 (m, 3H), 7.72 (d, J =  8.2 Hz, 1H), 7.81 (d, J = 8.2 Hz, 1H), 
7.86 (d, J = 8.8 Hz, 1H). 13C-NMR (125 MHz, CDCl3): δ (ppm) = 13.5, 33.1, 42.0, 59.7, 
120.3, 123.7, 124.8, 125.0, 125.7, 126.0, 127.6, 128.2, 128.5, 129.6, 130.5, 131.8, 133.4, 
138.2, 139.2, 156.8, 165.3. 
27Za: colourless oil; yield: 0.32 g (44 %); 1H-NMR (500 MHz, CDCl3): δ (ppm) = 1.36 (t, J 
= 7.2 Hz, 3H), 2.68-2.71 (m, 2H), 3.40-3.42 (m, 2H), 4.27 (q, J = 7.2 Hz, 2H), 5.97 (s, 1H), 
7.07 (d, J =  8.5 Hz, 2H), 7.17 (d, J =  8.5 Hz, 2H), 7.23-7.49 (m, 1H), 7.37-7.53 (m, 3H), 
7.80-7.90 (m, 3H). 13C-NMR (125 MHz, CDCl3): δ (ppm) = 14.3, 33.9, 36.0, 60.1, 121.2, 
124.8, 125.2, 125.3, 128.3, 128.4, 128.5, 129.8, 130.6, 131.6, 133.7, 134.5, 140.2, 159.9, 
166.3. 
 
(E)-5-(4-Chlorophenyl)-3-(naphthalen-1-yl)pent-2-enoic acid, (27E): 
Synthesized according to Method D using (E)-ethyl 5-(4-chlorophenyl)-3-(naphthalen-1-
yl)pent-2-enoate (0.3 g, 1.09 mmol) and NaOHaq (0.82 mL, 2.47 mmol); white solid; yield: 
0.15 g (54 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 2.81-2.84 (m, 2H), 3.58-3.60 (m, 2H), 6.15 (s, 1H), 
7.02 (d, J =  8.5 Hz, 2H), 7.20 (d, J = 8.5 Hz, 2H), 7.42-7.49 (m, 3H), 7.66 (d, J = 8.5 Hz, 
1H), 7.80 (d, J =  8.2 Hz, 1H), 7.85 (d, J =  7.6 Hz, 2H). 13C-NMR (125 MHz, CDCl3): 
δ (ppm) = 33.1, 42.2, 117.3, 119.2, 123.9, 124.6, 125.0, 125.9, 126.2, 126.3, 127.7, 127.9, 
129.6, 131.9, 133.4, 137.4, 138.9, 159.7, 168.4. 
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(Z)-5-(4-Chlorophenyl)-3-(naphthalen-1-yl)pent-2-enoic acid, (27Z): 
Synthesized according to Method D using (Z)-ethyl 5-(4-chlorophenyl)-3-(naphthalen-1-
yl)pent-2-enoate (0.32 g, 0.87 mmol) and NaOHaq (0.90 mL, 2.61 mmol); white solid; yield: 
0.20 g (68 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 2.72-2.74 (m, 2H), 3.42-3.45 (m, 2H), 6.05 (s, 1H), 
7.06 (d, J =  8.5 Hz, 2H), 7.17 (d, J = 8.5 Hz, 2H), 7.24-7.31 (m, 2H), 7.51-7.64 (m, 3H), 
7.83-7.93 (m, 2H). 13C-NMR (125 MHz, CDCl3): δ (ppm) = 34.0, 36.3, 120.2, 124.7, 125.1, 
125.2, 126.1, 126.5, 128.4, 128.5, 128.6, 128.8, 129.8, 133.7, 134.8, 137.0, 139.6, 163.2, 
170.2. 
 
 
5-(4-Chlorophenyl)-3-(4-methoxyphenyl)pent-2-enoic acids, (28Z & 28Z):  
 
(E)-3-(4-Chlorophenyl)-1-(4-methoxyphenyl)prop-2-en-1-one, (28c): 
Synthesized according to Method A using 4-chlorobenzaldehyde (5.0 g, 35.57 mmol) and 4’-
methoxyacetophenone (5.34 mL, 35.57 mmol); yellow solid; yield: 8.46 g (87 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 3.87 (s, 3H), 6.96 (d, J = 8.5 Hz, 2H), 7.36 (d, J = 
8.5 Hz, 2H), 7.50 (d, J = 15.4 Hz, 1H), 7.54 (d, J = 8.2 Hz, 2H), 7.72 (d, J = 15.8 Hz, 1H), 
8.01 (d, J = 8.8 Hz, 2H). 13C-NMR (125 MHz, CDCl3): δ (ppm) = 55.5, 113.9, 122.3, 129.2, 
129.5, 130.8, 130.9, 133.6, 136.2, 142.4, 163.5, 188.4. 
 
3-(4-Chlorophenyl)-1-(4-methoxyphenyl)propan-1-one, (28b): 
Synthesized according to Method B using 27c (1.0 g, 3.67 mmol), HEH (1.39 g, 5.50 mmol) 
and silica gel (7.34 g); colourless oil; yield: 0.84 g (84 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 3.04 (t, J = 7.2 Hz, 2H), 3.22 (t, J = 7.2 Hz, 2H), 
3.86 (s, 3H), 6.92 (d, J = 8.8 Hz, 2H), 7.17 (d, J = 8.8 Hz, 2H), 7.25 (d, J = 8.2 Hz, 2H), 7.93 
(d, J = 8.8 Hz, 2H). 13C-NMR (125 MHz, CDCl3): δ (ppm) = 29.6, 39.8, 55.5, 113.8, 128.6, 
129.8, 129.9, 130.3, 131.8, 139.9, 163.5, 197.4. 
 
Ethyl 5-(4-chlorophenyl)-3-(4-methoxyphenyl)pent-2-enoate, (28a): 
Synthesized according to Method C using 3-(4-chlorophenyl)-1-(4-methoxyphenyl)propan-1-
one (0.80 g, 2.91 mmol), NaH (0.35 g, 8.73 mmol) and triethyl phosphonoacetate (1.80 mL, 
9.0 mmol); 
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27Ea: colourless oil; yield: 0.48 g (48 %); 1H-NMR (500 MHz, CDCl3): δ (ppm) = 1.30 (t, J 
= 7.2 Hz, 3H), 2.69-2.72 (m, 2H), 3.34-3.57 (m, 2H), 3.85 (s, 3H), 4.19 (q, J = 7.2 Hz, 2H), 
6.04 (s, 1H), 6.91 (d, J = 9.1 Hz, 2H), 7.15 (d, J = 8.5 Hz, 2H), 7.22 (d, J = 8.5 Hz, 2H), 7.41 
(d, J = 9.1 Hz, 2H). 13C-NMR (125 MHz, CDCl3): δ (ppm) = 14.3, 32.6, 34.6, 55.3, 59.8, 
114.0, 116.2, 128.0, 128.3, 129.9, 131.6, 132.9, 140.0, 158.4, 160.5, 166.5. 
27Za: colourless oil; yield: 0.49 g (49 %); 1H-NMR (500 MHz, CDCl3): δ (ppm) = 1.15 (t, J 
= 7.2 Hz, 3H), 2.63-2.66 (m, 2H), 2.70-2.74 (m, 2H), 3.83 (s, 3H), 4.02 (q, J = 7.2 Hz, 2H), 
5.82 (s, 1H), 6.89 (d, J = 8.8 Hz, 2H), 7.04 (d, J = 8.5 Hz, 2H), 7.14 (d, J = 8.5 Hz, 2H), 7.23 
(d, J = 9.1 Hz, 2H).13C-NMR (125 MHz, CDCl3): δ (ppm) = 14.0. 33.3, 41.8, 55.2, 59.8, 
113.4, 117.4, 128.5, 128.8, 129.6, 131.3, 131.8, 139.3, 157.5, 159.4, 166.0. 
 
(E)-5-(4-Chlorophenyl)-3-(4-methoxyphenyl)pent-2-enoic acid, (28E): 
Synthesized according to Method D using 28Ea (0.35 g, 1.01 mmol) and NaOHaq (1.70 mL, 
5.07 mmol); pale beige solid; yield: 0.20 g (62 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 2.72-2.75 (m, 2H), 3.36-3.39 (m, 2H), 3.86 (s, 3H), 
6.10 (s, 1H), 6.94 (d, J = 8.8 Hz, 2H), 7.14 (d, J = 8.2 Hz, 2H), 7.23 (d, J = 8.5 Hz, 2H), 7.45 
(d, J = 9.1 Hz, 2H). 13C-NMR (125 MHz, CDCl3): δ (ppm) = 32.9, 34.7, 55.4, 114.1, 114.5, 
128.2, 128.4, 129.8, 131.7, 139.9, 156.5, 160.9, 161.5, 170.7. 
(Z)-5-(4-Chlorophenyl)-3-(4-methoxyphenyl)pent-2-enoic acid, (28Z): 
Synthesized according to Method D using 28Za (0.38 g, 1.10 mmol) and NaOHaq (1.85 mL, 
5.51 mmol); pale beige solid; yield: 0.20 g (57 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 2.63-2.66 (m, 2H), 3.33-3.36 (m, 2H), 3.85 (s, 3H), 
6.10 (s, 1H), 6.91 (d, J =  8.8 Hz, 2H), 7.14 (d, J = 8.5 Hz, 2H), 7.22 (d, J = 8.5 Hz, 2H), 7.44 
(d, J = 8.8 Hz, 2H). 13C-NMR (125 MHz, CDCl3): δ (ppm) = 32.9, 34.7, 55.3, 113.5, 114.8, 
128.2, 128.5, 128.9, 129.7, 129.8, 130.9, 139.1, 160.2, 170.6. 
 
 
3-(biphenyl-4-yl)-5-(4-chlorophenyl)pent-2-enoic acids, (29E & 29Z):  
 
(E)-1-(Biphenyl-4-yl)-3-(4-chlorophenyl)prop-2-en-1-one, (29c): 
Synthesized according to Method A using 4-chlorobenzaldehyde (3.58 g, 25.48 mmol) and 1-
(biphenyl-4-yl)ethanone (5.00 g, 25.48  mmol); pale yellow solid; yield: 7.74 g (95 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 7.41 (t, J = 8.2 Hz, 3H), 7.49 (t, J = 7.9 Hz, 2H), 
7.56 (d, J = 15.5 Hz, 1H), 7.60 (d, J = 8.8 Hz, 2H), 7.66 (d, J = 8.2 Hz, 2H), 7.74 (d, J = 8.5 
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Hz, 2H), 7.80 (d, J = 15.5 Hz, 1H), 7.81 (d, J = 8.5 Hz, 2H). 13C-NMR (125 MHz, CDCl3): 
δ (ppm) = 122.4, 127.3, 127.31, 128.2, 129.0, 129.1, 129.2, 129.6, 133.4, 136.4, 136.7, 139.9, 
143.2, 145.7, 189.6. 
 
1-(Biphenyl-4-yl)-3-(4-chlorophenyl)propan-1-one, (29b): 
Synthesized according to Method B using 29c (2.0 g, 6.27 mmol), HEH (2.38 g, 9.41 mmol) 
and silica gel (12.54 g); colourless oil; yield: 1.80 g (90 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 3.07 (t, J = 7.4 Hz, 2H), 3.31 (t, J = 7.4 Hz, 2H), 
7.20 (d, J = 8.5 Hz, 2H), 7.27 (d, J = 8.5 Hz, 2H), 7.40 (t, J = 7.6 Hz, 1H), 7.47 (t, J = 6.9 
Hz, 2H), 7.62 (t, J = 6.9 Hz, 2H), 7.68 (d, J = 8.5 Hz, 2H), 8.02 (d, J = 8.5 Hz, 2H). 13C-
NMR (125 MHz, CDCl3): δ (ppm) = 29.4, 40.2, 127.2, 127.3, 128.2, 128.6, 128.9, 129.8, 
131.9, 135.4, 139.7, 139.8, 145.8, 198.4. 
 
Ethyl 3-(biphenyl-4-yl)-5-(4-chlorophenyl)pent-2-enoate, (29a): 
Synthesized according to Method C using 29b (1.5 g, 4.67 mmol), NaH (0.56 g, 14.00 mmol) 
and triethyl phosphonoacetate (2.89 mL, 14.47 mmol); 
29Ea: colourless oil; yield: 0.85 g (47 %); 1H-NMR (500 MHz, CDCl3): δ (ppm) = 1.32 (t, J 
= 7.3 Hz, 3H), 2.74-2.77 (m, 2H), 3.41-3.44 (m, 2H), 4.21 (q, J = 7.0 Hz, 2H), 6.14 (s, 1H), 
7.17 (d, J =  8.5 Hz, 2H), 7.24 (d, J = 8.5 Hz, 2H), 7.38 (t, J = 7.3 Hz, 1H), 7.47 (d, J = 7.3Hz, 
2H), 7.53 (d, J = 8.2 Hz, 2H), 7.63 (d, J = 7.9 Hz, 4H). 13C-NMR (125 MHz, CDCl3): δ (ppm) 
= 14.3, 32.7, 34.5, 59.9, 117.8, 127.0, 127.2, 127.3, 127.7, 128.3, 128.9, 129.9, 131.6, 139.6, 
139.9, 140.2, 141.9, 146.7, 158.4, 166.3. 
29Za: colourless oil; yield: 0.89 g (49 %);1H-NMR (500 MHz, CDCl3): δ (ppm) = 1.09 (t, J = 
7.1 Hz, 3H), 2.69-2.73 (m, 2H), 2.77-2.86 (m, 2H), 4.02 (q, J = 7.1 Hz, 2H), 5.91 (s, 1H), 
7.26 (d, J = 8.2 Hz, 4H), 7.36 (t, J = 7.3 Hz, 2H), 7.46 (t, J = 1.9, 8.5 Hz, 1H), 7.61 (d, J = 8.2 
Hz, 2H), 7.64 (d, J = 7.3 Hz, 2H). 13C-NMR (125 MHz, CDCl3): δ (ppm) = 13.9, 33.2, 41.8, 
59.9, 118.0, 126.6, 127.0, 127.3, 127.8, 128.5, 128.7, 129.7, 131.8, 138.4, 139.2, 140.6, 157.5, 
165.9. 
 
(E)-3-(Biphenyl-4-yl)-5-(4-chlorophenyl)pent-2-enoic acid, (29E): 
Synthesized according to Method D using 29Ea (0.6 g, 1.53 mmol) and NaOHaq (1.50 mL, 
4.60 mmol); white solid; yield: 0.45 g (81 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 2.77-2.81 (m, 2H), 3.43-3.46 (m, 2H), 6.21 (s, 1H), 
7.16 (d, J = 8.2 Hz, 2H), 7.25 (d, J =  8.5 Hz, 2H), 7.39 (t, J = 7.2 Hz, 1H), 7.48 (t, J = 7.2 Hz, 
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1H), 7.56 (d, J = 8.2 Hz, 2H), 7.65 (d, J = 8.2 Hz, 4H). 13C-NMR (125 MHz, CDCl3): δ (ppm) 
= 33.1, 34.6, 116.7, 127.1, 127.2, 127.4, 127.8, 128.5, 128.9, 131.8, 139.4, 139.7, 140.1, 
142.4, 161.6, 171.2. 
(Z)-3-(biphenyl-4-yl)-5-(4-chlorophenyl)pent-2-enoic acid, (29Z): 
Synthesized according to Method D using 29Za (0.6 g, 1.53 mmol) and NaOHaq (1.50 mL, 
4.60 mmol); white solid; yield: 0.40 g (72 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 2.67-2.70 (m, 2H), 2.77-2.80 (m, 2H), 5.88 (s, 1H), 
7.05 (d, J = 8.8 Hz, 2H), 7.24 (d, J = 8.5 Hz, 2H), 7.25 (d, J =  8.2 Hz, 2H), 7.35 (d, J = 7.9 
Hz, 2H), 7.44 (t, J = 7.9 Hz, 2H), 7.58 (d, J = 7.58 Hz, 2H), 7.61 (t, J = 7.9 Hz, 2H). 13C-
NMR (125 MHz, CDCl3): δ (ppm) = 33.2, 42.1, 126.8, 127.1, 127.5, 127.8, 128.6, 128.7, 
129.7, 132.0, 137.7, 138.9, 139.0, 141.4, 161.0, 166.5. 
 
 
3,5-Di(naphthalen-2-yl)pent-2-enoic acids, (30Z & 30E):  
 
(E)-1,3-Di(naphthalen-2-yl)prop-2-en-1-one, (30c): 
Synthesized according to Method A using 2-naphthaldehyde (10.9 g, 64.03 mmol) and 1-
(naphthalen-2-yl)ethanone (11.9 g, 64.03 mmol); yellow solid; yield: 18.8 g (95 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 7.52-7.55 (m, 2H),  7.56-7.65 (m, 2H), 7.82 (d, J = 
15.8 Hz, 1H), 7.86-7.92 (m, 5H), 7.97 (d, J = 8.8 Hz, 1H), 8.02-8.07(m, 2H), 8.08 (s, 1H), 
8.14 (dd, J = 1.6, 8.5 Hz, 1H), 8.59 (s, 1H).13C-NMR (125 MHz, CDCl3): δ (ppm) = 117.7, 
122.2, 123.7, 124.5, 126.8, 127.4, 127.81, 127.84, 128.4, 128.6, 128.7, 128.8, 129.5, 129.9, 
130.7, 132.5, 132.6, 133.4, 134.4, 35.5, 135.7, 144.9, 190.2. 
 
1,3-Di(naphthalen-2-yl)propan-1-one, (30b): 
Synthesized according to Method B using 30c (2.0 g, 6.48 mmol), HEH (2.46 g, 9.73 mmol) 
and silica gel (12.96 g); colourless oil; yield: 1.25 g (62 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 3.30 (t, J = 7.6 Hz, 2H), 3.54 (t, J = 7.6 Hz, 2H), 
7.41-7.48 (m, 3H), 7.54 (t, J =6.9 Hz, 1H), 7.60 (t, J = 7.9 Hz, 1H), 7.74 (s, 1H), 7.79-7.83 
(m, 3H), 7.87-7.91 (m, 2H), 7.94 (d, J = 8.2 Hz, 1H), 8.06 (dd, J = 1.9, 8.8 Hz, 1H), 8.48 (s, 
1H), 13C NMR (CDCl3, 125 MHz): δ (ppm) = 30.4, 40.5, 123.8, 125.3, 126.0, 126.5, 126.8, 
127.2, 127.22, 127.4, 127.8, 128.2, 128.4, 128.5, 129.5, 129.7, 132.1, 132.5, 134.2, 135.6, 
138.8, 146.7, 199.1. 
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Ethyl 3,5-di(naphthalen-2-yl)pent-2-enoate, (30a):  
Synthesized according to Method C using 30b (1.0 g, 3.22 mmol), NaH (0.39 g, 9.66 mmol) 
and triethyl phosphonoacetate (2.00 mL, 9.98 mmol); 
30Ea: colourless oil; yield: 0.56 g (46 %); 1H-NMR (500 MHz, CDCl3): δ (ppm) = 1.32 (t, J 
= 7.3 Hz, 3H), 2.98-3.01 (m, 2H), 3.64-3.66 (m, 2H), 4.25 (q, J = 6.9 Hz, 2H), 7.59-7.61 (m, 
3H), 7.50-7.54 (m, 2H), 7.59 (dd, J = 1.9, 8.2 Hz, 1H), 7.65 (s, 1H), 7.75-7.80 (m, 3H), 7.84-
7.87 (m, 3H), 7.95 (ds, J = 1.9, 1H). 13C NMR (CDCl3, 125 MHz): δ (ppm) =  14.3, 33.0, 
35.4, 59.9, 118.6, 124.5, 125.1, 125.8, 126.3, 126.5, 126.6, 126.7, 127.4, 127.5, 127.6, 127.6, 
127.9, 128.3, 128.5, 132.3, 133.4, 133.7, 133.8, 138.6, 139.2, 159.0, 166.3. 
30Za: colourless oil; yield: 0.61 g (50 %); 1H-NMR (500 MHz, CDCl3): δ (ppm) = 0.99 (t, J 
= 7.3 Hz, 3H), 2.91-2.94 (m, 2H), 2.96-2.99 (m, 2H), 3.96 (q, J = 7.3 Hz, 2H), 7.27 (dd , J = 
1.9, 8.2 Hz, 1H), 7.35 (dd, J = 1.6, 8.2 Hz, 1H), 7.40-7.46 (m, 2H), 7.46-7.50 (m, 2H), 7.56 (s, 
1H), 7.68 (s, 1H), 7.73-7.76 (m, 2H), 7.79 (d, J = 9.2 Hz, 1H), 7.81-7.86 (m, 3H). 13C NMR 
(CDCl3, 125 MHz): δ (ppm) = 13.9, 34.3, 41.9, 59.8, 118.6, 125.3, 126.0, 126.02, 126.1, 
126.2, 126.22, 126.6, 127.0, 127.5, 127.5, 127.7, 127.8, 128.1, 128.2, 132.4, 133.1, 133.3, 
133.8, 137.6, 138.5, 157.8, 165.9. 
 
(E)- 3,5-Di(naphthalen-2-yl)pent-2-enoic acid, (30E): 
Synthesized according to Method D using 30Ea (0.50 g, 1.31 mmol) and NaOHaq (1.32 mL, 
3.94 mmol); white solid; yield: 0.20 g (43 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 2.98 -3.01 (m, 2H), 3.63-3.67 (m, 2H), 6.30 (s, 1H), 
7.40-7.45 (m, 3H), 7.53-7.57 (m, 2H), 7.63 (dd, J = 1.9, 8.2 Hz, 2H), 7.75-7.79 (m, 3H), 7.87-
7.91 (m, 3H), 7.99 (ds, J = 1.3 Hz, 1H). 13C NMR (CDCl3, 125 MHz): δ (ppm) = 33.3, 35.5, 
117.3, 124.4, 125.2, 125.9, 126.5, 126.6, 126.6, 126.9, 127.3, 127.5, 127.6, 128.0, 128.5, 
128.6, 133.2, 133.6, 138.1, 138.9, 162.4, 171.0, 178.9. 
(Z)- 3,5-Di(naphthalen-2-yl)pent-2-enoic acid, (30Z): 
Synthesized according to Method D using 30Za (0.55 g, 1.44 mmol) and NaOHaq (1.44 mL, 
4.32 mmol); white solid; yield: 0.22 g (51 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 2.86-2.89 (m, 2H), 2.95-2.98 (m, 2H), 6.00 (s, 1H), 
7.25 (dd, J = 1.5, 8.5 Hz, 1H), 7.32 (dd, J = 1.6, 8.5 Hz, 1H), 7.41-7.46 (m, 3H), 7.47-7.50 
(m, 1H), 7.53 (s, 1H), 7.58 (dd, J = 1.3, 8.8 Hz, 1H), 7.70 (s, 1H), 7.76 (d, J = 8.8 Hz, 1H), 
7.78-7.85 (m, 4H). 13C NMR (CDCl3, 125 MHz): δ (ppm) =  34.0, 35.7, 117.1, 124.4, 124.7, 
125.4, 125.8, 126.3, 126.9, 127.2, 127.7, 128.1, 128.2, 131.7, 132.2, 133.4, 133.5, 133.7, 
136.7, 137.4, 138.0, 138.8, 161.3, 169.8, 176.5. 
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5-(4-phenoxyphenyl)-3-phenylpent-2-enoic acids, (31E & 31Z): 
 
(E)-3-(4-Phenoxyphenyl)-1-phenylprop-2-en-1-one, (31c): 
Synthesized according to Method A using 4-phenoxybenzaldehyde (3.0 g, 15.1 mmol) and 1-
(naphthalen-2-yl)ethanone (2.58 g, 15.1 mmol); pale yellow solid; yield: 4.70 g (89 %);  
1H-NMR (CDCl3, 500 MHz): δ (ppm) = 7.05 (d, J = 7.6 Hz, 2H), 7.08 (d, J = 7.6 Hz, 2H), 
7.19 (t, J = 7.3 Hz, 1H), 7.40 (t, J = 7.6 Hz, 2H), 7.63-7.55 (m, 3H), 7.67 (d, J = 8.8 Hz, 2H), 
7.87 (t, J = 15.5 Hz, 1H), 7.90 (d, J = 8.5 Hz, 1H), 7.94 (d, J = 8.5 Hz, 1H), 8.00 (d, J = 7.9 
Hz, 1H), 8.11 (dd, J = 1.5, 8.8 Hz, 1H), 8.54 (s,1H). 13C NMR (CDCl3, 125 MHz): δ (ppm) = 
118.4, 119.7, 120.8, 124.2, 124.5, 126.7, 127.8, 128.3, 128.5, 129.5, 129.7, 129.8, 129.9, 
130.2, 132.5, 135.4, 135.6, 144.1, 156.0, 159.8, 190.1.  
 
3-(4-Phenoxyphenyl)-1-phenylpropan-1-one, (31b): 
Synthesized according to Method B using 31c (2.0 g, 5.70 mmol), HEH (2.20 g, 8.56 mmol) 
and silica gel (11.40 g); colourless oil; yield: 1.54 g (77 %);  
1H-NMR (CDCl3, 500 MHz): δ (ppm) = 3.13 (t, J = 7.4 Hz, 2H), 3.44 (t, J = 7.4 Hz, 2H), 6.86 
(d, J = 8.5 Hz, 2H), 6.99 (d, J = 8.8 Hz, 2H), 7.08 (t, J = 7.3 Hz, 1H), 7.25 (d, J = 8.5 Hz, 2H), 
7.32 (t, J = 8.5 Hz, 2H), 7.56 (dt, J = 1.3, 8.2 Hz, 1H), 7.61 (dt, J =6.9, 8.1 Hz, 1H), 7.89 (t, J 
= 8.5 Hz, 2H), 7.95 (d, J = 7.9 Hz, 1H), 8.05 (dd, J = 1.6, 8.8 Hz, 1H), 8.47 (s, 1H). 13C NMR 
(CDCl3, 125 MHz): δ (ppm) = 29.6, 40.6, 118.6, 119.2, 123.0, 123.8, 126.8, 127.8, 128.4, 
128.5, 129.5, 129.6, 129.71, 129.77, 132.5, 134.2, 135.6, 136.3, 155.5, 157.5, 199.2. 
 
Ethyl 5-(4-phenoxyphenyl)-3-phenylpent-2-enoate, (31a): 
Synthesized according to Method C using 3-(4-phenoxyphenyl)-1-phenylpropan-1-one (1.40 
g, 3.97 mmol), NaH (0.48 g, 12.31 mmol) and triethyl phosphonoacetate (2.46 mL, 12.31 
mmol); 
31Ea: colourless oil; yield: 0.78 g (52 %); 1H NMR (CDCl3, 500 MHz): δ (ppm) = 1.34 (t, J  
= 6.7 Hz, 3H), 2.78-2.81 (m, 2H), 3.52-3.55 (m, 2H), 4.25 (q, J 
 
= 6.7 Hz, 2H), 6.23 (s, 1H), 
6.93 (d, J 
 
= 7.9 Hz, 2H), 6.96 (d, J 
 
= 8.2 Hz, 2H), 7.08 (t, J = 7.3 Hz, 1H), 7.21 (d, J = 7.9 
Hz, 2H), 7.31 (t, J = 7.6, 2H), 7.55-7.51 (m, 2H), 7.58 (d, J = 8.5 Hz, 1H), 7.89-7.86 (m, 3H), 
7.93 (s, 1H). 13C NMR (CDCl3, 125 MHz): δ (ppm) = 14.4, 33.1, 34.6, 59.9, 118.3, 118.4, 
119.0, 122.8, 124.4, 126.3, 126.5, 126.7, 127.6, 128.3, 128.4, 129.6, 129.7, 133.2, 133.5, 
136.6, 138.3, 155.2, 157.7, 159.2, 166,3. 
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31Za: colourless oil; yield: 0.69 g (47 %); 1H NMR (CDCl3, 500 MHz): δ (ppm) = 1.02 (t, J  
= 7.3 Hz, 3H), 2.72-2.75 (m, 2H), 2.86-2.89 (m, 2H), 4.03 (q, J 
 
= 7.3 Hz, 2H), 6.00 (s, 1H), 
6.94 (d, J = 8.5 Hz, 2H), 6.99 (d, J = 8.8 Hz, 2H), 7.07-11 (m, 3H), 7.30-7.35 (m, 3H), 7.47-
7.51 (m, 2H), 7.67 (ds, J = 1.5 Hz, 1H), 7.87-7.83 (m, 3H). 13C NMR (CDCl3, 125 MHz): δ 
(ppm) = 13.9, 33.2, 42.2, 59.8, 118.2, 118.6, 119.0, 119.2, 123.0, 126.0, 126.1, 126.1, 127.4, 
127.4, 127.7, 128.1, 129.5, 129.7, 133.0, 135.7, 137.3, 139.2, 155.4, 157.5, 158.1, 166.9. 
 
(E)-5-(4-phenoxyphenyl)-3-phenylpent-2-enoic acid, (31E): 
Synthesized according to Method D using 31Ea (0.60 g, 1.42 mmol) and NaOHaq (1.6 mL, 
4.83 mmol); white solid; yield: 0.40 g (71 %);  
1H-NMR (CDCl3, 500 MHz): δ (ppm) = 2.79-2.83 (m, 2H), 3.53-3.56 (m, 2H), 6.27 (s,1H), 
6.91 (d, J = 8.5 Hz, 2H), 6.94 (d, J = 8.5 Hz, 2H), 7.06 (tt, J = 1.3, 7.3 Hz, 1H), 7.18 (d, J = 
8.8 Hz, 2H), 7.27-7.32 (m, 2H), 7.52-7.56 (m, 2H), 7.59 (dd, J = 1.2, 8.5 Hz, 1H), 7.86-7.90 
(m, 3H), 7.95 (ds, J = 1.6 Hz, 1H). 13C NMR (CDCl3, 500 MHz): δ (ppm) = 33.4, 34.6, 117.1, 
118.5, 119.0, 122.9, 124.3, 126.5, 126.7, 127.2, 126.9, 127.6, 128.4, 128.6, 129.6, 129.7, 
133.2, 133.7, 136.3, 138.1, 155.3, 157.6, 162.4.  
(Z)-5-(4-phenoxyphenyl)-3-phenylpent-2-enoic acid, (31Z): 
Synthesized according to Method D using (Z)-ethyl 5-(4-phenoxyphenyl)-3-phenylpent-2-
enoate (0.50 g, 1.18 mmol) and NaOHaq (1.8 mL, 5.37 mmol); white solid; yield: 0.41 g (88 
%); 
1H-NMR (CDCl3, 500 MHz): δ (ppm) = 2.67-2.70 (m, 2H), 2.84-2.87  (m, 2H), 5.92 (s, 1H), 
6.90 (d, J = 8.5 Hz, 2H), 6.98-6.95 (m, 2H), 7.05-7.09 (m, 3H), 7.27-7.33 (m, 3H), 7.46-7.51 
(m, 2H), 7.64 (ds, J = 1.6 Hz, 1H), 7.78-7.85 (m, 3H). 13C NMR (CDCl3, 500 MHz): δ (ppm) 
= 33.1, 42.6, 117.1, 118.6, 119.0, 123.0, 125.7, 126.1, 126.2, 126.3, 127.6, 127.7, 128.2, 
129.5, 129.7, 132.9, 133.0, 135.5, 136.6, 155.4, 157.5, 160.8, 169.8. 
 
 
3-(Naphthalen-2-yl)-5-(quinolin-2-yl)pent-2-enoic acids, (32E & 32Z):  
 
(E)-1-(Naphthalen-2-yl)-3-(quinolin-2-yl)prop-2-en-1-one, (32c): 
Synthesized according to Method A using quinoline-2-carbaldehyde (3.0 g, 19.09 mmol) and 
1-(naphthalen-2-yl)ethanone (3.25 g, 19.09 mmol); yellow solid; yield: 4.95 g (84 %);  
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1-(Naphthalen-2-yl)-3-(quinolin-2-yl)propan-1-one, (32b): 
Synthesized according to Method B using 32c (1.50 g, 4.85 mmol), HEH (1.71 g, 7.27 mmol) 
and silica gel (9.70 g); colourless oil; yield: 0.95 g (63 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) =  3.51 (t, J = 7.3 Hz, 2H), 3.77 (t, J = 7.3 Hz, 2H),  
7.43 (d, J = 8.5 Hz, 1H), 7.48 (t, J = 7.9 Hz, 1H), 7.54 (t, J = 7.9 Hz, 1H), 7.58 (t, J = 8.2 Hz, 
1H), 7.66 (t, J = 8.5 Hz, 1H), 7.78 (d, J = 9.1Hz, 1H), 7.87-7.91 (m, 2H), 7.97 (t, J = 9.1 Hz, 
2H), 8.07-8.10 (m, 2H), 8.57 (s, 1H). 13C NMR (CDCl3, 125 MHz): δ (ppm) = 32.9, 37.5, 
121.9, 124.0, 125.8, 126.7, 126.9, 127.5, 127.7, 128.3, 128.4, 128.8, 129.3, 129.6, 129.7, 
132.6, 134.4, 135.6, 136.2, 147.9, 161.2, 199.3. 
 
Ethyl 3-(naphthalen-2-yl)-5-(quinolin-2-yl)pent-2-enoate, (32a): 
Synthesized according to Method C using 32b (0.90 g, 2.89 mmol), NaH (0.35 g, 8.67 mmol) 
and triethyl phosphonoacetate (1.79 mL, 8.96 mmol); 
32Ea: yellow oil; yield: 0.53 g (48 %); 1H-NMR (500 MHz, CDCl3): δ (ppm) = 1.32 (t, J = 
6.9 Hz, 3H), 3.18-3.21 (m, 2H), 3.72-3.75 (m, 2H), 4.23 (t, J = 6.9 Hz, 2H), 6.25 (s, 1H), 7.42 
(d, J = 8.5 Hz, 1H), 7.45-7.51 (m, 3H), 7.62 (dd, J = 1.9, 8.5 Hz, 1H), 7.66 (dt, J = 1.6, 8.5 
Hz, 1H), 7.74 (dd, J = 1.3, 8.2 Hz, 1H), 7.81-7.83 (m, 3H),  7.97 (ds, J = 1.9 Hz, 1H), 8.01-
8.04 (m, 2H). 13C NMR (CDCl3, 125 MHz): δ (ppm) = 14.3, 31.2, 38.5, 60.0, 118.3, 121.6, 
124.4, 125.7, 126.4, 126.5, 126.6, 126.8, 127.4, 127.5, 128.3, 128.4, 128.9, 129.2, 133.2, 
133.5, 136.1, 138.2, 147.9, 159.4, 161, 7, 166.4. 
32Za: yellow oil; yield: 0.49 g (44 %); 1H-NMR (500 MHz, CDCl3): δ (ppm) = 0.99 (t, J = 
7.0 Hz, 3H), 3.10-3.17 (m, 4H), 3.95 (t, J = 7.0 Hz, 2H), 6.06 (s, 1H), 7.19 (d, J = 8.5 Hz, 
1H), 7.35 (d, J = 8.5 Hz, 1H), 7.36-7.50 (m, 3H), 7.67-7.70 (m, 2H), 7.75 (d, J = 8.5 Hz, 1H), 
7.79-7.85 (m, 3H), 8.01-8.04 (m, 2H). 13C NMR (CDCl3, 125 MHz): δ (ppm) = 13.9, 36.9, 
39.8, 59.8, 118.2, 121.3, 124.5, 125.9, 126.0, 126.1, 126.11, 126.9, 127.0, 127.4, 127.5, 127.7, 
128.1, 128.9, 129.4, 133.0, 136.3, 137.4, 148.0, 158.2, 160.8, 165.9. 
 
(E)-3-(Naphthalen-2-yl)-5-(quinolin-2-yl)pent-2-enoic acid, (32E): 
Synthesized according to Method D using 32Ea (0.45 g, 1.18 mmol) and NaOHaq (1.20 mL, 
3.53 mmol); white solid; yield: 0.20 g (48 %);  
1H-NMR (500 MHz, (CD3)2SO): δ (ppm) = 3.03-3.06 (m, 2H), 3.67-3.71 (m, 2H), 6.22 (s, 
1H), 7.42 (d, J = 8.5 Hz, 1H), 7.51-7.56 (m, 3H), 7.69-7.23 (m, 2H), 7.89 (dd, J = 1.3, 8.2 
Hz, 1H), 7.91-7.98 (m, 4H), 8.14 (ds, J = 1.6 Hz, 1H), 8.23 (d, J = 8.2 Hz, 1H). 
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13C NMR (125 MHz, (CD3)2SO): δ (ppm) = 29.4, 37.4, 121.3, 124.3, 125.6, 126.0, 126.3, 
126.6, 127.3, 127.6, 128.1, 128.2, 128.3, 129.2, 132,7, 132.9, 136.0, 137.6, 141.2, 147.1, 
161.1, 167.1, 170.1. 
 
(Z)-3-(Naphthalen-2-yl)-5-(quinolin-2-yl)pent-2-enoic acid, (32Z): 
Synthesized according to Method D using 32Za (0.40 g, 1.05 mmol) and NaOHaq (1.00 mL, 
3.16 mmol); white solid; yield: 0.15 g (36 %);  
1H-NMR (500 MHz, (CD3)2SO): δ (ppm) = 2.99-3.03 (m, 2H), 3.03-3.08 (m, 2H), 6.00 (s, 
1H), 7.38 (dd, J = 1.6, 8.5 Hz, 1H), 7.41 (d, J = 8.5 Hz, 1H), 7.50-7.55 (m, 3H), 7.71 (dt, J = 
1.6, 8.2 Hz, 1H), 7.78 (s, 1H), 7.88 (d, J = 8.2 Hz, 1H), 7.89-7.94 (m, 4H), 8.24 (d, J = 8.2 
Hz, 1H). 
 
 
5-(Biphenyl-4-yl)-3-(naphthalen-2-yl)pent-2-enoic acids, (33Z & 33Z): 
 
(E)- 3-(Biphenyl-4-yl)-1-(naphthalen-2-yl)prop-2-en-1-one, (33c): 
Synthesized according to Method A using biphenyl-4-carbaldehyde (5.0 g, 29.3 mmol) and 1-
(naphthalen-2-yl)ethanone (5.35 g, 29.3 mmol); yellow solid; yield: 7.80 g (79 %);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 7.40 (t, J = 7.6 Hz, 1H), 7.48 (t, J = 7.9 Hz, 2H), 
7.52-7.55 (m, 2H),  7.57-7.66 (m, 3H), 7.68 (d, J = 8.2 Hz, 2H), 7.73 (d, J = 15.7 Hz, 1H), 
7.76 (t, J = 8.2 Hz, 2H), 7.93 (q, J = 9.1 Hz, 2H), 8.02 (d, J = 7.9 Hz, 1H),  8.13 (d, J = 8.5 
Hz, 1H), 8.57 (s, 1H).  
 
3-(Biphenyl-4-yl)-1-(naphthalen-2-yl)propan-1-one, (33b): 
Synthesized according to Method B using 33c (2.0 g, 5.98 mmol), HEH (2.27 g, 8.97 mmol) 
and silica gel (11.96 g); colourless oil; yield: 1.74 g (86 %); 
1H NMR (CDCl3, 500 MHz): δ (ppm) = 8.49 (s, 1H), 8.07 (dd, 1H), 7.95 (d, J= 8.2 Hz, 1H), 
7.90 (t, 2H), 7.62-7.54 (m, 6H), 7.44 (t, J= 7.3 Hz, 2H), 7.38 (d, J= 8.5 Hz, 2H), 7.34 (tt, J= 
7.3 Hz, 1H), 3.49(t, J = 7.3 Hz, 2H), 3.19 (t, J = 7.9Hz, 2H). 13C NMR (CDCl3, 125 MHz): δ 
(ppm) = 199.1, 180.0, 141.0, 140.4, 139.2, 135.6, 134.2, 132.5, 129.7, 129.5, 128.9, 128.7, 
128.5, 128.4, 127.8, 127.3, 127.1, 127.0, 126.8, 126.8, 40.5, 29.9. 
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Ethyl 5-(biphenyl-4-yl)-3-(naphthalen-2-yl)pent-2-enoate, (33a): 
Synthesized according to Method C using 33b (1.5 g, 4.46 mmol), NaH (0.54 g, 12.93 mmol) 
and triethyl phosphonoacetate (2.68 mL, 13.4 mmol); 
33Ea: colourless oil; yield: 0.85 g (47 %); 1H NMR (CDCl3, 500 MHz): δ (ppm) = 1.35 (t, J = 
7.3 Hz, 5H), 2.82-2.86 (m, 2H ), 3.54-3.58 (m, 2H), 4.24 (q, J = 7.3 Hz, 2H), 7.31-7.34 (m, 
3H), 7.42 (t, J =7.9, 2H), 7.49-7.53 (m, 4H), 7.56 (dd, J =  1.9, 8.8 Hz, 2H), 7.60 (dd, J = 1.9, 
8.8 Hz, 2H), 7.83.-7.89 (m, 3H), 7.94 (ds, J =1.6 Hz, 1H). 13C NMR (CDCl3, 125 MHz): δ 
(ppm) = 14.4, 33.1, 35.0, 60.0, 118.3, 122.9, 123.4, 124.0, 124.4, 126.3, 126.5, 126.7, 127.0, 
127.02, 127.6, 128.3, 128.5, 128.7, 128.9, 133.1, 133.2, 133.5, 139.0, 140.7, 141.2, 149.6, 
153.5. 
33Za: colourless oil; yield: 0.83 g (46 %);1H NMR (CDCl3, 500 MHz): δ (ppm) = 1.01 (t, J = 
7.3 Hz, 3H), 2.77-2.80 (m, 2H ), 2.89-2.93 (m, 2H), 3.97 (q, J = 7.3 Hz, 2H), 6.03 (s, 1H), 
7.21 (d, J = 8.2 Hz, 2H), 7.32-7.36 (m, 2H), 7.41 (t, J =7.9 Hz, 2H), 7.48-7.52 (m, 4H), 7.57 
(t, J = 7.9 Hz, 2H), 7.68 (s, 1H), 7.87.-7.83 (m, 3H).13C NMR (CDCl3, 125 MHz): δ (ppm) =  
13.9, 33.6, 42.1, 59.9, 126.0, 126.1, 126.12, 127.0, 127.1, 127.2, 127.4, 127.7, 128.1, 128.7, 
128.7, 132.9, 133.0, 137.3, 139.0, 139.9, 140.9, 158.2, 166.0. 
 
(E)-5-(Biphenyl-4-yl)-3-(naphthalen-2-yl)pent-2-enoic acid, (33E): 
Synthesized according to Method D using 33Ea (0.60 g, 1.47 mmol) and NaOHaq (1.5 mL, 
4.41 mmol); white solid; yield: 0.37 g (63 %);  
1H NMR (CDCl3, 500 MHz): δ (ppm) = 2.87-2.90 (m, 2H), 3.57-3.61 (m, 2H), 6.30 (s, 1H), 
7.32 (t, J = 8.2Hz, 3H), 7.40 (t, J = 7.9 Hz, 2H), 7.52 (t, J =8.2 Hz, 2H), 7.53-7.57 (m, 4H), 
7.63 (dd, J = 1.6, 8.5 Hz, 1H), 7.88-7.91 (m, 3H), 7.99 (s, 1H). 
(Z)-5-(Biphenyl-4-yl)-3-(naphthalen-2-yl)pent-2-enoic acid, (33Z): 
Synthesized according to Method D using 33Za (0.60 g, 1.47 mmol) and NaOHaq (1.5 mL, 
4.41 mmol); white solid; yield: 0.42 g (72 %);  
1H NMR (CDCl3, 500 MHz): δ (ppm) = 2.73-2.76 (m, 2H), 2.89-2.91 (m, 2H), 5.98 (s, 1H), 
7.18 (d, J = 8.2 Hz, 2H), 7.30-7.34 (m, 2H), 7.42 (t, J =7.3 Hz, 2H), 7.47-7.51 (m, 4H), 7.55 
(dd, J = 0.9. 8.23 Hz, 2H), 7.66 (s, 1H), 7.80-7.85 (m, 3H). 
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5-(6-Hydroxynaphthalen-2-yl)-3-(naphthalen-2-yl)pent-2-enoic acid, (34Z & 34E): 
 
6-(Methoxymethoxy)-2-naphthaldehyde, (34e): 
Synthesized according to Method G using bromomethyl-methylether (1.50mL, 18.3 mmol), 6-
hydroxy-2-naphthaldehyde (2.1 g, 12.2 mmol) and sodium hydride (0.73 g, 18.3 mmol); 
yellow solid; yield: 2.64 g (91%);  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 3.53 (s, 3H), 5.33 (s, 2H), 7.31 (d, J = 8.8 Hz, 1H), 
7.44 (s, 1H), 7.73-7.82 (m, 1H), 7,91 (ds., J = 1.9 Hz, 2H), 8.26 (s, 1H), 10.10 (s. 1H). 13C-
NMR (125 MHz, CDCl3): δ (ppm) = 56.3, 94.4, 110.0, 120.1, 123.5, 128.1, 128.4, 131.2, 
132.7, 134.2, 138.0, 157.6, 192.0. 
 
(E)- 3-(6-(Methoxymethoxy)naphthalen-2-yl)-1-(naphthalen-2-yl)prop-2-en-1-one, (34c): 
Synthesized according to Method A using 34e (2.0 g, 9.25 mmol) and 1-(naphthalen-2-
yl)ethanone (1.57 g, 9.25 mmol); yellow solid; yield: 1.90 g (56 %);  
1H-NMR (500 MHz, CD3Cl): δ (ppm) = 3.54 (s, 3H), 5.32 (s, 2H), 7.27 (dd, J = 1.9, 8.8 Hz, 
1H), 7.42 (ds, J = 2.2 Hz, 1H), 7.56-7.63 (m, 2H), 7.76-7.84 (m, 4H), 7.91 (d, J = 7.9 Hz, 
1H),  7.95 (d, J = 8.8 Hz, 1H), 8.04-8.01 (m, 3H), 8.14 (dd, J = 1.6, 8.2 Hz, 1H), 8.58 (s, 1H). 
13C NMR (125 MHz, CDCl3): δ (ppm) = 56.2, 94.5, 110.0, 119.7, 121.4, 124.4, 124.6, 126.7, 
127.8, 127.8, 128.3, 128.5, 129.3, 129.5, 129.8, 130.3, 130.5, 130.8, 132.6, 135.7, 135.7, 
135.8, 145.0, 156.4, 190.2. 
 
3-(6-(Methoxymethoxy)naphthalen-2-yl)-1-(naphthalen-2-yl)propan-1-one, (34b): 
Synthesized according to Method B using 34c (1.5 g, 4.07 mmol), HEH (1.44 g, 6.11 mmol) 
and silica gel (8.14 g); colourless oil; yield: 1.10 g (73 %); 
1H-NMR (500 MHz, CD3Cl): δ (ppm) = 3.26 (t, J = 7.9 Hz, 2H), 3.51 (t, J = 7.9 Hz, 2H) 3.53 
(s, 3H), 5.29 (s, 2H), 7.21 (dd, J = 2.4, 8.8 Hz, 1H), 7.38-7.41 (m, 2H), 7.54 (t, J = 7.9 Hz, 
1H), 7.59 (d, J = 8.2 Hz, 1H), 7.67 (s, 1H), 7.70-7.73 (m, 2H), 7.89 (t, J = 7.9 Hz, 2H),  7.94 
(d, J = 8.8 Hz, 1H), 8.06 (dd, J = 1.5, 8.2 Hz, 1H), 8.48 (s, 1H). 13C NMR (125 MHz, CDCl3): 
δ (ppm) = 30.3, 40.5, 56.0, 94.6, 109.9, 123.8, 126.3, 126.7, 127.3, 127.7, 127.8, 128.4, 128.5, 
129.0, 129.5, 129.7, 132.5, 133.0, 134.2, 135.6, 136.9, 154.7, 199.1. 
 
Ethyl 5-(6-(methoxymethoxy)naphthalen-2-yl)-3-(naphthalen-2-yl)pent-2-enoate, (34a1): 
Synthesized according to Method C using 34b (0.8 g, 2.16 mmol), NaH (0.25 g, 6.26 mmol) 
and triethyl phosphonoacetate (1.30 mL, 6.26 mmol); 
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34Ea1: colourless oil; yield: 0.45 g (47 %); 1H-NMR (500 MHz, CD3Cl): δ (ppm) = 1.30 (t, J 
= 7.0 Hz, 3H), 2.90-2.93 (m,2H), 3.53 (s, 3H), 3.58-3.61 (m, 2H), 4.22 (q, J = 7.0 Hz, 2H), 
5.29 (s, 2H), 6.21 (s, 1H), 7.18 (dd, J = 2.5, 8.8 Hz, 1H), 7.35-7.38 (m, 2H), 7.51-7.54 (m, 
2H), 7.56 (s, 1H), 7.60 (dd, J = 2.5, 8.5 Hz, 1H), 7.65- 7.69 (m, 2H), 7.84-7.88 (m, 3H), 7.93 
(ds, J = 1.6 Hz, 1H). 13C NMR (CDCl3, 125 MHz): δ (ppm) =  14.3, 33.0, 35.2, 56.0, 59.9, 
94.6, 109.9, 116.8, 188.3, 118.8, 124.4, 126.3, 126.5, 126.7, 127.0, 127.6, 127.9, 128.3, 128.5, 
129.0, 129.6, 133.2, 137.2, 138.4, 154.6, 159.2, 166.4. 
34Za1: colourless oil; yield: 0.46 g (48 %); 1H-NMR (500 MHz, CD3Cl): δ (ppm) = 1.01 (t, J 
= 7.2 Hz, 3H), 2.85-2.89 (m,2H), 2.92-2.96 (m, 2H), 3.52 (s, 3H), 3.96 (q, J = 7.2 Hz, 2H), 
5.29 (s, 2H), 6.01 (s, 1H), 7.19 (dd, J = 2.5, 8.8 Hz, 1H), 7.20 (dd, J = 2.5, 8.5 Hz, 1H),7.33-
7.36 (m, 2H), 7.47-7.50 (m, 3H), 7.65-7.68 (m, 3H), 7.82- 7.86 (m, 3H). 13C NMR (CDCl3, 
125 MHz): δ (ppm) = 13.9, 33.9, 42.1, 56.0, 59.8, 94.6, 109.9, 118.2, 119.0, 125.9, 126.0, 
126.1, 126.3, 127.2, 127.4, 127.5, 127.7, 128.1, 129.6, 132.9, 133.0, 133.02, 136.4, 137.3, 
154.7, 158.3, 165.9. 
 
(E)-Ethyl 5-(6-hydroxynaphthalen-2-yl)-3-(naphthalen-2-yl)pent-2-enoate, (34Ea2): 
Synthesized according to Method K using 34Ea1 (0.25 g, 0.57 mmol) and 2 mL 10 % HCl; 
yellow oil; yield: 0.095 g (quant, without further purification);  
1H-NMR (500 MHz, CD3Cl): δ (ppm) = 1.31 (t, J = 7.0 Hz, 3H), 2.89-2.93 (m,2H), 3.58-
3.621 (m, 2H), 4.23 (q, J = 7.0 Hz, 2H), 5.15 (s, OH), 6.21 (s, 1H), 7.06 (dd, J = 2.5, 8.5 Hz, 
1H), 7.10 (ds, J = 1.6 Hz, 1H), 7.35 (dd, J = 1.6, 8.2 Hz, 1H), 7.52- 7.61 (m, 5H), 7.63 (d, J = 
8.8 Hz, 1H),  7.85-7.88 (m, 3H), 7.94 (ds, J = 1.6 Hz, 1H). 
(Z)-Ethyl 5-(6-hydroxynaphthalen-2-yl)-3-(naphthalen-2-yl)pent-2-enoate, (34Za2): 
Synthesized according to Method K using 34Ea2 (0.35 g, 0.80 mmol) and 2 mL 10 % HCl; 
yellow oil; yield: 0.32 g (quant, without further purification);  
1H-NMR (500 MHz, CD3Cl): δ (ppm) = 1.01 (t, J = 7.0 Hz, 3H), 2.83-2.86 (m,2H), 2.92-2.96 
(m, 2H), 4.11 (q, J = 7.0 Hz, 2H), 6.02 (s, 1H), 7.04 (dd, J = 2.4, 8.8 Hz, 1H), 7.08 (ds, J = 2.4 
Hz, 1H), 7.21 (dd, J = 1.9, 8.2 Hz, 1H), 7.32- 7.35 (m, 1H), 7.47-7.50 (m, 3H), 7.58 (d, J = 
8.5 Hz, 1H),  7.63 (d, J = 8.8 Hz, 1H), 7.68 (s, 1H), 7.82-7.86 (m, 3H). 
 
(E)- 5-(6-Hydroxynaphthalen-2-yl)-3-(naphthalen-2-yl)pent-2-enoic acid, (34E): 
Synthesized according to Method D using 34Ea2 (0.07 g, 0.18 mmol) and NaOHaq (0.2 mL, 
0.53 mmol); white solid; yield: 0.55 g (83 %);  
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1H-NMR (500 MHz, (CD3)2SO): δ (ppm) = 2.75-2.77 (m, 2H), 3.48-3.52 (m, 2H), 6.17 (s, 
1H), 6.21 (s, 1H), 6.99 (dd, J = 2.4, 8.5 Hz, 1H), 7.02 (ds, J = 2.1 Hz, 1H), 7.28 (dd, J = 1.5, 
8.5 Hz, 1H), 7.52- 7.57 (m, 4H), 7.62 (d, J = 8.8 Hz, 1H), 7.69 (dd, J = 1.5, 8.2 Hz, 1H), 7.91-
7.95 (m, 2H), 7.98-8.00 (m, 1H), 8.13 (s, 1H), 9.57 (s, OH). 
(Z)- 5-(6-Hydroxynaphthalen-2-yl)-3-(naphthalen-2-yl)pent-2-enoic acid, (34Z): 
Synthesized according to Method D using 34Za2 (0.30 g, 0.76 mmol) and NaOHaq (1.30 mL, 
3.78 mmol); white solid; yield: 0.16 g (57 %);  
1H-NMR (500 MHz, (CD3)2SO): δ (ppm) = 2.72-2.75 (m, 2H), 2.90-2.93 (m, 2H), 5.97 (s, 
1H), 7.02-7.09 (m, 2H), 7.24 (dd, J = 1.5, 8.2 Hz, 1H), 7.37 (dd, J = 1.9, 8.5 Hz, 1H), 7.51- 
7.53 (m, 3H), 7.58 (d, J = 8.5 Hz, 1H), 7.65 (d, J = 8.8 Hz, 1H), 7.78 (s, 1H), 7.88-7.93 (m, 
3H), 9.59 (s, OH), 11.94 (s, OH). 
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6.2. Biological Section 
6.2.1. Material and reagents 
6.2.1.1. Apparatus 
EP-Motion 5070 Pipetting workstation (Eppendorf) 
Typhoon Phosphoimager (GE Healthcare); Fla9000 Starion (Fujifilm) 
VP-ITC titration calorimetric system (MicroCal Inc, MA) 
Origin7 Software 
Cell culture incubator Biosafe (Revco) 
Cell counter (Casy) 
Centrifuge universal 30 RF (Hettich GmbH) 
Table centrifuge Micro (Hettich GmbH) 
Ultracentrifuge 2330 Ultraspin 55 Hitachi (Pharmacia) 
Sonicator Sonopuls HD60 (Bandelin) 
HPLC system Agilent  
LC-MS/MS: TSQ quantum (Thermo Electron Corporation) instrument equipped with an ESI    
                     source and a triple quadrupole mass detector (Thermo Finnigan) 
PolarStar plate reader (BMG Labtech) 
 
6.2.1.2. Materials for kinase activity assays 
96 well plate (V-bottom; Greiner) 
DMSO > 99,8 % (Roth) 
MgCl2 (Sigma) 
ATP (Sigma) 
Tris-HCl (Sigma) 
β-mercaptoethanol (Sigma) 
Albumin from bovine serum (Sigma) 
Brij (Sigma) 
Phosphoric acid (Sigma) 
[γ 32P]ATP (GE Amersham Pharmacia) 
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T308tide (KTFCGTPEZLAPEVRR) 
PIFtide (REPRILSEEEQEMFRDFDYIADWC) 
Crosstide (GRPRTSSFAEG) 
P81 3MM paper (Whatman) 
 
6.2.1.3. Materials for ITC 
PDK150-359[Tyr228Gly-Gln2922Ala]  
TrisHCl (Sigma) 
NaCl (Sigma) 
DTT (Sigma) 
 
6.2.1.4. Materials for Cell assays  
Petri dishes (Greiner) 
Falcon tubes (Greiner) 
Cell culture flasks (Greiner) 
DMEM (Gibco) 
RPMI-1640 
FBS (Sigma) 
Trypsin (Sigma) 
PenStrep (Invitrogen) 
PBS (Sigma) 
HCl (Sigma) 
Ethyl acetate (Sigma) 
Methanol (Sigma) 
Trifluoracetic acid (Sigma) 
Reporter gene plasmid (pGL4.32[luc2P/NF-κB-RE/Hygro] (Promega) 
Fu Gene HD (Roche Diagnostics) 
TNFα (Sigma) 
Luciferase detection reagent (Bright-Glo, Promega) 
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6.2.2. Protein kinases assays 
To test the effect of the compounds on the activity of the AGC protein kinases, 
radioactivity kinase assays were performed.11, 26, 30, 74, 167 The corresponding kinase were 
incubated with the radiolabeled phosphate from [γ 32P]ATP in the presence of the appropriate 
substrate and the compounds. The amount of the radioactivity incorporated into the substrate 
was measured. The assays were performed in a 96-well formate, at least in dublicates and 
with less than 10 % difference between the duplicates. The total volume of each reaction was 
20 µL.  
1) A reaction mixture I was prepared on ice using the enzyme, the corresponding 
substrate, 50 mM Tris-HCl (pH 7.5), dilution buffer containing 0.05 mg/ml of BSA, 
0.1 % ß-mercaptoethanol and 0.003% of Brij.  
2) For each test-compound, appropriate dilution of the stock solution was prepared with 
DMSO. 
3) The enzyme mixture was preincubated with the compound for 20 min at room 
temperature.  
4) The reaction was started by addidtion of mixture II containing the [γ 32P]ATP (5–50 
c.p.m./pmol), 10 mM MgCl2 and ATP. The reaction time was 30 min. 
5)  The enzymatic reaction was quenched by the addition of 0.01 % phosphoric acid. 
6) 4 µL aliquots were spotted on P81 phosphocellulose paper using the pipetting 
workstation ep motion 5070 (Eppendorf). 
7) The P81 paper was washed 4 x 15 min in 0.01 % phosphoric acid in order to remove 
the [γ 32P]ATP not bound to the peptide substrate and dried. 
8) The incorporated radioactivity into the appropriate substrate was quantified in a 
PhosphoImager. 
 
Wild type and mutant protein kinases were expressed in HEK293 cells after transient 
transfection as GST fusion proteins and purified using glutathione sepharose. Determination 
of the cell-free protein kinase activity of the wild-type and mutants of PDK1 was performed 
using T308tide (KTFCGTPEYLAPEVRR) as substrate peptide.26 The activity of PKCζ and 
PKCι was measured using myelin basic protein (MBP, Millipore) as substrate.Fröhner11 For 
activity assays of classical PKCs, the enzymes PKCα (Millipore) and PKCβ (ProQinase) were 
used and for the novel PKCs, PKCθ (ProQinase) and PKC δ (ProQinase). For both families 
Histone H1 (Millipore) served as substrate.154 In order to measure the activity of the 
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compounds toward S6K and SGK the method was performed as described previously using 
S6K1-T2[T412E] and SGK1-∆N[S422D] and Crosstide (GRPRTSSFAEG).11, 74 
 
6.2.3. Isothermal titration calorimetry20, 74 
Isothermal titration calorimetry was performed using the high precision VP-ITC titration 
calorimetric system (MicroCal Inc, MA) to determine binding energetics of the 3,5-
diarylpent-2-enoic acid series. We followed the protocol previously described by Schaeffer et 
al.169  
1) PDK150-359[Tyr228Gly-Gln2922Ala] was dissolved in the buffer containing 50 mM 
TrisHCl (pH 7.5), 200 mM NaCl and 1 mM DTT. 
2) The ligand solutions were also prepared with the buffer containing 50 mM TrisHCl 
(pH 7.5), 200 mM NaCl and 1 mM DTT. 
3) Both solutions were degased by generating of vacuum for 3 min. 
4) Setting of the apparatus temperature (3-4 °C below the experimental run 
temperature) and of the experimental parameters: 
  Cell:   20 µM PDK1 
  Syringe:  450 µM ligand 
  Buffer: TrisHCl (pH 7.5), 200 mM NaCl and 1 mM DTT  
5) Loading of the reference cell with degased water. 
6) Rinsing of the sample cell with buffer (2x) and loading with the protein solution. 
7) Loading of the ITC syringe with the ligand solution. 
8) The pipette was inserted into the sample cell and the ITC run was started. 
9) Each experiment was performed at 20°C by one injection of 2 µl followed by 29 
injections of 10 µl with 210 seconds between injections using a 290 rpm rotating 
syringe.  
10) Heat signals were corrected for the heats of dilution and normalized to the amount 
of compound injected. Normalization and deconvolution of the binding isotherms 
was carried out using Origin7 170 provided by the manufacturer. 
 
6.2.4. HPLC-MS/MS detection of hydrolysis of the prodrugs in L6 cells 
L6 cells were seeded in 10 cm petri dishes at the density of 106/mL in DMEM, 
supplemented with peniclillin and streptomycin and 10% FBS. To induce differentiation to 
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myocytes, the cells were allowed to reach confluence for two days after plating, and the 
medium was changed to medium containing 2 % of FBS for four days, with medium change 
after 2nd day. After the 4th day the L6 cells were washed with PBS, the medium was replaced 
to DMEM without FBS and the cells were treated with the compounds at appropriate time 
intervals (5-90 min). At the end of the incubation the supernatant was removed and the cells 
were washed three times with phosphate-buffered saline (PBS). The cells were harvested and 
the cell suspensions transferred to a flask and counted. At that point, carbamazepine was 
added to the suspension as an internal standard to determine the recovery rate. 1 mL 0.6N HCl 
in water was added and the dicarboxylic acids were extracted using 3 mL of ethyl acetate 
shaking the samples for 20 min. The samples were centrifuged and 1 mL aliquots of the ethyl 
acetate supernatant were taken and evaporated to dryness. The samples were resuspended in 
500 µl of methanol and analyzed using HPLC-ESI-MS/MS, and the amount of the 
compounds was calculated using a standard calibration curve. DMSO-treated cells were 
processed in parallel and analyzed as a control. The disappearance of the ester and the 
appearance of the correspondic dicarboxylic acid were additionally confirmed by UV peak 
quantifications and spiking of the samples with the purified compounds. Mobile phase A was 
water containing 0.5 % trifluoracetic acid and mobile phase B was methanol containing 0.5 % 
trifluoracetic acid. The following elution profile was used: 0-8 min, 100 % B. The gradient of 
B from 70 to 100 % was applied, followed by 100 % B until end; sample volume was 25 µL, 
the flow rate 0.5 mL/min, and the column temperature 40 °C. 
 
6.2.5. Reporter Gene Assay167 
U937 cells were cultured in RPMI-1640 containing 10% FCS and penicillin/streptomycin. 
Transfection was performed in 6-well plates at a density of 106 cells/ml (2 ml per well) in the 
same medium without antibiotics. The transfection complex was prepared by mixing the 
reporter gene plasmid (pGL4.32[luc2P/NF-κB-RE/Hygro], with FuGene HD transfection 
reagent at a ratio of 1:6 (Ng DNA : Nl transfection reagent) in RPMI-1640 medium according 
to the manufacturer´s instructions. The transfection mixture was added dropwise to the wells 
while gently shaking, and the plates were incubated at 37°C/5% CO2 for 6h. Medium was 
then exchanged to serum-free RPMI-1640/ penicillin/ streptomycin without phenol red and 
the cells starved overnight. The next day, test compounds dissolved in DMSO were pipetted 
into white 96-well plates (0.2 Nl), followed by 100 Nl of the transfected cells per well. After 
3h at 37°C/5% CO2, the NF-κB pathway was induced by addition of 50 ng/Nl TNFα to the 
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wells (except uninduced controls). The cells were incubated at 37°C/5% CO2 for 2.5 h, then 
the luciferase detection reagent was added (100Nl per well) and the luminescence measured 
after 5min. at RT in a PolarStar plate reader.  
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